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ABSTRACT

A MODELING PLATFORM TO PREDICT CANCER SURVIVAL AND THERAPY
OUTCOMES USING TUMOR TISSUE DERIVED METABOLOMICS DATA

Hunter A. Miller
April 19th,2022

Cancer is a complex and broad disease that is challenging to treat, partially due
to the vast molecular heterogeneity among patients even within the same subtype.
Currently, no reliable method exists to determine which potential first-line therapy would
be most effective for a specific patient, as randomized clinical trials have concluded that
no single regimen may be significantly more effective than others. One ongoing
challenge in the field of oncology is the search for personalization of cancer treatment
based on patient data. With an interdisciplinary approach, we show that tumor-tissue
derived metabolomics data is capable of predicting clinical response to systemic therapy
classified as disease control vs. progressive disease and pathological stage classified as
stage I/II/III vs. stage IV via data analysis with machine-learning techniques (AUROC =
0.970; AUROC=0.902). Patient survival was also analyzed via statistical methods and
machine-learning, both of which show that tumor-tissue derived metabolomics data is
capable of risk stratifying patients in terms of long vs. short survival (OS AUROC =
0.940TEST; PFS AUROC = 0.875TEST). A set of key metabolites as potential biomarkers
and associated metabolic pathways were also found for each outcome, which may lead
to insight into biological mechanisms. Additionally, we developed a methodology to

vi

calibrate tumor growth related parameters in a well-established mathematical model of
cancer to help predict the potential nuances of chemotherapeutic response. The
proposed methodology shows results consistent with clinical observations in predicting
individual patient response to systemic therapy and helps lay the foundation for further
investigation into the calibration of mathematical models of cancer with patient-tissue
derived molecular data. Chapters 6 and 8 were published in the Annals of Biomedical
Engineering. Chapters 2, 3, and 7 were published in Metabolomics, Lung Cancer, and
Pharmaceutical Research, respectively. Chapters 4 has been accepted for publication at
the journal Metabolomics (in press) and Chapter 5 is in review at the journal
Metabolomics. Chapter 9 is currently undergoing preparation for submission.
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CHAPTER 1

INTRODUCTION

Accounting for an estimated 12-13% of new cancer diagnoses in 2021, lung
cancer is one of the most prevalent cancer types in the U.S. Of ~600,000 deaths
attributed to cancer by the end of 2022, 21.3% are estimated to be lung cancer [1].
Cancer is a complex and broad disease that is challenging to treat, due to the vast
molecular heterogeneity among patients even within the same subtype. Cancer
treatments often rely on chemotherapy, which involves the injection of cytotoxic drugs
whose aim is to target tumor tissue by perturbing the proliferation of tumorigenic cells. A
major limitation of systemic chemotherapy is dose-dependent cytotoxicity, which can
produce a range of side-effects. Major hurdles have included concerns about toxicity,
lower than expected efficacy, and off-target effects [2]. In particular, the tumor
microenvironment can present a formidable barrier that not only hinders the transport of
drug molecules but also that of nano-sized vehicles [3-5]. For non-small cell lung cancer
(NSCLC) patients with advanced disease (stage IIIB-IVB) and performance status ≤ 2,
chemotherapy is the treatment option with best long term outcomes [6]. Paclitaxel,
gemcitabine, docetaxel, vinorelbine, irinotecan, or pemetrexed are often used in
combination with platinum drugs [7]. Randomized clinical trials have concluded that no
single regimen may be significantly more effective than others [8]. Consequently, no
reliable method exists to determine which potential first-line therapy would be most
effective for a specific patient, who essentially is an experimental subject with drug
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choice and dosing determined post-hoc first-line therapy based on response and
tolerability [6]. The efficacy of anti-cancer therapies are typically evaluated with in vitro
and in vivo experimental models, indispensable for pre-clinical evaluation. However, in
vitro models lack key features of cancerous tissue found in vivo, including a vascular
network and dynamic immune cell population, while in vivo models present challenges
due to systemic interactions that may be difficult to tease apart. As a complement to
these experimental approaches, computational simulation of cancer nanotherapy has
aimed to provide the capability for system-level analysis [9-20]. However, mathematical
models of cancer have failed to reach clinical relevance due to the inherent
heterogeneity of cancer tissue. Ideally, predictive models would be calibrated to patientspecific data to allow for more accurate long-term prognosis.
A promising avenue of approach towards the concept of personalized medicine is
the collection of high-throughput molecular data from human samples. These “omics”
technologies encompass a variety of experimental and instrumental techniques whose
goal is to obtain large amounts of meaningful data from biological samples, and include
genomics, transcriptomics, proteomics, metabolomics, lipidomics, etc.. Metabolomics
has emerged as an important method of biomarker discovery [21], giving insight into the
rate of chemical reactions occurring within cells and providing a closer representation of
phenotype compared to other omics technologies [22]. In particular for lung cancer,
multiple studies have evaluated biomarker candidates obtained from patient samples,
including plasma, sputum, and urine [23]. The overall aim of this dissertation is to lay the
foundation for a modeling platform to predict overall survival, progression-free survival,
and patient-specific responses to chemotherapy. A challenge associated with highthroughput molecular data is interpretation and analysis. Since there is no standard preprocessing pipeline for exploratory metabolomics studies, we propose recommendations
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during the pre-processing phase of analytical workflows based on data collected from
patients at the University of Louisville and Norton Hospital interventional radiology
departments.
We investigated the capability of tumor-tissue derived metabolomics data in
predicting individual response to chemotherapy utilizing both machine-learning
approaches and a mathematical model of tumor growth. Chapters 2-5 of this dissertation
focus on data-driven predictive modeling of therapy outcomes and survival using
statistical methods and machine learning. Chapters 6-10 of this dissertation involve
mathematical modeling studies which help build the foundation towards a modeling
platform for evaluating a variety of systemic therapies in silico.
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CHAPTER 21

DISCREPENCIES IN METABOLOMIC BIOMARKER IDENTIFICATION FROM
PATIENT-DERVIED LUNG CANCER REVEALED BY COMBINED VARIATION IN
DATA PRE-TREATMENT AND IMPUTATION METHODS

2.1 INTRODUCTION
Metabolomics has emerged as an important technique of biomarker discovery
[21], giving insight into the rate of chemical reactions occurring within cells and providing
a closer representation of phenotype compared to other omics technologies [22]. Yet the
identification of viable cancer metabolomic-derived biomarkers has proven frustratingly
elusive, and especially so in regard to lung cancer. Multiple studies have evaluated
biomarker candidates obtained from patient samples, including plasma, sputum, and
urine, with results struggling to provide a consistent set of potential clinical utility [23].
Even when accounting for differences expected due to tissue origins, biomarker
candidates often do not match across different studies.

Nuanced data analysis is a critical component of interpreting omics data [24].
Omics data sets are complex and specific, warranting the investigation of the most
appropriate method of analysis for particular experiments. Currently, there is no ‘gold
standard’ analytical pipeline for most omics fields [25]. This reduces the reproducibility of
omics studies, especially when studying disease states in human patients due to the
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large number of confounding variables. In particular, data pre-treatment is a necessary
step to normalize data before statistical analysis is performed [26], and is often underemphasized in metabolomics studies. Sample volume differences, different feature
abundances and heteroscedasticity can cause misinterpretations of biological data if an
inadequate pre-treatment method is selected [27]. Consequently, metabolomics studies
with human patients often reach different conclusions, limiting their clinical insight.
Possibly even worse, improperly planned experiments or statistical analyses can result
in false positives which can yield misleading conclusions. This is partially due to the lack
of comprehensive data analysis protocols, with many studies using different techniques.

Although metabolomics approaches are not as high-throughput as other omics
technologies such as genomics, metabolomics can generate large data sets that are
difficult or impossible to interpret without proper data analysis. As part of the
metabolomics standards initiative (MSI) [28], the minimum reporting standards for data
analysis in metabolomics was proposed in 2007 [29]. However, in 2017 a call for a
revision to the MSI was published, mentioning that the minimum reporting standards are
often not followed [30]. In a critical review of the reporting of metabolomics data analysis,
Considine et al. [24] found that the pretreatment phase was consistently the most
underreported step of the analytical pipeline in studies related to disease prediction from
serum metabolomics. For example, 89% of studies failed to mention missing values or
how they were handled [24]. Missing data reveals a potential for bias, depending on the
mechanism causing the missing data and the analytical methods applied [31]. Failure to
carefully plan missing value substitutions may cause large discrepancies during both
supervised and unsupervised analysis methods [32]. van den Berg et al. found that
different data pre-treatment methods (scaling, centering and transformations) greatly
affected the outcome of principal component analysis (PCA) in terms of score plot
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clustering and metabolite rankings based on loadings [33]. Gromski et al. [32] reported
that different methods of handling missing data had a significant impact on group
clustering in supervised and unsupervised analysis methods. The random forest (RF)
imputation technique and k-nearest neighbor (kNN) performed best in supervised
methods of principal component linear discriminant analysis (PC-LDA) and partial least
squares-discriminant analysis (PLS-DA), while mean and zero substitutions generally
performed the worst [32]. Different methods of scaling or transformations were not
considered, as only autoscaling was used. Sim et al. [34] found that the performance of
different imputation methods changed depending on the type of data set, which infers
that studies on imputation methods are only applicable to specific types of data sets.
Additionally, they found that different missing value characteristics affected imputation
methods to different degrees. For example, the ‘hot deck’ method was more accurate
than ‘group mean imputation’ between 16% and 24% missing values but became less
accurate in a non-linear fashion as the percentage of missing values increased.

Here, we evaluate discrepancies in metabolomic biomarker identification from
patient-derived lung cancer core biopsies. Patient response to chemotherapy
categorized based on the RECIST guideline [35] as well as disease stage were
evaluated. Due to the nature of human patient tissue collection and analysis, biological
replicates are sometimes not possible and sample volume cannot be controlled. Further,
mass spectrometry (MS) data sets typically contain approximately 10-20% missing
values [24, 32] for various technical or biological reasons. This is an issue because
statistical analysis techniques, including PCA and PLS-DA, typically require complete
data sets [36]. Unlike other studies exclusively focused on either data pre-treatment
methods or missing value substitutions [32-34, 37], the unique data set in this study
enables testing pre-treatment methods on a novel source of metabolomics data with true
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missing values, obtained from patient-derived tumor samples. We are therefore able to
systematically investigate how the combination of different data pre-treatment and
imputation methods changes the outcomes and biomarker selection from both
unsupervised (PCA) and supervised (PLS-DA) multivariate data analysis.

2.2 MATERIAL AND METHODS
2.2.1 Raw Data Processing
De-identified metabolomic data were previously obtained as part of a separate
lung cancer patient study [38]. In that study, after tissue homogenization and metabolite
extraction from patient tumor core biopsies, samples were randomly analyzed on a
Thermo Q Exactive HF Hybrid Quadrupole-Orbitrap Mass Spectrometer coupled with a
Thermo DIONEX UltiMate 3000 HPLC system (Thermo Fisher Scientific, Waltham, MA,
USA) equipped with a hydrophilic interaction chromatography (HILIC) column and a
reversed phase chromatography (RPC) column configured to create a parallel 2DLC-MS
system.[39]. For metabolite identification, one unlabeled sample in each group was
analyzed by 2DLC-MS/MS in positive mode (+) and negative mode (-) to acquire MS/MS
spectra at three collision energies (20, 40 and 60 eV). For 2DLC-MS data analysis,
XCMS software was used for spectrum deconvolution [40] and MetSign software was
used for metabolite identification, cross-sample peak list alignment, normalization, and
statistical analysis [41-43]. 2DLC-MS/MS data of unlabeled samples were first matched
to our in-house database that has parent ion m/z, MS/MS spectra, and retention time of
authentic standards (MSI Level 1 identification). Data without a match were analyzed
(MSI Level 2 identification) using Compound Discoverer software v2.0 (Thermo Fisher
Scientific, Inc., Germany).

2.2.2 Common metabolites
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A common set of metabolites was chosen among the 36 samples. If a metabolite
was detected in at least 31 samples, it was considered a “common” metabolite. A
threshold of 31 was chosen because with a higher threshold, some metabolites would
not have sufficiently detected occurrences to be imputed, while a lower threshold would
exclude some metabolites that could be imputed. This resulted in a set of 36 common
metabolites. MS data from positive and negative alignment tables were combined into a
single data set by choosing the data set (positive or negative) that contained the greater
number of occurrences among the 36 samples.

2.2.3 Software Packages
Data analysis methods were conducted in R version 4.0.2, while PCAtoTree
software [44] was used to quantify score plots. Following R packages were employed for
statistical analysis and data visualization: mice package version 3.9.0 for CART, RF, and
PMM imputation [45]; stats package in base R for PCA, using the prcomp function; VIM
version 6.1.0 package for kNN imputation; pcaMethods version 1.80.0 package for
BPCA and PPCA imputation; PLS-DA with mdatools version 0.11.2 package [46].

2.2.4 Pre-Treatment Methods for Data Normalization
A data frame was created to contain the raw data with the 36 samples as rows
and the 36 metabolite MS peak areas (intensities) as columns. Three general types of
pre-treatment methods were applied, with representative methods chosen from each
type. Details on the formulations of these methods along with their characteristics can be
found in van den Berg et al. [33]. Briefly, centering methods transform values to
fluctuations centered at zero instead of the mean of the values, adjusting for variation in
the offset between low and high values [47]. Scaling methods divide each variable by a
unique scaling factor, adjusting for variation in fold differences between values by
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converting the data into differences relative to this factor. One type of scaling methods
uses a size measure, e.g., the mean, as a factor (including level scaling [33]), while
another type uses a measure of the data dispersion, e.g., standard deviation (including
range scaling [48], vast scaling [49], autoscaling [50], and pareto scaling [51]). Lastly,
transformations are nonlinear conversions of the data that convert multiplicative relations
into additive relations and correct for heteroscedasticity [52]. Transformations typically
used with biological data include the log transform and the power transform (such as a
square root or arcsine transform). Tukey’s Ladder of Powers provides a means to
systematically scan across various power transformations [53], as does the slightly more
complex Box-Cox transform [54].

2.2.5 Imputation Methods to Handle Missing Values
The data set analyzed in this study contains a complex mixture of different types
of missing data. Based on Figure 2.1, some data appears to be missing not at random
(MNAR) while some is missing at random (MAR). It is clear that certain metabolites were
not detected in the control sample when certain batches of samples were analyzed, but
there are other instances of seemingly random missing values. Therefore, we could not
operate under the assumption that all missing values are either MNAR, MAR, or MCAR
(missing completely at random). However, the data set is likely representative of other
metabolomics data sets derived from human patient specimens, and thus provides a
real-world example of how different pre-treatment and imputation methods applied in this
study may affect the results of a statistical analysis.
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Figure 2.1. Original patient tumor core biopsy metabolomic data. MS peak areas
(intensities, black to white) of 36 analyzed samples of human lung cancer tissue. Red
cells indicate missing values. The data set contains approximately 10% missing values,
which is typical for MS data sets [24, 32].

Ten different methods of handling missing values were evaluated, as
summarized in Supplementary Table 1. The imputation methods were chosen to be
compatible with the data analysis methods (described further below). Since MS peak
areas are represented by continuous values, only methods appropriate for imputing
continuous data were evaluated. Perhaps the simplest method of dealing with missing
data (besides ignoring features with missing values) is to replace them with constants
[55]. Here, we focus on the zero, mean, median, and ½ minimum (half-min) constant
substitution methods, which simply replace all missing values with zero, the mean, the
10

median, or half the minimum value of each feature, respectively. We also considered
more sophisticated methods of imputation (described in Supplementary Materials)
such as multiple imputation by chained equations (MICE), including: predictive mean
matching (PMM), random forest (RF) and classification and regression trees (CART).
These multiple imputation methods were performed with the R package mice and
seeded with a value of ‘1234’ to allow for reproducibility. k nearest neighbor (kNN)
imputation was performed with the VIM package with number of nearest neighbors set to
10 and the weights for the variables for the distance calculation based on variable
importance from random forest regression. Bayesian principal component analysis
imputation (BPCA) and probabilistic principal component analysis (PPCA) were
performed with the pcaMethods package seeded with a value of ‘1234’ to allow for
reproducibility. “maxSteps” was set to 10 for BPCA and “maxIterations” was set to 1000
for PPCA.

2.2.6 Data Analysis Methods
Two commonly used multivariate statistical analysis methods were chosen to
quantitatively evaluate the variation in the pretreatment and imputation methods.

2.2.6.1 Principal Component Analysis
PCA is useful for visualization and feature extraction and is commonly used as a
first step in the analytical pipeline to check for clustering, separation, and outliers among
groups of samples [56]. Although a variety of unsupervised analysis techniques exist, we
chose PCA due to its ability to reduce the dimensionality of the feature space with
minimal information loss. This is convenient considering that metabolomics data sets
often involve a large number of predictor variables. PCA relies on an eigenvector
decomposition of the covariance matrix of 𝐗, cov(𝐗) = 𝐗 𝑇 𝐗/𝑛 − 1, where 𝐗 (𝑛 x 𝑁) is the
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data matrix containing samples and features. If only the first 𝐴 (𝐴 < 𝑁) dimension of
scores is needed, PCA decomposes 𝐗 into the sum of the outer products of score
vectors 𝐭 𝑖 and loadings vectors 𝐩𝑖 plus a residual matrix 𝐄 [57]:
𝐗 = 𝐭1 𝐩1𝑇 + 𝐭 2 𝐩𝑇2 + ⋯ + 𝐭𝐴 𝐩𝑇𝐴 + 𝐄 = 𝐓𝐏 𝑇 + 𝐄

[Equation 2.1]

The contribution of individual features in each principal component dimension is
accounted for by the loading vectors 𝒑𝑖 obtained from the eigenvectors of the covariance
of 𝐗 [58].

2.2.6.2 Partial Least-Squares Discriminant Analysis
Partial least squares-discriminant analysis (PLS-DA) was used to generate
predictive models and rank the metabolites by the variable importance in the projection
(VIP score). The major advantage of a supervised method such as PLS-DA over PCA is
that the dependent ‘response’ variable is taken into consideration along with the
independent ‘predictor’ variables during the matrix decomposition. PLS seeks to find a
set of latent features that maximizes the covariance between 𝐗 (𝑛 x 𝑁) and 𝐘 (𝑛 x 𝑀),
where 𝐗 and 𝐘 are the independent variables and dependent variables, respectively [57].
Similar to PCA, it is used to produce a low-dimensional representation of a data set. It is
able to handle situations where multicollinearity is present and when the number of
predictor variables is larger than the number of observations [59].

2.2.7 Model validation and performance
A bootstrapping procedure was performed on PCA to obtain stable metabolite
loadings which were used to rank metabolites. Briefly, bootstrapping involves resampling
a data set with replacement n number of times and calculating the desired statistic on
the resampled data sets. This allows for the calculation of confidence intervals and
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statistics of interest can be averaged across all resampled data sets to simulate having a
larger data set [60]. 10,000 iterations of bootstrapping were applied to every working
data set, after which the loadings of every metabolite were averaged.

For PLS-DA, internal model validation was achieved with 5-fold cross-validation,
performed with 100 iterations of random subsampling. Although bootstrapping is often
touted as a superior method to cross validation [61, 62], the small sample size in this
study (n = 23 with chemotherapy response data) does not warrant the use of
bootstrapping for PLS-DA. Small sample sizes may result in large differences between
results after multiple bootstrap resampling, depending on how the samples are split into
training and test sets.

2.2.8 Quantifying group separation in PCA and PLS-DA score plots
Score plots generated from PCA and PLS-DA are useful visual tools for
inspecting separation between sample classifications. However, quantitatively
interpreting subtle differences between score plots is often difficult. We chose to quantify
the score plots with the J2 criterion [63] and by finding p-values of the overlap between
groups by using the PCAtoTree software developed by Worley et. al. [44]. The J2
criterion is used to measure how tightly clustered groups of samples are, and is defined
as follows [63]:

𝐽2 =

|𝑆𝑤 +𝑆𝑏 |

[Equation 2.2]

|𝑆𝑤 |

where 𝑆𝑤 is the within-class scatter and 𝑆𝑏 is the between-class scatter. Briefly, p-values
are determined by the Mahalanobis distance metric, Hotelling’s T2 statistic and an F
distribution [63], with the null hypothesis: points in groups i and j are drawn from the
same multivariate normal distribution. Text files of the scores on the first two principal
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components for all pre-treatment and imputation methods for both PCA and PLS-DA
were used as inputs for the PCAtoTree software.

2.2.9 Patient sample categorizations
To evaluate the results in terms of potential biomarkers predictive of response to
therapy and of disease stage, three patient sample categorizations were analyzed:
disease control (DC) vs. progressive disease (PD); complete response (CR) and partial
response (PR) vs. stable disease (SD) and PD; cancer stage I/II/III vs. stage IV.

2.3 RESULTS
2.3.1 Experimental workflow
The workflow diagram is outlined in Supplementary Figure 2.1. Data pretreatment methods were applied to the MS peak areas, and then imputation methods
were applied to handle missing values. These pre-treated and imputed data sets
represent the working data. The working data sets were then analyzed by unsupervised
(PCA) and supervised (PLS-DA) analyses. Model validation was achieved by
bootstrapping PCA with 10,000 iterations for finding PCA loadings, and a 5-fold cross
validation with 100 permutations with PLS-DA. Results of the analyses were found by
quantification of score plots and identification of key metabolites for every working data
set.

2.3.2 Effect of pre-treatment on data
The effects of pre-treatment methods on the original data set are evident in
Figure 2.2, where the average peak areas among all samples for each metabolite in the
data set are shown for a representative case for which zero imputation was applied to
the data. In the raw data (Figure 2.2A), some metabolites stand out with large values
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and dwarf most of the other peaks. Scaling methods, such as autoscaling (Figure 2.2C)
and the log transformation (Figure 2.2H) clearly reduce the spread between the largest
and smallest magnitudes of metabolite peak areas. Additionally, the data patterns
change with different methods. For example, autoscaling, pareto scaling and range
scaling (Figure 2.2C, 2.2D, 2.2E) leave several large peaks while the log transformation
(Figure 2.2H) reduces these large peaks to a scale more similar to the other peaks.
Altogether, these results highlight the potential effects that data pre-treatment methods
may have on results further down the analytical pipeline.
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Figure 2.2. Effect of pre-treatment methods and zero imputation on original data
set. Peak areas were averaged among all 36 samples for each metabolite (x-axis). The
following pre-treatment methods were applied: (A) Raw data, (B) Centering, (C)
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Autoscaling, (D) Pareto scaling, (E) Range scaling, (F) Vast scaling, (G) Level scaling,
(H) Log transform, (I) Square root transform.

2.3.3 Effect of combined pre-treatment and imputation on PCA scores
The performance of different pre-treatment and imputation methods was first
evaluated by clustering and separation of samples in the respective score plots, where
samples are expected to be clustered within their respective groups and each group
separated from one another. Representative PCA score plots are shown in Figure 2.3.
In all score plots, the first two components were used as the x and y-axes. The pretreatment and imputation combinations of vast scaling/CART (Figure 2.3A) and pareto
scaling/RF (Figure 2.3C) achieved a statistically significant separation between the DC
and PD groups, while level scaling/CART (Figure 2.3B) and range scaling/RF (Figure
2.3D) did not. These results highlight the fact that different scaling methods may offer
varying performance for group separation in PCA score plots when paired with certain
imputation methods. Quantification of the plots for the top 20 performing pre-treatment
and imputation methods is shown in Supplementary Table 2.2A. Pareto scaled data
with zero substitution performed best at separating the two groups (p = 0.028). The zero,
half-min, and BPCA imputations occurred more often in the top 20 performing methods.
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Figure 2.3. Effect of pre-treatment and imputation methods on PCA scores.
Representative PCA score plots of all 36 samples in the data set. The following pretreatment methods and imputation methods were applied: (A) Vast scaling and CART
imputation, (B) Level scaling and CART imputation, (C) Pareto scaling and RF
imputation, (D) Range scaling and RF imputation. Panels A and C achieved a
statistically significant separation between the disease control (DC) and progressive
disease (PD) groups (p ≤ 0.05), while panels B and D did not reach significance. N/A:
not applicable (sample was not used for patient categorization in our dataset).

Effect of pre-treatment and imputation for the other sample categorizations
(CR/PR vs. SD/PD and stage I/II/III vs. IV) are in Supplementary Materials. Note that
the score plots do not change with different sample categorizations, since the dependent
response variable is not taken into consideration during PCA. However, overlap p-values
and J2 values are expected to be different.
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2.3.4 Effect of combined pre-treatment and imputation on PCA loadings
Representative PCA loadings are shown for half-min substitution and PPCA
imputation in Figure 2.4A, 2.4C. The log transformation clearly reduced the variance
between metabolite loadings compared to vast scaling. The rankings of metabolites
based on PCA loadings (Figure 2.4B, 2.4D) changed considerably between the two pretreatment methods and between the two imputation methods. Vast scaling resulted in
isoleucine being ranked as the top metabolite with both half-min substitution and PPCA
imputation, while the log transformation ranked phenylalanine highest with half-min
substitution and choline highest with PPCA imputation. On the other hand, N3,N4dimethyl-L-arginine was ranked consistently as the 7th most important metabolite by the
log transformation but with vast scaling was ranked 10th with half-min substitution and
14th with PPCA imputation. Additionally, lactate consistently ranked 3rd with both pretreatment methods and both imputation methods. Since the dependent response
variable is not taken into consideration during PCA, the PCA loadings will not change
with the other sample categorizations (CR/PR vs. SD/PD or stage I/II/III vs. stage IV).
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Figure 2.4. Effect of pre-treatment and imputation methods on PCA loadings and
metabolite ranks. (A,B) Half-min substitution and (C,D) PPCA imputation of missing
values was applied after pre-treatment (vast scaled or log transformation).

2.3.5 Effect of combined pre-treatment and imputation on PLS-DA score plots
The performance of different pre-treatment and imputation methods was further
investigated by clustering and separation of samples in PLS-DA score plots. In all score
plots, the first two components were used as the x and y-axes. Representative PLS-DA
score plots for DC vs. PD patient categorization are shown in Figure 2.5. The pretreatment and imputation combinations of log transformation/RF (Figure 2.5A) and vast
scaling/PMM (Figure 2.5C) achieved a statistically significant separation between the
DC and PD groups, while level scaling/RF imputation (Figure 2.5B) and pareto
scaling/PMM (Figure 2.5D) did not. Quantification of PLS-DA score plots for the top 20
performing pre-treatment and imputation methods is shown in Supplementary Table
2.2B. Log transformed data with median substitution performed best at separating the
two groups (p = 0.0000). Overall, the pre-treatment methods of log transformation and
vast scaling and the substitution methods of median and mean outperformed most other
methods for separating groups in score plots. The log transformed data in general had
higher J2 values for the PD group compared to other pre-treatment methods, meaning
that the PD groups were clustered more tightly.
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Figure 2.5. Effect of pre-treatment and imputation methods on PLS-DA scores.
Representative PLS-DA score plots of 23 samples with chemotherapy response data
categorized as disease control (DC) vs. progressive disease (PD). The following pretreatment methods and imputation methods were applied: (A) Log transformation and
RF imputation, (B) Level scaling and RF imputation, (C) Vast scaling and PMM
imputation, (D) Pareto scaling and PMM imputation. Panels A and C achieved a
statistically significant separation between the DC and PD groups (p ≤ 0.05), while
panels B and D did not reach significance.

2.3.6 Effect of combined pre-treatment and imputation on PLS-DA accuracy and
variable importance measures
PLS-DA misclassification rates for the top 20 performing pre-treatment and
imputation methods are shown in Supplementary Table 2.5, where the best
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misclassification rate was 13% across five different combinations of methods. The log
transformation performed well regarding classification accuracy. When paired with the
imputation methods of PMM, mean, median, and zero, the log transformation achieved a
misclassification rate of 17.4%, the second-best possible misclassification rate for this
particular data set (data not shown). There was little consistency in which imputation
methods resulted in the best misclassification rates, but generally the square root
transform outperformed other pre-treatment methods.

Representative PLS-DA VIP scores are shown for kNN and BPCA imputation in
Figure 2.6A, 2.6C. A pronounced difference between the VIP score pattern for level
scaling after kNN or BPCA imputation is evident, while the log transform seemed to
maintain the relative patterns after the imputation. Metabolite rankings based on VIP
scores show clear differences between both the pre-treatment methods and imputation
methods (Figure 2.6B, 2.6D). A pronounced difference between the two imputation
methods is the presence of choline in the top ten most important metabolites with BPCA
but not with kNN. This indicates that BPCA is likely replacing missing values for choline
in a manner that increases the variance between samples. In contrast, metabolites such
as glutamic acid and phenylalanine were ranked the same between the imputation
methods with level scaling but changed rank with log transformation.
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Analyses of PLS-DA with respect to CR/PR vs. SD/PD and stage I/II/III vs. IV sample
categorizations are in the Supplementary Materials.

Figure 2.6. Effect of pre-treatment and imputation methods on PLS-DA VIP scores
and metabolite ranks. (A,B) kNN imputation and (C,D) BPCA imputation of missing
values applied after pre-treatment (level scaling or log transformation) using samples
with chemotherapy response data categorized as disease control (DC) vs. progressive
disease (PD).

2.4 DISCUSSION
This study evaluated variations in potential metabolomic biomarkers caused by
the combined choice of data pre-treatment and imputation methods applied to
metabolomics data. We used a metabolomics data set generated from human derived
lung cancer tissue specimens that contained a complex mixture of true missing values to
capture errors commonly seen in applied metabolomics. The results demonstrate that
changes made to a metabolomics data set by pre-treatment and imputation methods can
have downstream effects on the data analysis. These effects can potentially lead to
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misinterpretations of results and difficulty with replicating metabolomics studies in
general.

According to Rubin et al., there are three ways to classify missing data [64]:
MCAR, MAR, and MNAR. Specifically for MS data, there are various potential causes of
missing data, including biological and technical origins, such as: sample heterogeneity
resulting in metabolites being below the MS detection limit, an inability of the
deconvolution software to separate peaks, or a temporary reduction in performance in
electrospray due to particulate material in the spray nozzle [65, 66]. According to
Jakobsen et al. [67], multiple imputation is appropriate when missing values represent
between 5% and 40% of the data set and the MCAR or MNAR assumptions are
plausible. In our data set, we can safely assume that both of these types of missing data
are present based on the distribution of missing values seen in the original data set
(Figure 2.1). For example, missing values for taurine in samples 15-25 (Figure 2.1)
were most likely caused by taurine not being detected in the quality control sample for
that particular analytical batch, making missing values for taurine MNAR. Additionally,
since taurine is known to be one of the most abundant free amino acids in mammalian
tissues [68], it is unlikely that the missing values were MAR or MCAR. Missing values for
pyruvate, on the other hand, are most likely MAR or MCAR since there is no apparent
pattern to the distribution of missing values. There are a number of metabolomics data
analysis tools which include methods to deal with missing values such as: XCMS [69],
MeltDB [70], and MetaboAnalyst [71]. For example, the web tool MetaboAnalyst
provides a total of 12 modules for exploratory statistical analysis, functional enrichment
analysis, data integration and system biology, and data processing utility functions tools
designed for metabolomics data. However, since it has limited options for data pretreatment and missing value imputation, it may lead to choosing sub-optimal methods.
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The default method of handling missing data in MetaboAnalyst version 4.0 is the halfmin substitution method, which studies have shown to be an inferior method [72],
especially when missing values are not necessarily caused by low abundance
metabolites.

The effects of data pre-treatment on the original data are shown in Figure 2.2.
Peak patterns across all metabolites have the potential to change dramatically with
different pre-treatment types, indicating that the results of any imputation or analysis
method applied further down the pipeline could be influenced by the choice of pretreatment method. We utilized PCA and PLS-DA as representative examples of
unsupervised and supervised analyses, respectively, after applying various pretreatment and imputation methods to the original data. Vast, level, pareto and range
scaling produced different distributions of samples in the PCA score plots (Figure 2.3).
For example, although CART imputation achieved significance for separating the DC
and PD groups after vast scaling, CART failed to achieve significant separation after
level scaling. A similar trend can be observed with PLS-DA in Figure 2.5, where RF
imputation achieved a significant separation after log transformation, but failed after level
scaling, while PMM imputation achieved a significant separation after vast scaling but
failed after pareto scaling. These results indicate that the performance of an imputation
method may change depending on the pre-treatment method used. We also investigated
how changing the binary response categorization of the samples could affect the results
of the PCA and PLS-DA analyses. There is little consistency for which imputation
methods performed best for separating groups between the different response
categorizations (Supplementary Tables 2.2, 2.3, 2.4). However, certain pre-treatment
methods such as log transformation and vast scaling generally performed better than
other methods at separating groups in PLS-DA (Supplementary Tables 2.2B, 2.3B,
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2.4B). An important aspect of metabolomics studies is the identification of small
molecule biomarkers for disease diagnosis and prognosis. Here, we show that ranking
metabolites based on importance with either PCA loadings or PLS-DA VIP scores can
vary considerably depending on the pre-treatment and imputation methods applied
(Figure 2.4B, 2.4D, Figure 2.6B, 2.6D, Supplementary Figure 2.3B, 2.2D,
Supplementary Figure 2.5B, 2.4D). From these results it is apparent that
extemporaneous data pre-treatment and imputation could result in important biomarkers
either being overlooked or reported as a false positive.

To our knowledge, this is the first study that has evaluated the effects of both
pre-treatment and imputation methods on the interpretation of unsupervised and
supervised analyses of human metabolomics data. One limitation is that conclusive
performance metrics of pre-treatment and imputation methods cannot be obtained from
using a data set with true missing values. However, we were able to show that there is a
complex relationship between pre-treatment methods, imputation methods, and sample
categorizations depending on the methods used. A potential pitfall of applying a
“shotgun” approach with pre-treatment and imputation methods is the tendency to
choose biased results based on score plot group separation and misclassification rate
(i.e., AUROC) of the supervised learning method. It is important to note that better group
separations and misclassification rates do not necessarily reflect that the data is being
represented more accurately. It is possible that inaccurate imputation methods could
result in better group separation, which the results here demonstrate. For instance, the
substitution methods of zero, mean and median imputation have previously been shown
to have poor performance for estimating missing values [72]. However, these
substitution methods along with the half-min substitution were shown to outperform other
methods such as RF, kNN, and PPCA for separating groups and achieving higher
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classification accuracy within the same pre-treatment method. Therefore, it would be
valuable to perform internal testing by using subsets of original data that only contain
complete cases and introducing simulated missing values to evaluate the accuracy of
imputation methods before performing statistical analyses on the working data set, as
has been previously suggested [34, 72].

Additionally, the accuracy of imputation methods will likely be affected by data
pre-treatment. Previously, both Gromski et al. and Kokla et al. have shown that the RF
method of imputation produced the most accurate results when imputing metabolomics
data [32, 73]. The RF method achieved the best classification rates using principal
component-linear discriminant analysis (PC-LDA) and PLS-DA using cell culture data
with groups based on incubator oxygen concentration [32]. The RF method performed
best at replacing missing values in complete data sets that had values removed to
simulate missing data [73]. Vast scaling and autoscaling were shown to be stable pretreatment methods in a study using four different classification models on representative
GC-TOF MS and NMR metabolomics data sets [74]. However, [74] used complete data
sets and classification accuracy was the sole performance metric. The average
classification accuracy of the GC-TOF MS Arabidopsis thaliana data using a log
transformation did not differ considerably compared to the other methods but resulted in
smaller confidence intervals during resampling for all four methods tested. Overall, in our
study the log transformation appeared to normalize the original data most effectively and
resulted in the highest classification accuracies in the stage I/II/III vs. stage IV
classification, while the square root transformation also consistently performed well and
represented three of the top five performing models in the DC vs. PD classification.
However, the performance of the imputation methods applied after the transformation
was highly dependent on the characteristics of the data set. The results indicate that log
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transformation and square root transformation could be recommended as starting points
for analyzing human metabolomics data. Based on [74], vast scaling and autoscaling
could be further options if a log transformation or square root transformation proves
unsatisfactory. The combined choice of pre-treatment and imputation methods,
therefore, needs to be carefully evaluated prior to metabolomic data analysis from
human tumors. This approach would enable a more consistent identification of potential
biomarkers predictive of response to therapy and of disease stage, and thus advance
the clinical utility of biomarker discovery, especially in regard to lung cancer.

2.5 SUPPLEMENTARY MATERIALS
2.5.1 Data imputation methods (additional description)
2.5.1 Predictive mean matching
Predictive mean matching (PMM) is an example of a “hot deck” method, where
missing values are imputed using values from the complete cases matched in similarity
with respect to some metric [75, 76]. PMM fills each missing entry with the observed
values from randomly drawn donors from a small set of candidate donors. The sets of
candidate donors are formed from complete cases which have predicted values closest
to the predicted values of the missing entries. It is versatile and fairly robust to
transformations [75]. The major potential pitfalls of PMM are small sample sizes and
large unbalanced regions of missing values within the data set [75]. PMM is an adequate
all-around method and is the default method of the R package mice for continuous data.

2.5.2 k-Nearest Neighbor
Another example of a “hot deck” method, nearest neighbor (NN) methods are
similarity based, borrowing information from other areas in the data set and relying on
distance metrics [77]. Versions of NN which use several neighbors (instead of 1) to
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generate predicted values are referred to k nearest neighbor (kNN) methods. Beretta et
al. [77] found that a value of k = 3 is a reasonable choice, but was unable to provide a
method to determine the optimal number of neighbors to select. In general, it seems that
low values of k (greater than 1) are preferable, since as k approaches the number of
neighbors, the method converges to ordinary mean imputation [78]. kNN predicts
missing values by averaging the non-missing values of its neighbors [77]. Similar to
PMM, kNN is weak when a missing value is surrounded by other missing values.
However, kNN can deal with data sets that contain a large number of variables with
missing values [79].

2.5.3 Classification and regression trees
Classification and regression trees (CART) are a class of machine learning
algorithms which seek predictors and cut points in the predictors that split the sample
into more homogenous subsamples [75]. CART methods are robust against outliers and
handle non-linear data well [75]. Similar to PMM, CART randomly draws a case from the
donor group and takes its observation as the imputed value, but values are predicted by
a tree model rather than a regression model. CART tends to overfit by following patterns
of noise too closely, resulting in poor predictive power in a validation set [80].

2.5.4 Random forest
Random forest (RF) methods, an extension of classification and regression trees,
are able to overcome the drawbacks associated with single decision trees while
maintaining the benefits [81]. RF uses bootstrap aggregation (bagging) of multiple
regression trees, which reduces the risk of overfitting normally observed with CART [80].
RF is an attractive option in that it addresses non-linearity, avoids overfitting when
scaling to high dimensions, and can yield measures of variable selection [36]. A potential
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pitfall of RF includes an inability to predict values beyond the highest and lowest values
in the training data, meaning it is important that the training data cover the entire range
of response data values [81]. Also, RF tends to overestimate low values and
underestimate high values.

2.5.5 Probabilistic and Bayesian principal component analysis
Principal component analysis (PCA) based methods for imputation are
considered efficient and reliable. Probabilistic PCA (PPCA), originally proposed by
Tipping et al. [82], is capable of handling data sets with missing values. PPCA uses the
Expectation-Maximization (EM) algorithm to find the Maximum Likelihood Estimates
(MLE) for data sets with missing values [82]. A recent study by Hegde et al. [83] found
that PPCA outperformed MICE for replacing missing values in a data set comprised of
demographic, medical and dental variables for patients diagnosed with diabetes mellitus;
it is important to note that the missing values were simulated as MCAR at a proportion of
30%. A potential pitfall of PPCA includes the assumption that the factor scores obey a
normal distribution. Similar to PPCA, Bayesian principal component analysis (BPCA) is
based on principal component regression and an EM algorithm. However, BPCA uses a
Bayesian estimation rather than MLE [84].

2.5.2 Effect of pre-treatment and imputation on PCA: CR/PR vs. SD/PD
Quantification of PCA score plots for the top 20 performing pre-treatment and
imputation methods is shown in Supplementary Table 2.3A for the CR/PR vs. SD/PD
sample categorization. Centered data with BPCA imputation performed best at
separating the two groups (p = 0.017). The, BPCA, PPCA, and median imputations
occurred more often.
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2.5.3 Effect of pre-treatment and imputation on PCA: Stage I/II/III vs. IV
Quantification of PCA score plots for the top 20 performing pre-treatment and
imputation methods is shown in Supplementary Table 2.4A for the stage I/II/III vs.
stage IV sample categorization. Square root transformed data with PPCA imputation
ranked best at separating the two groups (p = 0.279). The half-min, BPCA, and zero
substitution occurred more often.

2.5.4 Effect of pre-treatment and imputation on PLS-DA: CR/PR vs. SD/PD
The performance of different pre-treatment and imputation methods was further
investigated by clustering and separation of samples in PLS-DA complete
response/partial response (CR/PR) vs. stable disease/progressive disease (SD/PD)
score plots. In all score plots, the first two components were used as the x and y-axes.
Representative score plots are shown in Supplementary Figure 2.2. The pre-treatment
and imputation combinations of autoscaling/CART and range scaling/median substitution
achieved a statistically significant separation between the CR/PR and SD/PD groups
(Supplementary Figure 2.2A, 2.1C) while pareto scaling/CART and pareto
scaling/median substitution did not (Supplementary Figure 2.2B, 2.1D). Quantification
of PLS-DA score plots for the top 20 performing pre-treatment and imputation methods
is shown in Supplementary Table 2.3B. Range scaled data with median substitution
performed best at separating the CR/PR and SD/PD groups (p = 0.0009). Log
transformation and range scaling outperformed most other pre-treatment methods, while
the median and mean substitution methods worked best overall. PLS-DA
misclassification rates for the top 20 performing pre-treatment and imputation methods
are shown in Supplementary Table 2.6. Although there was little consistency for which
pre-treatment and imputation methods resulted in better rates, the log transformation
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generally resulted in a larger percentage of the variance being explained by fewer
components.

Representative VIP scores are shown for RF and PPCA imputation in
Supplementary Figure 2.3A, 2.3C. There were large differences in the VIP scores of
certain metabolites between level scaling and square root transformation with these
imputation methods. Metabolites 14 and 15 had the highest VIP scores with level scaling
and RF imputation, while metabolites 7 and 8 had the highest VIP scores with square
root transformation and RF imputation. A similar trend can be observed with PPCA
imputation, where the VIP score of metabolite 15 drops considerably between level
scaling and square root transformation.

Metabolite rankings based on VIP scores are shown in Supplementary Figure
2.3B, 2.3D. Creatine was ranked as the top metabolite for RF imputation, while choline
was the top metabolite PPCA imputation. Some metabolites stand out as having very
different ranks between pre-treatment methods, such as isoleucine ranked 2nd with level
scaling vs. 14th with square root when RF imputation was applied, and phenylalanine
ranking 20th with level scaling and 4th with square root when PPCA imputation as done.
Whereas some metabolites ranked high regardless of pre-treatment and imputation
(such as choline and creatine), the ranking of others was severely affected (such as urea
and taurine).

2.5.5 Effect of pre-treatment and imputation on PLS-DA: Stage I/II/III vs. IV
The performance of different pre-treatment and imputation methods were further
investigated by clustering and separation of samples in PLS-DA (stage I/II/II vs. stage
IV) score plots. In all plots, the first two components were used as the x and y-axes.
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Representative score plots are shown in Supplementary Figure 2.4. The pre-treatment
and imputation combinations of log transformation/zero substitution and range
scaling/BPCA achieved a statistically significant separation between the stage I/II/II vs.
stage IV groups (Supplementary Figure 2.4A, 2.4C) while centering/zero substitution
and raw data/BPCA did not (Supplementary Figure 2.4B, 2.4D). Quantification of PLSDA score plots for the top 20 performing pre-treatment and imputation methods are
shown in Supplementary Table 2.4B. Log transformed data with CART imputation
performed best at separating the two groups (p = 0.0000). Interestingly, the log
transform performed best regardless of imputation method. PLS-DA misclassification
rates for the top 20 performing pre-treatment and imputation methods are shown in
Supplementary Table 2.7. The two best misclassification rates of 17.6% and 23.5%
were achieved with a log transformation paired with CART and kNN imputation,
respectively.

Representative VIP scores are shown for mean substitution and BPCA
imputation in Supplementary Figure 2.5A, 2.5C. There were large differences in the
VIP scores of certain metabolites based on centering and autoscaling pre-treatments.
Metabolites 7, 25, and 26 had the highest scores with centering and mean substitution,
while metabolites 14 and 30 had the highest VIP scores with autoscaling and mean
substitution. While the same trend is present with centering and BPCA imputation as
with centering and mean substitution, applying autoscaling with BPCA increased the VIP
score of metabolite 7 dramatically compared to mean substitution and BPCA. Metabolite
rankings based on VIP scores are shown in Supplementary Figure 2.5B, 2.5D.
Methionine ranked as the top metabolite with mean substitution while choline ranked as
the top metabolite with BPCA imputation. Certain metabolites showed ranking instability
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across combinations of pre-treatment and imputation methods, such as proline with
mean substitution and isoleucine with BPCA imputation. Interestingly, lactate and
methionine remained stable with autoscaling across both imputation methods. In
contrast, the rank of choline increased from 10th place with autoscaling and mean
substitution to 1st with autoscaling and BPCA imputation.

Supplementary Figure 2.1. Workflow diagram highlighting data analysis steps in this
study.

34

Supplementary Figure 2.2. Effect of pre-treatment and imputation methods on
PLS-DA scores (CR/PR vs. SD/PD). Representative PLS-DA score plots of 23 samples
with chemotherapy response data categorized as complete response/partial response
(CR/PR) vs. stable disease/progressive disease (SD/PD). The following pre-treatment
methods and imputation methods were applied: (A) Autoscaling and CART imputation,
(B) Pareto scaling and CART imputation, (C) Range scaling and median substitution, (D)
Pareto scaling and median substitution. Panels A and C achieved a statistically
significant separation between the CR/PR and SD/PD groups (p ≤ 0.05), while panels B
and D did not reach significance.
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Supplementary Figure 2.3. Effect of pre-treatment and imputation methods on VIP
scores and metabolite ranks. (A,B) RF imputation and (C,D) PPCA imputation of
missing values applied after pre-treatment (level scaling or square root transformation)
using samples with chemotherapy response data categorized as CR/PR vs. SD/PD.
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Supplementary Figure 2.4. Effect of pre-treatment and imputation methods on
PLS-DA scores (stage I/II/II vs. stage IV). Representative PLS-DA score plots of 23
samples with chemotherapy response data categorized as stage I/II/II vs. stage IV. The
following pre-treatment methods and imputation methods were applied: (A) Log
transformation and zero substitution, (B) Centering and zero substitution, (C) Range
scaling and BPCA imputation, (D) Raw data and BPCA imputation. Panels A and C
achieved a statistically significant separation between the stage I/II/II and stage IV
groups (p ≤ 0.05), while panels B and D did not reach significance.
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Supplementary Figure 2.5. Effect of pre-treatment and imputation methods on VIP
scores and metabolite ranks. (A,B) Mean substitution and (C,D) BPCA imputation of
missing values applied after pre-treatment (centering or autoscaling) using samples with
chemotherapy response data categorized as stage I/II/III vs. stage IV.
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Processing Step

DATA
NORMALIZATION
(Pre-Treatment)

HANDLE MISSING
VALUES
(Imputation)

DATA ANALYSIS

Method:

Application:

Reference

CENTERING

Implemented in R

[33]

AUTOSCALING

Implemented in R

[33]

PARETO SCALING

Implemented in R

[33]

RANGE SCALING

Implemented in R

[33]

VAST SCALING

Implemented in R

[33]

LEVEL SCALING

Implemented in R

[33]

LOG TRANSFORMATION

Implemented in R

[33]

SQUARE ROOT
TRANSFORMATION

Implemented in R

[33]

ZERO

Implemented in R

[55]

HALF-MIN

Implemented in R

[55]

MEDIAN

Implemented in R

[55]

MEAN

Implemented in R

[55]

kNN
(k-nearest neighbor)

R package: VIM

[77]

CART
(classification and regression
trees)

R package: mice

[45]

RF
(random forest)

R package: mice

[45]

PMM
(predictive mean matching)

R package: mice

[45]

BPCA
(Bayesian principal component
analysis)

R package:
pcaMethods

[84]

PPCA
(probabilistic principal
component analysis)

R package:
pcaMethods

[82]

PCA
(principal component analysis)

R package: stats
(base R)

[56]

PLS-DA
(partial least squaresdiscriminant analysis)

R package:
mdatools

[57]

PCAtoTree software

C source code
compiled and
executed on
Windows 10

[44]

Supplementary Table 2.1. Description of pre-treatment, imputation, and data
analysis methods used in this study. These methods were applied to test the
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potential differences in results found in studies using metabolomics data derived from
human tissue specimens.
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A PCA
Overlap p-value

J 2 (DC)

J 2 (PD)

PRE-TREATMENT

IMPUTATION

0.028
0.031
0.031
0.037
0.040
0.040
0.043
0.046
0.048
0.049
0.057
0.063
0.064
0.065
0.068
0.070
0.076
0.077
0.078
0.090

1.38
1.12
1.37
1.37
1.43
1.35
1.44
1.39
1.06
1.80
1.26
1.25
1.15
1.09
1.68
1.09
1.08
1.05
1.08
1.03

1.88
10.57
1.82
1.66
0.74
1.87
0.72
1.75
10.13
0.36
2.19
2.07
2.70
2.48
0.34
6.81
6.73
3.81
2.24
3.20

paretoscaled
raw
paretoscaled
paretoscaled
vastscaled
square root transform
vastscaled
square root transform
centered
vastscaled
log transform
log transform
square root transform
vastscaled
vastscaled
raw
raw
paretoscaled
vastscaled
vastscaled

ZERO
BPCA
HALF-MIN
RF
RF
ZERO
CART
HALF-MIN
BPCA
MEAN
MEDIAN
MEAN
BPCA
ZERO
MEDIAN
ZERO
HALF-MIN
BPCA
HALF-MIN
BPCA

B PLS-DA
Overlap p-value

J 2 (DC)

J 2 (PD)

PRE-TREATMENT

IMPUTATION

0.00000
0.00001
0.00001
0.00001
0.00001
0.00002
0.00003
0.00003
0.00003
0.00003
0.00003
0.00004
0.00004
0.00005
0.00005
0.00005
0.00006
0.00007
0.00007
0.00008

3.27
3.15
3.39
5.03
3.49
2.88
2.56
3.24
3.17
2.61
3.18
2.72
3.11
1.97
2.52
2.10
3.15
2.54
2.07
2.00

4.84
6.04
13.33
1.44
3.66
4.49
5.75
3.06
3.09
3.64
3.25
3.30
2.88
74.19
3.57
21.65
3.73
4.50
10.30
41.26

log transform
log transform
log transform
vastscaled
autoscaled
vastscaled
vastscaled
vastscaled
vastscaled
autoscaled
rangescaled
log transform
rangescaled
log transform
autoscaled
autoscaled
vastscaled
vastscaled
log transform
log transform

MEDIAN
MEAN
RF
PMM
RF
ZERO
HALF-MIN
MEAN
MEDIAN
MEAN
MEAN
PMM
MEDIAN
ZERO
MEDIAN
PMM
RF
CART
KNN
HALF-MIN
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Supplementary Table 2.2. Quantification of PCA and PLSDA score plots (DC vs.
PD). Overlap p-values and J2 values for disease control (DC) vs. progressive disease
(PD) groups are shown for the top 20 performing pre-treatment and imputation methods
for (A) PCA and (B) PLS-DA score plots.
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A PCA
Overlap p-value

J 2 (CR/PR)

J 2 (SD/PD)

PRE-TREATMENT

IMPUTATION

0.017
0.018
0.018
0.020
0.023
0.025
0.031
0.032
0.039
0.047
0.048
0.049
0.052
0.055
0.057
0.060
0.060
0.060
0.062
0.062

14.28
6.29
6.29
4.90
3.71
9.60
10.33
7.19
8.83
3.99
5.90
7.31
7.76
1.19
1.26
37.19
1.63
5.16
30.80
0.97

0.61
0.63
0.72
0.68
0.98
0.60
0.52
0.59
0.54
0.67
0.67
0.56
0.55
2.51
2.19
0.54
0.95
0.57
0.55
2.93

centered
square root transform
rangescaled
paretoscaled
square root transform
raw
paretoscaled
square root transform
square root transform
autoscaled
rangescaled
paretoscaled
paretoscaled
vastscaled
log transform
centered
autoscaled
vastscaled
centered
levelscaled

BPCA
BPCA
MEDIAN
BPCA
PPCA
BPCA
PPCA
ZERO
HALF-MIN
MEDIAN
MEAN
ZERO
HALF-MIN
PPCA
MEDIAN
HALF-MIN
CART
MEDIAN
ZERO
PPCA

B PLS-DA
Overlap p-value

J 2 (CR/PR)

J 2 (SD/PD)

PRE-TREATMENT

IMPUTATION

0.00009
0.00011
0.00017
0.00025
0.00025
0.00026
0.00026
0.00027
0.00030
0.00041
0.00042
0.00043
0.00043
0.00046
0.00046
0.00048
0.00050
0.00051
0.00051
0.00053

7.05
6.74
2.99
2.22
3.40
2.18
1.47
3.25
2.45
1.17
1.19
6.19
3.31
1.98
3.22
4.51
4.55
4.11
2.26
11.91

1.21
1.19
2.05
2.26
1.99
2.26
3.20
1.57
1.99
3.90
3.89
1.13
1.50
2.68
1.54
1.21
1.25
1.27
1.92
0.96

rangescaled
rangescaled
log transform
log transform
log transform
log transform
log transform
autoscaled
autoscaled
log transform
log transform
vastscaled
rangescaled
autoscaled
rangescaled
rangescaled
vastscaled
vastscaled
autoscaled
vastscaled

MEDIAN
MEAN
RF
MEDIAN
CART
MEAN
PMM
MEDIAN
MEAN
ZERO
KNN
BPCA
RF
CART
CART
PMM
MEDIAN
ZERO
PMM
PMM

Supplementary Table 2.3. Quantification of PCA and PLSDA score plots. Overlap pvalues and J2 values for complete response/partial response (CR/PR) vs. stable
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disease/progressive disease (SD/PD) groups are shown for the top 20 performing pretreatment and imputation methods for (A) PCA and (B) PLS-DA score plots.
A PCA
Overlap p-value

J 2 (Stage I/II/III)

J 2 (Stage IV)

PRE-TREATMENT

IMPUTATION

0.279
0.300
0.326
0.329
0.329
0.334
0.335
0.337
0.339
0.346
0.349
0.352
0.356
0.359
0.367
0.372
0.376
0.390
0.394
0.395

1.58
1.41
1.01
8.25
8.23
8.37
6.39
8.06
8.10
1.24
1.13
1.24
6.09
7.96
2.21
7.47
2.30
2.63
1.73
2.71

0.60
0.64
1.19
0.32
0.32
0.32
0.33
0.32
0.32
0.79
0.88
0.78
0.34
0.32
0.45
0.32
0.42
0.42
0.55
0.42

square root transform
vastscaled
levelscaled
centered
centered
centered
centered
raw
raw
levelscaled
levelscaled
levelscaled
raw
centered
square root transform
raw
square root transform
paretoscaled
paretoscaled
paretoscaled

PPCA
RF
BPCA
ZERO
PPCA
HALF-MIN
BPCA
ZERO
HALF-MIN
ZERO
PPCA
HALF-MIN
BPCA
MEDIAN
RF
MEDIAN
CART
ZERO
BPCA
HALF-MIN

B PLS-DA
Overlap p-value

J 2 (Stage I/II/III)

J 2 (Stage IV)

PRE-TREATMENT

IMPUTATION

0.00000
0.00000
0.00000
0.00000
0.00000
0.00000
0.00000
0.00000
0.00001
0.00004
0.00007
0.00011
0.00016
0.00026
0.00028
0.00036
0.00038
0.00040
0.00041
0.00044

2.12
1.96
1.85
1.67
1.77
1.61
1.55
2.25
1.66
2.03
2.08
1.93
1.83
1.82
1.27
1.26
1.11
1.48
2.77
1.11

6.66
4.02
11.27
5.42
16.01
7.31
7.10
4.72
3.73
1.74
1.68
1.54
1.42
2.25
2.75
6.49
5.29
1.73
1.35
5.88

log transform
log transform
log transform
log transform
log transform
log transform
log transform
log transform
log transform
log transform
vastscaled
rangescaled
vastscaled
rangescaled
rangescaled
autoscaled
rangescaled
rangescaled
autoscaled
rangescaled

CART
KNN
MEAN
BPCA
MEDIAN
ZERO
PMM
RF
HALF-MIN
PPCA
RF
CART
PMM
RF
BPCA
MEAN
MEDIAN
PMM
KNN
MEAN
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Supplementary Table 2.4. Quantification of PCA and PLS-DA score plots. Overlap
p-values and J2 values for stage I/II/II vs. stage IV groups are shown for the top 20
performing pre-treatment and imputation methods for (A) PCA and (B) PLS-DA score
plots.

PLS-DA

Supplementary Table 2.5. Misclassification rate of PLS-DA models. The optimum
number of components used for classification accuracy and cumulative percent of
variance explained by the components for complete disease control (DC) vs.
progressive disease (PD) groups are shown for the top 20 performing pre-treatment
and imputation methods.
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PLS-DA

Supplementary Table 2.6. Misclassification rate of PLS-DA models. The optimum
number of components used for classification accuracy and cumulative percent of
variance explained by the components for complete response/partial response
(CR/PR) vs. stable disease/progressive disease (SD/PD) groups are shown for the
top 20 performing pre-treatment and imputation methods.
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PLS-DA

Supplementary Table 2.7. Misclassification rate of PLS-DA models. The optimum
number of components used for classification accuracy and cumulative percent of
variance explained by the components for stage I/II/II vs. stage IV groups are shown for
the top 20 performing pre-treatment and imputation methods.
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CHAPTER 32

EVALUATION OF DISEASE STAGING AND CHEMOTHERAPEUTIC RESPONSE IN
NON-SMALL CELL LUNG CANCER FROM PATIENT TUMOR-DERIVED
METABOLOMIC DATA

3.1 INTRODUCTION

Lung cancer is estimated to account for approximately 13% of all new cancer
cases and 24% of all cancer deaths in the U.S. [85]. For non-small cell lung cancer
(NSCLC) patients with advanced disease (stage IIIB-IVB) and performance status ≤2,
chemotherapy is the treatment option with best long term outcomes [6]. Paclitaxel,
gemcitabine, docetaxel, vinorelbine, irinotecan, or pemetrexed are often used in
combination with platinum drugs [7]. Randomized clinical trials have concluded that no
single regimen may be significantly more effective than others [8]. Consequently, no
reliable method exists to determine which potential first-line therapy would be most
effective for a specific patient, who essentially is an experimental subject with drug
choice and dosing determined post-hoc first-line therapy based on response and
tolerability [6].
This study uses metabolomics to explore the potential to a priori exclude “nonresponders” of certain first-line therapy treatment regimens to avoid burdening patients

2

Miller, H.A., Yin, X., Smith, S.A., Hu, X., Zhang, X., Yan, J., Miller D.M., van Berkel, V.H.,
Frieboes, H.B. Evaluation of disease staging and chemotherapeutic response in non-small cell
lung cancer from patient tumor-derived metabolomic data. Lung Cancer 156, 20-30 (2021).
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with ineffective treatment. Metabolomics has emerged as a method to potentially resolve
the link between genotype and phenotype, giving insight into patient response [23],
although no standard methodology has been developed [86, 87]. One advantage of
mass spectrometry (MS) over other techniques such as nuclear magnetic resonance
(NMR) spectroscopy is that MS has high sensitivity and peak capacity, especially when
coupled with liquid chromatography (LC). Stable isotope resolved metabolomics (SIRM)
uses stable isotope tracers (e.g., 13C, 18O and/or 15N) to support studies of biochemical
regulation. SIRM follows the fate of the heavy atoms and their incorporation into a
multitude of metabolites produced from the labeled primary substrate, and thus
quantifies heavy atom-containing metabolites, leading to exact biochemical pathway
assignment. Therefore, SIRM allows for a detailed view into cancer metabolism and
enables metabolic pathway reconstruction [88]. With a sufficiently high resolution, MS
can distinguish the m/z differences between 13C labeled molecules and unlabeled
molecules, which can lead to insights about glucose metabolism alteration. In particular
for NSCLC, an increased capacity for carbon incorporation from glucose into lactate,
alanine, citrate, glutamate, succinate, aspartate, and ribosyl moiety of nucleotides has
been observed [89].

In contrast to recent lung cancer patient serum metabolomic [86, 87] or radiomic
[90] profiling, here we report metabolomic analysis of fresh tumor core biopsies, which
are typically more difficult to obtain for analysis than biofluids or imaging. Our hypothesis
is that a comprehensive machine learning analysis of biopsied tissue metabolomic data
is able to differentiate between DC vs. PD and CR/PR vs. SD/PD responses, and
between stage I/II/III and stage IV disease. We explore this hypothesis by establishing a
workflow that includes patient-derived tissue processing, 13C glucose enrichment, high
resolution 2DLC-MS/MS, chemotherapy response assessment, and machine learning.
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Metabolites are categorized for their ability to differentiate between patient responses
and disease staging based on model training with forward feature selection based on
variable importance. Relative metabolite abundance is evaluated via a correlation
analysis. The output of the workflow offers patient-specific metabolomic profiling for
potential prediction of response to first-line chemotherapy.
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3.2 MATERIALS AND METHODS
3.2.1 Patient sample tissue collection
Informed consent was obtained to participate in this study. All specimens were
collected following approved Institutional Review Board protocols at University of
Louisville Hospital (IRB 05.0523) and Norton Hospital (IRB 18.0264) from patients with
known or suspected NSCLC. Demographic information including age, sex, race,
smoking history, personal history of malignancy, and relevant family history were
recorded. Chemotherapy response was also recorded. Samples were collected by the
clinical team, blinded to the research analysis. Patient information was de-identified by
the clinical team before evaluation by the research team.

3.2.2 Sex as a biological variable
As lung cancer affects both women and men, samples from both were collected.

3.2.3 Patient sample tissue processing and extraction
Tumor core biopsies were obtained from the University of Louisville and the
Norton Hospital interventional radiology departments. Samples were placed in 1.8mL
cryovials with either DMEM or RPMI cell culture medium and kept on ice during
transport. In laboratory, they were immediately placed into 1mL 13C labeled glucose
medium in 24-well cell culture plates and incubated at 5% CO2 and 37oC on a shaker for
24h. After incubation, media and tissue sample were transferred to 1.5mL
microcentrifuge tube and centrifuged 180xg for 5min. 13C-glucose media was aspirated
and specimen was washed with PBS and centrifuged for 5min, twice. After wash, 500mL
acetonitrile was added and tissue was homogenized with pellet mixer. After 2-3min
homogenization, 376mL of DNase/RNase free water and 250mL chloroform were added.
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Contents were vortexed until milky-white color and centrifuged 180xg for 20min. Top
(polar) layer was aspirated and frozen at -80oC. As control, a NSCLC tissue biopsy was
incubated in unlabeled glucose media for 24h and processed likewise. Sample polar
layers were flash frozen in liquid N2, then lyophilized for 24-48h until dried, and
transported on ice to CREAM core facility for 2DLC-MS/MS analysis.

3.2.4 2DLC-MS/MS analysis and data pre-processing
Dried samples were dissolved in 100µL 50% acetonitrile and vigorously vortexed
for 3min. After centrifugation at 14,000 rpm and 4oC for 20min, 80µL of supernatant was
collected. All samples were randomly analyzed on Thermo Q Exactive HF Hybrid
Quadrupole-Orbitrap Mass Spectrometer coupled with Thermo DIONEX UltiMate 3000
HPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with a reversed
phase chromatography (RPC) column and a hydrophilic interaction chromatography
(HILIC) column configured to form a parallel 2DLC-MS system[39]. To obtain full MS data,
every sample was analyzed by parallel 2DLC-MS in positive (+) and negative (-) modes.
For metabolite identification, one unlabeled sample in each group was analyzed by 2DLCMS/MS in positive and negative modes to acquire MS/MS spectra at 20, 40, and 60 eV
collision energies.

For

2DLC-MS

data

analysis,

(XCMS,

RRID:SCR_015538,

xcmsonline.scripps.edu) was used for spectrum deconvolution [40] and MetSign software
was used for metabolite identification, cross-sample peak list alignment, normalization,
and statistical analysis [41]. To identify metabolites, 2DLC-MS/MS data of unlabeled
sample was first matched to our in-house database that contains parent ion m/z, MS/MS
spectra, and retention time of authentic standards (MSI Level 1 identification). Threshold
for the spectral similarity of the MS/MS spectra of a metabolite standard and a spectrum
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of the unlabeled sample were set ≥0.4, while thresholds of retention time difference and
m/z variation window were respectively set ≤0.15min and ≤4ppm. 2DLC-MS/MS data
without a match (MSI Level 2 identification) were analyzed using Compound Discoverer
software v2.0 (Thermo Fisher Scientific, Germany), where MS/MS spectra similarity score
threshold was set ≥40 with a maximum score of 100. Identification results of unlabeled
metabolites were used for isotopologue assignment in the labeled samples using same
parameters for identification of unlabeled metabolites [91].

3.2.5 Organization of MS peak intensity data

2DLC-MS data was presented as an alignment table for each batch with
retention time, m/z, signal intensity, stable isotope labeling, name of identified
metabolite, and database used for metabolite identification. Building on R package
MSCombine[92], a script was employed to combine the dataset into a single data frame
by combining metabolites from both positive and negative ion modes. For metabolites
with multiple occurrences, the metabolite with lower average peak area across all
samples was considered to have lower sensitivity and was left out of the combined
dataset. Once metabolites from positive and negative modes were combined after
eliminating the low sensitivity redundant metabolites, a preliminary step to handle
missing values was performed by removing features which contained more than 50%
missing values. This resulted in a dataset of 66 metabolites with approximately 21.8%
missing values.

3.2.6 Data normalization and imputation of missing data
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The data were normalized by a log transformation, which is commonly applied to
biological data, both centering the data and correcting for heteroscedasticity [33]. The
transformation was applied within each sample independently to prevent data leakage
between the training and test sets during cross validation. Multiple imputation is a
commonly used multivariate statistical technique to fill in missing data for unlabeled
metabolites, particularly in MS-based metabolomics [72]. Although it was previously
determined that the random forest (RF) method had the highest performance compared
to other methods when imputing MS-based metabolomics data [72], we chose to
evaluate the performance of various imputation methods on our unique dataset due to
their potential influence on the analysis [93]. After taking a subset of the original data
that only included complete cases (19 metabolic features x 33 samples) and introducing
simulated missing values (~10%), the RMSE of various imputation methods were found
and used as the measurement for their performance. Probabilistic principal component
analysis (PPCA) [82] was found to be the most accurate method of imputation for the
complete case subset. Therefore, we applied PPCA to the original data to replace
missing values. The R package pcaMethods was used to perform PPCA. The function
was seeded with an integer of ‘1234’ to allow for reproducibility and “maxIterations” was
set to 1000.

3.2.7 Patient response data

Out of 39 enrolled patients, 23 received chemotherapy and a clinical response
assessment while 34 had staging information available. Data collected included subject
(age, gender, primary ethnicity, primary race, status, age at death, overall survival,
cancer description, histology subtypes, cancer stage and substage, and progression free
survival in days), treatment (therapy type, therapy details, days of therapy,
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chemotherapy agent type, chemotherapy agent repeat units, number of chemotherapy
cycles completed, surgery results, overall response to surgery/chemotherapy, days
since diagnosis and response assessment types), and other information regarding the
specimens. Response assessment was performed clinically or radiologically. The
Response Evaluation Criteria in Solid Tumors Group (RECIST) [35] is widely used to
categorize target lesions: Complete Response (CR), Partial Response (PR), Progressive
Disease (PD), or Stable Disease (SD). Accordingly, clinical assessment was captured by
the following classifications: DC (includes CR, PR, and SD), CR/PR, SD/PD, and PD. As
a preliminary step for data visualization, principal component analysis (PCA) was
performed on imputed MS signal intensity datasets, using prcomp function from stats
package in base R.

3.2.8 Data analysis

3.2.8.1 Model Selection
In a comprehensive study which analyzed the performance of 179 classification
methods from 17 method families across 121 datasets [94], the top 3 method families
(summarized in Supplementary Materials) most likely to be best classifiers were
random forest (RF), support vector machines (SVM) and artificial neural networks
(ANN). Therefore, we chose to use learning methods from these 3 families in addition to
partial least squares discriminant analysis (PLS-DA). Samples were divided into
classifications based on either clinical response assessment or staging: DC vs. PD;
CR/PR vs. SD/P; Stage I/II/III vs. Stage IV. To prevent overfitting of the models, a
rigorous combination of feature selection and cross validation was performed. Test set
validation was achieved with 5-fold cross-validation, performed with 100 iterations of
random subsampling. Results were reported as the average across all folds and
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iterations. Methods were performed on imputed unlabeled MS signal intensity datasets,
organized with sample ID by row and metabolite by column, using the R package caret
[95]. For all learning methods implemented with train function, “tuneLength” was set to
10 and “Kappa” was used as the metric for tuning optimal hyperparameter combinations.

3.2.8.2 Feature Selection and Variable Importance
Three basic approaches were previously evaluated to determine features in
metabolomics data [57]: PCA loadings, Fisher Discrimination Analysis (FDA) weights,
and VIP in PLS-DA, finding that better classification was achieved using features
determined from PLS-DA. Therefore, we used PLS-DA variable importance calculated
with the generic function “varImp()” from caret package to determine importance of
metabolites for classification of patient therapy outcomes and staging, and used these
for feature selection, as in[96]. The variable importance measure applied to PLS-DA is
based on weighted sums of the absolute regression coefficients, where contribution of
coefficients is weighted proportionally to reduction in sum of squares. We used these
selected features to train PLS-DA, SVM and DNN. For RF method, RF variable
importance was used to select features by using “varImp()” from caret package. The
variable importance measure applied to RF is based on accuracy for each tree, where
out-of-bag prediction accuracy is averaged over all trees after permutations of each
predictor variable. For all methods, forward feature selection was performed by training
each model independently on a subset of features, incrementing from 5 to 30, chosen by
variable importance. The optimal number of features for training each model was chosen
based on which subset resulted in the highest average AUROCTest after 100 iterations of
5-fold cross validation.
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3.2.8.3 Measures of Model Performance
Thresholder function within caret package was used to return summary statistics
from each model with a range of classification probability thresholds from 0 to 1,
incremented by 0.005. For test data, receiver operating characteristics (ROC) curves
were found from these summary statistics and area-under-the-ROC (AUROC) was
calculated using trapezoid rule by approximating the definite integral. For training data,
predictions were found using function extractPredictions from caret package. AUROC of
training data was then found using observations and predictions from extractPredictions
object with roc function from package pROC. Due to class imbalances (i.e., skewed
class distribution) present in dataset, balanced accuracy was reported rather than simply
averaging accuracies found on each cross-validation fold[97]. Balanced accuracy is
simply the average of sensitivity and specificity at a particular classification probability
threshold. Another useful measure of model performance is kappa, which measures
‘true agreement’ by taking into account the random chance of a model selecting the
correct outcome[98]. In our dataset, the concept of optimizing probability thresholds for
class imbalances is highly relevant. Therefore, we chose the optimum values of
balanced accuracy and kappa across a range of probability thresholds.

3.2.8.4 Correlations, Statistical Significance and Score Plot Quantification
A Spearman correlation analysis was performed using R package stats and
cor.test function. To capture potentially significant metabolites, a 95% confidence level
was chosen. Wilcoxon-rank sum test (Mann-Whitney U test), used to test for significant
differences between relative abundance of metabolites, was performed using R package
stats and wilcox.test function. Differences across survival curves were found using the
G-rho family of tests, performed with the R package survival and survdiff function. PCA
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and PLS-DA score plots were quantified with a version of PCAtoTree software[44]. J2
criterion and overlap p-values between classes are reported in all score plots.

3.2.8.5 Metabolic Network Visualization and Quantitative Enrichment Analysis
Quantitative enrichment analysis (QEA) was performed on unlabeled metabolite
dataset using (MetaboAnalyst 4.0, RRID:SCR_015539, www.metaboanalyst.ca/) [71].
The log transformed/imputed working dataset was used, so no missing value estimation
or normalization was necessary. (Small Molecule Pathway Database (SMPD),
RRID:SCR_004844, www.smpdb.ca/) and (KEGG, RRID:SCR_012773, www.kegg.jp/)
databases were accessed (Nov. 2020). Metabolic networks were visualized with
(Cytoscape 3.7.2, RRID:SCR_003032, cytoscape.org/) and (MetScape 3.1.3,
RRID:SCR_014687, metscape.ncibi.org/) using the imputed and log transformed
metabolite intensity values for DC vs. PD classification.

3.3 RESULTS

3.3.1 Patient characteristics and feature selection
Of 39 patients enrolled in the study and who had metabolomics data generated,
36 had confirmed NSCLC and they were included in working dataset during imputation.
Patient characteristics are described in Table 3.1. Key steps of experimental design
from tissue specimen collection to analysis are summarized in Figure 3.1. Working
dataset with metabolites combined from positive and negative ion modes is visualized in
Supplementary Figure 3.1. Collinearity was high when considering the common 66
metabolites in working dataset. This warranted a feature selection approach to
determine important features to differentiate classifications within the dataset.
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Patient #

Sex

Age

Stage

Sub stage

Therapy

1

F

50

1

b

Cisplatin; Carboplatin

2

F

53

2

a

3

M

42

3

b

4

M

64

4

5
6

M
M

63
60

3
2

a
b

7

F

55

1

a

8
9

F
M

50
61

3
4

N/A

Carboplatin and Paclitaxel
Carboplatin;
Pemetrexed
Carboplatin and
Pemetrexed
Cisplatin and Etoposide
Cisplatin and Docetaxel
Carboplatin and
Pemetrexed
Carboplatin and Paclitaxel

10

M

74

4

11

F

57

4

12

M

68

3

13

M

59

4

14
15

F
M

70
60

3
2

16

M

65

4

17
18
19
20
21

F
M
F
F
F

67
58
61
65
57

1
3
4
3
3

22

F

77

4

23
24

F
M

70
75

3
N/A

25

M

57

4

26
27
28
29
30
31
32
33
34
35
36

F
F
F
M
M
F
F
M
F
M
F

65
85
63
63
75
74
68
84
79
62
95

3
1
1
1
N/A
3
4
2
4
4
2

N/A
Carboplatin and
Pemetrexed
Carboplatin and
Pemetrexed

b
b
a

a
b
b
a
a
N/A
a
a
b
a
N/A
a
b

b

Table 3.1. Patient characteristics.
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N/A
Carboplatin, Pemetrexed
and Bevacizumab
Carboplatin and Paclitaxel

RECIST
Adverse
Event;
NED
PR
SD; SD
PD
SD
NED
SD
PD

N/A
PR
SD

N/A
PD
SD

N/A

N/A

Paclitaxel;
Pemetrexed;
Carboplatin;

Adverse
Event; PD;
PD

N/A

N/A

Cisplatin and Pemetrexed

SD

N/A
N/A

N/A
N/A

Carboplatin and Paclitaxel
Carboplatin, Pemetrexed
and Pembrolizumab
Cisplatin and Pemetrexed

PR

N/A

N/A

Carboplatin, Pemetrexed
and Pembrolizumab
Durvalumab

SD
PR
PR
PR

N/A

N/A

Cisplatin and Docetaxel

NED

N/A
N/A

N/A
N/A

Carboplatin and Paclitaxel
Pembrolizumab

SD
PR

N/A
N/A

N/A
N/A

Cisplatin and Etoposide

PR

N/A

N/A

Figure 3.1. Work-flow of study design. (A) Study profile. Of the 39 patients who were
considered eligible for the study, 34 patients had disease staging determined clinically
and 23 patients received chemotherapy. (B) PLS-DA variable importance was used to
select feature subsets when training PLS-DA, SVM and DNN models; while RF variable
importance was used to select feature subsets when training the RF model. (C) Visual
example of model training and validation. The permuted (randomly sorted) dataset is
split into k folds (subsets; here, k=5). Model is trained with k-1 folds and validated with
the kth fold. This process is repeated until all folds have been used once as the
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validation set. The next iteration of the cross validation involves another permutation of
the complete dataset and repeating the whole process. Final results of each model are
the averages of the validations across all folds and all iterations.

3.3.2 Classification results
For each patient classification, Figure 3.2 shows PLS-DA score plot with
distribution of samples on the first two components using the optimum subset of features
after forward feature selection. Score plots, illustrating separation between classes and
within samples of same class after selecting optimal number of features with PLS-DA,
were quantified with the J2 criterion and overlap p-values, showing that statistically
significant (p≤0.05) separation was achieved for all classes. Comparison of score plots
for classifications before and after feature selection (Supplementary Figure 3.2) shows
that whereas PLS-DA is able to separate the classes, PCA would have been insufficient.
Figure 3.2 further shows the highest-performing model classifications: DC vs. PD with
SVM (AUC = 0.970 (0.961 – 0.979) 95% CI), CR/PR vs. SD/PD with PLS-DA (AUC =
0.880 (0.865 – 0.895) 95% CI), and stage I/II/III vs. stage IV with SVM (AUC = 0.902
(0.880 – 0.924) 95% CI). Supplementary Figure 3.3 illustrates performance measures
(AUC, balanced accuracy, and kappa) of all learning methods as a function of features
retained for each classification. While SVM performed well with DC vs. PD and stage
I/II/III vs. stage IV, PLS-DA and DNN performed better with CR/PR vs. SD/PD.
Generally, RF had the lowest performance. AUROC curves for all learning methods
using optimal subset of features are shown with corresponding performance measures
in Supplementary Figure 3.4. Highest balanced accuracy (0.92) was achieved for DC
vs. PD with SVM. Figure 3.2 further shows Kaplan–Meier survival curves for
progression-free survival (PFS) and overall survival (OS).
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Figure 3.2. Classification model results: (A) DC vs. PD; (B) CR/PR vs. SD/PD; (C)
Stage I/II/III vs. Stage IV. For each classification (left to right): PLS-DA score plot with
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distribution of samples on the first two components using optimum subset of features
after forward feature selection; AUROC curve for highest performing model; Kaplan–
Meier curves for overall (OS) and progression-free (PFS) survival; PLS-DA variable
importance ranking for all 66 features (darker bars: features used to train highestperforming model).

3.3.3 Key metabolites identified by variable importance
Ranking of PLS-DA variable importance for the three patient comparisons is
shown in Figure 3.2. For DC vs. PD, the top 12 metabolites trained the SVM model:
pyruvate, proline, arginine, glutamine, isoleucine, methionine, inosine, uric acid, N3,N4dimethyl-L-arginine, salicylic acid, creatine, and levulinic acid (Supplementary Table
3.1). Isoleucine, creatinine, and serine correlated with DC, while pyruvate and uric acid
correlated with PD. For CR/PR vs. SD/PD, the top 6 metabolites trained the PLS-DA
model: (R) 2-Hydroxybutyric acid, N8-acetylspermidine, urea, cystine, uric acid, and
isoleucine (Supplementary Table 3.2). Fumarate, tryptophan, methionine sulfoxide, and
creatinine correlated with CR/PR, while N8-acetylspermidine, uric acid, and malonic acid
correlated with SD/PD. For Stage I/II/III vs. Stage IV, the top 9 metabolites trained the
SVM model: urea, malonic acid, N3,N4-dimethyl-L-arginine, lidocaine, 3,4hydroxyphenyllactic acid, glutamic acid, adipic acid, levulinic acid, and pyruvate
(Supplementary Table 3.3). Glutaric acid correlated with stage 4. Key metabolites
identified by RF are summarized in Supplementary Tables 3.4-3.6.

Figure 3.3 shows metabolites with a significant effect of group in terms of relative
abundance (Wilcoxon rank-sum test, p≤0.05). Pyruvate, methionine, salicylic acid,
creatinine, and serine were associated with DC vs. PD, while uric acid, fumarate,
malonic acid, tryptophan, methionine sulfoxide, and creatinine were associated with
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CR/PR vs. SD/PD. Supplementary Figure 3.5 shows the set of metabolites not
reaching significance with p≤0.1. Key metabolites for all patient classifications are
summarized in Table 3.2.

Figure 3.3. Relative abundance of key metabolites. Each box represents 1st and 3rd
quartiles. Bands within represent the median and x is the mean. Ends of whiskers are
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maximum and minimum, with points outside being outliers. P-values found by Wilcoxon
rank-sum test (*p≤0.05). (A) DC (blue) vs. PD (red); (B) CR/PR (blue/left) vs. SD/PD
(red/right).

METABOLITE
Pyruvate
Isoleucine
Uric Acid
Creatinine
Serine
N8-Acetylspermidine
Fumarate
Malonic Acid
Tryptophan
Methionine Sulfoxide
Glutaric Acid
Methionine
Salicylic Acid
Threonine
Valine
Phenylalanine
(R) 2-Hydroxybutyric acid
Cystine
3,4-Hydroxyphenyllactic Acid
Lysine

DC

PD

CR/PR

SD/PD

Stage I/II/III

Stage IV

√
√
√
√

√

√
√
√
√
√
√

Table 3.2. Metabolites as a function of patient classification. Subset of metabolites
identified by variable importance correlated to chemotherapy response and staging
(Spearman correlation; p≤0.05). Medium gray: favorable response/staging; dark gray:
poor response or Stage IV; light gray: not statistically significant with correlation p≤0.1.
Checkmarks: significant effect of group in terms of relative abundance (Wilcoxon ranksum test, p≤0.05; unchecked: p≤0.1).

3.3.4 13C stable-isotope resolved metabolomics
Log transformed relative abundances and labeled fraction relative abundances of
lactate for patient classifications are in Supplementary Figure 3.6. Labeled fractions
were calculated as (13C -Labeled metabolite x peak area)/(Unlabeled metabolite x peak
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area). Due to the number of missing values in 13C labeled metabolite dataset, we relied
on complete case analysis, as imputation would be inaccurate. Although results were not
statistically significant, interesting trends emerge. 13C -labeled lactate was higher in PD,
SD/PD and stage IV classifications by median, and DC and stage I/II/III had a larger
range of values in log transformed set. Medians between DC and PD, and between
stage I/II/III and IV, were similar in the labeled fraction set.

3.3.5 Metabolic pathway enrichment and network analysis
Top metabolic pathways identified in MetaboAnalyst 4.0 by the chosen
databases are shown in Figure 3.4 and listed with associated statistics in
Supplementary Table 3.7. Top 5 metabolic pathways identified by KEGG database by
p-value were: glycine, serine and threonine metabolism; arginine and proline
metabolism; purine metabolism; lysine degradation; pantothenate and CoA biosynthesis.
Top 5 metabolic pathways identified by SMPD database by p-value were: arginine and
proline metabolism; glycine and serine metabolism; carnitine synthesis; oxidation of
branched chain fatty acids; D-arginine and D-ornithine metabolism. Visualization of an
integrated metabolic network of serine, methionine, and isoleucine related to DC vs. PD
is shown in Supplementary Figure 3.7.
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Figure 3.4. Quantitative Enrichment Analysis. Enriched metabolic pathways (see
Supplementary Table 3.7) were found with MetaboAnalyst 4.0 using (A) KEGG
pathway database and (B) SMPD database.
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3.4 DISCUSSION

This proof-of-concept study explored the hypothesis that a comprehensive
machine learning analysis of biopsied tissue metabolomic data would be able to
differentiate between DC vs. PD and CR/PR vs. SD/PD responses, and between stage
I/II/III and stage IV NSCLC disease. The study adhered to CHARMS checklist[99] and
REMARK criteria[100] to ensure the integrity of the prediction models. A metabolite set
of 66 common metabolites was selected among 36 total samples. Potential sets of
metabolites associated with disease staging and patient response to chemotherapy were
identified in terms of PLS-DA variable importance (Figure 3.2, Supplementary Tables
3.1-3.3), and to train PLS-DA, SVM and DNN learning models. A rigorous combination of
feature selection and k-fold cross validation was performed to minimize overfitting of the
models. While for all three models AUROCTrain=1.0, SVM performed the best with DC vs.
PD (AUROCTest=0.970) and Stage I/II/III vs. Stage IV (AUROCTest=0.902) while PLS-DA
performed best with CR/PR vs. SD/PD (AUROCTest=0.880) (Supplementary Figure
3.4). Although RF as a learning model did not perform as well, the ranking of metabolites
in terms of RF variable importance was generally consistent with those of PLS-DA
variable importance (Supplementary Tables 3.4-3.6).

Isoleucine was a key metabolite identified by both PLS-DA and RF variable
importance and correlated to disease control. Branched-chain amino acids (BCAA’s:
isoleucine, leucine, and valine) are preferentially uptaken by tumor cells and used for
protein synthesis or oxidized for energy production[101]. Enzymes BCAT1 and BCAT2
catalyze the first step in BCAA degradation and are overexpressed in many cancers
[102]. Isoleucine can be converted into acetyl-coA through BCAA metabolism [103],
which can then fuel the TCA cycle. High levels of isoleucine as well as valine may imply
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lower activity of BCAA metabolism-related enzymes, thereby limiting acetyl-coA
available for the TCA cycle and restraining the cancer aggressiveness. Creatinine
correlated with improved response (DC and CR/PR), while serine correlated with DC.
These metabolites are shown to support an anti-tumor immune response [104, 105]. In
contrast, pyruvate correlated with PD, as it promotes tumor proliferation [106],
angiogenesis [107], and immune response downstaging [108]. Malonic acid, associated
with epithelial-mesenchymal transition indicative of aggressive cancer[109], correlated
with SD/PD, while uric acid correlated with poor response (PD and SD/PD). N8Acetylspermidine, known to induce cell differentiation [110], also correlated with SD/PD.
Interestingly, fumarate correlated with CR/PR, although fumarate accumulation could
confer a proliferative signal [111] and prevent HIF degradation [112]. Methionine
sulfoxide and tryptophan correlated with CR/PR, with the former known to relieve acidityinduced cellular stress [113] while the latter supports immune system activity [114].
Lastly, glutaric acid correlated with Stage IV.

Although it is no surprise that glycolysis, purine metabolism and several amino
acid metabolism pathways were considered significant (Figure 3.4 & Supplementary
Table 3.7), the detection of gluconeogenesis is interesting and may warrant further
investigation. The only organ tissues normally expressing genes necessary for
gluconeogenic pathway are kidneys and liver [115]. In cancer, upregulated
phosphoenolpyruvate carboxykinase (PEPCK) transcription is a known marker of
tumorigenic cells, enhancing gluconeogenesis [115]. In non-gluconeogenic tissues (such
as lung), PEPCK plays a protumorigenic role by expanding the source of nutrition rather
than increasing glucose production [115]. Additionally, pathways related to fatty acid
oxidation were found to be significant, implying an important role of fatty acid (FA)
metabolism in NSCLC. Although FA metabolism in cancer is poorly understood, it is
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thought to be complex and dependent on specific tissue types [116]. Metastasis can only
occur when cell membranes have high fluidity by incorporation of high amounts of
unsaturated FAs relative to saturated FAs [117]. In contrast, cancer cells with high lipid
saturation and low membrane fluidity show resistance to chemotherapeutics [118],
possibly linking FA synthesis and drug resistance. Lung cancer patients with high
plasma membrane fluidity tend to have worse prognosis [119]. Fatty acid oxidation is
also an important source of ATP production, especially after loss of attachment to the
extracellular matrix [116]. Several studies have examined the role of fatty acid
metabolism related genes in relation to various cancer types [116], finding that FA
metabolism genes may be tumor-suppressive in some cancers while being prooncogenic in others.

While most patients in this study received combination chemo- and
immunotherapy, a few received either chemo- or immunotherapy only (Table 3.1).
Differences expected in metabolic profiles with immunotherapy vs. chemotherapy could
be explored with a larger patient set in the future. Further, investigation of interactions of
drug action mechanisms with key metabolites could yield insight into treatment response
beyond potential variations in tumor types. Chemotherapeutics included cisplatin and
carboplatin, which exert cytotoxic effects by generating ROS and inhibiting cell
replication via DNA cross-linking; paclitaxel and docetaxel, which inhibit microtubule
depolymerization; etoposide, which damages DNA by targeting topoisomerase II;
pemetrexed, which inhibits enzyme targets related to folate metabolism and pyrimidine
and purine synthesis. Immunotherapeutics included pembrolizumab, which binds to PD1 receptor and blocks PD‑L1 and PD‑L2; durvalumab, which blocks PD-L1 interaction
with PD-1 and CD80.
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As depicted in Supplementary Figure 3.7, serine gives rise to cystathionine, a
precursor for glutathione, which is known to chelate cisplatin and play a role in coppertransporter-mediated cisplatin efflux [120]. Glutathione can also act protect against
platinum induced oxidative stress [120], implying that high serine levels may lead to
cisplatin/carboplatin resistance. This could explain elevated serine in PD patients, since
in this study all PD patients received carboplatin. It is unsurprising that pyruvate was a
strong predictor of chemotherapy response, since it has a central role is fundamental
metabolic pathways such as glycolysis, citric acid cycle, urea cycle, and amino acid
metabolism. Increased pyruvate levels in PD patients may indicate a general increase in
metabolic rate, resulting in a more aggressive NSCLC phenotype. Additionally, it has
been hypothesized that pyruvate is increased in mitochondria of cisplatin-resistant cells,
due to less dependence on glucose and lower lactate production, where it helps TCA
cycle replenishment[121].

Recently, lung cancer chemotherapy prediction models have been proposed
using metabolomics data derived from serum or plasma samples. Stage III and IV SCLC
and NSCLC patient samples were analyzed in terms of PR vs. PD response to platinumbased chemotherapy[86], finding eight out of 21 key metabolites (PLS-DA VIP scores
≥1) to be significant based on Spearman correlation analysis: phenylalanine, tyrosine,
tryptophan, citric acid/isocitric acid, α-ketoglutarate, succinate, d/l-2-hydroxyglutaric acid,
and pyroglutamic acid. Top metabolic pathways found during QEA in [86] matching
those in our study included tryptophan metabolism and gluconeogenesis (Figure 3.4).
Stage IIIB and IV nonsquamous NSCLC patient samples were analyzed in terms of DC
vs. PD response to pemetrexed plus platinum chemotherapy [87]. Out of 32 metabolites
with PLS-DA VIP scores ≥1, eight key metabolites had lower levels in DC: choline,
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taurine, hypotaurine, uridine, betaine, dimethylglycine, dodecanoylcarnitine and Lpalmitoylcarnitine, and three metabolites elevated in DC: palmitic amide, imidazole-4acetaldehyde, and niacinamide. Although several metabolites and metabolite derivatives
(structural analogues) identified in these studies were also detected in our samples,
most key metabolites in this study are different. Regarding chemotherapy response
classification, succinate and phenylalanine were in common with previous optimal
metabolic feature subsets, while tryptophan was in common in terms of correlation pvalue.

Phenylalanine was potentially elevated in PD patients in this study
(Supplementary Figure 3.5), in contrast with [86], which found phenylalanine to be
lowered in PD compared to PR. Elevated phenylalanine has been noted in
hepatocellular carcinoma tissue [122], possibly due to increased amino acid
consumption, and in sera of ovarian carcinoma patients [123], for which cancerassociated inflammation and immune activation may impair phenylalanine (4)hydroxylase (PAH) activity, leading to accumulation. Interestingly, neither of the previous
studies[86, 87] nor our study found lactate to be important for determining chemotherapy
response. Lactate has been shown to have multiple roles during tumor growth [124], with
production controlled by tumor cells to maintain pericellular pH homeostasis [125] and
regulate the microenvironment [126]. Lactate promotes M2-like macrophage polarization
and induces epigenetic regulation via lactate-derived histone lactylation [127]. Lactate
was considered for statistical analysis via SIRM, with 13C labeled lactate detected in 31
of 36 samples. However, we were unable to discern any predictive capacity of 13C
labeled lactate (Supplementary Figure 3.6) from tissue incubated immediately after
excision. 13C labeled lactate has previously detected altered regulation of lung cancer
metabolic pathways when infused into patients immediately prior to excision[89]. These
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results indicate that the amount of 13C labeled lactate present in any given sample,
which would be strictly due to glycolysis, may not necessarily reflect staging or
chemotherapy response.

A major difference with previous studies is that this study utilized fresh tumor
tissue samples, circumventing the assumption that serum metabolic profiles are directly
linked to tumor tissue behavior. This assumption may not hold, especially for amino
acids since low-mass intracellular proteins may have difficulty shedding into circulation
[128]. Another difference is that this study included NSCLC patients at all stages and
various chemotherapy regimens (Table 3.1). Further, cancer metabolomics studies often
exclude metabolites with missing values. The simplest approach for handling missing
data is the ad hoc method of complete case analysis (CCA)[129], as in [86, 87], for
which features with missing data are excluded from the dataset being analyzed. CCA
has the potential for excluding metabolites from the prediction model that may be
influential on the response. Working under the assumption that missing values were
missing at random (MAR), we chose to perform imputations using PPCA, after
concluding it was the most accurate imputation method on a complete subset of data
taken from the original data. We chose CCA as appropriate for the 13C labeled
metabolite set, as it was missing ~45% in total.

Altogether, these caveats and methodology differences may explain
discrepancies between our results and those from previous studies. We have presented
a proof-of-concept study with a relatively small patient number, laying a foundation for
systematically examining metabolic characteristics of patient-derived NSCLC tissue with
the longer term objective of predicting patient-specific response to established first-line
chemotherapy regimens. With a sufficiently large longitudinal dataset, the prognostic
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value of predictive metabolomic biomarkers could also be determined. For example, high
levels of uric acid may imply enhanced purine metabolism, where a therapeutic such as
pemetrexed, which inhibits purine synthesis, might be more efficacious. Although
metabolomics is a promising emerging field when applied for biomarker discovery, it
faces limitations which have largely prevented clinical translation. The complexity of the
data lends itself to mathematical and computational analyses, which would allow tissuescale simulation of a variety of tumor characteristics and chemotherapeutic responses to
a range of cytotoxic agents while providing further validation to statistical analyses.
Longer term, a higher dimensional framework integrating comprehensive omics data
could lead to enhanced understanding of how cancer metabolism influences NSCLC
progression and response to therapy.

3.5 SUPPLEMENTARY MATERIALS

3.5.1 Machine learning methods
3.5.1.1 Principal Component Analysis
Principal component analysis (PCA) is a multivariate statistical technique that
produces a low-dimensional representation of a dataset by finding a sequence of linear
combinations of mutually uncorrelated variables with maximal variance [130]. PCA is
useful for visualization and feature extraction and is commonly used as a first step in the
analytical pipeline to check for clustering, separation, and outliers among groups of
samples [56]. It can be used to avoid multicollinearity and to represent the pattern of
similarity of observations when they are projected onto the principal components [57].
PCA relies on an eigenvector decomposition of the covariance matrix of 𝐗, cov(𝐗) =
𝐗 𝑇 𝐗/𝑛 − 1, where 𝐗 (𝑛 x 𝑁) is the data matrix containing samples and features. If only
the first 𝐴 (𝐴 < 𝑁) dimension of scores is needed, PCA decomposes 𝐗 into the sum of
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the outer products of score vectors 𝐭 𝑖 and loadings vectors 𝐩𝑖 plus a residual matrix 𝐄
[57]:
𝐗 = 𝐭1 𝐩1𝑇 + 𝐭 2 𝐩𝑇2 + ⋯ + 𝐭𝐴 𝐩𝑇𝐴 + 𝐄 = 𝐓𝐏 𝑇 + 𝐄

[Equation 3.1]

The contribution of individual features in each principal component dimension is
accounted for by the loading vectors 𝒑𝑖 obtained from the eigenvectors of the covariance
of 𝐗 [58].

3.5.1.2 Partial-Least-Squares Discriminant Analysis
Partial least squares (PLS) is used for modeling relations between features
through latent variables [131]. Similar to principal component analysis (PCA), it is used
to produce a low-dimensional representation of a dataset. However, PLS takes into
account dependent response variables so they can be used to create a prediction
model. In particular, PLS-DA is useful when the response variable is categorized rather
than continuous. It is able to handle situations where multicollinearity is present and
when the number of dependent response variables is larger than the number of
observations [59]. PLS-DA seeks to find a set of latent features that maximizes the
covariance between 𝐗 (𝑛 x 𝑁) and 𝐘 (𝑛 x 𝑀), where 𝐗 and 𝐘 are the independent
variables and dependent variables, respectively [57]. Due to its interpretability and ability
to determine variable importance, PLS has been the most popular learning method used
in metabolomics studies since the year 2005 [132]. Since PLS-DA has only a single
tuning hyperparameter (number of components), it is fast to compute relative to other
methods. Here, we use PLS-DA as both a preliminary step for data visualization/feature
selection, and as a supervised learning method. PCA and PLS-DA score plots were
quantified by the J2 criterion [63] and overlap p-values, using a modified version of the
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pca-utils software developed by Worley et. al. [44]. Briefly, the J2 criterion is a
measurement of how tightly clustered groups of samples are, and is defined as follows:

𝐽2 =

|𝑆𝑤 +𝑆𝑏 |

[Equation 3.2]

|𝑆𝑤 |

3.5.1.3 Random forest
Random forests (RF) are commonly used machine learning algorithms based on
classification and regression trees (CART) and have seen applications in image
analysis, genomics, metabolomics, and cancer diagnosis [133, 134]. RF is a top-down
structure of nodes in which each node splits into two branches after applying a logical
decision. Once a leaf node is reached, a classification prediction is made. RF are known
to be robust against overfitting because they make use of multiple unique base
classifiers which are then aggregated to make a single prediction [135]. Since RF are
non-parameterized, performance tuning is straightforward (only one or two tuning
hyperparameters) which makes it fast to compute relative to other methods. RF was
implemented using the method “rf” called from the function train in the caret package,
where the number of randomly selected dependent response variables was optimized
during hyperparameter tuning.

3.5.1.4 Support vector machines
Support vector machines (SVM) are a class of machine learning techniques that
have been extensively used for classifying gene expression and microarray data [136,
137]. Primarily applied for predicting binary classification problems, SVM maps samples
in a space that maximally separates them based on their classification. SVM is known to
handle noisy data and to be robust against outliers [138]. Here, we used SVM as a nonlinear classifier with a radial basis function as the kernel function. SVM was implemented
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using method “svmRadialWeights” called from the function train in the caret package,
where parameters “Sigma”, “Cost” and “Weight” were optimized during hyperparameter
tuning.

3.5.1.5 Artificial neural networks
Artificial neural networks (ANN) are mathematical models inspired by biological
neural connections [132]. ANNs simulate signal transfer between neurons with simplified
equations and can be used as powerful machine learning tools. ANNs have been used
for metabolic profiling since 1992, when Goodacre et al. [139] used a neural network to
classify different types of olive oil by mass spectrometry. ANNs have seen a variety of
applications, particularly in genomics [132], although it remains one of the least popular
machine learning tools in the field of metabolomics, likely due to the difficulty of
interpreting variable importance. Multi-layer perceptrons (MLP) are a type of feedforward ANN that consist of multiple layers and fully connected nodes [140]. One
advantage of MLPs over linear methods such as principal component analysis (PCA) are
their ability to handle extremely non-linear relationships [140]. MLP was implemented
using the method “mlpWeightDecayML” called from the function train in the caret
package where the number of hidden units across 3 layers and “Weight Decay” were
optimized during hyperparameter tuning.

3.5.2 Model performance metrics

Q2 is sometimes considered the de facto performance statistic often used to
validate PLS models. Briefly, Q2 is defined as 1 minus the ratio of the predicted sum of
squares (PRESS) and the total sum of squares (TSS) [141]:
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𝑄2 = 1 −

𝑃𝑅𝐸𝑆𝑆

[Equation 3.3]

𝑇𝑆𝑆

While Q2 works well for regression analysis using continuous dependent response
variables, it has limitations when applied to classification models. Golbraikh et al. [142]
states that R2 and Q2 are questionable statistics for decribing the performance of
classification models since these metrics were designed for regression models, not
classification models. Golbraikh et al. found that a high value of Q2 alone is insufficient
for determining high predictive accuracy. Additionally, Szymanska et al. [141] found that
the parameter Q2 was outperformed by AUROC and number of misclassifications (NMC)
for optimizing the performance of PLS-DA, and recommend using AUROC or NMC as
diagnostic statistics for finding biomarkers with two-class PLS-DA models. Therefore, we
chose to rely on AUROC to evaluate the predictive accuracy of the classification models.

3.5.3 PCA and PLS-DA score plots
PCA and PLS-DA were utilized for data visualization to evaluate potential
clustering and separation of samples in each patient classification. Score plots for all
classifications in Supplementary Figure 3.2 illustrates differences in separation
between classes and within samples of the same class both before and after selecting
the optimal number of features with PLS-DA. The score plots were quantified with the J2
criterion and overlap p-values. After feature selection for PCA, J2 values increased with
the exception of stage 4 samples, indicating more separation between groups and more
tightly clustered groups, while overlap p-values improved for all classifications, with
CR/PR vs. SD/PD reaching significance. For PLS-DA, which is a more sophisticated
method than PCA, overlap p-values indicated significant separation (p<0.05) for all
cases. In some cases, J2 increased after feature selection, indicating more separation
and more tightly clustered groups, while in other cases J2 decreased. These results
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suggest that applying PLS-DA feature selection may or may not improve clustering and
separation of classes within PLS-DA score plots, depending on the characteristics of the
data and the classification variable.

3.5.4 Key metabolites identified by RF variable importance
Supplementary Table 3.4 provides a summary of all metabolites ranked by RF
variable importance for the DC vs. PD classification. The top 7 metabolites were used to
train the RF model for classification (AUROC=0.828): pyruvate, serine, isoleucine,
arginine, N3,N4-dimethyl-L-arginine, threonine, and methionine. Supplementary Table
3.5 provides a summary of all metabolites ranked by RF variable importance for the
CR/PR vs. SD/PD classification. The top 11 metabolites were used to train the RF model
for classification (AUROC=0.791): cystine, uric acid, phenylalanine, isoleucine, malonic
acid, ornithine, N8-acetylspermidine, creatinine, pipecolinic acid, fumarate, and 3,4hydroxyphenyllactic acid. Supplementary Table 3.6 provides a summary of all
metabolites ranked by RF variable importance for the stage I/II/III vs. stage IV
classification. The top 15 metabolites were used to train the RF model for classification
(AUROC=0.817): Adenosine, 9(S)-HODE*13(S)-HODE, pyruvate, levulinic acid, adipic
acid, glutaric acid, guanosine, propionylcarnitine, serine, citrulline, inosine, benzoic acid,
glutamic acid, phenylalanine, and guanine.
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Supplementary Figure 3.1. Visualization of working metabolite dataset. Log
transformed unlabeled data with missing values for the combined (positive and negative
mode) dataset (left) and imputed dataset with no missing values (right), which
represents the working dataset for the unlabeled metabolite analysis. Imputation was
performed using PPCA method. Red indicates missing values; i.e., no signal was
detected.
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Supplementary Figure 3.2. Score plots showing distribution of samples on the
first two components for each patient classification. (A) PCA score plots using the
full metabolite set (66 features). (B) PCA classifications using the optimum subset of
features after forward feature selection. (C) PLS-DA score plots using the full metabolite
set (66 features). (D) PLS-DA classifications using the optimum subset of features after
forward feature selection. Quantification of the score plots is provided by the J2 and
overlap p-values for each patient classification.
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Supplementary Figure 3.3. Performance of supervised learning methods for each
patient classification. AUROC, balanced accuracy, and kappa are shown after forward
feature elimination using features selected by PLSDA VIP scores. Each model was
trained independently on each feature subset incrementing from 5 to 30. Results shown
are the test set averages after 100 iterations of 5-fold cross validation. For each method,
the optimal feature subset was chosen based on the maximum AUROC.
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Supplementary Figure 3.4. AUROC curves. Learning methods with the optimal
number of features are shown for all patient classifications. SVM performed best for the
DC vs. PD classification with 12 features, PLSDA performed best for the CR/PR vs.
SD/PD classification with 6 features, and SVM performed best for the stage I/II/III vs.
stage IV classification with 9 features.
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Supplementary Figure 3.5. Relative abundance of key metabolites (not statistically
significant set). P-values (0.5<p≤ 0.1) were found by Wilcoxon rank-sum test. Each box
represents 1st and 3rd quartiles. Bands within represent the median and x is the mean.
Ends of whiskers are maximum and minimum, with points outside being outliers. (A) DC
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(blue) vs. PD (red); (B) CR/PR (blue) vs. SD/PD (red); (C) Stage I/II/III (blue) vs. Stage
IV (red).

Supplementary Figure 3.6. Relative abundance of 13C labeled lactate. Relative
abundance of lactate found with log transformed intensity values (top row) and relative
abundance found with 13C labeled fractions ((13C labeled intensity/unlabeled intensity)
(bottom row). Intensity values were left raw (no centering or scaling) before division.
Complete case analysis was used. Each box represents 1st and 3rd quartiles. Bands
within represent the median and x is the mean. Ends of whiskers are maximum and
minimum, with points outside being outliers. (A) DC (blue) vs. PD (red); (B) CR/PR (blue)
vs. SD/PD (red); (C) Stage I/II/III (blue) vs. Stage IV (red).
comprehensive omics data could lead to enhanced understanding of how cancer
metabolism influences NSCLC progression and response to therapy.
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Supplementary Figure 3.7. Integrated metabolic network of serine (p ≤ 0.05),
methionine (p ≤ 0.05), and isoleucine (p ≤ 0.1) related to DC vs. PD. Blue = gene
node, green = enzyme node, pink = compound node, red = compound of interest, gray =
reaction node. Numbers denote reactions defined in the KEGG database.
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Metabolite

Correlation
Coefficient

p-value

Variable
importance

*Pyruvate

0.605

0.002

0.036

Proline

-0.242

0.266

0.027

Arginine

-0.225

0.302

0.027

Glutamine

-0.277

0.201

0.025

*Isoleucine

-0.415

0.049

0.025

Pathway
Pyruvate
metabolism;
Glycolysis/Gluconeo
genesis; TCA cycle;
Fatty acid
biosynthesis
Arginine and Proline
metabolism
Arginine
biosynthesis;
Arginine and proline
metabolism
Arginine
biosynthesis; Purine
metabolism;
Pyrimidine
metabolism; Alanine,
aspartate and
glutamate
metabolism; DGlutamine and Dglutamate
metabolism
Valine, leucine and
isoleucine
degradation/biosynth
esis
Cysteine and
methionine
metabolism;
Glucosinolate
metabolism,
Aminoacyl-t-RNA
biosynthesis

Methionine

-0.380

0.073

0.025

Inosine

0.173

0.430

0.024

Purine metabolism

*Uric acid

0.415

0.049

0.024

Purine metabolism;
Bile secretion

N3,N4DimethylL-arginine

-0.259

0.232

0.024

N/A

Salicylic
acid

0.398

0.060

0.023

*Creatinine

-0.467

0.025

0.022

Levulinic
acid

0.173

0.430

0.022

Glutamic
acid

Succinate

-0.311

0.311

0.148

0.148

0.022

0.021

Phenylalanine
metabolism; Dioxin
degradation;
Polycyclic aromatic
hydrocarbon
degradation
Glycine, serine, and
threonine
metabolism; Arginine
and proline
metabolism
N/A
Arginine
biosynthesis;
Alanine, aspartate
and glutamate
metaboilsm; Arginine
and proline
metabolism
Citrate cycle (TCA
cycle); Alanine,
aspartate and
glutamate
metabolism; Central
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PLSDA

SVM

DNN

KEGG
(map00620; map
00010;
map00020; map
00061)

X

X

X

KEGG
(map00330)

X

X

X

KEGG
(map00220,
map00330)

X

X

X

KEGG
(map00220;
map00230;
map00240;
map00250;
map00471)

X

X

X

KEGG
(map00280;
map00290)

X

X

X

KEGG
(map00270;
map00966;
map00970)

X

X

X

X

X

X

X

X

X

N/A

X

X

X

KEGG
(map00360;
map00621;
map00624)

X

X

X

KEGG
(map00260,
map00330)

X

X

X

N/A

X

X

X

KEGG
(map00220;
map00250;
map00330)

X

X

KEGG
(map00020,
map00250,
map05230,
map00620)

X

X

Reference

KEGG
(map00230)
KEGG
(map00230;
map04976)

carbon metabolism
in cancer; Pyruvate
metabolism; etc.
Acetyl-Lcarnitine
Lidocaine

0.208
-0.104

0.342
0.638

0.020
0.020

Fatty acid oxidation
Drug metabolism cytochrome P450
Phenylalanine
metabolism;
Benzoate
degradation, Dioxin
degradation
Fructose and
mannose
metabolism;
Galactose
metabolism; Starch
and sucrose
metabolism; Insulin
resistance

HMBD (LAcetylcarnitine)
KEGG
(map00982)
KEGG
(map00360;
map00362;
map00621)

Benzoic
acid

0.346

0.106

0.019

Fructose

0.190

0.385

0.019

N8Acetylsper
midine

0.190

0.385

0.019

N/A

N/A

Nicotinami
de

-0.329

0.126

0.018

Nicotinate and
nicotinamide
metabolism

KEGG
(map00760)

(R) 2Hydroxybu
tyric acid

0.121

0.582

0.018

Propanoate
metabolism

KEGG
(map00640)

Malonic
acid

0.277

0.201

0.018

Isocitrate

0.242

0.266

0.017

Fatty acid
metabolism;
Pyrimidine
metabolism; betaAlanine metabolism
Citrate cycle (TCA
cycle); Glyoxylate
and dicarboxylate
metabolism
Arginine
biosynthesis;
Arginine and proline
metabolism; Purine
metabolism,
Pyrimidine
metabolism
Pyrimidine
metabolism

HMBD (LAcetylcarnitine)

KEGG
(map00061;
map00240;
map00410)
KEGG
(map0020;
map00630)
KEGG
(map00220;
map00330;
map00230;
map00240)

Urea

-0.294

0.173

0.017

Pseudouri
dine

0.069

0.754

0.017

Guanosine

-0.104

0.638

0.017

Purine metabolism

KEGG
(map00350;
map00650;
map00760)

Maleic acid

3,4Hydroxyph
enyllactic
acid
Propionylc
arnitine

Threonine

KEGG
(map00240)
KEGG
(map00240)

0.225

0.302

0.016

Tyrosine
metabolism;
Butanoate
metabolism;
Nicotinate and
nicotinamide
metabolism

0.225

0.302

0.016

N/A

N/A

0.208

0.342

0.015

N/A

N/A

0.015

Glycine, serine, and
threonine
metabolism; Valine,
leucine and
isoluecine
biosynthesis

KEGG
(map00260;
map00290)

-0.380

0.073
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X

Malate

0.035

0.876

0.015

Methionine
Sulfoxide

-0.294

0.173

0.015

Taurine

-0.052

0.814

0.015

Guanine

-0.190

0.385

0.014

Ornithine

0.259

0.232

0.014

Lysine

-0.156

0.478

0.014

Fumarate

-0.190

0.385

0.014

*Serine

-0.432

0.039

0.013

Glutaric
acid

0.294

0.173

0.013

Creatine

0.242

0.266

0.012

Histamine

0.069

0.754

0.012

Valine

-0.380

0.073

0.012

Tryptopha
n

-0.294

0.173

0.011

Xanthine

-0.052

0.814

0.011

Itaconic
acid

0.173

0.430

0.011

Lactate

0.035

0.876

0.011

N/A
Cysteine and
methionine
metabolism
Primary bile acid
biosynthesis;
Taurine and
hypotaurine
metabolism, Sulfur
metabolism
Purine metabolism
Arginine
biosynthesis;
Arginine and proline
metabolism;
Glutathione
metabolism
Lysine biosynthesis;
Lysine degradation;
Biotin metabolism;
etc.
Citrate cycle (TCA
cycle); Alanine,
aspartate and
glutamate
metabolism; Central
carbon metabolism
in cancer; etc.
Glycine, serine and
threonine
metabolism;
Cysteine and
methionine
metabolism
Fatty acid
degradation; Lysine
degradation
Glycine, serine and
threonine
metabolism; Arginine
and proline
metabolism;
Histidine
metabolism;
Biosynthesis of
alkaloids derived
from histidine and
purine
Valine, leucine and
isoluecine
degradation/biosynth
esis
Glycine, serine and
threonine
metabolism;
Tryptophan
metabolism;
Phenylalanine,
tyrosine and
tryptophan
biosynthesis; etc.
Purine metabolism;
Caffeine metabolism
C-5Branched dibasic
acid metabolism
Glycolysis/Gluconeo
genesis
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N/A
KEGG
(map00270)
KEGG
(map00120;
map00430;
map00920)
KEGG
(map00230)
KEGG
(map00220;
map00330;
map00480)
KEGG
(map00300;
map00310;
map00780)
KEGG
(map00020;
map00250;
map05230)

KEGG
(map00260;
map00261)
KEGG
(map00071;
map00310)
KEGG
(map00260;
map00330)

KEGG
(map00340;
map01065)

KEGG
(map00280;
map00290)

KEGG
(map00260;
map00380;
map00400)

KEGG
(map00230;
map00232)
KEGG
(map00660)
KEGG
(map00010)

Urocanic
acid

Adenosine

0.208

0.069

0.342

0.754

0.011

0.011

Histidine metabolism
Purine metabolism;
cGMP-PKG
signaling pathway;
cAMP signaling
pathway
Glycine, serine and
threonine
metabolism;
Glycerophospholipid
metabolism; Choline
metabolism in
cancer

KEGG
(map00010)
KEGG
(map00230;
map04022;
map04024)

KEGG
(map00260;
map00564;
map05231)

Choline

-0.138

0.529

0.011

3Hydroxypy
ridine

-0.242

0.266

0.010

Cystine

-0.104

0.638

0.010

Phenylalan
ine

-0.363

0.089

0.010

Acetylcholi
ne

0.242

0.266

0.009

0.069

0.754

0.009

N/A

N/A

0.121

0.582

0.008

Lysine degradation

KEGG
(map00310)

-0.208

0.342

0.008

Lysine degradation;
ABC transporters

KEGG
(map00310;
map02010)

alphaKetoglutar
ate
N6,N6,N6TrimethylL-lysine
Carnitine

N/A

N/A

Cysteine and
methionine
metabolism
Phenylalanine
metabolism;
Phenylalanine,
tyrosine and
tryptophan
biosynthesis;
Glycerophospholipid
metabolism; cAMP
signaling pathway

Fructose and
mannose
metabolism;
Galactose
metabolism
Lysine degradation;
Tropane, piperidine
and pyridine alkaloid
biosynthesis
Pyrimidine
metabolism; ABC
transporters
Arginine
biosynthesis

KEGG
(map00270)

KEGG
(map00360;
map00400)
KEGG
(map00564;
map04024)

KEGG
(map00051;
map00052)

Sorbitol

-0.190

0.385

0.008

Pipecolinic
acid

-0.242

0.266

0.007

Uridine

0.017

0.938

0.007

Citrulline

0.052

0.814

0.007

-0.138

0.529

0.006

N/A

N/A

0.086

0.695

0.006

Purine metabolism

KEGG
(map00230)

Azelaic
acid
Hypoxanth
ine

Tyrosine

-0.277

0.201

0.006

Adipic acid

-0.104

0.638

0.006

Tyrosine
metabolism;
Phenylalanine
metabolism;
Phenylalanine,
tyrosine and
tryptophan
metabolism
Caprolactam
degradation;
Degradation of
aromatic compounds
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KEGG
(map00310;
map00960)
KEGG
(map00240;
map02010)
KEGG
(map00220)

KEGG
(map00350;
map00360;
map00400)

KEGG
(map00930,
map01220)

Adenine

0.035

0.876

0.005

Purine metabolism;
Zeatin biosynthesis

9(S)HODE*13(
S)-HODE

0.035

0.876

0.004

Linoleic acid
metabolism; PPAR
signaling pathway

KEGG
(map00230;
map00908)
KEGG
(map00591;
map03320)

Supplementary Table 3.1. Ranking of key metabolites based on PLS-DA variable
importance for DC vs. PD classification. Columns with “X” indicate subset of
metabolites used to train the indicated classification model. Correlation coefficients and
p-values were determined by Spearman correlation analysis *p<=0.05). Positive value
correlates with PD; negative value correlates with DC.

Metabolite
(R) 2Hydroxybuty
ric acid
*N8Acetylspermi
dine

Correlation
Coefficient

pvalue

Variable
importance

0.367

0.085

0.420

0.046

PLSDA

SVM

DNN

KEGG
(map00640)

X

X

X

N/A

X

X

X

KEGG
(map00220;
map00330;
map00230;
map00240)

X

X

X

KEGG
(map00270)

X

X

X

KEGG
(map00230;
map04976)

X

X

X

KEGG
(map00280;
map00290)

X

X

Pathway

Reference

0.077

Propanoate
metabolism

0.069

N/A
Arginine
biosynthesis;
Arginine and
proline
metabolism;
Purine
metabolism,
Pyrimidine
metabolism
Cysteine and
methionine
metabolism
Purine
metabolism; Bile
secretion
Valine, leucine
and isoluecine
degradation/biosy
nthesis
Citrate cycle (TCA
cycle); Alanine,
aspartate and
glutamate
metabolism;
Central carbon
metabolism in
cancer; etc.

Urea

-0.328

0.126

0.054

Cystine

-0.407

0.054

0.053

*Uric acid

0.499

0.015

0.052

Isoleucine

-0.407

0.054

0.052

*Fumarate

-0.472

0.023

0.051

3,4Hydroxyphen
yllactic acid

0.394

0.063

0.049

N/A

N/A

*Malonic acid

0.459

0.027

0.048

Fatty acid
metabolism;
Pyrimidine
metabolism; beta-

KEGG
(map00061;
map00240;
map00410)
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KEGG
(map00020;
map00250;
map05230)

*Tryptophan

Glutamine

-0.472

-0.105

0.023

0.634

0.048

0.042

Glutamic
acid

-0.249

0.251

0.040

*Methionine
Sulfoxide

-0.446

0.033

0.037

*Creatinine

-0.459

0.027

0.033

Lactate

-0.249

0.251

0.029

Nicotinamide

-0.328

0.126

0.029

Xanthine

-0.249

0.251

0.028

Propionylcar
nitine

0.197

0.368

0.027

Methionine

-0.262

0.226

0.027

Acetyl-Lcarnitine

0.197

0.368

0.025

Lysine

-0.407

0.054

0.025

Itaconic acid

0.157

0.473

0.024

Alanine
metabolism
Glycine, serine
and threonine
metabolism;
Tryptophan
metabolism;
Phenylalanine,
tyrosine and
tryptophan
biosynthesis; etc.
Arginine
biosynthesis;
Purine
metabolism;
Pyrimidine
metabolism;
Alanine, aspartate
and glutamate
metabolism; DGlutamine and Dglutamate
metabolism
Arginine
biosynthesis;
Alanine, aspartate
and glutamate
metaboilsm;
Arginine and
proline
metabolism
Cysteine and
methionine
metabolism
Glycine, serine,
and threonine
metabolism;
Arginine and
proline
metabolism
Glycolysis/Glucon
eogenesis
Nicotinate and
nicotinamide
metabolism
Purine
metabolism;
Caffeine
metabolism
N/A
Cysteine and
methionine
metabolism;
Glucosinolate
metabolism,
Aminoacyl-t-RNA
biosynthesis
Fatty acid
oxidation
Lysine
biosynthesis;
Lysine
degradation;
Biotin metabolism;
etc.
C-5Branched
dibasic acid
metabolism
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KEGG
(map00260;
map00380;
map00400)

KEGG
(map00220;
map00230;
map00240;
map00250;
map00471)

KEGG
(map00220;
map00250;
map00330)

KEGG
(map00270)

KEGG
(map00260,
map00330)
KEGG
(map00010)
KEGG
(map00760)
KEGG
(map00230;
map00232)
N/A

KEGG
(map00270;
map00966;
map00970)
HMBD (LAcetylcarnitine)
KEGG
(map00300;
map00310;
map00780)
KEGG
(map00660)

Arginine

-0.289

0.182

0.024

Adipic acid

-0.341

0.111

0.023

Pseudouridin
e

0.171

0.436

0.022

Sorbitol

-0.289

0.182

0.022

Creatine

0.144

0.511

0.021

alphaKetoglutarate

0.171

0.436

0.020

Adenine

0.236

0.278

0.020

Taurine

-0.039

0.858

0.019

Ornithine

0.276

0.203

0.019

Phenylalanin
e

-0.354

0.097

0.019

Hypoxanthin
e

0.184

0.401

0.019

Arginine
biosynthesis;
Arginine and
proline
metabolism
Caprolactam
degradation;
Degradation of
aromatic
compounds
Pyrimidine
metabolism
Fructose and
mannose
metabolism;
Galactose
metabolism
Glycine, serine
and threonine
metabolism;
Arginine and
proline
metabolism;
N/A
Purine
metabolism;
Zeatin
biosynthesis
Primary bile acid
biosynthesis;
Taurine and
hypotaurine
metabolism,
Sulfur metabolism
Arginine
biosynthesis;
Arginine and
proline
metabolism;
Glutathione
metabolism
Phenylalanine
metabolism;
Phenylalanine,
tyrosine and
tryptophan
biosynthesis;
Purine
metabolism
Citrate cycle (TCA
cycle); Alanine,
aspartate and
glutamate
metabolism;
Central carbon
metabolism in
cancer; Pyruvate
metabolism; etc.
Arginine
biosynthesis

KEGG
(map00220,
map00330)

KEGG
(map00930,
map01220)
KEGG
(map00240)
KEGG
(map00051;
map00052)

KEGG
(map00260;
map00330)

N/A
KEGG
(map00230;
map00908)
KEGG
(map00120;
map00430;
map00920)

KEGG
(map00220;
map00330;
map00480)

KEGG
(map00360;
map00400)
KEGG
(map00230)

KEGG
(map00020,
map00250,
map05230,
map00620)

Succinate

0.144

0.511

0.019

Citrulline

0.052

0.812

0.018

Levulinic
acid

-0.184

0.401

0.018

N/A

N/A

0.018

Glycine, serine,
and threonine
metabolism;
Valine, leucine
and isoluecine
biosynthesis

KEGG
(map00260;
map00290)

Threonine

-0.184

0.401
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KEGG
(map00220)

Benzoic acid

0.118

0.592

0.017

Phenylalanine
metabolism;
Benzoate
degradation,
Dioxin
degradation

3Hydroxypyrid
ine

-0.210

0.336

0.016

N/A

Serine

-0.131

0.551

0.016

Choline

-0.223

0.306

0.016

Azelaic acid

-0.262

0.226

0.015

Inosine

-0.144

0.511

0.014

Urocanic
acid

0.105

0.634

0.014

Pyruvate

0.131

0.551

0.014

Acetylcholin
e

0.092

0.677

0.014

Tyrosine

-0.223

0.306

0.013

Glutaric acid

0.171

0.436

0.012

N6,N6,N6Trimethyl-Llysine

0.105

0.634

0.012

Histamine

0.000

1.000

0.011

Malate

-0.092

0.677

0.010

Guanine

-0.079

0.721

0.009

Valine

-0.131

0.551

0.008

Adenosine

0.144

0.511

0.008

Glycine, serine
and threonine
metabolism;
Cysteine and
methionine
metabolism
Glycine, serine
and threonine
metabolism;
Glycerophospholi
pid metabolism;
Choline
metabolism in
cancer
N/A
Purine
metabolism
Histidine
metabolism
Pyruvate
metabolism;
Glycolysis/Glucon
eogenesis; TCA
cycle; Fatty acid
biosynthesis
Glycerophospholi
pid metabolism;
cAMP signaling
pathway
Tyrosine
metabolism;
Phenylalanine
metabolism;
Phenylalanine,
tyrosine and
tryptophan
metabolism
Fatty acid
degradation;
Lysine
degradation
Lysine
degradation
Histidine
metabolism;
Biosynthesis of
alkaloids derived
from histidine and
purine
N/A
Purine
metabolism
Valine, leucine
and isoluecine
degradation/biosy
nthesis
Purine
metabolism;
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KEGG
(map00360;
map00362;
map00621)

N/A

KEGG
(map00260;
map00261)

KEGG
(map00260;
map00564;
map05231)

N/A
KEGG
(map00230)
KEGG
(map00010)
KEGG
(map00620;
map 00010;
map00020;
map 00061)
KEGG
(map00564;
map04024)

KEGG
(map00350;
map00360;
map00400)

KEGG
(map00071;
map00310)
KEGG
(map00310)

KEGG
(map00340;
map01065)
N/A
KEGG
(map00230)
KEGG
(map00280;
map00290)
KEGG
(map00230;

Carnitine

-0.039

0.858

0.006

Isocitrate

-0.144

0.511

0.006

9(S)HODE*13(S)HODE

-0.131

0.551

0.005

N3,N4Dimethyl-Larginine

-0.052

0.812

0.004

Salicylic acid

0.092

0.677

0.003

Uridine

-0.066

0.766

0.003

Lidocaine

0.013

0.953

0.002

Pipecolinic
acid

-0.157

0.473

0.002

Maleic acid

0.092

0.677

0.002

Guanosine

0.013

0.953

0.001

Fructose

0.066

0.766

0.000

Proline

-0.066

0.766

0.000

cGMP-PKG
signaling
pathway; cAMP
signaling pathway
Lysine
degradation; ABC
transporters
Citrate cycle (TCA
cycle); Glyoxylate
and dicarboxylate
metabolism
Linoleic acid
metabolism;
PPAR signaling
pathway

map04022;
map04024)

N/A

N/A

Phenylalanine
metabolism;
Dioxin
degradation;
Polycyclic
aromatic
hydrocarbon
degradation
Pyrimidine
metabolism; ABC
transporters
Drug metabolism cytochrome P450
Lysine
degradation;
Tropane,
piperidine and
pyridine alkaloid
biosynthesis
Tyrosine
metabolism;
Butanoate
metabolism;
Nicotinate and
nicotinamide
metabolism
Purine
metabolism
Fructose and
mannose
metabolism;
Galactose
metabolism;
Starch and
sucrose
metabolism;
Insulin resistance
Arginine and
Proline
metabolism

KEGG
(map00310;
map02010)
KEGG
(map0020;
map00630)
KEGG
(map00591;
map03320)

KEGG
(map00360;
map00621;
map00624)

KEGG
(map00240;
map02010)
KEGG
(map00982)
KEGG
(map00310;
map00960)

KEGG
(map00350;
map00650;
map00760)
KEGG
(map00240)

HMBD (LAcetylcarnitine)

KEGG
(map00330)

Supplementary Table 3.2. Ranking of key metabolites based on PLS-DA variable
importance for CR/PR vs. SD/PD classification. Columns with “X” indicate subset of
metabolites used to train the indicated classification model. Correlation coefficients and
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p-values were determined by Spearman correlation analysis *p<=0.05). Positive value
correlates with SD/PD; negative value correlates with CR/PR.

Metabolite

Urea

Correlation
Coefficient

0.220

pvalue

0.212

Variable
importance

0.069

PLSDA

SVM

DNN

KEGG
(map00220;
map00330;
map00230;
map00240)

X

X

X

KEGG
(map00061;
map00240;
map00410)

X

X

X

Pathway
Arginine
biosynthesis;
Arginine and
proline
metabolism;
Purine
metabolism,
Pyrimidine
metabolism
Fatty acid
metabolism;
Pyrimidine
metabolism; betaAlanine
metabolism

Reference

Malonic
acid

0.289

0.098

0.053

N3,N4DimethylL-arginine

-0.194

0.270

0.049

N/A

N/A

X

X

X

Lidocaine

0.194

0.270

0.046

Drug metabolism cytochrome P450

KEGG
(map00982)

X

X

X

3,4Hydroxyph
enyllactic
acid

0.157

0.376

0.044

N/A

N/A

X

X

X

KEGG
(map00220;
map00250;
map00330)

X

X

X

KEGG
(map00930,
map01220)

X

X

X

N/A

X

X

X

KEGG
(map00620;
map 00010;
map00020;
map 00061)

X

X

X

Glutamic
acid

0.075

0.672

0.043

Adipic acid

0.251

0.152

0.041

Levulinic
acid

0.201

0.255

0.041

Pyruvate

0.289

0.098

0.039

Cystine

0.163

0.357

0.039

Taurine

0.082

0.647

0.038

*Glutaric
acid

0.339

0.050

0.037

Arginine
biosynthesis;
Alanine, aspartate
and glutamate
metaboilsm;
Arginine and
proline
metabolism
Caprolactam
degradation;
Degradation of
aromatic
compounds
N/A
Pyruvate
metabolism;
Glycolysis/Glucon
eogenesis; TCA
cycle; Fatty acid
biosynthesis
Cysteine and
methionine
metabolism
Primary bile acid
biosynthesis;
Taurine and
hypotaurine
metabolism,
Sulfur metabolism
Fatty acid
degradation;
Lysine
degradation

96

KEGG
(map00270)

X

KEGG
(map00120;
map00430;
map00920)

X

KEGG
(map00071;
map00310)

X

Creatinine

-0.119

0.502

0.036

Inosine

0.207

0.240

0.035

Ornithine

-0.207

0.240

0.033

Guanosine

0.220

0.212

0.033

Histamine

0.125

0.480

0.032

Benzoic
acid

0.276

0.114

0.031

Citrulline

0.270

0.123

0.031

Maleic acid

0.107

0.548

0.029

Propionylc
arnitine

0.220

0.212

0.027

Glutamine

-0.138

0.436

0.026

Uric acid

-0.044

0.805

0.026

Uridine

0.113

0.525

0.025

Proline

0.025

0.888

0.024

3Hydroxypy
ridine

0.182

0.303

0.024

0.023

Succinate

0.100

0.572

Glycine, serine,
and threonine
metabolism;
Arginine and
proline
metabolism
Purine
metabolism
Arginine
biosynthesis;
Arginine and
proline
metabolism;
Glutathione
metabolism
Purine
metabolism
Histidine
metabolism;
Biosynthesis of
alkaloids derived
from histidine and
purine
Phenylalanine
metabolism;
Benzoate
degradation,
Dioxin
degradation
Arginine
biosynthesis
Tyrosine
metabolism;
Butanoate
metabolism;
Nicotinate and
nicotinamide
metabolism
N/A
Arginine
biosynthesis;
Purine
metabolism;
Pyrimidine
metabolism;
Alanine, aspartate
and glutamate
metabolism; DGlutamine and Dglutamate
metabolism
Purine
metabolism; Bile
secretion
Pyrimidine
metabolism; ABC
transporters
Arginine and
Proline
metabolism

KEGG
(map00260,
map00330)

X

KEGG
(map00230)

X

KEGG
(map00220;
map00330;
map00480)

X

KEGG
(map00240)

X

KEGG
(map00340;
map01065)

X

KEGG
(map00360;
map00362;
map00621)

X

KEGG
(map00220)

X

KEGG
(map00350;
map00650;
map00760)

X

N/A

X

KEGG
(map00220;
map00230;
map00240;
map00250;
map00471)

X

KEGG
(map00230;
map04976)
KEGG
(map00240;
map02010)

X

X

KEGG
(map00330)

X

N/A

N/A

X

Citrate cycle (TCA
cycle); Alanine,
aspartate and
glutamate
metabolism;

KEGG
(map00020,
map00250,
map05230,
map00620)

X
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Guanine

0.063

0.724

0.022

Isocitrate

0.144

0.416

0.022

Itaconic
acid

0.082

0.647

0.022

Serine

-0.295

0.090

0.020

Methionine

0.063

0.724

0.020

Lactate

0.151

0.395

0.020

(R) 2Hydroxybu
tyric acid

-0.019

0.916

0.020

Adenosine

0.238

0.175

0.020

Pseudouri
dine

-0.063

0.724

0.019

Fumarate

Central carbon
metabolism in
cancer; Pyruvate
metabolism; etc.
Purine
metabolism
Citrate cycle (TCA
cycle); Glyoxylate
and dicarboxylate
metabolism
C-5Branched
dibasic acid
metabolism
Glycine, serine
and threonine
metabolism;
Cysteine and
methionine
metabolism
Cysteine and
methionine
metabolism;
Glucosinolate
metabolism,
Aminoacyl-t-RNA
biosynthesis
Glycolysis/Glucon
eogenesis
Propanoate
metabolism
Purine
metabolism;
cGMP-PKG
signaling
pathway; cAMP
signaling pathway
Pyrimidine
metabolism
Citrate cycle (TCA
cycle); Alanine,
aspartate and
glutamate
metabolism;
Central carbon
metabolism in
cancer; etc.
Purine
metabolism
Histidine
metabolism
Purine
metabolism;
Zeatin
biosynthesis

KEGG
(map00230)
KEGG
(map0020;
map00630)
KEGG
(map00660)

KEGG
(map00260;
map00261)

KEGG
(map00270;
map00966;
map00970)
KEGG
(map00010)
KEGG
(map00640)
KEGG
(map00230;
map04022;
map04024)
KEGG
(map00240)

KEGG
(map00020;
map00250;
map05230)

0.075

0.672

0.017

0.113

0.525

0.017

0.031

0.860

0.017

Adenine

0.163

0.357

0.016

N8Acetylsper
midine

0.025

0.888

0.016

N/A

N/A

Acetyl-Lcarnitine

0.100

0.572

0.015

Fatty acid
oxidation

HMBD (LAcetylcarnitin
e)

Xanthine

0.038

0.833

0.014

Malate

-0.019

0.916

0.014

Hypoxanth
ine
Urocanic
acid

Purine
metabolism;
Caffeine
metabolism
N/A
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KEGG
(map00230)
KEGG
(map00010)
KEGG
(map00230;
map00908)

KEGG
(map00230;
map00232)
N/A

Glycine, serine,
and threonine
metabolism;
Valine, leucine
and isoluecine
biosynthesis
Glycine, serine
and threonine
metabolism;
Arginine and
proline
metabolism;

KEGG
(map00260;
map00290)

Threonine

-0.132

0.458

0.014

Creatine

0.132

0.458

0.014

-0.019

0.916

0.014

N/A

N/A

0.025

0.888

0.013

N/A

N/A
KEGG
(map00591;
map03320)
KEGG
(map00310)

Azelaic
acid
alphaKetoglutar
ate
9(S)HODE*13(
S)-HODE

0.194

0.270

0.013

Linoleic acid
metabolism;
PPAR signaling
pathway

N6,N6,N6TrimethylL-lysine

-0.063

0.724

0.013

Lysine
degradation

Valine

-0.031

0.860

0.013

Salicylic
acid

0.100

0.572

0.012

Methionine
Sulfoxide

-0.063

0.724

0.012

Choline

0.176

0.320

0.012

Isoleucine

-0.088

0.621

0.012

Pipecolinic
acid

-0.100

0.572

0.012

Tyrosine

-0.082

0.647

0.009

Sorbitol

-0.031

0.860

0.009

Valine, leucine
and isoluecine
degradation/biosy
nthesis
Phenylalanine
metabolism;
Dioxin
degradation;
Polycyclic
aromatic
hydrocarbon
degradation
Cysteine and
methionine
metabolism
Glycine, serine
and threonine
metabolism;
Glycerophospholi
pid metabolism;
Choline
metabolism in
cancer
Valine, leucine
and isoluecine
degradation/biosy
nthesis
Lysine
degradation;
Tropane,
piperidine and
pyridine alkaloid
biosynthesis
Tyrosine
metabolism;
Phenylalanine
metabolism;
Phenylalanine,
tyrosine and
tryptophan
metabolism
Fructose and
mannose
metabolism;
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KEGG
(map00260;
map00330)

KEGG
(map00280;
map00290)

KEGG
(map00360;
map00621;
map00624)

KEGG
(map00270)

KEGG
(map00260;
map00564;
map05231)

KEGG
(map00280;
map00290)

KEGG
(map00310;
map00960)

KEGG
(map00350;
map00360;
map00400)

KEGG
(map00051;
map00052)

Lysine

-0.069

0.698

0.009

Tryptopha
n

0.000

1.000

0.008

Phenylalan
ine

-0.006

0.972

0.008

Fructose

0.013

0.944

0.007

Nicotinami
de

0.044

0.805

0.006

Arginine

0.056

0.751

0.006

Acetylcholi
ne

0.031

0.860

0.005

Carnitine

-0.013

0.944

0.004

Galactose
metabolism
Lysine
biosynthesis;
Lysine
degradation;
Biotin metabolism;
etc.
Glycine, serine
and threonine
metabolism;
Tryptophan
metabolism;
Phenylalanine,
tyrosine and
tryptophan
biosynthesis; etc.
Phenylalanine
metabolism;
Phenylalanine,
tyrosine and
tryptophan
biosynthesis;
Fructose and
mannose
metabolism;
Galactose
metabolism;
Starch and
sucrose
metabolism;
Insulin resistance
Nicotinate and
nicotinamide
metabolism
Arginine
biosynthesis;
Arginine and
proline
metabolism
Glycerophospholi
pid metabolism;
cAMP signaling
pathway
Lysine
degradation; ABC
transporters

KEGG
(map00300;
map00310;
map00780)

KEGG
(map00260;
map00380;
map00400)

KEGG
(map00360;
map00400)

HMBD (LAcetylcarnitin
e)

KEGG
(map00760)
KEGG
(map00220,
map00330)
KEGG
(map00564;
map04024)
KEGG
(map00310;
map02010)

Supplementary Table 3.3. Ranking of key metabolites based on PLS-DA variable
importance for stage I/II/III vs. stage IV classification. Columns with “X” indicate
subset of metabolites used to train the indicated classification model. Correlation
coefficients and p-values were determined by Spearman correlation analysis *p<=0.05).
Positive value correlates with stage IV; negative value correlates with stage I/II/III.
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Metabolite

Correlation
Coefficient

pvalue

Variable
importance

*Pyruvate

0.605

0.002

3.361

*Serine

-0.432

0.039

0.358

*Isoleucine

-0.415

0.049

0.240

Arginine

-0.225

0.302

0.224

N3,N4Dimethyl-Larginine

-0.259

0.232

0.158

Threonine

-0.380

0.073

0.153

Methionine

-0.380

0.073

0.130

Valine

-0.380

0.073

0.127

*Creatinine

-0.467

0.025

0.119

Phenylalani
ne

-0.363

0.089

0.113

alphaKetoglutarat
e

0.069

0.754

0.106

Maleic acid

Benzoic
acid

0.225

0.346

0.302

0.106

0.093

0.083

Pathway
Pyruvate metabolism;
Glycolysis/Gluconeoge
nesis; TCA cycle; Fatty
acid biosynthesis
Glycine, serine and
threonine metabolism;
Cysteine and
methionine metabolism
Valine, leucine and
isoluecine
degradation/biosynthes
is
Arginine biosynthesis;
Arginine and proline
metabolism
N/A
Glycine, serine, and
threonine metabolism;
Valine, leucine and
isoluecine biosynthesis
Cysteine and
methionine
metabolism;
Glucosinolate
metabolism,
Aminoacyl-t-RNA
biosynthesis
Valine, leucine and
isoluecine
degradation/biosynthes
is
Glycine, serine, and
threonine metabolism;
Arginine and proline
metabolism
Phenylalanine
metabolism;
Phenylalanine, tyrosine
and tryptophan
biosynthesis;
N/A
Tyrosine metabolism;
Butanoate metabolism;
Nicotinate and
nicotinamide
metabolism
Phenylalanine
metabolism; Benzoate
degradation, Dioxin
degradation
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Reference
KEGG
(map00620;
map 00010;
map00020;
map 00061)

RF

X

KEGG
(map00260;
map00261)

X

KEGG
(map00280;
map00290)

X

KEGG
(map00220,
map00330)

X

N/A

X

KEGG
(map00260;
map00290)

X

KEGG
(map00270;
map00966;
map00970)

X

KEGG
(map00280;
map00290)
KEGG
(map00260,
map00330)
KEGG
(map00360;
map00400)

N/A
KEGG
(map00350;
map00650;
map00760)
KEGG
(map00360;
map00362;
map00621)

Purine metabolism;
Bile secretion

KEGG
(map00230;
map04976)
KEGG
(map00061;
map00240;
map00410)

*Uric acid

0.415

0.049

0.078

Malonic
acid

0.277

0.201

0.068

Creatine

0.242

0.266

0.062

0.225

0.302

0.060

N/A

N/A

-0.294

0.173

0.055

Cysteine and
methionine metabolism

Citrulline

0.052

0.814

0.054

Arginine biosynthesis

Acetyl-Lcarnitine

0.208

0.342

0.050

Fatty acid oxidation

Glutaric
acid

0.294

0.173

0.047

Fatty acid degradation;
Lysine degradation

Lidocaine

-0.104

0.638

0.045

KEGG
(map00270)
KEGG
(map00220)
HMBD (LAcetylcarnitine)
KEGG
(map00071;
map00310)
KEGG
(map00982)

3,4Hydroxyphe
nyllactic
acid
Methionine
Sulfoxide

Succinate

0.311

0.148

0.044

N8Acetylsper
midine

0.190

0.385

0.042

Salicylic
acid

0.398

0.060

0.040

Cystine

-0.104

0.638

0.036

Adipic acid

-0.104

0.638

0.034

Pipecolinic
acid

-0.242

0.266

0.032

Tryptophan

-0.294

0.173

0.030

Fatty acid metabolism;
Pyrimidine metabolism;
beta-Alanine
metabolism
Glycine, serine and
threonine metabolism;
Arginine and proline
metabolism;

Drug metabolism cytochrome P450
Citrate cycle (TCA
cycle); Alanine,
aspartate and
glutamate metabolism;
Central carbon
metabolism in cancer;
Pyruvate metabolism;
etc.
N/A
Phenylalanine
metabolism; Dioxin
degradation; Polycyclic
aromatic hydrocarbon
degradation
Cysteine and
methionine metabolism
Caprolactam
degradation;
Degradation of
aromatic compounds
Lysine degradation;
Tropane, piperidine
and pyridine alkaloid
biosynthesis
Glycine, serine and
threonine metabolism;
Tryptophan
metabolism;
Phenylalanine, tyrosine
and tryptophan
biosynthesis; etc.
Purine metabolism;
cGMP-PKG signaling
pathway; cAMP
signaling pathway

KEGG
(map00260;
map00330)

KEGG
(map00020,
map00250,
map05230,
map00620)

N/A
KEGG
(map00360;
map00621;
map00624)
KEGG
(map00270)
KEGG
(map00930,
map01220)
KEGG
(map00310;
map00960)

KEGG
(map00260;
map00380;
map00400)
KEGG
(map00230;
map04022;
map04024)

Adenosine

0.069

0.754

0.026

(R) 2Hydroxybut
yric acid

0.121

0.582

0.024

Propanoate
metabolism

KEGG
(map00640)

Adenine

0.035

0.876

0.023

Purine metabolism;
Zeatin biosynthesis

KEGG
(map00230;
map00908)
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3Hydroxypyri
dine

-0.242

0.266

0.021

N/A
Fructose and mannose
metabolism; Galactose
metabolism; Starch
and sucrose
metabolism; Insulin
resistance
Arginine biosynthesis;
Alanine, aspartate and
glutamate metaboilsm;
Arginine and proline
metabolism
Arginine and Proline
metabolism
Arginine biosynthesis;
Arginine and proline
metabolism;
Glutathione
metabolism
Histidine metabolism;
Biosynthesis of
alkaloids derived from
histidine and purine

N/A

HMBD (LAcetylcarnitine)

Fructose

0.190

0.385

0.021

Glutamic
acid

-0.311

0.148

0.018

Proline

-0.242

0.266

0.017

Ornithine

0.259

0.232

0.016

Histamine

0.069

0.754

0.015

0.121

0.582

0.015

Lysine degradation

0.173

0.430

0.014

C-5Branched dibasic
acid metabolism

Guanosine

-0.104

0.638

0.014

Purine metabolism

Guanine

-0.190

0.385

0.013

Purine metabolism

Isocitrate

0.242

0.266

0.012

Citrate cycle (TCA
cycle); Glyoxylate and
dicarboxylate
metabolism

KEGG
(map0020;
map00630)

Levulinic
acid

0.173

0.430

0.011

N/A

N/A

N6,N6,N6Trimethyl-Llysine
Itaconic
acid

Glutamine

-0.277

0.201

0.010

9(S)HODE*13(S)
-HODE

0.035

0.876

0.010

Sorbitol

-0.190

0.385

0.010

Malate

0.035

0.876

0.007

Arginine biosynthesis;
Purine metabolism;
Pyrimidine metabolism;
Alanine, aspartate and
glutamate metabolism;
D-Glutamine and Dglutamate metabolism
Linoleic acid
metabolism; PPAR
signaling pathway
Fructose and mannose
metabolism; Galactose
metabolism
N/A

Azelaic acid

-0.138

0.529

0.007

N/A

Carnitine

-0.208

0.342

0.007

Lysine degradation;
ABC transporters

Nicotinamid
e

-0.329

0.126

0.007

Fumarate

-0.190

0.385

0.006

Nicotinate and
nicotinamide
metabolism
Citrate cycle (TCA
cycle); Alanine,
aspartate and
glutamate metabolism;
Central carbon
metabolism in cancer;
etc.
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KEGG
(map00220;
map00250;
map00330)
KEGG
(map00330)
KEGG
(map00220;
map00330;
map00480)
KEGG
(map00340;
map01065)
KEGG
(map00310)
KEGG
(map00660)
KEGG
(map00240)
KEGG
(map00230)

KEGG
(map00220;
map00230;
map00240;
map00250;
map00471)
KEGG
(map00591;
map03320)
KEGG
(map00051;
map00052)
N/A
N/A
KEGG
(map00310;
map02010)
KEGG
(map00760)

KEGG
(map00020;
map00250;
map05230)

Choline

-0.138

0.529

0.006

Glycine, serine and
threonine metabolism;
Glycerophospholipid
metabolism; Choline
metabolism in cancer

Inosine

0.173

0.430

0.003

Purine metabolism

Acetylcholi
ne

0.242

0.266

0.003

Taurine

-0.052

0.814

0.003

0.208

0.342

0.003

Histidine metabolism

KEGG
(map00010)

0.208

0.342

0.003

N/A

N/A
KEGG
(map00350;
map00360;
map00400)

Urocanic
acid
Propionylca
rnitine

Glycerophospholipid
metabolism; cAMP
signaling pathway
Primary bile acid
biosynthesis; Taurine
and hypotaurine
metabolism, Sulfur
metabolism

Tyrosine

-0.277

0.201

0.003

Tyrosine metabolism;
Phenylalanine
metabolism;
Phenylalanine, tyrosine
and tryptophan
metabolism

Uridine

0.017

0.938

0.003

Pyrimidine metabolism;
ABC transporters

Xanthine

-0.052

0.814

0.003

Purine metabolism;
Caffeine metabolism

Hypoxanthi
ne

0.086

0.695

0.000

Purine metabolism

Lactate

0.035

0.876

0.000

Glycolysis/Gluconeoge
nesis

Lysine

-0.156

0.478

0.000

Lysine biosynthesis;
Lysine degradation;
Biotin metabolism; etc.

Urea

-0.294

0.173

0.000

Arginine biosynthesis;
Arginine and proline
metabolism; Purine
metabolism, Pyrimidine
metabolism

Pseudouridi
ne

0.069

0.754

0.000

Pyrimidine metabolism

KEGG
(map00260;
map00564;
map05231)
KEGG
(map00230)
KEGG
(map00564;
map04024)
KEGG
(map00120;
map00430;
map00920)

KEGG
(map00240;
map02010)
KEGG
(map00230;
map00232)
KEGG
(map00230)
KEGG
(map00010)
KEGG
(map00300;
map00310;
map00780)
KEGG
(map00220;
map00330;
map00230;
map00240)
KEGG
(map00240)

Supplementary Table 3.4. Ranking of key metabolites based on RF variable
importance for DC vs. PD classification. Columns with “X” indicate subset of
metabolites used to train the classification model. Correlation coefficients and p-values
were determined by Spearman correlation analysis *p<=0.05). Positive value correlates
with PD; negative value correlates with DC.
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Correlation
Coefficient

pvalue

Variable
importance

Cystine

-0.407

0.054

0.309

*Uric acid

0.499

0.015

0.302

Phenylala
nine

-0.354

0.097

0.269

Isoleucine

-0.407

0.054

0.259

*Malonic
acid

0.459

0.027

0.250

Ornithine

0.276

0.203

0.243

*N8Acetylsper
midine

0.420

0.046

0.240

Metabolite

Pathway
Cysteine and
methionine
metabolism
Purine metabolism;
Bile secretion
Phenylalanine
metabolism;
Phenylalanine,
tyrosine and
tryptophan
biosynthesis;
Valine, leucine and
isoluecine
degradation/biosynthe
sis
Fatty acid
metabolism;
Pyrimidine
metabolism; betaAlanine metabolism
Arginine biosynthesis;
Arginine and proline
metabolism;
Glutathione
metabolism

Reference

N/A
Glycine, serine, and
threonine metabolism;
Arginine and proline
metabolism
Lysine degradation;
Tropane, piperidine
and pyridine alkaloid
biosynthesis
Citrate cycle (TCA
cycle); Alanine,
aspartate and
glutamate
metabolism; Central
carbon metabolism in
cancer; etc.

KEGG (map00270)

X

KEGG (map00230;
map04976)

X

KEGG (map00360;
map00400)

X

KEGG (map00280;
map00290)

X

KEGG (map00061;
map00240;
map00410)

X

KEGG (map00220;
map00330;
map00480)

X

N/A

X

KEGG (map00260,
map00330)

X

KEGG (map00310;
map00960)

X

KEGG (map00020;
map00250;
map05230)

X

X

*Creatinin
e

-0.459

0.027

0.239

Pipecolini
c acid

-0.157

0.473

0.233

*Fumarate

-0.472

0.023

0.228

0.394

0.063

0.227

N/A

N/A

-0.446

0.033

0.223

Cysteine and
methionine
metabolism

KEGG (map00270)

0.367

0.085

0.213

Propanoate
metabolism

KEGG (map00640)

0.210

Arginine biosynthesis;
Purine metabolism;
Pyrimidine
metabolism; Alanine,
aspartate and
glutamate

KEGG (map00220;
map00230;
map00240;
map00250;
map00471)

3,4Hydroxyp
henyllactic
acid
*Methionin
e
Sulfoxide
(R) 2Hydroxyb
utyric acid

Glutamine

-0.105

0.634
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RF

metabolism; DGlutamine and Dglutamate metabolism
Propionylc
arnitine

0.197

0.368

0.207

Lysine

-0.407

0.054

0.203

Histamine

0.000

1.000

0.197

Urea

-0.328

0.126

0.194

Glutamic
acid

-0.249

0.251

0.192

Nicotinami
de

-0.328

0.126

0.186

*Tryptoph
an

-0.472

0.023

0.183

Arginine

-0.289

0.182

0.183

Levulinic
acid

-0.184

0.401

0.180

Fructose

0.066

0.766

0.180

Adenosine

0.144

0.511

0.180

Sorbitol

-0.289

0.182

0.176

Adipic
acid

-0.341

0.111

0.176

Lactate

-0.249

0.251

0.173

Guanosine
Itaconic
acid

0.013

0.953

0.161

0.157

0.473

0.161

0.171

0.436

0.159

Glutaric
acid

N/A
Lysine biosynthesis;
Lysine degradation;
Biotin metabolism;
etc.
Histidine metabolism;
Biosynthesis of
alkaloids derived from
histidine and purine
Arginine biosynthesis;
Arginine and proline
metabolism; Purine
metabolism,
Pyrimidine
metabolism
Arginine biosynthesis;
Alanine, aspartate
and glutamate
metaboilsm; Arginine
and proline
metabolism
Nicotinate and
nicotinamide
metabolism
Glycine, serine and
threonine metabolism;
Tryptophan
metabolism;
Phenylalanine,
tyrosine and
tryptophan
biosynthesis; etc.
Arginine biosynthesis;
Arginine and proline
metabolism
N/A
Fructose and
mannose metabolism;
Galactose
metabolism; Starch
and sucrose
metabolism; Insulin
resistance
Purine metabolism;
cGMP-PKG signaling
pathway; cAMP
signaling pathway
Fructose and
mannose metabolism;
Galactose metabolism
Caprolactam
degradation;
Degradation of
aromatic compounds
Glycolysis/Gluconeog
enesis
Purine metabolism
C-5Branched dibasic
acid metabolism
Fatty acid
degradation; Lysine
degradation
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N/A
KEGG (map00300;
map00310;
map00780)
KEGG (map00340;
map01065)

KEGG (map00220;
map00330;
map00230;
map00240)

KEGG (map00220;
map00250;
map00330)

KEGG (map00760)

KEGG (map00260;
map00380;
map00400)

KEGG (map00220,
map00330)
N/A

HMBD (LAcetylcarnitine)

KEGG (map00230;
map04022;
map04024)
KEGG (map00051;
map00052)
KEGG (map00930,
map01220)
KEGG (map00010)
KEGG (map00240)
KEGG (map00660)
KEGG (map00071;
map00310)

Acetylchol
ine
Citrulline
Hypoxanth
ine
Azelaic
acid

0.092

0.677

0.158

0.052

0.812

0.158

Glycerophospholipid
metabolism; cAMP
signaling pathway
Arginine biosynthesis

0.184

0.401

0.157

Purine metabolism

KEGG (map00230)

-0.262

0.226

0.157

N/A

N/A

Purine metabolism;
Caffeine metabolism
Purine metabolism
Glycine, serine and
threonine metabolism;
Cysteine and
methionine
metabolism
Arginine and Proline
metabolism
Purine metabolism;
Zeatin biosynthesis

KEGG (map00230;
map00232)
KEGG (map00230)

Lysine degradation

KEGG (map00310)

Xanthine

-0.249

0.251

0.153

Guanine

-0.079

0.721

0.152

Serine

-0.131

0.551

0.152

Proline

-0.066

0.766

0.152

Adenine

0.236

0.278

0.150

N6,N6,N6TrimethylL-lysine

0.105

0.634

0.149

Cysteine and
methionine
metabolism;
Glucosinolate
metabolism,
Aminoacyl-t-RNA
biosynthesis
Glycine, serine and
threonine metabolism;
Arginine and proline
metabolism;
Tyrosine metabolism;
Butanoate
metabolism;
Nicotinate and
nicotinamide
metabolism
Citrate cycle (TCA
cycle); Alanine,
aspartate and
glutamate
metabolism; Central
carbon metabolism in
cancer; Pyruvate
metabolism; etc.
Phenylalanine
metabolism; Dioxin
degradation;
Polycyclic aromatic
hydrocarbon
degradation
Glycine, serine, and
threonine metabolism;
Valine, leucine and
isoluecine
biosynthesis

KEGG (map00564;
map04024)
KEGG (map00220)

KEGG (map00260;
map00261)

KEGG (map00330)
KEGG (map00230;
map00908)

KEGG (map00270;
map00966;
map00970)

Methionin
e

-0.262

0.226

0.148

Creatine

0.144

0.511

0.147

Maleic
acid

0.092

0.677

0.143

Succinate

0.144

0.511

0.142

Salicylic
acid

0.092

0.677

0.140

Threonine

-0.184

0.401

0.139

alphaKetoglutar
ate

0.171

0.436

0.139

N/A

N/A

0.132

Tyrosine metabolism;
Phenylalanine
metabolism;
Phenylalanine,
tyrosine and

KEGG (map00350;
map00360;
map00400)

Tyrosine

-0.223

0.306
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KEGG (map00260;
map00330)

KEGG (map00350;
map00650;
map00760)

KEGG (map00020,
map00250,
map05230,
map00620)

KEGG (map00360;
map00621;
map00624)

KEGG (map00260;
map00290)

Pyruvate

0.131

0.551

0.128

Inosine
N3,N4DimethylL-arginine
9(S)HODE*13(
S)-HODE

-0.144

0.511

0.124

tryptophan
metabolism
N/A
Glycine, serine and
threonine metabolism;
Glycerophospholipid
metabolism; Choline
metabolism in cancer
Pyruvate metabolism;
Glycolysis/Gluconeog
enesis; TCA cycle;
Fatty acid
biosynthesis
Purine metabolism

-0.052

0.812

0.117

N/A

-0.131

0.551

0.116

Isocitrate

-0.144

0.511

0.115

Benzoic
acid

0.118

0.592

0.114

Malate

-0.092

0.677

0.130

Choline

-0.223

0.306

0.128

Linoleic acid
metabolism; PPAR
signaling pathway
Citrate cycle (TCA
cycle); Glyoxylate and
dicarboxylate
metabolism
Phenylalanine
metabolism; Benzoate
degradation, Dioxin
degradation

N/A
KEGG (map00260;
map00564;
map05231)
KEGG (map00620;
map 00010;
map00020; map
00061)
KEGG (map00230)
N/A
KEGG (map00591;
map03320)
KEGG (map0020;
map00630)
KEGG (map00360;
map00362;
map00621)

Urocanic
acid
3Hydroxypy
ridine
Pseudouri
dine

0.105

0.634

0.105

Histidine metabolism

KEGG (map00010)

-0.210

0.336

0.103

N/A

N/A

0.171

0.436

0.096

Valine

-0.131

0.551

0.096

Carnitine

-0.039

0.858

0.094

Lidocaine

0.013

0.953

0.093

Taurine

-0.039

0.858

0.091

Uridine

-0.066

0.766

0.089

Acetyl-Lcarnitine

0.197

0.368

0.085

Pyrimidine
metabolism
Valine, leucine and
isoluecine
degradation/biosynthe
sis
Lysine degradation;
ABC transporters
Drug metabolism cytochrome P450
Primary bile acid
biosynthesis; Taurine
and hypotaurine
metabolism, Sulfur
metabolism
Pyrimidine
metabolism; ABC
transporters
Fatty acid oxidation

KEGG (map00240)
KEGG (map00280;
map00290)
KEGG (map00310;
map02010)
KEGG (map00982)
KEGG (map00120;
map00430;
map00920)
KEGG (map00240;
map02010)
HMBD (LAcetylcarnitine)

Supplementary Table 3.5. Ranking of key metabolites based on RF variable
importance for CR/PR vs. SD/PD classification. Columns with “X” indicate subset of
metabolites used to train the classification model. Correlation coefficients and p-values
were determined by Spearman correlation analysis *p<=0.05). Positive value correlates
with SD/PD; negative value correlates with CR/PR.
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Metabolite

Correlation
Coefficient

pvalue

Variable
importance

Adenosine

0.238

0.175

0.972

9(S)HODE*13(S)
-HODE

0.194

0.270

0.770

Pyruvate

0.289

0.098

0.750

Levulinic
acid

0.201

0.255

0.610

Adipic acid

0.251

0.152

0.540

*Glutaric
acid

0.339

0.050

0.539

Guanosine

0.220

0.212

0.452

Purine metabolism

Propionylca
rnitine

0.220

0.212

0.447

N/A

N/A

X

KEGG
(map00260;
map00261)

X

Pathway
Purine metabolism;
cGMP-PKG signaling
pathway; cAMP
signaling pathway
Linoleic acid
metabolism; PPAR
signaling pathway
Pyruvate metabolism;
Glycolysis/Gluconeog
enesis; TCA cycle;
Fatty acid
biosynthesis

Reference
KEGG
(map00230;
map04022;
map04024)
KEGG
(map00591;
map03320)
KEGG
(map00620;
map 00010;
map00020;
map 00061)

N/A

N/A

X

KEGG
(map00930,
map01220)

X

Caprolactam
degradation;
Degradation of
aromatic compounds
Fatty acid
degradation; Lysine
degradation

Serine

-0.295

0.090

0.403

Glycine, serine and
threonine metabolism;
Cysteine and
methionine
metabolism

Citrulline

0.270

0.123

0.380

Arginine biosynthesis

Inosine

0.207

0.240

0.376

Purine metabolism

Benzoic
acid

0.276

0.114

0.336

X
X

X

KEGG
(map00230)

X

0.291

Glycine, serine, and
threonine metabolism;
Arginine and proline
metabolism

KEGG
(map00260,
map00330)

0.276

Arginine biosynthesis;
Arginine and proline
metabolism; Purine
metabolism,

KEGG
(map00220;
map00330;
map00230;
map00240)

-0.006

0.972

0.295

Guanine

0.063

0.724

0.295

0.212

X

Purine metabolism

Phenylalani
ne

0.220

X

X

0.299

Urea

X

KEGG
(map00360;
map00400)

0.672

0.502

X

X

0.075

-0.119

KEGG
(map00220)
KEGG
(map00230)
KEGG
(map00360;
map00362;
map00621)

X

KEGG
(map00220;
map00250;
map00330)

Glutamic
acid

Creatinine

Phenylalanine
metabolism; Benzoate
degradation, Dioxin
degradation
Arginine biosynthesis;
Alanine, aspartate
and glutamate
metaboilsm; Arginine
and proline
metabolism
Phenylalanine
metabolism;
Phenylalanine,
tyrosine and
tryptophan
biosynthesis;

KEGG
(map00071;
map00310)
KEGG
(map00240)

RF
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Lidocaine

0.194

0.270

0.263

Hypoxanthi
ne

0.113

0.525

0.261

Malonic
acid
Malate
Pseudouridi
ne
alphaKetoglutarat
e

Ornithine

0.289

0.098

0.245

-0.019

0.916

0.234

-0.063

0.724

0.232

0.025

0.888

0.226

-0.207

0.240

Pyrimidine
metabolism
Drug metabolism cytochrome P450
Purine metabolism
Fatty acid
metabolism;
Pyrimidine
metabolism; betaAlanine metabolism
N/A
Pyrimidine
metabolism
N/A
Arginine biosynthesis;
Arginine and proline
metabolism;
Glutathione
metabolism
Citrate cycle (TCA
cycle); Alanine,
aspartate and
glutamate
metabolism; Central
carbon metabolism in
cancer; Pyruvate
metabolism; etc.
Arginine and Proline
metabolism
Pyrimidine
metabolism; ABC
transporters
Cysteine and
methionine
metabolism;
Glucosinolate
metabolism,
Aminoacyl-t-RNA
biosynthesis
Histidine metabolism;
Biosynthesis of
alkaloids derived from
histidine and purine
Glycine, serine and
threonine metabolism;
Glycerophospholipid
metabolism; Choline
metabolism in cancer

0.211

Succinate

0.100

0.572

0.202

Proline

0.025

0.888

0.201

Uridine

0.113

0.525

0.190

Methionine

0.063

0.724

0.185

Histamine

0.125

0.480

0.178

Choline

0.176

0.320

0.178

Urocanic
acid

0.031

0.860

0.175

Histidine metabolism

Arginine

0.056

0.751

0.171

Arginine biosynthesis;
Arginine and proline
metabolism

Adenine

0.163

0.357

0.165

Purine metabolism;
Zeatin biosynthesis

Acetyl-Lcarnitine

0.100

0.572

0.164

Fatty acid oxidation

0.162

Primary bile acid
biosynthesis; Taurine
and hypotaurine
metabolism, Sulfur
metabolism

Taurine

0.082

0.647
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KEGG
(map00982)
KEGG
(map00230)
KEGG
(map00061;
map00240;
map00410)
N/A
KEGG
(map00240)
N/A
KEGG
(map00220;
map00330;
map00480)

KEGG
(map00020,
map00250,
map05230,
map00620)
KEGG
(map00330)
KEGG
(map00240;
map02010)
KEGG
(map00270;
map00966;
map00970)

KEGG
(map00340;
map01065)
KEGG
(map00260;
map00564;
map05231)
KEGG
(map00010)
KEGG
(map00220,
map00330)
KEGG
(map00230;
map00908)
HMBD (LAcetylcarnitine
)
KEGG
(map00120;
map00430;
map00920)

Isocitrate

0.144

0.416

0.156

Threonine

-0.132

0.458

0.152

Lysine

Citrate cycle (TCA
cycle); Glyoxylate and
dicarboxylate
metabolism
Glycine, serine, and
threonine metabolism;
Valine, leucine and
isoluecine
biosynthesis
Lysine biosynthesis;
Lysine degradation;
Biotin metabolism;
etc.

KEGG
(map0020;
map00630)
KEGG
(map00260;
map00290)
KEGG
(map00300;
map00310;
map00780)

-0.069

0.698

0.144

0.182

0.303

0.141

N/A

N/A

-0.019

0.916

0.141

N/A

Pipecolinic
acid

-0.100

0.572

0.140

Lactate

0.151

0.395

0.137

N/A
Lysine degradation;
Tropane, piperidine
and pyridine alkaloid
biosynthesis
Glycolysis/Gluconeog
enesis

Xanthine

0.038

0.833

0.130

3Hydroxypyri
dine
Azelaic acid

Salicylic
acid

0.100

0.572

0.126

Valine

-0.031

0.860

0.125

(R) 2Hydroxybut
yric acid

-0.019

0.916

0.118

Cystine

0.163

0.357

0.118

Glutamine

-0.138

0.436

0.111

Nicotinamid
e

0.044

0.805

0.107

Methionine
Sulfoxide

-0.063

0.724

0.106

Tryptophan

0.000

1.000

0.106

Maleic acid

0.107

0.548

0.105

Purine metabolism;
Caffeine metabolism
Phenylalanine
metabolism; Dioxin
degradation;
Polycyclic aromatic
hydrocarbon
degradation
Valine, leucine and
isoluecine
degradation/biosynthe
sis
Propanoate
metabolism
Cysteine and
methionine
metabolism
Arginine biosynthesis;
Purine metabolism;
Pyrimidine
metabolism; Alanine,
aspartate and
glutamate
metabolism; DGlutamine and Dglutamate metabolism
Nicotinate and
nicotinamide
metabolism
Cysteine and
methionine
metabolism
Glycine, serine and
threonine metabolism;
Tryptophan
metabolism;
Phenylalanine,
tyrosine and
tryptophan
biosynthesis; etc.
Tyrosine metabolism;
Butanoate
metabolism;
Nicotinate and
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KEGG
(map00310;
map00960)
KEGG
(map00010)
KEGG
(map00230;
map00232)
KEGG
(map00360;
map00621;
map00624)
KEGG
(map00280;
map00290)
KEGG
(map00640)
KEGG
(map00270)

KEGG
(map00220;
map00230;
map00240;
map00250;
map00471)

KEGG
(map00760)
KEGG
(map00270)

KEGG
(map00260;
map00380;
map00400)

KEGG
(map00350;
map00650;
map00760)

nicotinamide
metabolism
N3,N4Dimethyl-Larginine

-0.194

0.270

0.105

N/A

N/A

Uric acid

-0.044

0.805

0.103

Purine metabolism;
Bile secretion

KEGG
(map00230;
map04976)

Fructose

0.013

0.944

0.102

Itaconic
acid

0.082

0.647

0.098

Fumarate

0.075

0.672

0.097

Creatine

0.132

0.458

0.096

Fructose and
mannose metabolism;
Galactose
metabolism; Starch
and sucrose
metabolism; Insulin
resistance
C-5Branched dibasic
acid metabolism
Citrate cycle (TCA
cycle); Alanine,
aspartate and
glutamate
metabolism; Central
carbon metabolism in
cancer; etc.
Glycine, serine and
threonine metabolism;
Arginine and proline
metabolism;
Tyrosine metabolism;
Phenylalanine
metabolism;
Phenylalanine,
tyrosine and
tryptophan
metabolism
Valine, leucine and
isoluecine
degradation/biosynthe
sis

HMBD (LAcetylcarnitine
)

KEGG
(map00660)
KEGG
(map00020;
map00250;
map05230)

KEGG
(map00260;
map00330)

KEGG
(map00350;
map00360;
map00400)

Tyrosine

-0.082

0.647

0.090

Isoleucine

-0.088

0.621

0.089

0.025

0.888

0.088

N/A

N/A

0.157

0.376

0.087

N/A

N/A

Carnitine

-0.013

0.944

0.083

Lysine degradation;
ABC transporters

KEGG
(map00310;
map02010)

N6,N6,N6Trimethyl-Llysine

-0.063

0.724

0.083

Lysine degradation

KEGG
(map00310)

Acetylcholi
ne

0.031

0.860

0.058

Sorbitol

-0.031

0.860

0.050

Glycerophospholipid
metabolism; cAMP
signaling pathway
Fructose and
mannose metabolism;
Galactose metabolism

KEGG
(map00564;
map04024)
KEGG
(map00051;
map00052)

N8Acetylsper
midine
3,4Hydroxyphe
nyl-lactic
acid

KEGG
(map00280;
map00290)

Supplementary Table 3.6. Ranking of key metabolites based on RF variable
importance for stage I/II/III vs. stage IV classification. Columns with “X” indicate
subset of metabolites used to train the classification model. Correlation coefficients and
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p-values were determined by Spearman correlation analysis *p<=0.05). Positive value
correlates with stage IV; negative value correlates with stage I/II/III.
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Supplementary Table 3.7. Quantitative Enrichment Analysis. Top 20 enriched
metabolic pathways ranked by p-value were found with MetaboAnalyst 4.0 using (A)
KEGG pathway database and (B) SMPD database.
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CHAPTER 43

LUNG CANCER METABOLOMIC DATA FROM TUMOR CORE BIOPSIES ENABLES
RISK-SCORE CALCULATION FOR PROGRESSION-FREE AND OVERALL SURVIVAL

4.1 INTRODUCTION
Accounting for an estimated 12-13% of new cancer diagnoses in 2021, lung
cancer is one of the most prevalent cancer types in the U.S. Of ~600,000 deaths
attributed to cancer by the end of 2021, 22% are estimated to be lung cancer [143].
Survival has increased since the early 1990s, likely due to improvements in early
diagnosis and treatment options. Yet, the outlook for any particular patient is dire, with a
5-year survival rate <5% for all stages combined [144]. Reasons for this poor survival
are multifactorial, with two dominant issues being presentation at an advanced stage
and poor treatment success rates for patients at an advanced stage [145, 146]. Once
patients have been diagnosed, identifying metabolic markers associated with high risk of
early death has potential clinical utility for risk stratification and management of patient
care.

Metabolomics aims to quantify a broad spectrum of small molecule metabolites
within a biological sample and has emerged as a powerful tool for phenotyping a variety
of diseases, including cancer [147]. Mass spectrometry (MS) and nuclear magnetic

3

Miller, H.A., Rai, S., Yin X., Zhang X., Chesney J., van Berkel V.H., Frieboes, H.B. Lung cancer
metabolomic data from tumor core biopsies enables risk-score calculation for progression-free
and overall survival. Metabolomics 2022 (in press).
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resonance spectroscopy (NMR) are two major techniques commonly employed in
metabolomics studies. Specifically for lung cancer, metabolomics has proven useful in a
variety of diagnostic and prognostic roles [23], helping to resolve the link between
genotype and phenotype. Several studies have investigated the metabolic profiles of
lung cancer patients compared to healthy controls [89, 148, 149], showing profound
metabolic dysregulation in lung cancer. Metabolic alterations have also been found in
different histology types [149, 150] and pathological stages [146, 149] indicating that
metabolomics is useful for determining disease progression.

Recent studies have investigated the use of metabolic profiles from serum,
plasma, urine, and tissue samples for predicting survival in a variety of cancers [151154]. In particular, a study using high-resolution magic angle spinning nuclear magnetic
resonance (HR-MAS NMR) metabolomics data derived from paired serum-tissue
samples discovered 9 spectral regions with significant differentiation between short and
prolonged survival groups of early stage lung cancer patients in a Kaplan-Meier survival
analysis (p = 0.0100) [154]. Recently, 4 metabolites in were included in a weighted risk
score calculation and significant differences in survival probability were found between
low- and high-risk advanced non-small cell lung cancer (NSCLC) patients receiving firstline chemotherapy [155]. Based on the literature, there is a promising outlook on the use
of metabolomics for survival prediction in lung cancer patients, and the area is relatively
unexplored.

In contrast to recent cancer patient serum metabolomic [86, 87] or radiomic [90]
profiling, we report patient survival based on metabolomic analysis of tumor core
biopsies routinely obtained during lung cancer patient care. In [154], tissue samples
were found to result in better prediction accuracy for differentiating lung cancer subtypes
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(AUROCTest = 0.82) compared to serum samples (AUROCTest = 0.73). In our previous
study [38], metabolomic profiles of patient tissue samples successfully predicted lung
cancer disease control and progressive disease groups as response to first-line therapy.
In the current study, tissue-derived metabolites along with the covariates pathological
staging at diagnosis, age at diagnosis, sex, histology subtype, and treatment vs. nontreatment were evaluated as markers for determining hazard ratios and survival
probability in lung cancer patients. Our hypothesis is that metabolomic analysis of the
tumor tissue itself has the potential to reveal biomarkers for distinguishing patients
based on survival. These metabolic biomarkers would have clinical utility for calculating
a weighted risk score to separate patients into low- and high-risk groups for OS and
PFS.

4.2 MATERIALS AND METHODS
The data for this study were obtained from an on-going study [38]. Experimental
workflow and data wrangling pipeline are summarized below and in Figure 4.1.
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Figure 4.1. Diagram of study workflow.

4.2.1 Tissue collection
Patients were recruited from an ongoing study, as described in [38]. Informed
consent was obtained to participate. All specimens were collected following approved
Institutional Review Board protocols at University of Louisville Hospital (IRB 05.0523)
and Norton Hospital (IRB 18.0264) from patients with known or suspected NSCLC.
Demographic information, including age, sex, race, smoking history, personal history of
malignancy, and relevant family history were recorded. Samples were collected by the
clinical team, blinded to the research analysis.

4.2.3 Tissue processing and metabolite extraction
Tumor core biopsies were immediately placed into 1 mL 13C labeled glucose
medium in 24-well cell culture plates and incubated at 5% CO2 and 37 oC on a shaker for
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24 h. Following incubation, a liquid-liquid metabolite extraction was performed. Briefly,
500 mL acetonitrile was added, and tissue was homogenized with a pellet mixer. After 23 min homogenization, 376 mL of DNase/RNase free water and 250 mL chloroform were
added. Contents were vortexed and centrifuged 180xg for 20 min. The top (polar) layer
was aspirated and frozen at -80 oC. A quality control sample was prepared from an
NSCLC tissue biopsy incubated in unlabeled glucose media for 24 h and processed
likewise. Sample polar layers were flash frozen in liquid N2, then lyophilized for 24-48 h
until dried and transported on ice to CREAM core facility for 2DLC-MS/MS analysis.

4.2.4 2DLC-MS/MS analysis and data pre-processing
All samples were analyzed in random order on a Thermo Q Exactive HF Hybrid
Quadrupole-Orbitrap Mass Spectrometer coupled with a Thermo DIONEX UltiMate 3000
HPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with a reversedphase chromatography (RPC) column and a hydrophilic interaction chromatography
(HILIC) column configured to form a parallel 2DLC-MS system[39]. To obtain full MS data,
every sample was analyzed by parallel 2DLC-MS in positive (+) and negative (-) modes.
One unlabeled sample in each group was analyzed by 2DLC-MS/MS in positive and
negative modes to acquire MS/MS spectra at 20, 40, and 60 eV collision energies as a
quality control for metabolite identification. Data of unlabeled samples were first matched
to an in-house database that contains parent ion m/z, MS/MS spectra, and retention time
of authentic standards (MSI Level 1 identification). Data without a match (MSI Level 2
identification) were analyzed using Compound Discoverer software v2.0 (Thermo Fisher
Scientific, Germany).

4.2.5 Organization of MS peak intensity data
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2DLC-MS data was presented as an alignment table for each batch with
retention time, m/z, signal intensity, stable isotope labeling, name of identified
metabolite, and database used for metabolite identification. Once metabolites from
positive and negative modes were combined, a preliminary step to handle missing
values was performed by removing features that contained more than 50% missing
values and resulted in a dataset of 52 metabolites with approximately 25.7% missing
values. Based on previous analyses, some data appeared to be missing not at random
(MNAR) while some was missing at random (MAR). It is clear that certain metabolites
were not detected in the quality control samples when particular batches of samples
were analyzed, but there were other instances of seemingly random missing values.
Therefore, we chose to handle missing values by imputation rather than limit of detection
(LOD) substitution. Data were log-transformed [33], which is a common method to
normalize biological data by centering it and correcting for heteroscedasticity [33], and
imputed by probabilistic principal component analysis (PPCA) [82]. A complete subset of
the original data was taken and simulated missing values were introduced. A variety of
substitution and imputation methods were tested, where imputation by PPCA resulted in
the lowest RMSE [38]. The R package pcaMethods was used to perform PPCA. The
function was seeded with an integer of ‘1234’ to allow for reproducibility and
“maxIterations” was set to 1000.

4.2.6 Patient clinical data
Out of 54 eligible patients, 46 had follow-up and survival time information, 44 of
which had staging information. Data collected included subject (age, sex, primary
ethnicity, primary race, status, age at death, overall survival, cancer description,
histology subtypes, cancer stage and substage, and progression-free survival in days),
treatment (therapy type, therapy details, days of therapy, chemotherapy agent type,
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chemotherapy agent repeat units, number of chemotherapy cycles completed, surgery
results, overall response to surgery/chemotherapy, days since diagnosis and response
assessment types), and other information regarding the specimens.

4.2.7 Data analysis
All statistical analyses were conducted in the R programming language version
4.1.0. Hazard ratios were calculated by Cox proportional hazards regression model
(coxph function in survival package). Survival curves were generated by Kaplan-Meier
analysis with p-values found by log-rank test using high and low log transformed
metabolite intensity values to stratify patient groups, defined as metabolite levels above
or below the median (survfit function in survival package; ggsurvplot function in
survminer package). Transformed metabolite intensity values were visualized by
heatmap.2 function in gplots package. Metabolite correlations were calculated by the cor
function in the base R stats package. All possible combinations of three significant
metabolites from the univariable Cox regression models were investigated in addition to
covariates in the multivariable models. The optimal model was chosen based on the
lowest average p-value across all three statistical tests (likelihood ratio test, Wald test,
score (logrank) test). Dimensionality reduction was achieved with partial least squares
discriminant analysis (PLS-DA) to ensure the discrete dependent responses were taken
into account. For PLS-DA component analysis, the dependent response variable was
found by stratifying patients according to event (death or progression) vs. non-event.
PLS-DA was implemented with plsda function in mdatools package. Pathological stage
at diagnosis, sex, histological subtype, and treatment vs. non-treatment included as
covariates, were one-hot encoded and classified as stage I/II (1) vs. stage III/IV (2),
female (1) vs. male (2), adenocarcinoma (1) vs. squamous cell carcinoma (2), and nontreatment (1) vs. treatment (2).
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4.2.8 Metabolite-based risk score analysis
A linear equation was developed to stratify patients into low and high risk groups
based on significant metabolites. Univariable Cox proportional hazards regression model
coefficients divided by the standard errors were used as weight coefficients multiplied by
log-transformed metabolite intensity and summed to generate a risk score for each
patient (Equation 4.1). Patients categorized as high risk are expected to experience
increased risk of event (death or progression), as defined by the median risk score as
the cut-off:
𝑆𝑐𝑜𝑟𝑒𝑖 = ∑𝑛𝑢𝑚
𝑘=1 𝑤𝑘 𝑀𝑖,𝑘

[Equation 4.1]

where 𝑆𝑐𝑜𝑟𝑒𝑖 is the weighted risk score of each patient 𝑖, 𝑤𝑘 is the weight coefficient
assigned to metabolite 𝑘, 𝑀𝑖,𝑘 is the log-transformed metabolite intensity for sample 𝑖
and metabolite 𝑘, and 𝑛𝑢𝑚 is the total number of significant metabolites identified by
univariable Cox regression.

4.2.9 Validation of metabolite-based risk score
A sparse partial least squares discriminant analysis (SPLS-DA) classification
model was created using the covariates only and covariates combined with the
metabolite-based risk scores for predicting event vs. non-event OS and PFS with 5-fold
cross validation and 10 resampling iterations. Covariates included age, sex and stage
classified as stage I/II vs. stage III/IV. Classification model was trained using train
function in caret package with method “spls”. P-values between covariates only and
covariates + risk scores AUROC values were calculated using unpaired T-test
(assuming equal variances).
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4.3 RESULTS
4.3.1 Patient characteristics
Patient clinical characteristics are summarized in Table 4.1. Out of 46 patients
with follow-up information, 14 expired and 32 were alive at the end of the respective
follow-up period. The median overall survival was 20.50 months, and median
progression-free survival was 17.41 months. Patients were evenly distributed in terms of
pathological stage, while 44 of the 46 patients had pathological staging information, 30
of 46 patients received systemic therapy as some form of chemotherapy or
immunotherapy, 17 had a surgical resection and 23 received radiation treatment.
Primary histology of all 46 patients was non-small cell. Histology subtypes included 38
with adenocarcinoma and 8 with squamous cell carcinoma. All patients with pathological
staging information (n = 44) were considered for analysis.

All Patients (n = 46)
Age at Diagnosis
Median age (range)
Gender
Male
Female

67 (42 - 95)
19
27

Stage
I

11

II

9

III

12

IV
Not available
Primary Histology
Non-small cell
Histology Subtype
Adenocarcinoma
Squamous cell carcinoma
Treatment
Chemotherapy
Immunotherapy

12
2
46

38
8
19
6
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Chemotherapy + Immunotherapy
Surgical Resection
Radiation
Status
Alive
Expired
Survival Time
Median: Overall (range)
Median: Progression-Free (range)

5
17
23
32
14
20.50 months
(0.69 - 101.94)
17.41 months
(0.69 - 76.40)

Table 4.1. Clinical and pathological patient population characteristics.

4.3.2 Metabolomic data and correlation analysis
A heatmap of the dataset with missing values present is in Supplementary
Figure 4.1. The maximum, minimum, and number of missing values in each patient
category for the log-transformed metabolite intensity values are shown in
Supplementary Table 4.1. Correlations were found between all metabolites in the
dataset, displayed as a heat map (Supplementary Figure 4.2A). Several pairs of
strongly correlated (≥ 0.75) metabolites were identified (Supplementary Figure 4.2B)
and these pairs were filtered from univariable and multivariable Cox regression models.
Correlations between metabolites identified as significant in the univariable Cox
proportional hazards model analysis are reported for OS and PFS (Supplementary
Table 4.2).

4.3.3 Univariable and multivariable analysis of metabolomic profiles
Metabolites were considered as separate variables during Cox proportional hazards
model analysis, independent of patient characteristics. Covariates significant in the
univariable models were adjusted for in the multivariable models. Cox regression
coefficients and hazard ratios for metabolites related to OS and PFS are in Table 4.2.
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In univariable analysis, 6 of 52 metabolites were identified as significant (0.01≤ p≤0.05)
and 4 were identified as highly significant (p≤0.01) for OS, while 4 metabolites were
identified as significant and 1 was identified as highly significant for PFS. The first 3
components of PLS-DA analysis (PC1, PC2, PC3) were significant covariates for OS,
while only PC2 was significant for PFS. The covariates pathological stage and sex were
significant in the OS model, while none of the covariates were significant in the PFS
model. Male patients and those having pathological stage III/IV had an increased risk of
death (HR=4.75; HR=6.65). A similar trend (not significant) was observed for PFS.
Significant metabolites from the univariable models were included in multivariable
analysis along with the significant covariates (Table 4.2). All possible combinations of
three significant metabolites from the univariable Cox regression models were
investigated in addition to covariates in the multivariable models. The optimal model was
chosen based on the lowest average p-value across all three statistical tests (likelihood
ratio test, Wald test, score (logrank) test). Multivariable models achieved significance for
OS (likelihood ratio test p=7E-05, Wald test p=0.002, log-rank test p=4E-05) and for PFS
(likelihood ratio test p=0.008, Wald test p=0.002, log-rank test p=4E-04).
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Table 4.2. Cox proportional hazards regression models of metabolites, PLS-DA
components (PC’s) and covariates. Univariable analysis revealed 10 significant
metabolites, 3 significant PC’s and two significant covariates for Overall Survival (OS)
while 5 significant metabolites and one significant PC were found for Progression Free
Survival. (PFS) Multivariable analysis resulted in a significant model after adjusting for
sex and pathological stage, where guanosine remained as the only significant metabolite
for OS, while glutamic acid remained as the only significant metabolite for PFS.
Pathological stage at diagnosis, sex, histological subtype, and treatment vs. nontreatment included as covariates, were one-hot encoded and classified as stage I/II (1)
vs. stage III/IV (2), female (1) vs. male (2), adenocarcinoma (1) vs. squamous cell

carcinoma (2), and non-treatment (1) vs. treatment (2).
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Kaplan-Meier survival analysis (Figure 4.2) revealed that several metabolites
contributed to OS and PFS probability over time, where the maximum OS was 101.6
months. Metabolites contributing to lower OS probability included hypoxanthine, Lpyroglutamic acid, N6,N6,N6-trimethyl-L-lysine, proline, adipic acid, benzoic acid, and
inosine (Figure 4.2A). For PFS, low levels of adenine and histamine and high levels of
inosine contributed to shorter survival (Figure 4.2B).

Figure 4.2. Kaplan-Meier survival analysis. Survival curves of lung cancer patients
with high metabolite levels (red; >median) and low metabolite levels (blue; ≤median) for
overall survival (A) and progression-free survival (B). P-values from log-rank test.

4.3.4 Risk score analysis
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Metabolite based risk scores were calculated using Equation 4.1 for OS and
PFS (Figure 4.3 and Figure 4.4, respectively). For both OS and PFS, key metabolites
were selected by significance in the univariable Cox proportional hazards regression
model and correspond to the transformed intensity for each sample. In each case, the
cut-off was defined as the median risk score to stratify high and low risk patients (Figure
4.3A/Figure 4.4A). Probability of survival for low and high risk patients was determined
by Kaplan-Meier analysis, resulting in a marginally significant survival difference for OS
and highly significant difference for PFS (p=0.0764; p=0.0012) (Figure 4.3B/Figure
4.4B). Transformed intensity values of key metabolites among low and high risk patients
are visualized as a heatmap (Figure 4.3C/Figure 4.4C). A Cox proportional hazards
regression model was generated to determine hazard ratios of metabolite-based risk
score and pathological stage at diagnosis (Figure 4.3D/Figure 4.4D). In univariable
models, metabolite-based risk scores for OS (HR=1.15 (1.08 – 1.23), p=6.36E-06) and
for PFS (HR=1.29 (1.14 – 1.46), p=7.97E-05) were significant predictors of survival. In
OS multivariable model, metabolite-based risk score remained significant (HR=1.12
(1.06 – 1.19), p=2.46E-04) after adjusting for sex and pathological stage. The
multivariable model overall was significant for OS (likelihood ratio test p=2E-06; Wald
test p=2E-05; log-rank test p=8E-08).
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Figure 4.3. Metabolite-based risk score analysis of lung cancer patient overall
survival (OS). Patients were stratified into low and high risk based on the median risk
score as the cut-off (A). Kaplan-Meier survival analysis revealed that low and high risk
patients had a significant difference in survival probability over time (B). Heatmap of log
transformed intensity values of key metabolites for low risk (left) and high risk (right)
patients (C). Cox proportional hazards regression results with metabolite-based risk
score and pathological stage at diagnosis as predictors (D). Multivariable analysis
indicates that the metabolite-based risk score was a more significant predictor of overall
survival than sex or pathological stage at diagnosis. Pathological stage at diagnosis,
sex, histological subtype, and treatment vs. non-treatment included as covariates, were
one-hot encoded and classified as stage I/II (1) vs. stage III/IV (2), female (1) vs. male
(2), adenocarcinoma (1) vs. squamous cell carcinoma (2), and non-treatment (1) vs.
treatment (2).
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Figure 4.4. Metabolite-based risk score analysis of lung cancer patient
progression-free survival (PFS). Patients were stratified into low and high risk based
on the median risk score as the cut-off (A). Kaplan-Meier survival analysis revealed that
low and high risk patients had a significant difference in survival probability over time (B).
Heatmap of log transformed intensity values of key metabolites for low risk (left) and
high risk (right) patients (C). Cox proportional hazards regression results with metabolitebased risk score and pathological stage at diagnosis as predictors (D). Univariable
analysis indicates that the metabolite-based risk score was a significant predictor of
progression-free survival. Pathological stage at diagnosis, sex, histological subtype, and
treatment vs. non-treatment included as covariates, were one-hot encoded and
classified as stage I/II (1) vs. stage III/IV (2), female (1) vs. male (2), adenocarcinoma (1)
vs. squamous cell carcinoma (2), and non-treatment (1) vs. treatment (2).

4.3.5 Risk score validation
SPLS-DA classification model was employed for validation of metabolite-based
risk scores in predicting event vs. non-event. With covariates only (sex, age, pathological
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stage, histological subtype, treatment vs. non-treatment), OS and PFS predictions
achieved AUROC =0.819 and AUROC=0.652, respectively (Supplementary Figure
4.5A). Classification model performance improved noticeably when covariates were
combined with metabolite-based risk scores, resulted in statistically significantly (p<1E10) higher AUROC=0.868 and AUROC=0.755 for OS and PFS, respectively
(Supplementary Figure 4.5B).

4.4 DISCUSSION
This proof-of-concept study tests the hypothesis that metabolomic analysis of
tumor core biopsy samples routinely obtained during lung cancer patient care can reveal
biomarkers for distinguishing patients based on OS and PFS. The study adhered to
REMARK guidelines [100]. The univariable analysis revealed metabolite-based risk
scores derived from 10 key metabolites for OS and 5 key metabolites for PFS as
significant predictors of survival. For OS, the multivariable model was significant after
adjusting for sex and pathological stage at diagnosis, and the metabolite-based risk
score was a more significant predictor than either of these covariates. In the
multivariable model, guanosine remained as a significant metabolite for OS and glutamic
acid remained significant for PFS. Five metabolites were identified in common for OS by
both Kaplan-Meier survival analysis and Cox proportional hazards regression models (Lpyroglutamic acid, proline, benzoic acid, inosine, and N6,N6,N6-Trimethyl-L-lysine) and
one metabolite was identified in common by both methods for PFS (inosine). The
metabolite-based risk scores proved useful for predicting event vs. non-event in OS and
PFS; when the risk scores were combined with covariates age, sex, pathological stage,
histological subtype, and treatment vs. non-treatment, the AUROC improved compared
to the AUROC obtained through the covariates alone. To our knowledge, this is the first
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study to show that tumor core biopsy-derived metabolomic profiles analyzed by 2DLCMS/MS can risk stratify lung cancer patients based on survival probability.

Several metabolites related to nucleic acids were identified as significant by the
models in this study, including the nucleobase adenine, nucleosides guanosine and
inosine, and the purine derivative hypoxanthine. A recent study which investigated
serum/plasma metabolomics for survival prediction in lung cancer patients receiving firstline chemotherapy found 4 metabolites which differed significantly (p<0.05) between a
discovery and validation cohort, including caffeine, paraxanthine, stachydrine, and
methyl glucopyranoside [155]. Metabolites related to caffeine metabolism generally had
higher levels in patients with poor survival. In the current study, hypoxanthine was
significantly associated with OS (Figure 4.2A). Interestingly, hypoxanthine is also
related to caffeine metabolism [156]. However, the link to caffeine metabolism may be
coincidental. Hypoxanthine guanine phosphoribosyltransferase (HPRT) was found to be
expressed in cell membranes of NSCLC cell lines H460 and A549 [157]. H460 cells
have nearly double HPRT expression than A549 and have roughly double the growth
rate, indicating that HPRT expression may be directly related to cell proliferation [157].
HPRT is an enzyme that functions by transferring phosphoribose from phosphoribosyl
pyrophosphate (PRPP) to hypoxanthine or guanine bases to form inosine
monophosphate (IMP) and guanine monophosphate (GMP) [158, 159]. Therefore, it is
unsurprising that high levels of hypoxanthine and inosine were strongly associated with
shorter survival (Figure 4.2A) as well as progression and death (Table 4.2).
Interestingly, the opposite trend was observed with guanosine and adenine. High levels
of adenine resulted in greater PFS probability over time (Figure 4.2B), while increased
guanosine was associated with OS (HR=0.41, p=0.0202) (Table 4.2).
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Several amino acids and amino acid derivatives were identified as significant,
including glutamic acid, proline, L-pyroglutamic acid, N6,N6,N6-trimethyl-L-lysine, and
pipecolinic acid. Hori et al. discovered that glutamic acid levels were lower in serum and
higher in lung tissue samples of lung cancer patients compared to healthy controls [149].
However, another study found that glutamic acid was significantly increased in serum of
lung and breast cancer patients compared to healthy controls [160]. In the current study,
increased glutamic acid in lung tumor tissue was associated with decreased risk of
progression (HR=0.42, p=0.0082) (Table 4.2). This suggests a complex relationship
between lung cancer survival and glutamic acid levels in tumor tissue compared to
serum, and a more targeted experimental approach is required to elucidate the
mechanisms involved.

The results further show that elevated proline was associated with death
(HR=3.63, p=0.0124) (Table 4.2), consistent with its role supporting cancer cell survival,
proliferation [161]. High levels of pyroglutamic acid (PGA) were also associated with
death (HR=3.90, p=0.0265) (Table 4.2). PGA is known to accumulate during oxidative
stress [162] due to aberrant cancer cell redox homeostasis. Elevated N6,N6,N6Trimethyl-L-lysine strongly associated with death (HR=18.21, p=2.59E-04), highlighting
its known role in cancer progression [163]. Pyruvate was associated with decreased
PFS (HR= 3.47, p= 0.0468), likely due to its promotion of angiogenesis [107], tumor
proliferation [106], and immune downstaging [108]. Itaconic acid was also associated
with decreased PFS (HR= 2.95, p= 0.0257).

Higher abundance of cystine, composed of two cysteine molecules, was strongly
associated with OS (HR=0.21, p=1.89E-04) (Table 4.2). Cysteine is critical for cancer
metabolic remodeling [164], and abundance potentially due to reduced uptake may
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indicate decreased tumor metabolic dysregulation – consistent with previous findings
that enhanced cystine processing is associated with more aggressive cancers [165]. On
the other hand, elevated acetyl-L-carnitine was associated with death (HR=4.73,
p=0.0175) (Table 4.2), consistent with its role in promoting angiogenesis [166] and
cancer cell proliferation [167]. Increased creatine was further associated with death
(HR=44.57, p=0.0020) (Table 4.2). Creatine can be converted into phosphocreatine,
which acts as an energy reservoir and is involved in the production of ATP from ADP
[168]. Increased creatine in tumor tissue may lead to an increase in ATP production,
which is associated with high cancer metabolic activity [146]. In another study, creatine
was significantly increased in lung cancer tissue compared to normal tissue, measured
by NMR [169]. In contrast, although several benzoic acid derivatives have shown antitumor activity [170-173], little is known about how benzoic acid is involved in lung cancer
metabolism. Previously, increased benzoic acid was found in late stage lung cancer
patients relative to early stage and healthy controls [149], consistent with our findings
that increased benzoic acid levels were associated with progression (HR=6.17,
p=0.0190) and death (HR=5.55, p=0.0257) (Table 4.2).

PLS-DA component analysis was performed as an alternative to the metabolite
based risk score as calculated in Equation 4.1, where the PC1 and PC2 scores were
used for OS and PFS, respectively. The PLS-DA component was ineffective for
separating low risk and high risk patients based on PFS in Kaplan-Meier analysis
(p=0.165) (data not shown). To increase separation, follow-up time was restricted to 048 months (p=0.0615, Supplementary Figure 4.3 and Supplementary Figure 4.4).
Although PLS-DA component analysis resulted in significant Cox proportional hazards
regression models (Supplementary Figure 3D/4D), they were not as significant as the
metabolite based risk score (Figure 4.3D/4.4D). Further, to ensure that missing value
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imputation was not contributing to the survival analysis, the metabolomic data was onehot-encoded as detected (0) vs. not-detected (1) and a Cox proportional hazards model
was performed (Supplementary Table 4.3). None of the metabolites were significant,
while only one and three different metabolites were marginally significant (0.05≤p≤0.1)
for OS and PFS, respectively, indicating that the presence or absence of metabolites in
patient tissue samples was not affected by the events of progression or death.

This study includes a small and heterogeneous patient population, which limits
the interpretation of results. Potential confounding factors include type and duration of
chemotherapy/ immunotherapy cycles, smoking status, and differences in biopsy
collection date relative to date of diagnosis. However, it was previously reported that
adjusting for confounding factors such as age and cancer stage at diagnosis, smoking
status, hypertension, diabetes mellitus, BMI, HDL/LDL levels, and time between sample
collection and diagnosis had minimal significant effect on metabolite hazard ratios
associated with prostate cancer-specific mortality [152]. Our study along with [152] found
that metabolomic profiles were able to uncover biomarkers relevant to cancer survival
prediction without adjusting for these potential confounding factors, emphasizing the
predictive capability of the metabolomics data. Additionally, it was previously found that
number of chemotherapy cycles was a weak predictor of survival in epithelial ovarian
cancer, being overpowered by pathological stage and a metabolite-based risk score
[151]. Further limitations of this study are that the data on association of metabolic score
and OS or PFS would have to be validated in a larger and independent cohort.
Considerations for future studies include integrating machine learning algorithms into a
more comprehensive multivariable predictive modeling framework for high-accuracy
predictions of patients in survival groups and simultaneous determination of a reliable
set of key metabolites as biomarkers.
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4.5 SUPPLEMENTARY MATERIALS

Supplementary Figure 4.1. Heatmap of log-transformed metabolite intensity values
including missing data organized by increasing OS/PFS for event vs. non-event
patients. Metabolites (y-axis) are organized by decreasing average intensity. Gray cells
represent missing values.
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Supplementary Figure 4.2. Heatmap of log-transformed metabolite correlations
(A). Pairs of strongly correlated metabolites (≥0.75) (B).
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Supplementary Figure 4.3. PLS-DA component-based risk score analysis of lung
cancer patient overall survival (OS) using scores of the most significant
component from the univariable Cox regression analysis (PC1). Patients were
stratified into low and high risk based on the median risk score as the cut-off (A). In
Kaplan-Meier survival analysis, survival times were restricted to 0-48 months, which
revealed that low and high risk patients had a significant difference in survival probability
over time (B). Heatmap of log transformed intensity values of key metabolites for low risk
(left) and high risk (right) patients (C). Cox proportional hazards regression results with
PLS-DA component-based risk score and pathological stage at diagnosis as predictors
(D). Univariable analysis indicates that the metabolite-based risk score was a significant
predictor of progression-free survival. Pathological stage at diagnosis, sex, histological
subtype, and treatment vs. non-treatment included as covariates, were one-hot encoded
and classified as stage I/II (1) vs. stage III/IV (2), female (1) vs. male (2),
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adenocarcinoma (1) vs. squamous cell carcinoma (2), and non-treatment (1) vs.
treatment (2).

Supplementary Figure 4.4. PLS-DA component-based risk score analysis of lung
cancer patient progression-free survival (PFS) using scores of the most
significant component from the univariable Cox regression analysis (PC2).
Patients were stratified into low and high risk based on the median risk score as the cutoff (A). In Kaplan-Meier survival analysis, survival times were restricted to 0-48 months,
which revealed that low and high risk patients had a significant difference in survival
probability over time (B). Heatmap of log transformed intensity values of key metabolites
for low risk (left) and high risk (right) patients (C). Cox proportional hazards regression
results with PLS-DA component-based risk score and pathological stage at diagnosis as
predictors (D). Univariable analysis indicates that the metabolite-based risk score was a
significant predictor of progression-free survival. Pathological stage at diagnosis, sex,
histological subtype, and treatment vs. non-treatment included as covariates, were onehot encoded and classified as stage I/II (1) vs. stage III/IV (2), female (1) vs. male (2),
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adenocarcinoma (1) vs. squamous cell carcinoma (2), and non-treatment (1) vs.
treatment (2).

Supplementary Figure 4.5. ROC curves of event vs. non-event OS and PFS
predictions using covariates only (A) and covariates combined with metabolitebased risk score (B). Covariates included sex, age, pathological stage, histological
subtype, and treatment vs. non-treatment. Sparse partial least squares discriminant
analysis (SPLS-DA) model predictions were performed with 5-fold cross-validation and
100 resampling iterations. P-value between the OS AUROC values in (A) and (B), and
between the PFS AUROC values in (A) and (B) was calculated as <1E-10 using a
simple unpaired T-test (assuming equal variances).

Total
missing
METABOLITE
Choline
Isoleucine
Phenylalanine
Lactate
Tyrosine
Leucine
Methionine
Arginine
Proline
Azelaic acid
Nicotinamide

Max
value
2.629
2.471
2.236
2.638
2.066
2.129
2.000
2.071
2.167
1.557
1.834

Min
value
0.978
-0.047
0.756
0.276
0.612
-0.101
-0.469
0.217
-0.033
0.382
-0.013

OS

PFS

A
(out of 46)

B
(out of
15)

C
(out of 31)

D
(out of 19)

E
(out of 27)

3 (6.82%)
17 (38.64%)
1 (2.27%)
12 (27.27%)
11 (25.00%)
21 (47.73%)
13 (29.55%)
0 (0.00%)
0 (0.00%)
0 (0.00%)
3 (6.82%)

2 (14.29%)
5 (35.71%)
0 (0.00%)
1 (7.14%)
2 (14.29%)
7 (50.00%)
1 (7.14%)
0 (0.00%)
0 (0.00%)
0 (0.00%)
2 (14.29%)

1 (3.33%)
12 (40.00%)
1 (3.33%)
11 (36.67%)
9 (30.00%)
14 (46.67%)
12 (40.00%)
0 (0.00%)
0 (0.00%)
0 (0.00%)
1 (3.33%)

1 (5.56%)
8 (44.44%)
0 (0.00%)
3 (16.67%)
4 (22.22%)
9 (50.00%)
3 (16.67%)
0 (0.00%)
0 (0.00%)
0 (0.00%)
1 (5.56%)

2 (7.69%)
9 (34.62%)
1 (3.85%)
9 (34.62%)
7 (26.92%)
12 (46.15%)
10 (38.46%)
0 (0.00%)
0 (0.00%)
0 (0.00%)
2 (7.69%)
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Glutamine
Adenosine
Acetyl-L-carnitine
Itaconic acid
L-pyroglutamic acid
Histamine
Creatine
Methionine sulfoxide
Lysine
Hypoxanthine
Benzoic acid
Malate
Urocanic acid
Urea
Glutamic acid
Tryptophan
Pantothenic acid
Pyruvate
Creatinine
Pipecolinic acid
Ornithine
Adipic acid
Xanthine
Salicylic acid
Levulinic acid
Guanine
Uridine
N8-Acetylspermidine
Inosine
Adenine
Acetylcholine
Malonic acid
Fructose
Serine
alpha-Ketoglutarate
Guanosine
Cystine
Propionylcarnitine
Lidocaine
N3,N4-Dimethyl-L-arginine
N6,N,N6-Trimethyl-L-lysine

1.998
1.817
2.074
2.402
1.659
2.036
2.166
1.404
1.654
1.652
1.321
1.735
1.515
1.831
1.856
1.415
1.808
1.367
1.524
1.331
0.804
0.998
1.494
0.814
2.006
1.403
1.237
1.272
1.020
0.722
0.834
1.105
0.373
0.472
0.724
0.691
0.501
1.318
2.523
0.487
0.171

-1.228
-0.402
-0.608
-0.947
-0.372
-2.411
-0.460
-0.254
-0.418
-0.899
-0.416
-0.591
-0.877
-1.487
-1.576
-1.047
-0.842
-0.784
-0.900
-1.683
-0.655
-0.638
-1.333
-0.981
-1.129
-1.443
-1.727
-2.509
-1.750
-1.761
-1.344
-1.637
-1.095
-1.227
-1.102
-2.789
-2.928
-1.671
-2.064
-2.014
-1.575

15 (34.09%)
5 (11.36%)
6 (13.64%)
13 (29.55%)
20 (45.45%)
13 (29.55%)
12 (27.27%)
14 (31.82%)
0 (0.00%)
0 (0.00%)
14 (31.82%)
17 (38.64%)
17 (38.64%)
12 (27.27%)
2 (4.55%)
12 (27.27%)
20 (45.45%)
6 (13.64%)
6 (13.64%)
16 (36.36%)
12 (27.27%)
12 (27.27%)
16 (36.36%)
2 (4.55%)
21 (47.73%)
15 (34.09%)
8 (18.18%)
6 (13.64%)
14 (31.82%)
19 (43.18%)
5 (11.36%)
12 (27.27%)
21 (47.73%)
13 (29.55%)
21 (47.73%)
15 (34.09%)
12 (27.27%)
10 (22.73%)
19 (43.18%)
17 (38.64%)
16 (36.36%)

4 (28.57%)
4 (28.57%)
3 (21.43%)
4 (28.57%)
7 (50.00%)
5 (35.71%)
1 (7.14%)
3 (21.43%)
0 (0.00%)
0 (0.00%)
6 (42.86%)
5 (35.71%)
5 (35.71%)
3 (21.43%)
1 (7.14%)
1 (7.14%)
8 (57.14%)
2 (14.29%)
2 (14.29%)
7 (50.00%)
3 (21.43%)
1 (7.14%)
3 (21.43%)
1 (7.14%)
4 (28.57%)
9 (64.29%)
5 (35.71%)
4 (28.57%)
4 (28.57%)
7 (50.00%)
3 (21.43%)
1 (7.14%)
5 (35.71%)
3 (21.43%)
6 (42.86%)
9 (64.29%)
5 (35.71%)
5 (35.71%)
6 (42.86%)
3 (21.43%)
2 (14.29%)

11 (36.67%)
1 (3.33%)
3 (10.00%)
9 (30.00%)
13 (43.33%)
8 (26.67%)
11 (36.67%)
11 (36.67%)
0 (0.00%)
0 (0.00%)
8 (26.67%)
12 (40.00%)
12 (40.00%)
9 (30.00%)
1 (3.33%)
11 (36.67%)
12 (40.00%)
4 (13.33%)
4 (13.33%)
9 (30.00%)
9 (30.00%)
11 (36.67%)
13 (43.33%)
1 (3.33%)
17 (56.67%)
6 (20.00%)
3 (10.00%)
2 (6.67%)
10 (33.33%)
12 (40.00%)
2 (6.67%)
11 (36.67%)
16 (53.33%)
10 (33.33%)
15 (50.00%)
6 (20.00%)
7 (23.33%)
5 (16.67%)
13 (43.33%)
14 (46.67%)
14 (46.67%)

6 (33.33%)
3 (16.67%)
2 (11.11%)
5 (27.78%)
9 (50.00%)
5 (27.78%)
3 (16.67%)
5 (27.78%)
0 (0.00%)
0 (0.00%)
7 (38.89%)
6 (33.33%)
6 (33.33%)
3 (16.67%)
1 (5.56%)
3 (16.67%)
9 (50.00%)
4 (22.22%)
2 (11.11%)
8 (44.44%)
5 (27.78%)
3 (16.67%)
5 (27.78%)
1 (5.56%)
7 (38.89%)
9 (50.00%)
4 (22.22%)
4 (22.22%)
7 (38.89%)
8 (44.44%)
1 (5.56%)
3 (16.67%)
6 (33.33%)
5 (27.78%)
6 (33.33%)
9 (50.00%)
4 (22.22%)
4 (22.22%)
8 (44.44%)
6 (33.33%)
5 (27.78%)

9 (34.62%)
2 (7.69%)
4 (15.38%)
8 (30.77%)
11 (42.31%)
8 (30.77%)
9 (34.62%)
9 (34.62%)
0 (0.00%)
0 (0.00%)
7 (26.92%)
11 (42.31%)
11 (42.31%)
9 (34.62%)
1 (3.85%)
9 (34.62%)
11 (42.31%)
2 (7.69%)
4 (15.38%)
8 (30.77%)
7 (26.92%)
9 (34.62%)
11 (42.31%)
1 (3.85%)
14 (53.85%)
6 (23.08%)
4 (15.38%)
2 (7.69%)
7 (26.92%)
11 (42.31%)
4 (15.38%)
9 (34.62%)
15 (57.69%)
8 (30.77%)
15 (57.69%)
6 (23.08%)
8 (30.77%)
6 (23.08%)
11 (42.31%)
11 (42.31%)
11 (42.31%)

Supplementary Table 4.1. Maximum and minimum log-transformed metabolite
values and number of samples with missing values. A: Total samples with missing
values. B: OS event samples with missing values. C: OS non-event samples with
missing values. D: PFS event samples with missing values. E: PFS non-event samples
with missing values.
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Supplementary Table 4.2. Correlation coefficients among all metabolites identified
as significant in univariable Cox proportional hazards regression models.

Supplementary Table 4.3. Cox proportional hazards regression models of
metabolites one-hot-encoded and classified as detected (0) vs. not-detected (1).
Univariable analysis revealed only 1 marginally significant metabolite for OS (A) and 4
marginally significant metabolites were found for PFS (B). Multivariable analysis resulted
in insignificant models after adjusting for sex and pathological stage for both OS and
PFS (C) (D). Pathological stage at diagnosis, sex, histological subtype, and treatment
vs. non-treatment included as covariates, were one-hot encoded and classified as stage
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I/II (1) vs. stage III/IV (2), female (1) vs. male (2), adenocarcinoma (1) vs. squamous cell
carcinoma (2), and non-treatment (1) vs. treatment (2).
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CHAPTER 54

LUNG CANCER SURVIVAL PREDICTION AND BIOMARKER IDENTIFICATION WITH
AN ENSEMBLE MACHINE LEARNING ANALYSIS OF TUMOR CORE BIOPSY
METABOLMOIC DATA

5.1 INTRODUCTION
The 5-year survival rate for lung cancer remains <5% for all stages combined
[144], despite improvements in survival since the early 1990’s. Identification of patients
likely to experience short or long survival has clinical utility by helping to minimize overor under-treatment, potentially leading to improved clinical decision making. Staging
relying on tumor (T) size, location of cancerous lymph nodes (N), and presence of
metastasis (M) has been the gold standard for stratifying survival probability in the
clinical setting [174], with mixed results. Linear methods such as Cox proportional
hazards regression and logistic regression have seen routine use for diagnostic and
prognostic applications (e.g., [175]). However, these linear methodologies may be
unable to capture complex hidden features within high-dimensional data sets [176],
leading to unreliable biomarker selection.

More complex analyses such as machine learning have been employed to
improve upon these linear methods, yielding a variety of results that have yet to find
clinical application. A deep neural network (DNN) was combined with gene expression
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Miller, H.A., van Berkel V.H., Frieboes, H.B. Lung cancer survival prediction and biomarker
identification with an ensemble machine-learning analysis of tumor core biopsy metabolomic
data. (in review, submitted to Metabolomics).
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and clinical data in [177] to predict 5-year survival of NSCLC patients (AUC = 0.8163,
accuracy = 75.44%). In [178] a deep learning model trained and externally validated with
patient clinical data outperformed prediction of lung cancer–specific survival via Cox
proportional hazard regression (C statistic = 0.739 vs 0.716). A deep learning model
using pretreatment and follow-up time series computed tomography (CT) images of
NSCLC tumors was applied in [179] to predict survival. Another deep learning model
was trained to extract prognostic information from pre-operative CT examinations in
[180]. In [181], deep learning models (artificial neural networks (ANN), recurrent neural
networks (RNN), and convolutional neural networks (CNN)) were applied to the SEER
database to predict lung cancer survival, obtaining 71.18 % accuracy when survival
periods were segmented into three classes (less than 6 months, 6 to 24 months, and
over 24 months). An ensemble data mining approach was applied to the SEER database
in [182] to predict survival for 6-month, 9-month, 1-year, 2-year and 5-years.

Part of the challenge in finding a reliable method to improve upon current clinical
measures is the identification of a consistent set of molecular signatures as biomarkers
for the prediction of survival [183]. In this regard, metabolomics holds promise as a
method for generating high-dimensional molecular data, from which a more accurate
prognosis can be made [147]. Although previous work has contributed to the
understanding of lung cancer metabolism, the use of metabolomics data for survival
prediction remains relatively unexplored [23]. We have recently shown that tumor core
biopsy-derived metabolomic data is capable of discriminating patients based on therapy
outcome [38], where a support vector machine (SVM) trained and validated on features
selected by partial least squares discriminant analysis (PLS-DA) performed best at
predicting disease control vs. progressive disease groups (AUC = 0.970).
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This study implements and validates a novel machine-learning based ensemble
workflow to predict overall survival (OS) and progression-free survival (PFS) in lung
cancer patients by analyzing tumor core biopsy derived metabolomic data. Unlike
samples obtained from biofluids, analysis of the tumor tissue itself is expected to
accurately reflect the cancer metabolism and its impact on patient survival. Our
hypothesis is that an ensemble machine learning analysis of biopsied tumor tissue
metabolomic data is able to predict short vs. long survival in terms of OS and PFS. We
test this hypothesis by implementing a comprehensive suite of machine learning
algorithms that were trained as base learners and then combined into a stackedensemble meta-learner for predicting “short” vs. “long” survival on an external validation
cohort. Further, an ensemble method of feature selection is employed to produce a
reliable set of biomarkers with potential clinical utility.

5.2 MATERIALS AND METHODS
5.2.1 Data pre-processing and statistical analysis
Metabolomic data from NSCLC patient tumor core biopsies were previously
obtained from an ongoing study as described in [38], for which sample processing and
metabolite extraction, 2DLC-MS/MS analysis and data pre-processing, and organization
of MS peak intensity data were already performed. As reported previously, 2DLCMS/MS data of unlabeled samples were first matched to an in-house database that
contains parent ion m/z, MS/MS spectra, and retention time of authentic standards (MSI
Level 1 identification). Data without a match (MSI Level 2 identification) were analyzed
using Compound Discoverer software v2.0 (Thermo Fisher Scientific, Germany).

In the study in [38], informed consent was obtained to participate, and all
specimens were collected following approved Institutional Review Board protocols at
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University of Louisville Hospital (IRB 05.0523) and Norton Hospital (IRB 18.0264) from
patients with known or suspected NSCLC. Demographics including sex, race, age,
personal history of malignancy, smoking history, and relevant family history were
recorded. Samples were collected by the clinical team, which was blinded to the data
analysis.

For this study, the MS data were log-transformed and imputed by probabilistic
principal component analysis (PPCA) prior to analysis. Patients were categorized into
“short” and “long” survival groups based on the mean OS and PFS across both data sets
(29.87 months for OS; 22.05 months for PFS). Significant differences in relative
abundance were evaluated by an unpaired T-test assuming equal variance and Pearson
correlations between survival groups and metabolites were found.

5.2.2 Machine learning methods (base learners)
Out of 46 total patients, 2/3 were kept for training as the internal validation set
and the remaining 1/3 were reserved as the external validation set (Table 5.1). The data
were randomly split using function createDataPartition from caret package in R, where
short vs. long OS was the grouping factor. The internal validation set was used for
parameter tuning with each base learner using a tune length of 10 and Cohen’s kappa
as the metric. Kappa represents classification accuracy for data with imbalanced classes
and is a superior metric over accuracy alone. The approach used for estimating model
performance within the internal validation set on unseen data was repeated k-fold crossvalidation where k=5 and 10 resampling iterations were performed for each base learner.
The Receiver Operating Characteristic curve (ROC) was plotted from the sensitivity and
false positive rate (1-specificity). The Area under the Receiver Operating Characteristic
curve (AUROC) was then calculated for model evaluation. An AUROC of 1.0 represents
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a perfect prediction, while an AUROC of 0.5 is equivalent to random chance showing no
discriminatory power of the model.

5.2.3 Feature Selection and Variable Importance
For each predictive model, the relative contribution of each feature was
determined from the variable importance scores which were calculated from the varImp
function in the caret package. The variable importance scores were used to rank key
features for each model during feature selection. Some prediction models such as
Random Forest, Neural Network (single-layer), and Nearest Shrunken Centroids have
specific variable importance methods used while other prediction models such as kNearest Neighbors and Naïve Bayes use a generic ROC curve analysis method.
Forward feature selection was employed after ranking features from each model by retraining the models on every feature subset incrementing by one predictor.

5.2.4 Ranking of Most Important Predictors
An ensemble feature selection method was used to determine the top key
features from the variable importance ranking and classification performance in each
predictive model. For each outcome, the highest AUROC from each predictive model
was weighted with an AUROC of 1 being 1 and an AUROC of 0.5 or less being 0.
Similar to Shahrjooihaghighi et al. [184] which found that ensemble approaches of
feature selection outperformed individual feature selection algorithms, we chose to
maximize the stability (i.e., reliability) of biomarkers by finding the weighted sum of ranks
by each variable importance feature selection method (a modified version of the Borda
count), with weights assigned proportionally to the performance of each machine
learning algorithm. All feature selection methods were weighted proportionally by their
performance with an AUROC of 1 weighted as one and an AUROC of 0.5 or less
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weighted as zero. The ranked features were found by the weighted sum of ranks of all
feature selection, as follows:

𝑅(𝑓𝑖 ) = ∑𝑛𝑢𝑚
𝑘=1 𝑤𝑘 𝑟𝑖,𝑘

[Equation 5.1]

where 𝑅(𝑓𝑖 ) is the overall sum of ranks of feature i, 𝑤𝑘 is the weight coefficient assigned
to method k, 𝑟𝑖,𝑘 is the rank of feature i by method k, and num is the total number of
methods used to rank the features.

5.2.5 Ensemble Machine Learning Method
After individual predictive models were trained and validated, an ensemble
machine learning approach was employed to arrive at the optimal predictive model
(Figure 5.1). Ensemble methods are powerful machine learning tools which combine the
predictions of several base learning models. By taking advantage of the unique
strengths present in each base learner, ensemble methods typically achieve better
prediction accuracy than any single base learner. Here, we employed a stacked
generalization technique using the caretEnsemble package. First, a list of models with
each base learner is produced, and the models are then stacked into a meta-model
which uses a base learner as the aggregating method (i.e. meta learner). We filtered the
base learners by choosing only those which had a maximum AUROC of 0.8 or higher
during feature selection. Using the key predictors identified by feature selection, the
stacked ensemble models were trained and validated using forward feature selection
where variable importance was calculated as in Equation 5.1.

5.2.6 Evaluation of Covariates
A nomogram of patient covariate data (staging, sex, and age) was created to
compare to the machine learning predictions of short vs. long OS and PFS. For the
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nomogram, staging, age, and sex were the predictors, and an inverse logit
transformation was used to transform the linear predictors to a probability [185].

5.2.7 Packages and libraries
All data analyses were conducted in the R programming language version 4.1.0.
The packages caret and caretEnsemble were implemented for data splitting, model
hyperparameter tuning, and creating stacked ensemble models using functions
createDataPartition, train, caretList, and caretStack. Feature selection and EFS score
calculation was implemented via a custom written R script. Packge rms was employed
for creating the nomogram with functions lrm and nomogram.

5.2.8 Metabolic Network Visualization and Quantitative Enrichment Analysis
Quantitative enrichment analysis (QEA) was performed on unlabeled metabolite
dataset with (MetaboAnalyst 5.0, RRID:SCR_015539, www.metaboanalyst.ca/) [71]. The
log transformed/imputed working dataset was used, obviating missing value estimation
or normalization. KEGG database (RRID:SCR_012773, www.kegg.jp/) was accessed
Sep. 2021. Metabolic networks were visualized with (Cytoscape 3.8.2,
RRID:SCR_003032, cytoscape.org/) and (MetScape 3.1.3, RRID:SCR_014687,
metscape.ncibi.org/) using imputed and log transformed metabolite intensity values for
short vs. long survival classification.

5.3 RESULTS
5.3.1 Patient population characteristics
Patient population characteristics are summarized in Table 5.1 (additional details
in Supplementary Table 5.1), showing the division between the internal validation and
external validation datasets. A total of 48 patients had follow-up information; 33 were
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alive and 15 had expired by the end of the respective follow-up period. In the internal
validation cohort, meanOS was 30.54 months, and meanPFS was 21.83 months. 32
patients had pathological staging information, with the staging being evenly distributed
among them. 22 patients received chemotherapy or immunotherapy. Primary histology
of all 33 patients was classified as non-small cell.. Histology subtypes 6 squamous cell
carcinoma, and 11 adenocarcinoma, while the remainder was unspecified. In the
external validation cohort, mean OS was 28.39 months, and mean PFS was 22.51
months. 14 of the 15 patients had pathological staging information. 9 patients received
chemotherapy or immunotherapy. Primary histology of 14 patients was classified as nonsmall cell, with the remainder being small cell. Histology subtypes included 1
neuroendocrine, 1 small cell carcinoma, 2 squamous cell carcinoma, and 2
adenocarcinoma, while the remainder was unspecified. Further details on patient
information can be found in Supplementary Table 5.2.

Age at Diagnosis
Median age (range)
Gender
Male
Female
Stage
I
II
III
IV
N/A
Primary Histology
Non-small cell
Small-cell
Histology Subtype
Adenocarcinoma
Squamous cell
carcinoma
Neuroendocrine

(n = 33)
Internal validation set

(n = 15)
External validation set

67 (50 – 95)

64 (42 – 87)

10
23

11
4

9
8
6
9
1

2
2
6
4
1

33
0

14
1

11

2

6

2

0

1
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Small cell carcinoma
Not specified

0
16

1
9

Treatment
Chemotherapy
Immunotherapy
Chemotherapy +
Immunotherapy

12
6

8
0

4

1

23
10
19
14

10
5
10
5

11
22
9
24

5
10
8
7

30.54(1.45 – 101.91)

28.39 (0.69 – 78.01)

21.83 (1.45 – 76.37)

22.51 (0.69 – 58.53)

Status
Alive
Expired
No Progression
Progression
Survival
categorization
OS: “Long”
OS: “Short”
PFS: “Long”
PFS: “Short”
Survival Time
(months)
Mean (range): Overall
Mean (range):
Progression-Free

Table 5.1. Patient population characteristics.

5.3.2 Classification results
Patients were stratified into “long” and “short” survival groups for classification by
the mean OS and PFS across both data sets. The machine learning workflow is
summarized in Figure 5.1. A heatmap of the log transformed and imputed 2DLC-MS
derived metabolite intensity values for short vs. long OS and PFS is shown in
Supplementary Figure 5.1 for the model internal validation (training) data and the
external validation (test) data. PLS-DA score plots of short vs. long overall and
progression-free survivals based on the patient tissue-derived metabolomics data are in
Supplementary Figure 5.2. Long and short survival groups were separated but with
some overlap for OS and PFS in the internal validation cohort. However, groups were
well separated in the external validation cohort for both PFS and OS.
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Figure 5.1. Diagram of machine learning workflow. Base learners are trained on
the internal validation set using 5-fold cross validation with 10 resampling
iterations on each feature subset. Feature selection is employed by base learner
variable importance. After all base learners are trained and evaluated, a stacked
ensemble model is evaluated after filtering base learners which did not achieve an
AUROC of 0.8 or greater across all feature subsets. The ensemble model is then
evaluated on all feature subsets using an ensemble method of feature selection
(Equation 5.1). The classification model performance of all base-learners and metalearners is evaluated across the feature subsets on the external validation data. RF =
random forest. NNET = neural network (single layer). MLP = multi-layer perceptron.
NSC = nearest shrunken centroids. NB = naïve Bayes. BGLM = boosted general linear
model. KNN = k-nearest neighbors. SVM = support vector machine. SPLS = sparse
partial least squares. BLR = boosted logistic regression. RLR = regularized logistic
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regression. NNFE = neural network with feature extraction. WKNN = weighted k-nearest
neighbors. MANN = model averaged neural network. RRF = regularized random forest.
BGAM = boosted generalized additive model. ORFSVM = oblique random forest with
SVM as splitting model. SVMPoly = support vector machine with polynomial kernel.

The maximum AUROC obtained from feature selection after external test set
validation of all base learner models (Figure 5.2) shows that the highest performance
was equally obtained with single layer neural network, support vector machine with class
weights and radial kernel, and regularized random forest for OS (AUROC = 0.840) and
the support vector machine with polynomial kernel for PFS (AUROC = 0.911). After
filtering base learners with a max AUROC < 0.8, the AUROC with stacked ensemble
meta learners (Figure 5.2) increased for OS with both boosted generalized linear model
and regularized logistic regression yielding AUROC = 0.94, while for PFS the AUROC
was 0.875 with boosted logistic regression. Supplementary Figure 5.3 further
summarizes the AUROC obtained from all base learner models and stacked ensemble
models during feature selection with predictions made on the external validation set.
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Figure 5.2. Maximum AUROC obtained from feature selection after external test
set validation of all base learner models and stacked ensemble meta learners for
(A) Overall Survival and (B) Progression-Free Survival. Patients were stratified into
“long” and “short” survival groups for classification by the prediction models. Base
learners that achieved max AUROC of 0.8 or higher (gray bars, top row) were selected
for the stacked ensemble models (second row). ROC curves of optimal stacked
ensemble meta learners with repeated internal cross-validation and external validation
for prediction of “long” and “short” OS and PFS are shown for each case (third row).
SVM = support vector machine; NN = neural network; RF = random forest.
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ROC curves of optimal stacked ensemble meta learners with repeated internal
cross-validation as well as external validation for prediction of “long” and “short” OS and
PFS are further shown in Figure 5.2. OS predictions achieved an AUROC of 0.925 with
model averaged neural network meta learner on the internal validation set and an
AUROC of 0.940 with regularized logistic regression meta learner model on the external
validation set. PFS predictions achieved an AUROC of 0.947 with support vector
machine with class weights and radial kernel meta learner on the internal validation set
and an AUROC of 0.875 with boosted logistic regression meta learner on the external
validation set.

To compare to a linear prognostic model, a nomogram of covariate data (sex,
age, staging) was implemented to predict short vs. long OS and PFS probability
(Supplementary Figure 5.4). The nomogram results (internal validation: OS
AUROC=0.591; PFS AUROC=0.761; external validation: OS AUROC=0.711; PFS
AUROC=0.521) were outperformed by the metabolomics based machine-learning
ensemble.

5.3.3 Key metabolites identified by variable importance
Top 25 key metabolic biomarkers identified by ensemble feature selection (EFS)
are shown in Table 5.2. The EFS score is calculated as a linear weighted sum of ranks
of features identified by all base learners (Equation 5.1). For OS, N6,N6,N6-trimethyl-Llysine, levulinic acid, and cystine correlated with improved survival, while all other topranked metabolites correlated with decreased survival, including guanosine, lidocaine,
guanine, choline, leucine, phenylalanine, adenosine, creatinine, and lactate. For PFS,
pipecolinic acid, leucine, guanosine, guanine, azelaic acid, pantothenic acid, malate,
adenosine, fructose, uridine, pyruvate and lactate correlated with decreased survival,
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while glutamine, N6,N6,N6-trimethyl-L-lysine, N8-acetylspermidine, propionylcarnitine,
acetyl-L-carnitine, alpha-ketoglutarate, L-pyroglutamic acid and the other top-ranked
metabolites correlated with increased survival. The top 26 metabolites were used in the
optimal stacked ensemble model for predicting OS (AUROC=0.940), while the top 5
metabolites were used for predicting PFS (AUROC=0.875).

Rank
1

Overall Survival
▼ Guanosine* †

Correlation EFS EFS score
coefficient score (normalized)
-0.439

4.50

Progression-free
Survival

Correlation EFS EFS score
coefficient score (normalized)

100.0%

▲ Glutamine*

0.357

3.33

100.0%

0.304

6.66

50.0%

▼ Lidocaine

-0.432

7.31

61.6%

N6,N6,N6-Trimethyl▲
L-lysine

3

▼ Guanine**

-0.463

7.43

60.6%

▲ N8-Acetylspermidine

0.223

9.99

33.3%

4

▼ Choline

-0.336

9.55

47.2%

▼ Pipecolinic acid

-0.272

13.32

25.0%

5

▼ Leucine †

-0.307

10.70

42.1%

▲ Propionylcarnitine

0.283

16.65

20.0%

6

▼ Phenylalanine

-0.263

14.40

31.3%

▼ Leucine

-0.252

19.97

16.7%

7

▼ Adenosine* †

-0.419

16.63

27.1%

▼ Guanosine †

-0.253

23.30

14.3%

0.228

22.04

20.4%

▼ Guanine

-0.225

26.63

12.5%

2

8

▲

N6,N6,N6-Trimethyl-Llysine ††

9

▼ Creatinine

-0.242

22.63

19.9%

▲ Acetyl-L-carnitine

0.053

29.96

11.1%

10

▼ Lactate

-0.196

25.78

17.5%

▲ alpha-Ketoglutarate

0.225

33.29

10.0%

11

▼ Isoleucine

-0.219

27.21

16.6%

▲ L-pyroglutamic acid

0.227

36.62

9.1%

12

▼ Glutamic acid

-0.182

27.84

16.2%

▼ Azelaic acid

-0.195

39.95

8.3%

13

▼ Pipecolinic acid ††

-0.297

30.36

14.8%

▼ Pantothenic acid

-0.196

43.28

7.7%

14

▼ Fructose

-0.171

35.13

12.8%

▼ Malate

-0.201

46.61

7.1%

15

▲ Levulinic acid

0.171

38.74

11.6%

▼ Adenosine †

-0.225

49.94

6.7%

16

▼ Pantothenic acid

-0.233

38.80

11.6%

▼ Fructose

-0.181

53.26

6.3%

17

▼ Uridine

-0.197

39.23

11.5%

▲ Salicylic acid

0.206

56.59

5.9%

18

▼ Methionine

-0.168

39.31

11.5%

▼ Uridine

-0.151

59.92

5.6%

19

▼ Methionine sulfoxide †

-0.261

39.89

11.3%

▼ Pyruvate

-0.195

63.25

5.3%

20

▼ Tyrosine

-0.080

40.79

11.0%

▲ Serine

0.170

66.58

5.0%

21

▼ Acetyl-L-carnitine

-0.168

41.89

10.8%

▼ Lactate

-0.129

69.91

4.8%

22

▼ Hypoxanthine

-0.245

42.14

10.7%

▲ Glutamic acid

0.171

73.24

4.5%

23

▼ Creatine

-0.188

42.18

10.7%

▲ Nicotinamide

0.157

76.57

4.3%

0.055

79.90

4.2%

0.148

83.23

4.0%

24
25

▼ Nicotinamide

-0.174

42.64

10.6%

N3,N4-Dimethyl-L▲
arginine

▲ Cystine

0.151

44.07

10.2%

▲ Proline
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Table 5.2. Key metabolic biomarkers identified by ensemble feature selection
(EFS), where the top 25 metabolites are shown. EFS score is calculated as a linear
weighted sum of ranks of features identified by all base learners. Higher ranks result in a
lower score. Downward red arrows indicate an increase in the metabolite results in
worse survival (negative correlation with survival), while upward blue arrows indicate an
increase in the metabolite results in better survival (positive correlation with survival). *
Indicates significant difference in relative abundance between “short” and “long” survival
groups; *p ≤0.05; **p≤0.01. († indicates significance between event vs. non-event
groups as in Supplementary Figure 5.5; †p≤0.05; ††p≤0.01).

Figure 5.3 shows metabolites with a significant (p≤0.05) or marginally significant
(0.05≤ p≤0.1) effect of group in terms of relative abundance (Wilcoxon rank-sum test)
for short vs. long survival groups. Guanine, guanosine, adenosine, and lidocaine were
significantly higher for patients with shorter OS, while glutamine was lower for patients
with shorter PFS (p≤0.05). Additionally, choline and leucine trended higher for patients
with shorter OS, while pipecolinic acid trended higher and N6,N6,N6-Trimethyl-L-lysine
trended lower for patients with shorter PFS (p≤0.1). In comparison, relative abundance
analysis for event vs. non-event groups is shown in Supplementary Figure 5.5. In
patients that died, N6,N6,N6-Trimethyl-L-lysine, L-pyroglutamic acid, and malonic acid
were increased while pipecolinic acid, methionine sulfoxide, lysine, and leucine were
decreased (p≤0.05). Itaconic acid, and creatinine trended higher in these patients. In
patients with progression, guanosine and adenosine were decreased while methionine
sulfoxide and isoleucine trended lower. Interestingly, benzoic acid trended higher in
patients that either died or progressed.
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Figure 5.3. Relative abundance of metabolites identified as significant by unpaired
T-test assuming equal variance. Each box represents 1st and 3rd quartiles. Bands
within represent the median and x is the mean. Ends of whiskers are maximum and
minimum, with points outside being outliers. “Long” survival groups are in green while
“short” survival is in yellow (*p ≤ 0.05, **p ≤ 0.01).

5.3.4 Metabolic pathway enrichment and network analysis
Top metabolic pathways identified in MetaboAnalyst 4.0 by the chosen
databases are shown in Figure 5.4 and listed with associated statistics in
Supplementary Table 5.2. Significant (p≤0.05) metabolic pathways identified by KEGG
database by p-value were the following. For short OS: histidine metabolism, fatty acid
biosynthesis, and biotin metabolism; for long OS: glycine, serine, and threonine
metabolism, glycerophospholipid metabolism, histidine metabolism, nicotinate and
nicotinamide metabolism, tryptophan metabolism, and the citrate cycle (TCA cycle); for
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short PFS: histidine metabolism, biotin metabolism, glycine, serine, and threonine
metabolism, purine metabolism, fatty acid biosynthesis, and lysine degradation; for long
PFS: histidine metabolism, glutathione metabolism, arginine and proline metabolism,
and butanoate metabolism. Visualization of integrated metabolic networks of metabolites
with significant differences in relative abundance for short vs. long survival groups with
OS (adenine, guanine, guanosine) or PFS (glutamine) are shown in Supplementary
Figure 5.6.

160

Figure 5.4. Quantitative enrichment analysis. Enriched metabolic pathways were
found with MetaboAnalyst 5.0 using KEGG pathway database for (A) short Overall
Survival (OS), (B) long OS, (C) short Progression-Free Survival (PFS), and (D) long
PFS.
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5.4 DISCUSSION
This study examined the hypothesis that an ensemble machine learning analysis
of biopsied tissue metabolomic data is able to predict short vs. long survival in terms of
Overall Survival (OS) and Progression-Free Survival (PFS). The study adhered to
REMARK criteria [100] and CHARMS checklist [99] to ensure the integrity of the
modeling approach. An ensemble method of feature selection was employed to identify
key metabolites that correlated with survival and that proved able to differentiate
between short and long term survivals.

A rigorous combination of feature selection and parameter tuning during training
and validation of all base learner models and stacked ensemble meta-learners was
performed to minimize overfitting the models (Figure 5.1). OS predictions achieved an
AUROC of 0.925 with model averaged neural network meta learner model on the
internal validation set and an AUROC of 0.940 with regularized logistic regression meta
learner model on the external validation set (Figure 5.2A). PFS predictions achieved an
AUROC of 0.947 with support vector machine with class weights and radial kernel metalearner model on the internal validation set and an AUROC of 0.875 with boosted logistic
regression meta learner model on the external validation set (Figure 5.2B). Interestingly,
one base learner (Support Vector Machines with polynomial kernel) outperformed
(AUROC=0.911) the optimal meta-learner for PFS (AUROC = 0.875) (Figure 5.2B). On
average, however, the meta-learners outperformed individual base learners across all
feature subsets (Supplementary Figure 5.3), showing that the stacked ensemble
models after ensemble feature selection made consistently more accurate predictions.
Overall, high prediction accuracy was achieved during both internal cross-validation and
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external test set validation, demonstrating that tumor core biopsy derived metabolomic
data is useful for survival prognosis even with a small sample size.

Guanine, guanosine, adenosine and lidocaine were identified as significant
between long and short OS groups (Figure 5.3A), and were all included in the top 7
metabolites selected by the EFS score. Increased relative abundances of these
metabolites were associated with shorter OS. Guanine and guanosine are integral
components of various cellular proteins involved in cancer progression (e.g., [186]), and
abundance of guanosine nucleotides has been observed in cancer [187]. Adenosine is
known to accumulate in tumors, promoting angiogenesis and tumor growth and
increasing resistance to the immune system [188]. Lidocaine is a drug administered to
cancer patients, including for pain relief [189], and would reflect more severe disease.

Higher relative abundance of choline and leucine were marginally associated
with short OS (Figure 5.3A). These two metabolites were also within the top five of the
ranked metabolites selected by EFS score (Table 5.2). Abnormal choline cellular
metabolism leading to increased levels of choline-containing precursors is considered a
hallmark of oncogenesis and tumor progression [190]. Leucine is a branched-chain
amino acid (BCAA); along with isoleucine and valine, these essential amino acids are
needed by tumors for protein synthesis and oxidation for energy purposes [191]. In
contrast, glutamine was selected as the most important metabolite for predicting short
vs. long PFS by EFS score (Table 5.2), and lower relative abundance correlated with
shorter PFS (Figure 5.3B). Glutamine is a major carbon, nitrogen, and energy substrate
in tumors [192], known to be uptaken at higher rates by cancer cells [193]; lower
abundance would indicate enhanced tumor cell proliferative activity along with immune
system suppression [194], both of which can lead to more aggressive cancer. Lastly,
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higher relative abundances of N6,N6,N6-trimethyl-L-lysine and lower pipecolinic acid
were marginally associated with long PFS (Figure 5.3B).

In addition to analyzing metabolites between short vs. long survival groups, we
report relative abundance of significant metabolites between event vs. non-event groups
(Supplementary Figure 5.5). Interestingly, high levels of several metabolites which
were associated with short survival (guanosine, adenosine, leucine) (Figure 5.3A) or
short progression (pipecolinic acid) (Figure 5.3B) were not associated with events (OS
or PFS) (Supplementary Figure 5.5). Additionally, N6,N6,N6-trimethyl-L-lysine, which
trended higher for long PFS (Figure 5.3), was highly significantly associated with death
at high levels (Supplementary Figure 5.5). These discrepancies likely occur because
events and length of time to events or censorship are not necessarily correlated. Our
previous study [195], which analyzed this metabolomic dataset by Kaplan-Meier survival
analysis and Cox proportional hazards regression, consistently found that increased
guanosine, pipecolinic acid, and decreased N6,N6,N6-trimethyl-L-lysine were also not
associated with OS events. Overall, these results confirm the value of analyzing survival
time length in addition to the event occurrence, separately.

Histidine metabolism arose as the top metabolic pathway for short OS, short
PFS, and long PFS, and was the third most significant pathway for long OS (Figure 5.4,
Supplementary Table 5.2). Although histidine was not detected in our samples,
histamine, urocanic acid and glutamic acid were detected (Supplementary Figure 5.1),
which are involved in histidine metabolism. A previous study found histidine to be
upregulated in lung cancer patient serum compared to healthy controls [196], and
histidine metabolism was identified as a significant pathway in a study which analyzed
overlapping genes across KEAP1-overexpressing A549 cells and NRF2-KD microarray
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data [197]. Other significant metabolic pathways identified include fatty acid
biosynthesis, purine metabolism, glycerophospholipid metabolism, nicotinate and
nicotinamide metabolism, the citrate cycle (TCA cycle), and several amino acid
metabolism pathways (Figure 5.4).

The results of this study demonstrate that short vs. long term survival of NSCLC
patients can be predicted in an external validation cohort using a machine-learning
ensemble workflow that analyzes metabolomic data extracted from patient tumor core
biopsies. The approach resulted in higher accuracy predictions than a nomogram based
on patient covariate data (staging, age, and sex). The workflow enables assessment of
OS and PFS, with the goal to help clinical decision-making. A small sample size and
potential confounding factors (differences in biopsy collection date relative to date of
diagnosis, smoking status, and type and duration of treatment) are potential limitations of
this study. Nevertheless, previous work [152] has highlighted the predictive capability of
metabolomics data in spite of such potential confounding factors, showing that adjusting
for smoking status, cancer stage and age at diagnosis, and time between sample
collection and diagnosis had minimal significant effect on metabolite hazard ratios
associated with prostate cancer-specific mortality. Future work will evaluate the
proposed workflow with larger sample sizes and in the context of prospective evaluation,
including prediction of event vs. censorship (death or progression).
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5.5 SUPPLEMENTARY MATERIALS
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Supplementary Figure 5.1. Heatmap of log transformed 2DLC-MS derived
metabolite intensity values. Only common metabolites identified between analytical
batches were considered. Data were log transformed and imputed by probabilistic
principal component analysis (PPCA). 16 Negative ions and 36 positive ions were
considered for analysis. (A) Overall survival (OS); (B) Progression-free survival (PFS).
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Supplementary Figure 5.2. PLS-DA score plots of short vs. long (A) overall
survival and (B) progression-free survival based on patient tissue-derived
metabolomics data.
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Supplementary Figure 5.3. Boxplots of AUROC obtained from all base learner
models and stacked ensemble models during feature selection with predictions
made on the external validation set. Each box represents 1st and 3rd quartiles. Bands
within represent the median and x is the mean. Ends of whiskers are maximum and
minimum, with points outside being outliers. Base learners (left) that achieved a max
AUROC of 0.8 or higher were selected for the stacked ensemble models (right). SVM =
support vector machines; NN = neural network; RF = random forest.
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Supplementary Figure 5.4. Nomograms of covariate data for predicting short vs.
long OS and PFS probability.
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Supplementary Figure 5.5. Relative abundance of metabolites for alive vs. expired
(OS) and progression vs. no progression (PFS), identified as significant by
unpaired t-test assuming equal variance. Each box represents 1st and 3rd quartiles.
Bands within represent the median and x is the mean. Ends of whiskers are maximum
and minimum, with points outside being outliers. Event survival groups are in green and
non-event groups are in yellow (†p ≤ 0.05, ††p ≤ 0.01).
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Supplementary Figure 5.6. Network of metabolites significantly correlated with
overall survival (OS) (adenine, guanine, guanosine) or progression-free survival
(PFS) (glutamine). Red source nodes are shown connected to compounds (pink
hexagons), enzymes (green squares), genes (purple circles) and reactions (gray
diamonds).
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Supplementary Table 5.1. Additional patient characteristics for the internal and
external validation cohorts, organized by decreasing overall survival (OS) in
months. Patients were stratified into long and short survival groups based on the mean
survival time across both data sets (29.87 months for OS; 22.05 months for progressionfree survival (PFS)).
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Supplementary Table 5.2. Quantitative enrichment analysis. Top 25 enriched
metabolic pathways ranked by p-value were found with MetaboAnalyst 5.0 using the
175

KEGG pathway database. Internal validation set was stratified and analyzed according
to short vs. long survival classification for overall survival (OS) and progression-free
survival (PFS).
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CHAPTER 65

EVALUATION OF DRUG-LOADED GOLD NANOPARTICLE CYTOTOXICITY AS A
FUNCTION OF TUMOR VASCULATURE-INDUCED TISSUE HETEROGENEITY

6.1 INTRODUCTION

Although nanoparticle-mediated drug delivery offers the promise of more
targeted and effective treatment of cancer, few of the myriad of formulations evaluated in
the laboratory have reached clinical application. Major hurdles have included concerns
about toxicity, lower than expected efficacy, and off-target effects [2]. In particular, the
tumor microenvironment can present a formidable barrier that not only hinders the
transport of drug molecules but also that of nano-sized vehicles [3-5]. In order to be
effective, nanoparticle-mediated drug delivery needs to avoid uptake by the reticuloendothelial system (RES), utilize the vascular network to preferentially reach the tumor
site and penetrate into cancerous tissue, diffuse through the extra-cellular matrix (ECM)
mesh of proteins, remain close or be uptaken by the cancer cells, and efficiently release
the payload of drug molecules to achieve cytotoxicity. To address these requirements
and increase the efficacy of chemotherapy, nanoparticles can be functionalized in
various ways to help reduce systemic distribution and avoid intrinsic cellular resistance
mechanisms [198, 199]. Yet uncoordinated angiogenic stimuli by cancer and stromal
cells in the tumor microenvironment induce a heterogeneous vascular response,
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characterized by tortuous vessels with abnormal structure and irregular flow [200, 201].
The inadequacy of the vascular network promotes intra-tumoral tissue regions with
heterogeneous proliferative, hypoxic, and apoptotic states, while severely impairing the
transport of and the response to systematically-administered drugs and nanoparticles.

The efficacy of nanoparticles in cancer treatment is typically evaluated with in
vitro and in vivo experimental models, indispensable for pre-clinical evaluation. However,
in vitro models lack key features of cancerous tissue found in vivo, including a vascular
network, while in vivo models present challenges due to systemic interactions that may
be difficult to tease apart. As a complement to these experimental approaches,
computational simulation of cancer nanotherapy has aimed to provide the capability for
system-level analysis [9-20]. In particular, we have recently studied via mathematical
modeling the extravasation, uptake, and distribution of nanoparticles subject to
heterogeneous tumor tissue and vascular conditions [202-204].

The distribution and penetration of 2- and 3-layered gold nanoparticles were
recently evaluated in vitro [205] and in vivo [206]. The purpose of these nanoparticles
was to increase chemotherapy efficacy [207, 208] via enhanced distribution and
penetration into heterogeneous tumor tissue. The 3-layer gold nanoparticles were
functionalized with phosphatidylcholine, hexadecanethiol and high-density lipoprotein
[205]. Computational modeling was employed [202] to simulate the performance of these
nanoparticles in vivo given measurements in vitro, with the goal to begin bridging the
gap from the pre-clinical to the clinical setting. The model parameters were set from
experimental measurements with 2D and 3D cultures of A549, H358, and PC9 NonSmall Cell Lung Cancer (NSCLC) cells [205, 207].
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In this study, computational simulation is employed to evaluate the role of
vascular density-induced heterogeneity on the distribution of 3-layered gold
nanoparticles in tumor tissue and the associated drug release. Small metastatic lesions
are simulated in a well vascularized organ, such as the lung, and cisplatin is chosen as
the model drug. The nanoparticle effectiveness is evaluated for tumors of various blood
vessel densities after bolus administration of the drug loaded nanoparticles. The
fractions of control are defined to be the smallest tumor size after nanoparticles are
introduced into the system divided by the tumor size immediately before the start of
treatment. Tumor therapy is simulated with various drug inhibitory concentrations
calibrated to achieve a 50% reduction in tumor size (IC50) at four timepoints (24hr, 48hr,
72hr, 96hr) post treatment initiation, thus respectively defining four levels of decreasing
drug strength. This work represents a first step towards quantifying tumor response to
drug-loaded nanoparticles based on vascular-network induced tissue heterogeneity.

6.2 MATERIALS AND METHODS
6.2.1 Nanoparticle Synthesis and Characterization
Three-layered nanoparticles were previously created in [205]. Briefly, citratestabilized gold nanoparticles were synthesized by reducing chloroauric acid with
trisodium citrate [209]. The first layer applied was 1-Hexadecanethiol (TL), followed by
phosphatidylcholine (PC), and then HDL. Nanoparticles were characterized via
extinction spectra using ultraviolet-visible (UV-Vis) spectrometry, zeta potential
measurements, DLS (dynamic light scattering) to determine hydrodynamic size (intensity
distribution) in solution, determination of shape and size with scanning electron
microscopy (SEM), and confirmation of presence of lipids on the particle cores using a
Fourier transform infrared (FTIR) instrument. Cisplatin (7.5 mg) was then added to the
nanoparticles in solution and allowed to react for 2 h [205].
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6.2.2 Experimental Nanoparticle Data
The 3-layer gold nanoparticles were previously characterized as having a
maximum wavelength of 5.35 nm, a hydrodynamic diameter of 80.2 ± 12.4 nm, and a
zeta potential of -6 mV [202]. Cisplatin loading efficiency was 78.9 ± 0.7% [202]. The
nanoparticles released 59.1 ± 2.0% of drug within the first 3 hours, 76.7 ± 1.84% within
48 h, and 78.9 ± 2.1% by 96 h [207].

6.2.2 Experimental Cytotoxicity Data
As described in [205], A-549 cells were maintained in standard culture
conditions, and used to form 3D tumor spheroids. Cytotoxicity was first measured in 3D
cell culture with free drug at varying concentrations (1024, 256, 64, 16, 4, 1, 0.25, 0.0625
µM) for 48 h. The spheroids were exposed to varying concentrations of drug-loaded
nanoparticles calculated by considering two parameters: (1) the loading efficiency from
HPLC data showing the exact concentration of drug encapsulated onto the nanoparticles
[207] and (2) the percent of drug released over the 48-hour period.

6.2.3 Computational Modeling
6.2.3.1 Tumor Growth
The tumor growth component is based on [210, 211], for which tumor tissue is
divided into three regions: a proliferating region where cells have sufficient oxygen and
nutrients to proliferate, a hypoxic region where cells have sufficient oxygen and nutrients
to survive but insufficient for proliferation, and a necrotic region where cells lack
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sufficient oxygen and nutrients for survival. The tumor growth velocity vc follows a
generalized Darcy’s Law [210]:

vc = −P +  E E ,

[Equation 6.1]

where μ is cell-mobility, P is oncotic pressure, χE is haptotaxis, and E is the density of the
extracellular matrix (ECM). Refer to [210] for a more detailed description of E and χE.
The overall tumor growth can be associated with the rate of volume change by assuming
that the cell density within the proliferating region remains constant:

 vc =  p ,
where

[Equation 6.2]

 p is the net proliferation rate (described below).

6.2.3.2 Angiogenesis
The angiogenesis component is based on [212] to represent blood flow, vascular
leakage and vascular network remodeling resulting from wall shear stress and
mechanical stress imposed by the tumor tissue as it spatially evolves in time. Briefly, as
the tumor grows within a vascularized environment, the tissue has access to oxygen and
nutrients diffusing from the vasculature. The interstitial flow of oxygen and nutrients is
influenced by tissue pressure and by distance from the nearest vessel. Refer to [210,
211] for a more detailed description of the angiogenesis model.
6.2.3.3 Transport of oxygen and nutrients
Oxygen and nutrients σ are transported to the tumor from the location of
extravasation from the vasculature. The extravasation

ev represents the rate that σ are

supplied from the vasculature. These substances, diffusing with diffusivity Dσ, are taken
up by host tissue, proliferating tumor regions and hypoxic tissue with rates
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host
, tumor ,

and qs, respectively, and decay with rate

N in the necrotic region. Under steady-state

conditions, the formulation of oxygen and nutrient uptake and decay is [19, 210, 211]:

0 =   ( D  ) + ev (x, t , 1vessel , pi ,  , h) −   ( ) ,

[Equation 6.3]

where x is position, t is time, 1vessel is the characteristic function for the vasculature
(equals 1 at vessel locations and 0 otherwise), pi is interstitial pressure, h is the
hematocrit in the vascular network, and 𝜆𝜎 is the rate of uptake and decay of σ as
defined above [210]. Extravasation is modulated by the extravascular interstitial pressure
pi, scaled by the effective pressure pe. The weight of the convective transport component
of small molecules is k pi [19]:


ev =  ev 1vessel (x, t )(

p
h
− h min ) + (1 − k pi i )(1 −  ) .
pe
HD

[Equation 6.4]

H D and hmin are constants that represent the normal and minimum hematocrit necessary

for oxygen extravasation, respectively.



 ev represents the constant transfer rate from

pre-existing and tumor-induced vessels.

6.2.3.4 Transport of nanoparticles
Nanoparticle transport s through the tumor tissue is simulated from the point of
extravasation from the vasculature. The uptake rate of nanoparticles by host and tumor
s

cells is  uptake [17, 19]:
s
s
=   ( Ds s ) + evs (x, t , 1vessel , pi , s) −  uptake s .
t

Under the assumption that the transfer rate

s

[Equation 6.5]

 ev from vessels is constant, nanoparticle

extravasation is represented by [17, 19]:

182

s
ev

 =  1vessel (x, t )(1 − k p
s
ev

i

pi Cts
)(
− s) ,
pe C s

[Equation 6.6]

where diffusion of particles into the tumor tissue is modulated by the interstitial pressure
s

s

[19]. Particle extravasation is assumed to be Cts = C e− t , where C is the initial
concentration [19]. The extravasation is concentration dependent, simulating first order
kinetics. The decay constant α is measured from previous in vivo experiments, in which
the particle half-life is estimated to be 12 hours [213]. The diffusivity Ds was calibrated
from the combination of nanoparticle charge and size properties, based on
measurements obtained in vitro [205].

6.2.3.5 Transport of drug
Drug G is released at the point of extravasated particles and diffuses through the
G

tumor tissue with diffusivity DG. The rate  decay combines the effects of drug uptake by
tumor and normal cells and the wash-out from the interstitial space, and reflects the halflife of the drug [202]:
G
G
G
=   ( DG G ) + release
(t , s ) −  decay G .
t

The drug release

[Equation 6.7]

G
release
from the particles is approximated as in [202]:

G
release
= sCtG .

[Equation 6.8]

CtG is the release of drug, fitted in time to follow the results obtained from the in vitro
experiments in [207]. The drug release rate thus combines the effect of particle
concentration and the drug release profile. All diffusion equations are subject to the
boundary condition

B
= 0 where B is the diffusible substance.
n
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6.2.3.6 Drug effect on tumor
Cisplatin is a cell cycle dependent drug; hence, its cytotoxic effect is only exerted on
proliferating cells. Drug effect is included into the proliferation term

 p , where  effect is

the rate of drug-induced cell death [17]:
0

  (1 −  effect G ) − A
p =  M
0
−G
 N

outside the tumor
in proliferating tissue
in hypoxic tissue

[Equation 6.9]

in necrotic tissue

Here, λA is the apoptosis rate, λM is the mitosis rate, and GN is the non-dimensional rate
of volume loss in the necrotic tumor core (assuming that cellular debris is constantly
degraded and the fluid is removed[210]). This pharmacodynamic model assumes that
cell proliferation and apoptosis rates are similar before and after drug therapy, and that
cell death is instantaneous.

6.2.3.7 Calibration of Rate of Drug-Induced Cell Death
The model parameters for oxygen, drug effect and tumor growth were calibrated
using data obtained experimentally with NSCLC tumor spheroids to find an 48hr IC50 for
simulated avascular spheroids (in vitro simulations) [205]. A detailed description of the in
vitro experiments used to calibrate the simulations can be found in [202], which includes
the synthesis, functionalization, characterization, drug loading, and drug release of the
nanoparticles and cytotoxicity experiments in 2D and 3D cell cultures. The free drug
concentration after 48 h of exposure was set based on the data from our previous study
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[202]. The drug effect was determined via interpolation (running multiple simulations with
different values) to obtain a tumor that had shrunk by half within the 48h of simulated
drug exposure. This value was assigned the units of the drug concentration that had
achieved the 50% regression with the tumor spheroids in the experiments in vitro [202].
The 24hr, 72hr, and 96hr IC50 avascular treatment drug concentrations were scaled by
the same proportion as the change in the drug effect. The trapezoid method was used to
calculate the corresponding areas-under the-curve (AUC’s) to quantify the avascular
IC50’s. Thus, the AUC’s are proportional to the drug effect at each IC50.

6.2.3.8 Tumor Tissue Heterogeneity
The values for drug-induced cell death used for the avascular IC50’s were
employed in therapy simulations with vascularized lesions (simulations of in vivo
condition). To link the differences in drug effect to the effects of heterogeneous
vascularization density, the in vivo simulations used the same nanoparticle concentration
in a bolus dose as was needed in the in vitro simulations to achieve the IC50. Simulated
tumors were grown to the same initial radius of 0.57 mm with the same pre-existing
vessel densities, but different oxygen thresholds for hypoxia and necrosis. In vivo
simulations were run for a sufficient amount of time to obtain the smallest tumor radii
following NP bolus injection and were used to compare the efficacy of cisplatin-loaded
nanoparticles among the various cases. The tumor blood vessel density was calculated
by dividing vessel surface area (vessel length x vessel cross sectional area) by the
tumor area. The tumor, nanoparticle, and drug main parameters and their values are
summarized in Table 6.1.
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Parameter

Value

Reference

1 day-1

Measured in [202]

Oxygen diffusivity (Dσ)

1 (*)

[211]

Oxygen transfer rate from vasculature
(𝜆𝜎𝑒𝑣 )

5 (*)

[211]

Oxygen uptake rate by proliferating

1.5 (*)

[211]

1.3 (*)

[211]

0.12 (*)

[211]

Oxygen decay rate (𝜆𝜎 )

0.35 (*)

[211]

NP extravasation from angiogenic vs.

10

Estimated

NP diffusivity (Ds)

0.3 (*)

[205]

NP decay (α)

12hr half-life

Estimated

CDDP diffusivity (DG)

0.6 (*)

Estimated

27, 9.45, 5.6,
4.0

Calibrated to
experimental data

Tumor proliferation rate

tumor cells

(



tumor

( )
p

)

Oxygen uptake rate by hypoxic tumor
cells (qs)
Oxygen uptake rate by tumor
microenvironment

normal vessels

( )

host

( )

CDDP drug effect

s
ev

( )
effect

(for 24, 48, 72,
and 96 h IC50)
CDDP decay rate (𝜆−𝐺
𝑑𝑒𝑐𝑎𝑦 )

0.5hr half-life

[214]

CDDP release profile from NP Ct

Data shown in
Figure 5B in
[207]

Measured in [207]

CDDP in vitro IC50 (48 h) for A549
cells (spheroid)

15.9 ± 1.2 μM

Measured in [202]

( )
G

Table 6.1 Computational model main parameters and associated values. All other
model parameters are as in [211]. (*) Value is rescaled by the square of the simulation
system characteristic length (1 cm) and divided by the system characteristic time (1 sec)
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multiplied by the oxygen diffusivity [215] (1 x 10-5 cm2 s-1). CDDP: cisplatin; NP: 3layered gold nanoparticles characterized in [202, 205, 207].

Four levels of tissue heterogeneity were obtained, respectively labeled VERY
LOW, LOW, MEDIUM, and HIGH, by varying the angiogenesis-induced tissue
vascularization based on the response to tumor angiogenic factors (TAF) released in
proportion to the tumor tissue hypoxic level. In Table 6.2, the hypoxic threshold defines
the oxygen level at which tissue becomes hypoxic (quiescent but still viable) and ceases
to proliferate, while the necrotic threshold defines the oxygen level at which the tissue
becomes necrotic (not viable).

Level of Tissue
Heterogeneity
VERY LOW
LOW
MEDIUM
HIGH

Tumor hypoxic
threshold
0.305
0.405
0.485
0.575

Tumor necrotic
threshold
0.300
0.400
0.480
0.570

Table 6.2: Definition of levels of tumor tissue heterogeneity based on the thresholds for
inducing hypoxia and necrosis.
The values for HIGH were based on the previously calibrated tumors simulated in
[211], set so that the vasculature network provides sufficient oxygen (σ ranging from
0.76 to 1.00) to support normal tissue metabolism. These values led to a highly
vascularized tumor microenvironment and, consequently, to high tissue heterogeneity.
At the other end of the spectrum, the values for VERY LOW were chosen so that no
more than 95% of the tumor was proliferating. In this case, vascularization was
minimized along with the tissue heterogeneity. The intermediate LOW and MEDIUM
conditions were defined by growing tumors to the same size and finding values for these
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thresholds so that the respective proliferative fractions were incrementally in between
the VERY LOW and HIGH cases.

6.2.3.9 Numerical Methods
The numerical implementation is detailed in [211] and references therein. Briefly,
in all equations that involve a diffusion term, a fully nonlinear diffusion solver was used to
solve the equation, 𝑢(𝑡) = ∇(𝐷(𝑢, 𝑥, 𝑦) ∙ ∇ (𝑢) + 𝑠𝑜𝑢𝑟𝑐𝑒(𝑢, 𝑥, 𝑦). The equations were
discretized in space using centered finite difference approximations and the backward
Euler time-stepping algorithm. The equations were then solved using a nonlinear
adaptive Gauss-Seidel iterative method [216, 217]. This system of equations was
iteratively solved together to steady state at each timestep, to obtain the concentration of
diffusible elements and the tumor oncotic pressure. The level set method was used to
update the tumor viable/necrotic region as well as the interfaces between the tumor
viable–necrotic and tumor–host tissue regions. The model implementation in C/C++ was
run on an Asus PC with an Intel Core i7 processor and 24 Gb RAM.

6.3 RESULTS
6.3.1 Simulation of heterogeneous tumor growth
Tumors were first grown to the same size under the conditions of VERY LOW,
LOW, MEDIUM, and HIGH heterogeneity, as defined in Table 6.2. The simulated tumors
during the initial growth phase are shown in Figure 6.1. Depending on the level of
heterogeneity, this growth took varying amounts of time, with the HIGH case taking the
longest (22.7 simulated days). The tissue heterogeneity is characterized in Figure 6.2 as
a function of the tumor radius. Lower oxygen thresholds for hypoxia and necrosis, as in
the case of VERY LOW heterogeneity, allow the tumor to have more proliferative tissue
because a lower concentration of oxygen/nutrients is required for the tissue to thrive. In
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cases of higher oxygen thresholds, as with HIGH heterogeneity, more oxygen is required
for the tissue to thrive. The angiogenesis component of the model is thus activated to
generate more blood vessels, which supplies the tumor tissue with increased oxygen
and nutrients. Angiogenesis is stimulated by the concentration of tumor angiogenic
factors, which are released by the tumor hypoxic regions. Tumors with a higher fraction
of hypoxic tissue (higher oxygen threshold), as in the case of HIGH heterogeneity, would
be expected to release more tumor angiogenic factors.
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Figure 6.1 Simulation of tumor nodules growing in time with different levels of
vasculature-induced tissue heterogeneity. Red color denotes the proliferating region,
blue indicates hypoxia, and brown means necrosis. The pre-existing capillary grid is
shown as rectangular lines along with irregular sprouts growing from them due to the
angiogenesis process. Bar: 250 μm.

Figure 6.2 Characterization of tumor tissue heterogeneity, defining the four levels
of heterogeneity in this study. (A) Intra-tumoral vascular fraction (vascular surface
area divided by tumor area); (B) Proliferating fraction; (C) Hypoxic fraction; (D) Necrotic
fraction.

While the intra-tumoral vessel density initially increased for the VERY LOW and
LOW cases, it plateaued for radii beyond 0.40 mm (Figure 6.2A). In contrast, the density
for MEDIUM and HIGH conditions first decreased for radii below 0.31 and 0.28 mm,
respectively, before becoming larger. The angiogenesis model was calibrated in
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previous work [211] based on experimental data of tumor growth, and these results are
consistent with this calibration. The proliferative tissue fraction corresponding to these
vascular densities indicates that for a radius of 0. 57 mm at the start of treatment, these
fractions were 0.96, 0.82, 0.68, and 0.55 for VERY LOW, LOW, MEDIUM, and HIGH
conditions, respectively (Figure 6.2B). At this radius, the hypoxic tissue fractions were
correspondingly lower, at 0.02, 0.05, 0.10, and 0.20 (Figure 6.2C), while the necrotic
fractions were 0.01, 0.12, 0.22, and 0.25, respectively. Compared to the more stable
values for the proliferating and hypoxic fractions as the tumor radius increased, the
necrotic fractions (Figure 6.2D) (except for the VERY LOW condition) exhibited an initial
steep increase followed by a gentle decline past 0.350 μm as the proliferating portion
slowly started gaining in value. The proliferating fractions increased while the necrotic
fractions decreased due to the higher vessel density (more oxygen being transported
into the tissue as it grew; Figure 6.2A). The hypoxic fractions remained relatively stable
over time due to the level of angiogenic activity, as previously calibrated. The tumor
viable (proliferating and hypoxic) fractions at the start of treatment are summarized in
Table 6.3.

Level of Tissue
Heterogeneity
VERY LOW
LOW
MEDIUM
HIGH

Tumor Viable
Fraction
0.98
0.87
0.78
0.75

Table 6.3 Tumor viable (proliferating and hypoxic) fractions at the start of
treatment as a function of tissue heterogeneity.

6.3.2 Calibration of drug effect
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A simulated tumor growing in the dish in vitro, surrounded by plentiful oxygen
and nutrients, is shown in Figure 6.3A. This in silico tumor was exposed after 30 d to
drug for 48 h to determine the value for the drug effect  effect to achieve a 50% reduction
in tumor size (Figure 6.3B). A range of area-under-the-curve values was obtained for
different exposure times, as described in Methods, and summarized in Table 6.4.

Figure 6.3. Simulated tumor growing in avascular conditions in vitro. Red:
proliferating tissue; blue: hypoxic tissue; brown: necrotic tissue. Bar: 250 μm.

IC50 Range of Time
24hr IC50
48hr IC50
72hr IC50
96hr IC50

AUC
(μM.h)
1082
760
676
644

Table 6.4. Area-under-curve (AUC) calculated for the IC50 obtained at four
different ranges of time for a simulated tumor spheroid growing in in vitro
conditions.

6.3.3 Simulation of nanoparticle-mediated drug delivery
Representative simulation images of vascularized tumors at the start of treatment
(the time immediately after the bolus injection) with the various levels of tissue
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heterogeneity are shown in Figure 6.4. As the heterogeneity increases from VERY LOW
to HIGH, the penetration and spatial distribution of nanoparticles and the drug released
from them correspondingly becomes more heterogeneous. The deepest nanoparticle
penetration is achieved with the VERY LOW case, for which the drug release is
concentrated in the inner core of the tumor. In contrast, in the HIGH case the
nanoparticles become stuck in the tumor periphery, unable to penetrate into the tissue.
This is consistent with previous modeling work showing that tumor tissue heterogeneity
leads to inhomogeneous small molecular and nanoparticle distribution, with the highest
concentrations occurring on the periphery [218, 219]. Interestingly, although in the LOW
case the nanoparticles penetrate deeper, their concentration is more heterogeneously
distributed than in the MEDIUM case, suggesting that the relationship between
heterogeneity and nanoparticle penetration is not linear [218, 219].
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Figure 6.4. Representative simulation images of vascularized tumors with various
levels of heterogeneity shown at the start of treatment (immediately after bolus
injection) with cisplatin-loaded nanoparticles. At this time, nanoparticles and drug
can be seen within the system but the tumor tissue has not yet responded to the effect of
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the drug. Red: proliferating tissue; blue: hypoxic tissue; brown: necrotic tissue. Bar: 250
μm.

It is to be noted that the spatial distribution of the neo-vasculature in the
simulations (e.g., as in Figures 6.1 and 6.4) is stochastic because randomness is built
into the method of migration of the endothelial cells along the gradient of angiogenic
factors [210, 211], in order to more accurately simulate the angiogenesis process.
Hence, running multiple simulations using the same parameters will result in tumors with
slightly different vasculature layouts and tissue fractions. These differences are very
small and running multiple simulations (n=3) with the same parameters has confirmed
that there is no significant difference between the obtained results.

The nanoparticle concentration within tumor tissue for each value of the drug
strength (respectively based on 24, 48, 72, and 96 h IC50 values in vitro) is shown in
Figure 6.5. The initial sharp increase in nanoparticle concentration reflects the bolus
injection of nanoparticles into the system. In the case of the 24 h IC50 value, the
concentrations are similar regardless of level of tissue heterogeneity, with an initial sharp
peak at 2.5 h post-treatment initiation followed by a sharp drop to 35% of initial
concentration within 4 h. The concentration then declines slowly afterwards, to 10% of
initial by 30 h. For the other three drug strengths, the LOW case exhibits the highest
concentration of nanoparticles overall, with 30% still in tissue after 30 h. For the 48h
IC50 case, the VERY LOW case retains the second highest concentration, while for both
72 and 96 h, it is similar to the MEDIUM and HIGH conditions, decreasing to 20% of
initial value by 30 h. Noticeably, the nanoparticle concentrations are more
heterogeneous in time for the 48 and 72 h cases, while the 24 and 96 h evince more
consistent profiles. This suggests that the drug strength is also a key parameter that
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influences the nanoparticle concentration as the tissue responds temporally and spatially
to the drug, and is consistent with recent findings from an optimization model applied to
this tumor model system [220].

Figure 6.5. Nanoparticle concentration (as a percent of initial amount) within
tumor tissue after injection, for each level of tissue heterogeneity at the various
IC50-based drug strength values.

The drug release from the nanoparticles within the first 4 h for the various drug
strengths is shown in Figure 6.6. Consistently, the highest concentrations were
achieved for HIGH tissue heterogeneity and the lowest for the VERY LOW
heterogeneity. The 24 h IC50 strength exhibited the greatest differential between the
various levels of heterogeneity, with 7 μM for HIGH and 5 μM for VERY LOW, in contrast
to the 96 h IC50, which evinced 1 μM for HIGH and 0.75 μM for VERY LOW.
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Figure 6.6. Drug release from nanoparticles within the first 4 h after injection for
each level of tissue heterogeneity at the various IC50-based drug strength values.
As the half-life for cisplatin is 30 min, values beyond 4 h are negligible.

The area-under-the-curve (AUC) for the nanoparticles within tumor tissue is
shown in Figure 6.7. For all IC50 conditions, the lowest values were obtained for the
HIGH level of heterogeneity, while the highest values were obtained for the LOW level.
At this level, the 72 h IC50 predominated overall at 1750 %initial.h. In contrast, the
highest AUC for the other levels were achieved for the 96 h IC50, with 1530 for VERY
LOW, 1410 for MEDIUM and 1380 %initial.h for HIGH conditions, respectively. These
inhomogeneous outcomes reflect the variations in concentration as shown in Figure 6.5.
In contrast, the intratumoral AUC for the drug released from them had a more consistent
pattern across the levels of heterogeneity and drug strength (Figure 6.7B), following the
levels of drug release (Figure 6.6). The 24 h IC50 evinced the highest values overall,
increasing from 9.6 μM.h to 13.1 μM.h for the VERY LOW and HIGH levels, respectively.
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The values for the other drug strengths followed a similar increasing trend but with lower
values, ranging for the VERY LOW to HIGH levels from 3.5 to 4.7, 2.1 to 2.8, and 1.5 to
2.0 μM.h for the 48, 72, and 96 h IC50 strengths, respectively. Thus, the 96 h IC50 had
the lowest drug AUC values.

Figure 6.7. AUC values for intratumoral accumulation of (A) nanoparticles and (B)
drug. Drug strength increases with shorter IC50 times.

Figure 6.8 shows the minimum tumor radius achieved for each level of tissue
heterogeneity, as a function of the intratumoral drug AUC. In all cases, there was a
nearly linear relationship between tumor radius and AUC, with radius decreasing as the
AUC values increased. The largest radius reduction was achieved by the VERY LOW
case with the 24 h IC50 drug strength, yielding 52% shrinkage from the initial tumor
radius, while the smallest decrease at this drug strength was 41% for the MEDIUM case.
On the other hand, the 96 h IC50 drug strength was equally ineffective across all levels
of heterogeneity, achieving at best a 9% reduction in tumor radius for the HIGH case.
This information is summarized in Figure 6.9, highlighting the decrease in tumor radius
for the different drug strengths across the four levels of heterogeneity. While higher drug
strengths, as represented by lower IC50 values, yielded higher response, the magnitude
of this response was dependent on the level of tissue heterogeneity.
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Figure 6.8. Minimum tumor radius for each level of tissue heterogeneity as a
function of the intratumoral drug AUC. The points along each curve represent, from
left to right, 96, 72, 48, and 24 IC50-based drug strength values (AUC increases with
shorter IC50 times).

Figure 6.9. Minimum tumor radius achieved during therapy as a function of drug
strength and tissue heterogeneity (strength increases with shorter IC50 times).
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Figure 6.10 shows the minimum tumor radius as a function of drug strength
dependent on the size of the tumor tissue viable (proliferating and hypoxic) fraction and
intratumoral vascular density, both calculated at the start of the treatment. As expected,
as the drug strength increases (represented by lowering IC50 values), the tumor
regression is correspondingly higher. For the highest strength (24 h IC50), this
regression was maximized by higher values of the viable tumor tissue fraction (Figure
6.10A) and lower values of the intratumoral vascular density (Figure 6.10B), together
representing lower tumor heterogeneity. For the other drug strengths, the regression
was less dependent on viable fraction and vascular density.

Figure 6.10. Minimum tumor radius achieved during treatment as a function of
drug strength dependent on (A) size of tumor tissue viable (proliferating and
hypoxic) fraction and (B) intratumoral vascular fraction (vascular surface area
divided by tumor area), both calculated at the start of the treatment. The tumor
vasculature-induced tissue heterogeneity increases from VERY LOW (leftmost point) to
HIGH (rightmost point), while the drug strength increases with shorter IC50 times.
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6.4 DISCUSSION

This study builds upon previous experimental [205, 207] and modeling work [202]
to evaluate the effect of vascular density-driven tissue heterogeneity on NSCLC tumor
response to cisplatin delivered via 3-layered gold nanoparticles. As such, this work
represents a first step towards the development of a principled approach to predict
nanotherapy efficacy using patient-tumor-specific characteristics, such as proliferative
index and vascular density. Tumors with different intra-tumoral vascular densities
(Figure 6.1) were first generated in silico by varying the oxygen thresholds for hypoxia
and necrosis to yield different proportions of proliferating, hypoxic and necrotic tissue
(Figure 6.2), thus defining various levels of tissue heterogeneity. Next, using
experimentally-obtained data with 3-layered gold nanoparticles loaded with cisplatin
[205, 207], the magnitude of the drug effect in silico was calibrated for inhibitory drug
concentrations to achieve 50% tumor tissue remission over 24, 48, 72, and 96 h (Figure
6.3). The simulated vascularized tumors were then treated with these drug
concentrations. Figure 6.4 illustrates the nanoparticle and drug concentrations at the
time immediately following bolus injection in Figure 6.5, showing representative images
of these concentrations within the tumor tissue with various levels of heterogeneity. In
Figures 6.5 through 6.10, the information is summed over the whole tumor space for
each case of drug strength and tumor heterogeneity. The resulting inhomogeneous
intratumoral nanoparticle and drug AUC values (Figure 6.7) yield correspondingly
heterogeneous tumor regressions (Figures 6.8, Figure 6.9). This system was then used
to determine the expected tumor size based on the fraction of viable tumor tissue and
intratumoral vascular density (Figure 6.10).
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The results show that tumor vascular density coupled with the drug strength nontrivially influences the nanoparticle uptake and washout (Figure 6.5), and the associated
tissue response (Figure 6.8). The regions of the system with high vascular density also
have locally high nanoparticle and drug concentrations. Although regression generally
correlated with drug strength, the level of vasculature-driven tissue heterogeneity
additionally modulates this regression. The drug strength affects the proportion of
proliferating, hypoxic, and necrotic tissue fractions, which in turn dynamically affect and
are affected by the vascular density. The drug strength was varied in the model through
the “drug effect” term, which is related to the pharmacodynamic model that drives the
tumor growth. The simulations help to quantify the nonlinear relationship between drug
strength and response, showing that the response becomes more insensitive to variation
in the drug strength as this strength decreases or the tissue heterogeneity increases
(Figure 6.9). Higher drug strengths may be able to achieve a stronger tumor regression
but only if the intra-tumoral vascular density is below a certain threshold (Figure 6.10B).
In contrast, drug strengths of lower magnitude may yield similar responses regardless of
vascular density. Since drug strength is a key clinical parameter underlying both
response and systemic toxicity, the overall results support the notion that drug strength
remains a critical modeling parameter for predictive evaluation. This is consistent with
recent modeling work that combined an optimization approach to determine optimal
nanoparticle sizes for maximum tumor regression [220].

This modeling platform, while supporting the intuitive outcome that tumor
heterogeneity and drug strength influence the tumor response, provides a means to
quantify the understanding of these effects, e.g., to help define nanoparticle formulation
and delivery methods. For instance, if tumor heterogeneity could be measured in terms
of vascular density, drug efficacy in cases of higher drug strength is predicted to be
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highest against tumors with the lowest levels of heterogeneity (Figure 6.8 and Figure
6.9). In this case, the viable tissue fraction remains the same as at the start of treatment
while the tumor shrinks, since most of the tumor is proliferating (Figure 6.2B) and
responsive to the drug. When using weaker drug strengths, in contrast, drug efficacy is
predicted highest against tumors with high vascular heterogeneity. In this case, a smaller
viable fraction lessens the tissue responsiveness. Future work examining the balance
between tumor vascular heterogeneity and nanotherapy efficacy is expected to further
help elucidate the underlying mechanisms in order to maximize the tumor response for
specific drug strengths and vehicle formulations.

This study establishes a more systematic methodology to assess the effect of
tumor tissue vascular density on the response to nanotherapy. With specific tumor- and
nanotherapy- parameter values, the system could be expanded to evaluate other types
of nanoparticles and drugs. In particular for non-small cell lung cancer (NSCLC),
parameters such as vascular density could be measured via imaging or histological
analysis [221]. Vascular permeability and blood volume could be quantified by positron
emission tomography (PET) [222]. Additionally, there exist methods for detecting tumor
hypoxia, including the detection of hypoxia-induced proteins [223, 224]. The concept of
manipulating the vascular density to achieve improved response (e.g., “vascular
normalization” [225]), as has been tried for NSCLC with small molecule tyrosine kinase
inhibitors or monoclonal antibodies that target VEGF [226], may find further utility if
coupled with consideration of the chemotherapeutic drug strength. Clinically,
angiogenesis inhibitors have been shown to improve overall survival when combined
with standard first line and second line therapy [226]. In cases where tumor vascular
density were predicted by the model to be inadequate for a desired level of response,
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manipulation of angiogenesis might be explored as a means to change this density to
augment the nanotherapy efficacy.

The interaction between vasculature, cells, nanoparticles, and drug molecules is
a complex kinetic process in need of further consideration by computational modeling
and simulation studies. Recently, a vascularized tumor model system evaluated the drug
kinetics of combination chemotherapy among various cellular compartments [227].
Future studies could combine drug kinetics with a nanoparticle delivery model. The
model used herein simulates cell death as an instantaneous process. However, cell
cycle dependent drugs such as cisplatin rely on processes that may take several hours
before cytotoxic effects are realized [228]. Thus, accounting for the delay in the drug
cytotoxic action may yield more accurate results. Additionally, there are several well
characterized drug resistance mechanisms, such as decreased intracellular transport,
enzymatic deactivation, and alteration in proteins involved in apoptotic pathways
[229].These mechanisms could be integrated to create a more comprehensive
pharmacodynamics model, with the ultimate goal to predictively determine optimal
nanotherapy customized to patient-specific tumor vasculature conditions.
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CHAPTER 76

PHARMACOKINETIC/PHARMACODYNAMICS MODELING OF DRUG-LAODED PLGA
NANOPARTICLES TARGETING HETEROGENEOUSLY VASCULARIZED TUMOR
TISSUE

7.2 INTRODUCTION

Despite improvements in the understanding of cancer biology, cancer remains an
elusive disease difficult to treat, especially in advanced stages. Drug targeting systems
such as nanoparticle (NP) mediated drug delivery platforms offer potential for more
effective treatment. Unfortunately, the efficacy of many nanotherapeutic formulations has
been limited due to an incomplete understanding of the complex interactions between
NPs, drugs, immune system components, and heterogeneous tumor tissue conditions
[230]. In particular, a heterogeneously vascularized tumor microenvironment may act as
a barrier that prevents the penetration of NPs and their drug payload to reach all of the
cancerous cells [3, 5, 231]. Tumors produce uncoordinated angiogenic stimuli, resulting
in an irregular and inefficient vascular supply [200, 201] through which the NPs are
delivered. Inadequate vascularization impedes adequate delivery of therapeutic agents,
and also results in tumors with regions of transient or chronic hypoxic tissue which may
be insensitive to chemotherapeutic drugs targeting cycling cells [200]. Consequently,

6

Miller, H.A., Frieboes, H.B. Pharmacokinetic/Pharmacodynamics modeling of drug-loaded PLGA
nanoparticles targeting heterogeneously vascularized tumor tissue. Pharm Res 36, 185 (2019).
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lower than expected efficacy and off-target toxicity remain major concerns with cancer
nanotherapy.

Two major factors influencing NP efficacy in heterogeneously vascularized tumor
tissue include NP aggregation and cellular uptake. Aggregation is a well-known physical
phenomenon that has been observed with drug nanocarriers [232]. This phenomenon
can be evaluated at various length scales; up to the scale of one meter by turbulent
reacting flow, down to the sub-nanometer scale by quantum chemistry [233-237]. Much
effort has been spent studying the nature of aggregation within this wide range of length
scales, but there is currently no established methodology to determine how specific NP
formulations will behave in vivo. It has been observed that NPs can form large
aggregates around tumor tissue due to entrapment by capillaries [238], which can have
a direct impact on the efficacy of cancer nanotherapy. Whether or not NP aggregation
would be beneficial or detrimental in terms of tumor response remains poorly
understood.

A major challenge with the development and implementation of effective NP drug
delivery platforms has been the sheer number of combinations of NP and drug
parameters along with variable tumor tissue conditions. Due to cost and time constraints,
finding and fine-tuning effective platforms based purely on experimental effort is
practically not feasible. Detailed kinetic models that describe NP and drug behavior at
the cellular and tissue level are scarce yet are critically important for understanding
these interactions, as they enable abstracting complex biological behavior into
mathematical formulations to explore parameter variations and system constraints.
Simulation of cancer nanotherapy provides a platform that could allow faster and more
focused clinical translation of new NP formulations. In conjunction with experimental
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efforts such as in vitro laboratory studies, the flexibility provided by modeling and
simulation offers the potential to evaluate patient tumor-specific responses prior to a
particular treatment regimen [9-20]. Recently, mathematical modeling has been applied
to evaluate the extravasation, uptake, and distribution of NPs subject to heterogeneously
vascularized tumor tissue [202-204, 239], while NP aggregation has been modeled in
various materials [240, 241].

To further advance the ability to predictively simulate nanotherapy performance
in vivo, this study seeks to establish the capability to evaluate both the NP and drug
pharmacokinetics in a spatial model of heterogeneous tumor tissue. Previously, the
pharmacokinetics and pharmacodynamics of combination chemotherapy on
heterogeneously vascularized tumor tissue were evaluated [227] via multicompartmental
drug kinetic models for cisplatin [242] and gemcitabine [243]. This study implements a
NP multicompartmental kinetic model and couples it with the cisplatin
multicompartmental model in [242] to evaluate the efficacy of drug-loaded PLGA NPs.
The magnitude of NP extracellular to cytosolic transport is varied to evaluate tumordependent cellular uptake. The effect of NP aggregation is assessed in terms of drug
distribution and tumor response. Tumor lesions with various levels of vascular
heterogeneity, inducing differential viable and necrotic tissue fractions, are simulated for
evaluation of response. It has been shown that tumor tissue vascular heterogeneity can
have a dramatic effect on the efficacy of cisplatin nanotherapy [239]. Accordingly, the
range of tumor vascular heterogeneity was chosen to represent the characteristics of a
variety of cancer types. This study offers a further step towards understanding the
response to NP-mediated drug delivery in the heterogeneously vascularized tumor
microenvironment.
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7.2 MATERIALS AND METHODS
7.2.1 Tumor Growth
Tumor tissue is spatially represented by viable and necrotic regions. Viable
tissue with sufficient access to oxygen and nutrients σ above a certain threshold (σ > σH)
can proliferate, while tissue with sufficient oxygen and nutrients above a certain
threshold σN to survive but not proliferate is hypoxic (σN < σ < σH). Necrotic tissue lacks
sufficient oxygen and nutrients for viability (σ < σN). These three regions are updated
every output interval of the simulations in response to the change in the surrounding
availability of oxygen and nutrients, supplied by the vasculature. The tumor growth
component of the model is based on [210, 211], for which non-dimensionalized tumor
growth velocity is represented as a function of the tumor oncotic pressure P and
extracellular matrix (ECM) density E:

𝐯𝑐 = − µ∇𝑃 + 𝜒𝐸 ∇𝐸

[Equation 7.1]

where μ is cell-mobility and χE is haptotaxis. A more detailed description of μ and χE is in
[210].

The ECM density E modulates the tumor growth [211], as follows:
E
E
E
E
1
1
EM
,
=  sprout . production
1sprout .tips +  production
1V −  degradation
t
1+ kp E
1+ kp E
1 + kd E

[Equation 7.2]

E

E

where  sprout . production and  production are the rates of ECM production by angiogenic
vessels and proliferating tumor tissue, respectively, kp and kd are production and
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degradation scaling constants, 1sprout.tips and 1V are the locations of angiogenic vessel
E

tips and viable tumor tissue, and  degradation is degradation rate. The ECM degradation is
affected by the density M of matrix degrading enzymes (MDEs), which allows
remodeling of the ECM by angiogenic vessel tips and proliferating tumor cells [210, 211].

The overall tumor growth is associated with the rate of volume change by
assuming that the cell density within the proliferating region remains constant [210]:

∇ ∙ 𝐯𝑐 = 𝜆𝑝

[Equation 7.3]

where 𝜆𝑝 is the (non-dimensionalized) net rate of proliferation (described below).
Combining these equations enables solving for the position of the tumor boundary as it
changes in time [210].

7.2.2 Angiogenesis
The angiogenesis component is based on [212] to represent blood flow, vascular
leakage and vascular network remodeling resulting from wall shear stress and
mechanical stress imposed by the tumor tissue as it grows or shrinks in time. As the
tumor volume changes within this vascularized environment, the tissue has differential
access to oxygen and nutrients diffusing from the vasculature. The interstitial flow of
oxygen and nutrients is influenced by distance from the nearest vessel and the tumor
tissue pressure. For a detailed description of the angiogenesis component of the model,
please refer to [210, 211].

7.2.3 Transport of Oxygen and Nutrients
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Oxygen and nutrients σ are delivered by the vasculature and extravasate into the
tumor tissue. Neo- and pre-existing vessels have particular extravasation rates, while σ
is diffused with a coefficient Dσ and is taken up by host, proliferating, and hypoxic tissue,
and decays in necrotic tissue. The mass balance of oxygen and nutrients is modeled
under steady-state conditions [210]:

0 = ∇ ∙ (𝐷𝜎 ∇𝜎) + 𝜆𝜎𝑒𝑣 (𝐱, 𝑡, 𝟏vessel , 𝑝𝑖 , 𝜎, ℎ) − 𝜆𝜎 (𝜎)𝜎

[Equation 7.4]

where x is position, t is time, 1vessel is the characteristic function for the vasculature
(equals 1 at vessel locations and 0 otherwise), pi is interstitial pressure, h is the
hematocrit in the vascular network, and 𝜆𝜎 is the rate of decay of σ [210]. Extravasation
is modulated by the extravascular interstitial pressure pi, scaled by the effective pressure
pe. The weight of the convective transport component of small molecules is k pi [19].
Extravasation from the vascular network is represented as [211]:
ℎ

𝑝

𝑖
𝜆𝜎𝑒𝑣 = 𝜆−𝜎
𝑒𝑣 1𝑣𝑒𝑠𝑠𝑒𝑙 (𝑥, 𝑡) (𝐻 − ℎ𝑚𝑖𝑛 ) + (1 − 𝑘𝑝𝑖 𝑝 ) (1 − 𝜎)
𝐷

𝑒

[Equation 7.5]

where H D and ℎ𝑚𝑖𝑛 are the normal and minimum hematocrit necessary for


extravasation, and

 ev

is the constant transfer rate from tumor-induced and pre-existing

vessels. The main parameters associated with the tumor component are in Table 7.1.

Parameter
Tumor proliferation rate
Oxygen diffusivity
Oxygen transfer rate from
vasculature
Oxygen uptake rate by proliferating
tumor cells
Oxygen uptake rate by hypoxic
tumor cells
Oxygen uptake rate by tumor
microenvironment

Value
1 day-1
1 (*)
5 (*)

Reference
Measured in [202]
[211]
[211]

1.5 (*)

[211]

1.3 (*)

[211]

0.12 (*)

[211]
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Oxygen decay rate
NP extravasation from angiogenic
vs. normal vessels
NP decay
CDDP decay rate
CDDP in vitro IC50 (48 h) for A549
cells (spheroid)
CDDP release profile from NP

0.35 (*)
10

[211]
Estimated

6hr half-life
0.5hr half-life
15.9 ± 1.2 μM

[244]
[214]
Measured in [202]
Estimated from [245]

Table 7.1. Tumor component main parameters and associated values. All other
model parameters are as in [211]. (*) Value is rescaled by the square of the simulation
system characteristic length (1 cm) and divided by the system characteristic time (1 sec)
multiplied by the oxygen diffusivity [215] (1 x 10-5 cm2 s-1). CDDP: cisplatin;

7.2.4 Tumor Tissue Heterogeneity
The proportion of hypoxic and necrotic tissue and the extent of tissue
vascularization are varied in the simulations by changing the response to the tumor
angiogenic factors, as in [239]. Accordingly, angiogenesis-induced tumor vascularization
was varied to simulate four distinct levels of tissue heterogeneity, respectively labeled
“VERY LOW”, “LOW”, “MEDIUM”, and “HIGH.” The values for the levels and the
associated tumor characteristics are summarized in Table II.

Level of
Tissue
Heterogeneity
VERY LOW
LOW
MEDIUM
HIGH

Hypoxic
Threshold

Necrotic
Threshold

Viable
Fraction

Necrotic
Fraction

Vessel
Fraction

0.305
0.405
0.485
0.575

0.300
0.400
0.480
0.570

0.98
0.87
0.78
0.75

0.01
0.12
0.22
0.25

0.017
0.020
0.024
0.032

Table 7.2. Levels of tumor tissue heterogeneity based on the thresholds for
inducing hypoxia and necrosis. Values for HIGH are based on the previously
calibrated tumors simulated in [19, 202]. Tumor tissue characteristics resulting from
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these values include viable (proliferating + hypoxic) tumor tissue fraction, necrotic (dead)
tissue fraction, and vessel fraction (vascular surface area divided by tumor area).

7.2.5 Transport of Nanoparticles

NPs diffuse into the extracellular compartment from the location of
extravasation from the vasculature, modulated by the interstitial pressure [17,
19]. The extravasation is modeled as:
𝐶𝑡𝑠

𝑝

𝑖
𝑠
𝜆𝑒𝑣
= 𝜆−𝑠
𝑒𝑣 1𝑣𝑒𝑠𝑠𝑒𝑙 (𝑥, 𝑡) (1 − 𝑘𝑝𝑖 𝑝 ) (
𝑒

𝐶

𝑠

− 𝑠)

[Equation 7.6]
𝑠

NP concentration in the vasculature is initially 𝐶 , with extravasation assumed to be of
𝑠

the form 𝐶𝑡𝑠 = 𝐶 𝑒 −𝛼𝑡 . The decay 𝛼 was calibrated to match an estimated half-life of 6
hours,, based on experimental data measuring PLGA NP tissue concentration in vivo
[244].

A set of rate equations was implemented to describe the multicompartmental NP
kinetic model. This model, inspired by the kinetic model in [242], includes the
extracellular and cytosolic compartments:

𝜕𝐶𝐸
𝜕𝑡
𝜕𝐶𝐶
𝜕𝑡

= 𝐷𝐸 ∇2 𝐶𝐸 −
= 𝑘𝐸𝐶 𝐶𝐸 (

𝑉𝑐
106

𝑘𝐸𝐶 𝐶𝐸
𝐹

+

𝑘𝐶𝐸 𝐶𝐶 106
𝐹

( 𝑉 ) + 𝐷(𝑡)
𝑐

) − 𝑘𝐶𝐸 𝐶𝐶 − 𝑘𝐷 𝐶𝐶

[Equation 7.7]

[Equation 7.8]

where 𝐶𝐸 is NP concentration in the extracellular compartment, which equals s in
Equation 6, 𝐶𝐶 is NP concentration in the cytosolic compartment, 𝐷𝐸 is the diffusivity of
NPs coming out of the vasculature 𝑘𝐸𝐶 is the rate constant for the transport of NPs from
the extracellular to the cytosolic compartment, F is the extracellular fraction, 𝑘𝐶𝐸 is the
rate constant for the transport of NPs from the cytosolic to the extracellular
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compartment, 𝑘𝐷 is lysosomal loss, 𝑉𝑐 is cell volume, and 𝐷(𝑡) is a forcing function that
represents the source of NPs via a bolus injection into the vasculature. Drug is initially
released with a burst release, as has been experimentally observed for cisplatin-loaded
PLGA NPs [246], and is diffused from NPs in both the extracellular and cytosolic
compartments, and also transfers from the extracellular compartment into the cytosolic
and DNA-bound compartments (see below) [227]. The NP kinetic parameters are
defined in Table 7.3.

Parameter
Vc
F
DE
kEC
kCE
kD

Description
Cell Volume (fL/cell)
Interstitial Fraction
NP Diffusivity (μm2/min)
Cytosolic transfer coefficient
Cytosolic efflux coefficient
Lysosomal loss

Value
520
0.48
3E-3
Varied: 0,5,10 and 50
1.5E-3 (estimated)
2E-3 (estimated)

Table 7.3. Nanoparticle kinetic parameters (based on [242, 247] and associated
references).

To simulate a variety of NP and cell interactions, the NP cytosolic transfer
coefficient (𝑘𝐸𝐶 ) was varied between (non-dimensionalized) values of 0, 5, 10, and 50.
This range provided adequate values for the transfer, enabling investigation of different
cases of NP cellular uptake. Since the transfer saturated when using coefficients higher
than 50, this value was chosen as an upper bound.

7.2.6 Transport of Drug
The following rate equations, coupled with the NP kinetic model described above,
define the multi-compartmental pharmacokinetic model for cisplatin, based on [242] and
as implemented in [227].
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𝜕𝐶𝐸
𝜕𝑡
𝜕𝐶𝐶
𝜕𝑡

= 𝐷𝑠 ∇2 𝑠1 − 𝑘1 𝑠1 −

𝐹

𝑠1 +

𝑘21
𝐹

106

𝑠2 ( 𝑉 ) + 𝐷(𝑡)

[Equation 7.9]

𝑐

𝑉

𝑠

= 𝑘12 10𝑐6 𝑠1 − 𝑘2 𝑠2 − 𝑘21 𝑠2 + 𝑘32 𝑠3 − 𝑘23 𝑠2 (1 − 𝑠 3 ) + 𝐷(𝑡)

𝜕𝐶𝐷𝑁𝐴
𝜕𝑡

𝑘12

𝑚

𝑠

= 𝑘23 𝑠2 (1 − 𝑠 3 ) − 𝑘32 𝑠3 − 𝑘3 𝑠3

[Equation 7.10]

[Equation 7.11]

𝑚

Drug concentration in each compartment is represented by 𝑠, where 𝑠1 is the
extracellular compartment, 𝑠2 is the cytosolic (intracellular) compartment, 𝑠3 is the DNAbound compartment, 𝑠4 is the organelle compartment, and 𝑠𝑚 is the drug-DNA binding
capacity. 𝑘𝑖,𝑗 represents the transfer rate constants between the compartments, 𝐹 is the
extracellular fraction of the tissue (0.48), and 𝑉𝑐 is cell volume (estimated to be
520fL/cell). Drug diffused from NPs in either the extracellular or cytosolic compartment
can transfer into the DNA-bound compartment, where it then can exert its cytotoxic
effect. The drug pharmacokinetic parameters are defined in Table IV.

Parameter
Vc
F
Ds
k1
k12
k21
k23
k32
k3
sm

Description
Cell Volume (fL/cell)
Interstitial Fraction
Drug Diffusivity (μm2/min)
Plasma elimination rate (min-1)
Cytosolic transfer coefficient (min-1)
Cytosolic efflux coefficient (min-1)
DNA-Bound efflux coefficient (min-1)
Efflux from DNA (min-1)
Drug-DNA repair (min-1)
Drug-DNA capacity (fmole)

Value
520
0.48
0.6
2.77E-2 (25 min half-life)
5.4E-2
1.56E-3
3.82E-4
0
1.5E-2
∞

Table 7.4. Cisplatin pharmacokinetic parameters (from [242] and associated
references).

7.2.7 NP Aggregation
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NP concentration was calculated at every node in the system once every output
interval. For simplicity, three levels of drug-loaded NP aggregation were simulated by
changing the size of aggregation “blocks,” with each block size containing a different
number of nodes (5x5, 10x10, 15x15). With larger block sizes, a greater number of NPs
were contained within each aggregate, and the spatial separation between aggregates
was correspondingly larger. Block sizes larger than 15x15 did not appreciably change
the drug release, indicating saturation. A threshold value (300) was used to determine if
aggregation occurs in a particular block based on the total number of NPs within that
block. Aggregation was simulated by effectively “stacking” the extracellular drug-loaded
NPs within each block. Drug was then diffused away from the central aggregate in all
compartments immediately following the simulation output interval where the initial
aggregation occurred.

7.2.8 Cisplatin Cytotoxic Effect
Drug induced tissue death was included into the pharmacodynamic model that
describes the rate of net tumor proliferation (𝜆𝑝 ) (as in [227]):

0
outside tumor
𝜆𝑀 𝜎(1 − [𝜆𝐶𝐷𝐷𝑃 ∑𝑡𝑡−𝑡𝑑 𝑠3𝐶𝐷𝐷𝑃 ] − 𝜆𝐴 ) in proliferating tissue
𝜆𝑝 =
in hypoxic tissue
0
in necrotic tissue
{
−𝜆𝑁

[Equation 7.12]

where 𝜆𝑀 is the mitosis rate, 𝜆𝐴 is the apoptosis rate, and 𝜆𝑁 is the rate of tissue loss in
the necrotic region. 𝜆𝐶𝐷𝐷𝑃 is the rate of cisplatin induced tissue death. Currently,
apoptosis is simplified, as cell death is assumed to be instantaneous [210]. 𝜆𝐶𝐷𝐷𝑃
represents the overall drug effect which is a function of drug concentration within the
proliferating region. The DNA-bound drug concentration is multiplied by a scaling factor
to achieve the desired drug effect.
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7.2.9 Coupling of the Models
The NP kinetic model was applied before the aggregation model during each
simulation output interval, which allowed for a burst release of drug from the vessels into
the extracellular compartment before NP aggregation could occur. The drug kinetic
model was then applied after NP aggregation. In this case, it was assumed that no NPs
were transferred into the cytosolic compartment due to size constraints of the
aggregates. In all treatment cases, simulations were run for 30-hours in simulated realtime, as the cisplatin effect becomes null after this time.

7.2.10 Calibration of Drug-Induced Cell Death
Cytotoxicity data obtained with experiments with Non-Small Cell lung cancer
(NSCLC) tumor spheroids were used to calculate a 48hr IC50 for simulated avascular
spheroids, as in [202]. Interpolation was used to determine a scaling factor to achieve
the desired IC50, for which the simulated avascular spheroid size was reduced by 50%.
This factor was assigned the units of drug concentration that had achieved the IC50 with
the spheroids in vitro [202]. The trapezoid method was used to calculate the areas-under
the-curve (AUC’s) to quantify the NP and drug concentrations.

7.2.11 Numerical Methods
Briefly, the equations in the model are solved iteratively at each time step [211].
In all equations which involve a diffusion term, a fully nonlinear diffusion solver was used
to solve the equation:
𝑢(𝑡) = ∇(𝐷(𝑢, 𝑥, 𝑦) ∙ ∇ (𝑢) + 𝑠𝑜𝑢𝑟𝑐𝑒(𝑢, 𝑥, 𝑦).
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This equation is solved in space using centered finite difference approximations and the
backward Euler time-stepping algorithm [210, 211]. The discrete equations are then
solved using a nonlinear adaptive Gauss-Seidel iterative method [216, 217]. Further
details of the numerical solution are in [210] and references therein.

7.3 RESULTS
The transport of cisplatin-loaded PLGA NPs into heterogeneously vascularized
tumor tissue was evaluated as a function of the NP cytosolic transfer coefficient, thus
assessing the capability of the NPs to remain in the extracellular interstitium or penetrate
into the cellular compartment. The effect of the drug release from NPs both in the
interstitium and in the intracellular space was first qualitatively evaluated on the tumor
tissue. Figure 7.1 and Figure 7.2 show representative images of NP localization for the
HIGH and VERY LOW cases of vascular heterogeneity immediately after bolus injection,
with the NP transfer coefficient ranging from 0 (no transfer) to 5 (medium transfer) to 50
(high transfer). Supplementary Figure 7.1 and Supplementary Figure 7.2 show the
results for the intermediate MEDIUM and LOW vascular heterogeneity cases. The
corresponding drug concentrations are shown for the extracellular, cytosolic, and DNAbound compartments.
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Figure 7.1. Variation of NP cytosolic transfer for tumor lesion of HIGH vascular
heterogeneity, showing spatial distribution of PLGA NPs and cisplatin (CDDP) in the
three compartments of the model. The NP cytosolic transfer coefficient was varied from
low (=0), medium (=5), and high (=50) values. Images are from the first output interval
immediately after bolus injection of CDDP-loaded NPs (Panels A, C, E) and the second
output interval after the drug has taken effect (Panels B, D, F). The top left figure in
each panel depicts the tumor (red: proliferating tissue; blue: hypoxic tissue; brown:
necrotic tissue) along with surrounding capillary network (brown lines). Pre-existent
(normal) vasculature is shown as a regular rectangular grid and neo-vasculature induced
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by angiogenesis is shown as irregular lines. Drug concentration is shown for
extracellular (μM), cytosolic (Fmol x hr), and DNA-bound (Fmol x hr) compartments. Bar
= 200 μm.

Figure 7.2. Variation of NP cytosolic transfer for tumor lesion of VERY LOW
vascular heterogeneity, showing spatial distribution of PLGA NPs and cisplatin (CDDP)
in the three compartments of the model. The NP cytosolic transfer coefficient was varied
from low (=0), medium (=5), and high (=50) values. Images are from the first output
interval immediately after bolus injection of CDDP-loaded NPs (Panels A, C, E) and the
second output interval after the drug has taken effect (Panels B, D, F). Drug
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concentration is shown for extracellular (μM), cytosolic (Fmol x hr), and DNA-bound
(Fmol x hr) compartments. Colors are as in Figure 7.1. Bar = 200 μm.

In the case of no cytosolic transfer (NP transfer coefficient = 0), the NPs remain
confined to the extracellular space, with the NPs essentially acting as sources of drug
external to the tumor cells. Once the drug diffuses through the cytosolic compartment in
order to reach the DNA (Panels A), its cytotoxic effect shrinks the tumor (Panels B).
When the cytosolic transfer coefficient is of medium (= 5) value, a substantial number of
NPs are able to locate to the cytosolic compartment post injection (Panels C). The NP
distribution varies depending on the tissue heterogeneity, with a higher concentration in
the tumor tissue periphery in case of HIGH heterogeneity and more internalized, lower
concentrations within tumor tissue as this heterogeneity decreases. This phenomenon is
consistent with previous modeling work showing that tumor tissue heterogeneity has a
nonlinear effect on NP distribution [218] and effect [219], and with recent optimization
analyses of NP parameters [220].

As in the case of no NP cytosolic transfer, a medium value of transfer coefficient
leads to drug diffusion into the cytosol from the interstitium after release from the
extracellular NPs. Additionally, the drug is now transported by NPs into the cytosol and
released intracellularly. The drug concentration in the DNA-bound compartment can be
qualitatively observed to increase slower compared to the case with no cytosolic
transfer. The drug effect shrinks the tumor (Panels D), with the more heterogeneous
tumors showing a higher response. When the NP cytosolic transfer coefficient is high (=
50), the majority of NPs enters the cytosol (Panels E). Nevertheless, the NPs in the
extracellular compartment still release a substantial amount of drug, which has to diffuse
into the cytosol in order to reach the DNA. Compared to the previous two cytosolic
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transfer values, this case qualitatively seems to increase the DNA-bound drug the
slowest, while yielding the highest tumor regression (Panels F).

Next, the effect of varying levels of NP aggregation was qualitatively evaluated,
assuming no NP cytosolic transfer. Figures 7.3 and 7.4 show the spatial release of drug
for tumors with HIGH and VERY LOW vascular-induced heterogeneity. Supplementary
Figure 7.3 and Supplementary Figure 7.4 show the results for the intermediate
MEDIUM and LOW heterogeneity cases. As expected, as the level of NP aggregation
increases (Panels A, C, E), the drug released from the NPs becomes correspondingly
more localized (clustered) (Panels B, D, F). As the drug only affects proliferating tissue
due to its cell cycle-specific cytotoxicity, localized regions of eliminated tumor tissue
become evident as tumor tissue heterogeneity increases. These regions become larger
for higher aggregation, with correspondingly higher localized pockets of drug.
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Figure 7.3. Variation of NP aggregation for tumor lesion of HIGH vascular
heterogeneity, showing spatial distribution of PLGA NPs and cisplatin (CDDP) in the
three compartments of the model. NP aggregation was varied from low (5x5 blocks),
medium (10x10 blocks), and high (15x15 blocks). Images are from the first output
interval (immediately after bolus injection of CDDP-loaded NPs (Panels A, C, E)) and
the second output interval (after the drug has taken effect (Panels B, D, F)). Drug
concentration is shown for extracellular (μM), cytosolic (Fmol x hr), and DNA-bound
(Fmol x hr) compartments. Colors are as in Figure 1. Bar = 200 μm.
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Figure 7.4. Variation of NP aggregation for tumor lesion of VERY LOW vascular
heterogeneity, showing spatial distribution of PLGA NPs and cisplatin (CDDP) in the
three compartments of the model. NP aggregation was varied from low (5x5 blocks),
medium (10x10 blocks), and high (15x15 blocks). Images are from the first output
interval (immediately after bolus injection of CDDP-loaded NPs (Panels A, C, E)) and
the second output interval (after the drug has taken effect (Panels B, D, F)). Drug
concentration is shown for extracellular (μM), cytosolic (Fmol x hr), and DNA-bound
(Fmol x hr) compartments. Colors are as in Figure 1. Bar = 200 μm.
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Figure 7.5 quantifies the NP area-under-the-curve (AUC) achieved in the
extracellular, and cytosolic compartments, as a function of tumor vascular heterogeneity.
When considering no NP aggregation, the NP cytosolic transfer rate was varied from
none, to high. Increasing this rate dramatically reduced the NP concentration in the
extracellular compartment while increasing it in the cytosol, as expected (Figure 7.5A).
However, the AUC variation between the levels of tissue vascular heterogeneity was
nonlinear. As this heterogeneity increased from VERY LOW to MEDIUM, the
corresponding decrease in AUC became less pronounced as the transfer coefficient
increased, with, the highest transfer rate evincing a steady AUC increase from VERY
LOW to HIGH. The cytosolic NP AUCs corresponding to these cases (Figure 7.5B)
show that as the tumor vascular heterogeneity increases, the AUCs decrease
accordingly. The highest AUC values are established for the highest value of transfer
rate, as expected.
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Figure 7.5. Extracellular and cytosolic nanoparticle area-under-the-curve (AUC) as
a function of vasculature-induced tumor tissue heterogeneity. Graphs represent the
magnitude of the AUC calculated within the tumor boundary at every output interval
during treatment with cisplatin-loaded NPs. (A) Extracellular and (B) Cytosolic NP AUC
due to variation in NP cytosolic transfer rate (non-dimensional units); (C) Extracellular
and (D) NP AUC due to variation in NP aggregation (non-dimensional units).

In the case of NP aggregation, the extracellular NP AUC behaved nonlinearly
with respect to the tumor vascular heterogeneity as a function of the extent of this
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aggregation (Figure 7.5C). The AUC was similar for all values of aggregation in the case
of VERY LOW heterogeneity, whereas it was the most different based on aggregation
for HIGH heterogeneity. Overall, it seems that the AUC initially declines as heterogeneity
increases, and then starts to increase with even higher heterogeneity. The minimum
AUC along this trend as a function of heterogeneity shifts depending on the extent of
aggregation, with the low aggregation declining the most before increasing as
heterogeneity increases.
With no NP aggregation, the magnitude of the NP cytosolic transfer rate did not
seem to make much difference in regards to the extracellular drug AUC (Figure 7.6A).
This AUC increased with higher tissue vascular heterogeneity. The corresponding
cytosolic drug AUC also increased accordingly; however, a larger transfer rate led to
increased AUC values (Figure 7.6B). The same pattern was observed with the DNAbound AUC (Figure 7.6C). In contrast, NP aggregation evinced different dynamics. The
extracellular drug AUC increased not only as a function of tissue heterogeneity but also
with higher NP aggregation (Figure 7.6D). The cytosolic AUC also increased with higher
tissue heterogeneity but was lower for high aggregation for each level of heterogeneity
(Figure 7.6E), with the highest AUC attained for lowest aggregation and highest tissue
heterogeneity (2x10-7 Fmol/cell x hr). The DNA-bound AUC (Figure 7.6F) followed a
similar pattern, albeit at overall lower values of drug concentration than in the cytosol.
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Figure 7.6. Extracellular, cytosolic, and DNA-bound cisplatin area-under-the-curve
(AUC) as a function of vasculature-induced tumor tissue heterogeneity. Graphs
represent the magnitude of the AUC calculated within the tumor boundary at every
output interval during treatment with cisplatin-loaded NPs. (A) Extracellular (μM x hr), (B)
Cytosolic, and (C) DNA-Bound drug AUC due to variation in NP cytosolic transfer rate
(Fmol/cell x hr); (D) Extracellular (μM x hr), (E) Cytosolic, and (F) DNA-Bound drug AUC
due to variation in NP aggregation (Fmol/cell x hr).

The minimum tumor radius calculated as a fraction of Initial value is shown in
Figure 7.7. In general, the highest NP cytosolic transfer coefficient (=50) yielded the
highest response for each case of tumor vascular heterogeneity (Figure 7.7A). While in
the case of HIGH vascular heterogeneity the worst response resulted with the lowest
transfer coefficient (=0), as the tumor heterogeneity decreased, the worst response was
evinced by the low coefficient (=5). When NP aggregation occurs (Figure 7.7B), for each
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case of tissue heterogeneity the response was proportional to the level of aggregation,
with the most effective response resulting with the lowest aggregation.

Figure 7.7. Tumor response as a function of vasculature-induced tumor tissue
heterogeneity. (A) Minimum tumor radius resulting from variation in NP cytosolic
transfer rate (non-dimensional units); (B) Minimum tumor radius resulting from variation
in NP aggregation (non-dimensional units).

Interestingly, the case of medium (10x10) aggregation resulted in decreased
effectiveness as tissue heterogeneity increased. However, with low (5x5) or high (15x15)
aggregation, cases of VERY LOW and HIGH tissue heterogeneity responded more
strongly to the nanotherapy than the LOW and MEDIUM heterogeneity cases. For high
levels of NP aggregation, these two cases yielded the least tumor regression. Overall,
nanotherapy was most effective in the case of HIGH tissue heterogeneity, no NP
aggregation, and a high cytosolic transfer coefficient. However, depending on the level
of tissue heterogeneity and cytosolic transfer, NP aggregation, yielding only extracellular
drug release, could be more effective than NPs that avoid aggregation and are uptaken
by cells, releasing drug extra- and intra-cellularly.
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7.4 DISCUSSION
This study couples a multi-compartmental kinetics model of NP transport through
heterogeneously vascularized tumor tissue with a PKPD drug model to further enable in
silico evaluation of NP-mediated drug delivery and efficacy. The NP cytosolic transfer
rate is varied to evaluate the effect on tumor response of differential drug release in
extracellular and cytosolic compartments. This model is coupled with pharmacokinetic
and pharmacodynamics models of drug transport and cytotoxicity. The effect on tumor
response of varying degrees of NP aggregation are also assessed, simulating a
commonly occurring phenomenon known to affect NPs in solution as well as in vivo.

Although extracellular NP AUC increased for higher levels of tissue heterogeneity
as the cytosolic transfer coefficient became larger (Figure 7.5), cytosolic NP AUC
correspondingly decreased. This phenomenon reflects the difference in the proliferative
fraction for each case of tissue heterogeneity. Although tumors with higher vascular
heterogeneity are associated with a larger vascular network, which allows for increased
NP transport into tumor tissue, a smaller overall proliferative tissue region implies that
fewer NPs are able to transfer into the cytosolic compartment compared to tissue with
lower heterogeneity but larger proliferative region. Further, as cytosolic NP AUC
increased with higher cytosolic transfer coefficients and lower tissue vascular
heterogeneity (Figure 7.5), the associated drug AUC increased in the extracellular,
cytosolic and DNA-bound compartments, and also rose with higher tissue heterogeneity
(Figure 7.6). This observation implies that with the given NP and drug parameters,
release of drug in the extracellular compartment was a primary source of drug for the
cytosolic and DNA-bound compartments, especially for heterogeneous tissue, implying
that NP extracellular drug release was critical for achieving higher drug intracellularly.
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Although the extracellular NP AUC assumed a nonlinear pattern based on
amount of aggregation and degree of tissue vascular heterogeneity (Figure 7.5), initially
decreasing, or remaining constant for low and medium aggregation, respectively, as
tissue heterogeneity increased, the corresponding extracellular drug AUC increased
exponentially with higher aggregation and higher heterogeneity (Figure 7.6). The
associated cytosolic and DNA-bound drug AUC, however, did not increase as much with
increasing aggregation or tumor heterogeneity. Interestingly, both cytosolic and DNAbound drug AUC values were highest for the low aggregation when the tissue
heterogeneity was LOW or HIGH, while these AUC values were highest for medium
aggregation when the heterogeneity was VERY LOW or MEDIUM. This result suggests
that high NP aggregation coupled with highly heterogeneous tissue can lead to suboptimal DNA drug uptake, as the drug becomes concentrated at specific locations and
unable to adequately diffuse to all of the tumor tissue. In contrast, some aggregation
could be beneficial if the tissue is less heterogeneous, as it helps to create local “depots”
of concentrated drug, from which it can diffuse into the surrounding tissue. A similar
effect has been observed when modeling the uptake and transport of drug-loaded NPs
by macrophages into tumor tissue [248, 249].

The tumor response based on variation of the NP cytosolic transfer coefficient
correlates with the value of this coefficient as well as with the degree of tissue vascular
heterogeneity (Figure 7.7A). As expected, lower cytosolic transfer decreases the
response, and so does lower tissue heterogeneity. However, a low transfer coefficient
yields the least response as tissue heterogeneity decreases, worse than no transfer at
all, which suggests that tailoring the cytosolic transfer to this heterogeneity would be
critical in case the drug release from the NPs can only occur intracellularly.
230

The overall response based on variation in the degree of NP aggregation (Figure
7.7B) indicates that when aggregation is low, tumors with VERY LOW or HIGH tissue
heterogeneity respond best. Regardless of heterogeneity, higher aggregation leads to
worse response, although the magnitude of this response is not linearly dependent on
the level of tissue heterogeneity. These results indicate that NP aggregation can
sometimes be beneficial for increasing the efficacy of cancer nanotherapy, depending on
the drug used and the characteristics of the tumor tissue and associated vasculature.

Main NP parameters considered in this study include diffusivity (which depends
on NP size and affinity), cellular uptake, and aggregation potential. These parameters
depend on specific NP formulations, including surface modifications. For any particular
formulation, the goal would be to experimentally measure values for these parameters
(e.g., via in vitro experiments), and then to evaluate via the computational model how
adjusting these values affects the expected NP performance under conditions of varying
tissue vascularization and heterogeneity. These tissue conditions can be clinically
assessed and used as input to the model with the goal to tailor the NP formulations to
patient tumor-specific conditions. Given that tumor heterogeneity is typically not uniform,
a combination of NP formulations may be appropriate, which could also be explored via
the in silico model. Expansion of the model to include acidity in tumor tissue due to lactic
acid production as well as NP interactions with ECM may enhance the predictive value
of the performance to be expected from particular formulations.

The physio-chemical properties of a drug, and in particular its hydrophilic or
hydrophobic nature, are expected to affect the model primarily in terms of transport and
cellular uptake/retention. These properties relate directly to the drug diffusivity, decay,
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and kinetic parameters. In particular, for small hydrophilic drugs such as cisplatin,
passive transmembrane diffusion across the lipid bilayer would be facilitated, as
previously confirmed [250]. In comparison, hydrophobic drugs are expected to face
impaired transport as well as aggregation within cell membranes [251]. To improve
hydrophilicity, drugs such as Paclitaxel are commonly combined with a solvent (e.g.,
Cremophor EL) or delivered via encapsulation (e.g., albumin-stabilized Paclitaxel or nabPTX).

In future work, the aggregation model could be enhanced via a dynamic drug release
rate. This rate should be lower for aggregated NPs and dependent on the physical
interactions between drug and NPs. Further, a dynamic aggregation model could be
implemented, which does not rely on predetermined aggregation block sizes and spatial
positions, as the size and position of each aggregate could be based on the
concentration of NPs within a particular tissue region. The scope of this study focused
on the development of a theoretical framework, which will require validation in the future
by comparing model predictions to experimentally-observed in vivo data. With additional
refinement and capability and coupled with experimental data informing the model
parameter values, this modeling platform could move towards clinical application. This
would offer the capability to design nanotherapy based on patient tumor-specific
characteristics, such as vascularization density and associated tissue heterogeneity.

7.5 CONCLUSION
A novel coupling of a kinetic model of NP transport in heterogeneously
vascularized tumor tissue with a multicompartmental drug model was implemented to
evaluate the efficacy of cisplatin-loaded poly lactic-co-glycolic acid (PLGA) NPs in
heterogeneously vascularized tumor tissue. The magnitude of the extracellular to
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cytosolic NP transport was varied to assess tumor-dependent cellular uptake. NP
aggregation was simulated to evaluate its effects on drug distribution and tumor
response. The overall results highlight the nonlinear dynamics of NP and drug transport
into tumor tissue. The model system provides a means to evaluate customization of NPmediated drug treatment based on NP and drug design parameters, including cellular
uptake and aggregation, and taking into account patient-specific tumor tissue
characteristics such as proportion of viable tissue and vascular heterogeneity.

7.6 SUPPLEMENTARY MATERIALS
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Supplementary Figure 7.1. Variation of NP cytosolic transfer for tumor lesion of
MEDIUM vascular heterogeneity, showing spatial distribution of PLGA NPs and
cisplatin (CDDP) in the three compartments of the model. The NP cytosolic transfer
coefficient was varied from low (=0), medium (=5), and high (=50) values. Images are
from the first output interval immediately after bolus injection of CDDP-loaded NPs
(Panels A, C, E) and the second output interval after the drug has taken effect (Panels
B, D, F). The top left figure in each panel depicts the tumor (red: proliferating tissue;
blue: hypoxic tissue; brown: necrotic tissue) along with surrounding capillary network
(brown lines). Pre-existent (normal) vasculature is shown as a regular rectangular grid
and neo-vasculature induced by angiogenesis is shown as irregular lines. Drug
concentration is shown for extracellular (μM), cytosolic (Fmol x hr), and DNA-bound
(Fmol x hr) compartments. Bar = 250 μm.
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Supplementary Figure 7.2. Variation of NP cytosolic transfer for tumor lesion of
LOW vascular heterogeneity, showing spatial distribution of PLGA NPs and cisplatin
(CDDP) in the three compartments of the model. The NP cytosolic transfer coefficient
was varied from low (=0), medium (=5), and high (=50) values. Images are from the first
output interval immediately after bolus injection of CDDP-loaded NPs (Panels A, C, E)
and the second output interval after the drug has taken effect (Panels B, D, F). Drug
concentration is shown for extracellular (μM), cytosolic (Fmol x hr), and DNA-bound
(Fmol x hr) compartments. Colors are as in Supplementary Figure 7.1. Bar = 250 μm.
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Supplementary Figure 7.3 – Variation of NP aggregation for tumor lesion of
MEDIUM vascular heterogeneity, showing spatial distribution of PLGA NPs and
cisplatin (CDDP) in the three compartments of the model. NP aggregation was varied
from low (5x5 blocks), medium (10x10 blocks), and high (15x15 blocks). Images are
from the first output interval (immediately after bolus injection of CDDP-loaded NPs
(Panels A, C, E) and the second output interval (after the drug has taken effect (Panels
B, D, F)). Drug concentration is shown for extracellular (μM), cytosolic (Fmol x hr), and
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DNA-bound (Fmol x hr) compartments. Colors are as in Supplementary Figure 7.1. Bar
= 250 μm.

Supplementary Figure 7.4. Variation of NP aggregation for tumor lesion of LOW
vascular heterogeneity, showing spatial distribution of PLGA NPs and cisplatin (CDDP)
in the three compartments of the model. NP aggregation was varied from low (5x5
blocks), medium (10x10 blocks), and high (15x15 blocks). Images are from the first
output interval (immediately after bolus injection of CDDP-loaded NPs (Panels A, C, E)
and the second output interval (after the drug has taken effect (Panels B, D, F)). Drug
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concentration is shown for extracellular (μM), cytosolic (Fmol x hr), and DNA-bound
(Fmol x hr) compartments. Colors are as in Supplementary Figure 7.1. Bar = 250 μm.
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CHAPTER 87

MODELING OF TUMOR GROWTH WITH INPUT FROM PATIENT-SPECIFIC
METABOLOMIC DATA

8.1 INTRODUCTION
The nonlinear response of an individual patient’s tumor to a chosen therapy
continues to confound the treatment of cancer. Although therapy efficacy may have been
proven for patients with tumors of similar type and stage and may also have been
customized to specific tumor genetic characteristics, e.g., BRCA mutation, there is no
guarantee that any particular untreated tumor will favorably respond to the same
treatment. A major reason is that the tumor response is influenced by the individual
tumor cell and microenvironment conditions, as well as patient physiological and life
conditions. In order to provide for more accurate outcomes, the ability to gauge and
incorporate these conditions into treatment expectations is crucial. Due to the
dysregulation of metabolism in cancer, metabolomics in particular has shown promise to
provide critical information regarding cancer evaluation and prognosis [23]. Ideally,
metabolomics coupled with other molecular information, such as genomics,
transcriptomics, and proteomics would describe individual patient tumor conditions as a

•
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set of “signals” that reflect individual tumor conditions. However, the amount of data
generated by such analyses is large, and can be difficult to interpret [252].

To tackle this challenge, mathematical modeling and computational techniques
have been employed to study the nonlinear behavior of tumors. Advances in
metabolomics and mathematical modeling, as well as in the estimation of model
parameter values based on metabolome data were reviewed in [253], focusing on
metabolic reaction networks and kinetic models. The role of mathematical modeling in
attaining an enhanced understanding of cancer metabolic reprogramming as well as to
identify potential therapeutic interventions was recently reviewed [254]. In particular, Wnt
signaling has been linked via mathematical modeling to metabolism patterns in colon
cancer [255]. Although metabolism at the cellular scale has been modeled, (e.g., [256258]), along with the associated networks [259], it has been challenging to link the
metabolic to the tissue scale.

Part of the challenge lies in linking metabolomic measurements to mathematical
model parameters. A model system designed to simulate tumor behavior would ideally
provide sufficient dynamic range to represent various biological conditions while also
translating biological measurements into (usually dimensionless) model parameters. In
this study, a model system is constructed to mechanistically bridge from patient tumor
metabolomic measurements to mathematical model parameters. As proof of concept,
the model parameters are calibrated to simulate the progression of lung tumors.
Biologically relevant models must include an adequate number of parameters to provide
useful predictions. We propose a set of parameters which represent an adequate
number to simulate tumor growth based on metabolomic data. The ultimate goal is for
such a system to serve as a prognostic tool by projecting tumor behavior into future time,
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so that the response to particular treatment modalities could be evaluated and selected
for efficacy prior to patient administration.

8.2 MATERIALS AND METHODS
8.2.1 Vascularized Tumor Growth
We use a tumor growth component based on a 2D continuum representation of
tissue, as described in [210, 211] while the angiogenesis component represents blood
vessels as discrete elements, as described in [212]. Briefly, as the tumor grows within a
vascularized environment, the tissue has heterogeneous access to oxygen and nutrients
diffusing from the vasculature. Oxygen and nutrients are transported to the tumor from
the location of extravasation from the vasculature. The interstitial flow of oxygen and
nutrients is influenced by tissue pressure and by distance from the nearest vessels. Neovessel sprouts arise from the host vasculature, whose epithelial cell tips migrate semistochastically towards a gradient of tumor angiogenic factor (TAF) produced by tumor
tissue. The main equations of the vascularized tumor growth model in [210, 211] are
summarized in Supplementary Materials.

8.2.2 Tumor Aggressiveness
Tumor aggressiveness 𝐺 is a non-dimensional parameter that represents the
ratio of cell proliferation to the rate of tissue relaxation due to cell-cell adhesion.
Assuming uniform cell-cell adhesion throughout the tumor, 𝐺 is incorporated as a
surface-tension like jump boundary condition at the tumor-host interface [210]:
1

[𝑃] = (𝑃𝑖𝑛𝑛𝑒𝑟 − 𝑃𝑜𝑢𝑡𝑒𝑟 ) = 𝜅 ,
𝐺

[Equation 8.1]

where 𝜅 is the mean curvature of the interface, and P is the oncotic pressure
representing the balance of the intra-tumoral (Pinner) and extra-tumoral (Pouter) pressures.
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Thus, higher proliferation or lower cell-cell adhesion would raise the tumor
aggressiveness, meaning that the tumor would overall push stronger (be more invasive)
into its surroundings.

8.2.3 Tumor-Associated Macrophages
Tumor-associated macrophages (TAMs) of two different subtypes are simulated
in the vascularized tumor microenvironment, as described in [260, 261]. Briefly,
monocytes extravasate from the vasculature following local concentration of
chemoattractants secreted from hypoxic tissue, stimulating them to migrate towards
regions of tissue hypoxia. Monocytes undergo polarization into M1 (tumoricidal) or M2
(tumorigenic) subtypes in the vicinity of the tumor microenvironment based on the
concentration of chemokines released by proliferating and hypoxic tumor cells and affect
the net tumor proliferation [248, 262, 263]. As in [260], pressure, oxygen, and
chemoattractant gradients affect the semi-stochastic movement of monocyte precursors
and the M1 and M2 macrophage subtype movement through the interstitium.

8.2.4 Lactic Acid
Enhanced lactic acid production by anaerobic glycolysis (Warburg Effect) in
cancer is well known and contributes to a low pH within the tumor microenvironment.
Additionally, lactic acid is known to be uptaken by cancer cells through monocarboxylate
transporters (MCTs) and utilized as an energy substrate [264]. In the model, lactic acid is
produced by proliferating and hypoxic tumor cells and diffuses in the surrounding tissue.
It can be uptaken by tumor cells and wash out of the tissue into the vasculature, which
altogether represent the decay. Lactic acid production is represented as 2 moles of lactic
acid produced for every mole of glucose during anaerobic respiration [265]:
𝐿𝑎𝑐.
𝐿𝑎𝑐.
𝐿𝑎𝑐.
(1 − 𝐿) − 𝜆̅𝑤𝑎𝑠ℎ𝑜𝑢𝑡
0 = ∇ ⋅ (𝐷𝐿𝑎𝑐. ∇𝐿) + 𝜆̅𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛
𝟏𝑣𝑒𝑠𝑠𝑒𝑙 − 𝜆̅𝑢𝑝𝑡𝑎𝑘𝑒
𝐿,
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[Equation 8.2]

𝐿𝑎𝑐.
where 𝐷𝐿𝑎𝑐. is the diffusivity, 𝐿 is the local concentration of lactic acid, 𝜆̅𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛
is the
𝐿𝑎𝑐.
𝐿𝑎𝑐.
production rate, 𝜆̅𝑤𝑎𝑠ℎ𝑜𝑢𝑡
is the rate of washout, and 𝜆̅𝑢𝑝𝑡𝑎𝑘𝑒
is the cellular uptake rate

(assumed to be on the same order of magnitude as that of oxygen). The production rate
of lactic acid is concentration dependent, as it has been shown that cancer cells have
the ability to adjust their metabolic behavior by altering lactic acid production to maintain
a range of pH within the microenvironment [125].

Lac

For simplicity, it is assumed that lactic acid production  production gradually decreases as
the level of oxygen and nutrients σ increases towards areas of higher vascularization:



Lac
production

1 − 

=  2
 0


in proliferating tissue

[Equation 8.3]

in hypoxic tissue
in necrotic tissue

Since the molar mass of lactic acid (~90 g/mol) is on the order of magnitude of oxygen
(16 g/mol), the diffusion constant 𝐷𝐿𝑎𝑐. is for simplicity assumed to be on the same order
of magnitude as oxygen. Accordingly, lactic acid diffuses through the host and tumor
tissue relatively uninhibited by the ECM. Similarly, the lower bound rate of lactic acid
uptake by cells is assumed to be on the same order of magnitude as oxygen.

8.2.5 Chemotherapy
A number of chemotherapeutic agents are routinely administered to non-small
cell lung cancer (NSCLC) patients [227]. To test the proposed model linking
metabolomic data to tissue-scale behavior, we chose to simulate response to cisplatin
(CDDP), a representative NSCLC drug. The transport of drug c with diffusivity Dc was
simulated from the position of extravasation from the vasculature. Uptake by tumor and
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normal cells and wash-out from the interstitial space were included as a combined effect
in the rate λc,uptake, which reflects the drug half-life (assumed to be similar to the half-life in
plasma) [266]:
0 = ∇ ∙ (𝐷𝑐 ∇𝑐) + 𝜆𝑐,𝑒𝑣 (𝐱, 𝑡, 1vessel , 𝑝𝑖 , 𝑐) − 𝜆𝑐,𝑢𝑝𝑡𝑎𝑘𝑒 𝑐

[Equation 8.4]

A constant drug extravasation transfer rate λc,TR from the vasculature was assumed [19] :
𝜆𝑐,𝑒𝑣 = 𝜆𝑐,TR 𝟏vessel (𝐱, 𝑡)(1 − 𝑘𝑝,𝑖

𝑝𝑖 𝐶𝑐,𝑡
)(
𝑝𝑒 𝐶𝑐̅

− 𝑐)

[Equation 8.5]

where 𝜆𝑐,TR is the constant transfer rate from pre-existing and new vessels, 𝟏vessel (𝐱, 𝑡)
equals 1 at vessel locations and 0 elsewhere, kp,i represents the weight of convective
transport component of small molecules, pi is interstitial fluid pressure (IFP), and pe is
effective pressure (IFP at which there is no net volume flux out of the vasculature) [211].
Drug concentration in the vasculature is initially 𝐶𝑐̅ , where extravasation follows first
order kinetics for a constant drug infusion: Cc,t = 1 - e-αt, with α based on an average CDDP
half-life of 0.5 h [214].

8.2.6 Metabolomic Data
The metabolomic datasets based on lung tumor core biopsies from 23 patients in
[267] (available in Metabolomics Workbench Repository, record ST001527) were used
to illustrate the study methodology for patient-specific tumors. These data are described
in further detail in [267]. Briefly, patient tumor tissue samples were processed by liquidliquid metabolite extraction and analyzed by 2DLC-MS with negative and positive ion
modes. 2DLC-MS data was presented as an alignment table for each batch with
retention time, m/z, signal intensity, stable isotope labeling, name of identified
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metabolite, and database used for metabolite identification. After combining data from
positive and negative ion modes, a preliminary step to handle missing values was
performed by removing features which contained more than 50% missing values. This
resulted in a data set of 66 metabolites with approximately 21.8% missing values. The
data were normalized by a log transformation and imputed by probabilistic principal
component analysis (PPCA).

8.3 RESULTS
8.3.1 Linking of Metabolomic Data to Model Parameters
A baseline (representative) tumor nodule was first created in silico by calibrating
the model parameters to lung tumor experimental data, and a range for the parameter
values around baseline was determined (Supplementary Materials). The main model
parameters affected by metabolomic data include the rate of proliferation, angiogenesis,
lactic acid production, drug effect, monocyte production and polarization to the Type 1
and Type 2 macrophage phenotype. In turn, the lactic acid concentration locally
modulates the polarization of monocytes to the Type 2 macrophage, while the overall
lactic acid within the tumor tissue influences the tumor aggressiveness. Lactic acid is
also an important contributor to angiogenesis [126]. Table 8.1 summarizes a set of
relevant metabolites detected in lung tumor tissue samples [267], and highlights the
corresponding model parameters potentially affected by these metabolites, as has been
established from previous biological observations. Individual metabolites can overall
promote tumor progression or tumor control via the combination of increasing
(promoting) or decreasing (abating) particular parameters. Thus, each metabolite can
have “pro-parameter” and “anti-parameter” effects.
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MODEL PARAMETERS
METABOLITE

Tumor
Proliferation

Acetyl-LcarnitineA

▲

N8- AcetylspermidineA

▲

ArginineA

▲a,b

CreatinineA
CystineB

Type 1
Macrophage

Type 2
Macrophage

Angiogenesis

Drug
Effect

Lactic Acid
Production

Monocyte
Production

Refs.

[167]
[166]

▲

[110]

▲

▼

[114]
[268,
269]

▼

▲

[270,
271]
[272,
273]

▼c
▲d

FumarateB
Glutamic
AcidB
▲

▲

[274]
[275]

▲

[276]
[194,
277]

GlutamineB

▼

▼

Glutaric AcidA

▲

[278]

Hydroxybutyr
ic AcidA

▲

[279]

Hydroxyphen
yl-lactic AcidA

▼e

[280]

InosineA

▲

[281]

IsoleucineB

▼

[191]
[103]
▲

Lactic acidA
LysineB

[126]
[282]
[283]
[109]

▼g

Malonic AcidA
MethionineB

▲

▼f

▼f

[284]

Methionine
SulfoxideB

▼h

N3,N4Dimethyl-LarginineB

▲

[113]

▼

[285]
▼i

OrnithineA
Phenylalanine

▲

B

[269]
[286]
[194]

▼

ProlineA

▲

▲

PyruvateA

▲

▲

Salicylic
AcidA

[287]
[288]
▼

[107]
[106]
[108]

▼

[289]

▲j

▼j

[290]
[291]
[105]

SuccinateA

▼

▲

[292]

ThreonineB

▲

▼

[293]

SerineB

▼
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▲

TryptophanB

▼

[114]
▲k

UreaB
Uric AcidA

▲b

ValineB

▼f

▲

▼

[294]
[295]
[101]

Table 8.1. Potential effect of NSCLC metabolites on model parameters.
Metabolites detected in lung cancer patient tumor samples [267] (leftmost column), and
their potential promotion (▲) or abatement (▼) of key model parameters (top row).
Biological significance of the metabolites to NSCLC is indicated from literature sources
(rightmost column). APromoting tumor control; BPromoting tumor progression.
a
Arginine is a “conditionally essential” amino acid involved in the synthesis of
polyamines, which promote tumor growth, invasion and metastasis[269] and is also
involved in immune system activation[114] [268].
b
Although these metabolites promote immune system activation, they are considered to
favor tumor progression because the involvement in tumor growth, migration, and
contribution to cancer risk/mortality is considered a stronger overall effect.
c
Increased levels of cystine may be the result of decreased intracellular conversion to
cysteine for catabolic usage[272] and glutathione synthesis[273], which would reflect
decreased cancer growth.
d
Accumulation also leads to persistence of hypoxia-inducible factors in the
microenvironment [274], potentially promoting angiogenesis. In the context of
chemotherapy, angiogenesis combined with potentiation of the drug effect by fumarate is
assumed to improve the overall tumor drug response.
e
General effects of immune system activation or suppression are simulated by changing
the monocyte production rate [280].
f
Accumulation is assumed to reflect decreased cancer growth.
g
Promotes epithelial-mesenchymal transition (EMT), which involves enhanced
migration, invasiveness, elevated resistance to apoptosis, and increased ECM
production [296], overall decreasing the drug effect.
h
Relieves stress caused by acidic microenvironment [113]; simulated in the model by
lowering the lactic acid production rate.
i
Increased levels of ornithine may be the result of increased arginine, which promotes
tumor growth and immune system activation [114] [268, 269].
j
Promotes adaptive immune activity [105], simulated in the model by enhanced antitumor macrophage polarization.
k
Increases monocyte proliferation, simulated with higher overall macrophage numbers
[294].

A flowchart summarizing the process for determining parameter values based on
particular metabolomic data is shown in Fig 8.1.
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Figure 8.1. Workflow for coupling metabolomic data to model parameter values.

8.3.2 Determination of Model Parameter Values from Particular Metabolomic Data
Starting with a 2DLC-MS data set, as in [267], the weighted coefficients can be
determined via a Spearman correlation analysis of experimentally measured metabolite
intensities to the clinical response assessment, such as the Response Evaluation
Criteria in Solid Tumors Group (RECIST) [35, 297], or by the Variable Importance in
Projection (VIP) scores obtained from a PLS-DA model and scaling of these scores to
represent the fraction of their contribution to the parameter of interest. It is assumed for
each metabolite in a set of patient metabolomic data that the weighted coefficient W and
intensity value M [33] as described in Fig 8.1 are positive; if not, they are first rescaled
as follows:
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𝑊 = 𝑎𝑏𝑠(𝑤)

[Equation 8.6]

𝑀 = 𝑚 + 𝑎𝑏𝑠(𝑚𝑚𝑖𝑛 )

[Equation 8.7]

where for each metabolite, w is the weighted coefficient, m is the transformed intensity
value, and mmin is the minimum intensity value in the dataset. Transformations are
generally applied to a dataset to normalize and enable proper statistical analysis. For
each parameter, the metabolite weighted coefficients (𝑊) are rescaled to a scale of 0 to
1 by dividing each value by the sum of all coefficient values relevant to the given
parameter:
̅ = 𝑛𝑊
𝑊
∑
𝑊
𝑖=1

[Equation 8.8]

𝑖

̅ is the rescaled weighted coefficient and n is the total
where for each metabolite, 𝑊
number of metabolites associated with the parameter (as listed in Table 8.1). To
determine the values for a particular model parameter 𝑃𝑑𝑒𝑠𝑖𝑟𝑒𝑑 (Table 8.1, top row)
based on the associated metabolomic data, these data are first non-dimensionalized to
values Py:
𝑃𝑑𝑒𝑠𝑖𝑟𝑒𝑑 − 𝑃𝑚𝑖𝑛
)
𝑃𝑚𝑎𝑥 − 𝑃𝑚𝑖𝑛

𝑃𝑦 = (

[Equation 8.9]

where 𝑃𝑚𝑖𝑛 and 𝑃𝑚𝑎𝑥 are the minimum and maximum values calculated across all
samples for the desired parameter. 𝑃𝑑𝑒𝑠𝑖𝑟𝑒𝑑 , 𝑃𝑚𝑎𝑥 , and 𝑃𝑚𝑖𝑛 are calculated as the
weighted sums of pro-parameter metabolites minus the weighted sums of the antiparameter metabolites of the corresponding metabolite measurements M, 𝑀𝑚𝑎𝑥 and
𝑀𝑚𝑖𝑛 associated with the desired parameter (Table 8.1):
̅𝑖 𝑀𝑖,𝑝𝑟𝑜𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟 − ∑𝑚
̅
𝑃𝑑𝑒𝑠𝑖𝑟𝑒𝑑 = ∑𝑛𝑖=1 𝑊
𝑗=1 𝑊𝑗 𝑀𝑗,𝑎𝑛𝑡𝑖𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟

[Equation 8.10]

̅𝑖 𝑀𝑚𝑎𝑥,𝑖,𝑝𝑟𝑜𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟 − ∑𝑚
̅
𝑃𝑚𝑎𝑥 = ∑𝑛𝑖=1 𝑊
𝑗=1 𝑊𝑗 𝑀𝑚𝑖𝑛,𝑗,𝑎𝑛𝑡𝑖𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟

[Equation 8.11]

̅𝑖 𝑀𝑚𝑖𝑛,𝑖,𝑝𝑟𝑜𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟 − ∑𝑚
̅
𝑃𝑚𝑖𝑛 = ∑𝑛𝑖=1 𝑊
𝑗=1 𝑊𝑗 𝑀𝑚𝑎𝑥,𝑗,𝑎𝑛𝑡𝑖𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟

[Equation 8.12]
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where 𝑀𝑚𝑎𝑥 and 𝑀𝑚𝑖𝑛 are the rescaled maximum and minimum values for a particular
metabolite associated with the desired model parameter, and n and m are the total
number of pro-parameter and anti-parameter metabolites respectively associated with
this parameter (as listed in Table 8.1).

The weighted coefficients (i.e., relative contribution of specific metabolites
towards the dependent variable) can be objectively determined by applying multivariable
(e.g., partial least squares discriminant analysis (PLS-DA)) or univariable (e.g.,
correlation analyses) statistical techniques to the metabolomic dataset, as has been
previously shown [57, 86]. A representative set of non-dimensionalized Py values is
shown in Fig 8.2. The lines are generated by plotting the model-generated values at 400
h of tumor growth for every metabolism-associated model parameter (see
Supplementary Materials). The parameters were changed one at a time while holding
other parameters constant at their baseline values. The time of 400 h was selected
because by that time the simulated tumor growth had attained a steady rate of increase
(Supplementary Fig 8.1). Given Py on the y-axis, one can then interpolate the value for
a particular model parameter by mapping (or fitting) to the x-axis. Linear or logarithmic
functions were found to adequately map the experimentally measured metabolite values
to the model parameter space.
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Fig 8.2. Parameter curves showing Py vs. parameter values. These graphs map a set
of patient metabolomic data (y-axis, rescaled to values between 0 and 1) to the
parameter space of the model (x-axis).

8.3.3 Variation in Metabolic Dysregulation
Model parameter values representing a range of minimum to maximum metabolic
dysregulation (from LOW to HIGH, with BASELINE in between) were chosen in order to
simulate the corresponding extremes of metabolic-influenced tumor growth. The range
of parameter values listed in Table 8.2 defines a set of bounds for the values that could
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be utilized for NSCLC patient-specific tumor simulations based on the dataset in [267].
The ranges were determined by interpolating values that covered the capability of the
model to simulate a range of biologically relevant vascularized tumor growth. In this
study, as well as in previous work using these types of models [211, 260, 298-300], we
have found that values in these ranges are adequate to evaluate the parameters driving
this growth. Type 1 macrophages have the same LOW and MEDIUM values, and Type 2
macrophages have the same MEDIUM and HIGH values due to the calibration of
macrophage polarization to maintain tumor growth consistent with the baseline case, as
described earlier. The macrophage types are coupled, and their ratio determines the
overall range of interactions with the tumor tissue. For angiogenesis, the BASELINE
case already represents a highly vascularized condition [211].
Model Parameter
Proliferation rate
Type 1 macrophage
polarization constant
Type 2 macrophage
polarization constant
Angiogenesis rate (*)
Lactic acid production rate (*)
Monocyte production rate
Drug effect constant

LOW
0.600

BASELINE
1.100

HIGH
2.000

SAMPLE
1.356

20.000

20.000

0.000

9.863

2.000
25.0%
25.0%
0.005
1.0E+04

12.000
100.0%
100.0%
0.020
100.0

12.000
100.0%
400.0%
0.100
10.0

8.075
66.7%
192.4%
0.020
805,3

Table 8.2. Ranges for model parameter values. Model parameter values chosen to
define a range of metabolic-influenced tumor growth and drug response, in order to
simulate LOW, BASELINE, and HIGH metabolic dysregulation. For comparison,
SAMPLE values are calculated for a representative patient in the dataset. (*) Shown as
% of the corresponding rate for the baseline tumor.

Tumor radius and vessel surface area are shown over time for the three cases in
Fig 8.3 A-B. At 400 h, the HIGH case had 850% of the vasculature and 220% of the

252

radius of the LOW case. In Fig 8.3 C-E, the proliferating, hypoxic, and necrotic tissue
fractions are shown to highlight the differences in tumor tissue heterogeneity over time.
At 400 h, the HIGH case had 51%, 375%, and 124% of the proliferating, hypoxic and
necrotic tissue regions of the LOW case, respectively. The ratio of Type 1 to Type 2
macrophages is shown in Fig 8.3 F (the HIGH case has no Type 1 macrophages, Table
2).

Fig 8.3. Curves establishing a range of metabolic dysregulation during tumor
growth. LOW: minimum theoretical dysregulation (yellow error bars); BASELINE:
dysregulation based on baseline tumor values (green error bars); HIGH: maximum
theoretical dysregulation (blue error bars); SAMPLE: a representative patient case for
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illustration purposes (pink error bars). (A) Tumor radius, (B) tumor vessel surface area
(SA), (C) proliferating tissue fraction, (D) hypoxic tissue fraction, (E) necrotic tissue
fraction, (F) ratio of Type 1 to Type 2 macrophages (log10 scale). Type 1 macrophages
are not present in the HIGH case.

8.3.4 Simulation of Particular Tumors in Silico
To illustrate the methodology for patient-specific tumors, we simulated the growth
phase of a tumor incorporating metabolomic data (Table 8.3) previously measured from
a lung cancer tumor core biopsy [267]. These data represent log transformed metabolite
intensity values, e.g., measured from liquid chromatography mass spectroscopy (LCMS). Log transformation is commonly applied to biological data to center it and correct
for heteroscedasticity [33]. The parameter values are calculated in the following manner,
based on the workflow outlined in Fig 8.1: First, the transformed intensity value for each
metabolite (𝑀) is rescaled to a positive scale by summing the absolute value of the
largest negative value (𝑚𝑚𝑖𝑛 ) to all intensities (across all metabolites) so that the largest
negative value corresponds to zero (Fig 8.1, Step 1). A variety of methods could be
used to determine the weighted coefficients, including PLS-DA VIP scores, Spearman
correlation coefficients, and PLS-DA loadings. Spearman correlation coefficients are
found by analyzing clinical response as a function of the transformed metabolite
intensities. Similarly, in PLS-DA the transformed metabolite intensities are used as the
predictor variables and clinical outcome can be used as the response variable. All
metabolite weighted coefficients are rescaled to a positive scale by taking the absolute
value of each weighted coefficient (Fig 8.1, Step 1). Then, the metabolite weight
coefficients (𝑊) are rescaled to range from 0 to 1 by dividing each value by the sum of
all values relevant to the given parameter (Figure 8.1, Step 2) (Table 8.3). Here, we
chose a combination of PLS-DA VIP scores and Spearman correlation coefficients to
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illustrate the calculation of the weighted coefficients. A PLS-DA VIP score and
Spearman correlation coefficient are calculated for every metabolite using the clinical
patient response as the categorized outcome variable. After rescaling all correlation
coefficients to a positive scale, these two values are multiplied together and represent
the weight coefficient 𝑊. These are considered two different methods of assigning
weight to metabolites, relevant to the patient clinical outcome. We choose both by
multiplying them to be inclusive, as using only a single method of assigning weight to
metabolites could introduce bias into the parameter calculations.

Tumor
Proliferation

Type 1
Macrophage

Type 2
Macrophage

Angiogenesis

Drug
Effect

Lactic Acid
Production

Monocyte
Production

TRANSFORMED
& RESCALED
INTENSITIES Mi

Acetyl-LcarnitineA

0.0602

0

0

0.1854

0

0

0

1.13

N8-AcetylspermidineA

0.0571

0

0

0

0

0

0

2.59

ArginineA

0.0805

0.1392

0.1392

0

0

0

0

1.02

0

0.1148

0.1148

0

0

0

0

0.56

METABOLITE

CreatinineA

0.0303

0

0

0

0

0

0

1.45

FumarateB

0

0

0

0.1260

0.2559

0

0

2.16

Glutamic acidB

0

0

0

0

0.4090

0

0

0.48

GlutamineB

0.0766

0.1325

0.1325

0

0

0

0

0.20

Glutaric acidA

0.0381

0

0

0

0

0

0

0.15

Hydroxybutyric
acidA

0.0547

0

0

0

0

0

0

1.66

Hydroxyphenyllactic acidA

0

0

0

0

0

0

0.1503

0.00

InosineA

0.0738

0

0

0

0

0

0

1.88

IsoleucineB

0.0764

0

0

0

0

0

0

0.64

Lactic acid

0

0

0

0.1028

0

0.4306

0

1.02

0.0411

0

0

0

0

0

0

0.51

0

0

0

0

0.3351

0

0

0.92

MethionineB

0.0753

0

0

0

0

0

0

1.18

Methionine
SulfoxideB

0

0

0

0

0

0.5694

0

0.65

N3,N4Dimethyl-LarginineB

0

0.1244

0.1244

0

0

0

0

0.63

OrnithineA

0

0

0

0

0

0

0.1323

1.11

CystineB

LysineB
Malonic acidA
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0

0.0510

0.0510

0

0

0

0

0.88

ProlineA

0.0806

0

0

0.2485

0

0

0

1.31

PyruvateA

0.1095

0

0

0.3373

0

0

0.3418

1.46

0

0

0

0

0

0

0.2146

1.32

PhenylalanineB

Salicylic

acidA

0.0383

0.0663

0.0663

0

0

0

0

0.65

SuccinateA

0

0.1103

0.1103

0

0

0

0

0.34

ThreonineB

0

0.0764

0.0764

0

0

0

0

0.36

TryptophanB

0

0.0592

0.0592

0

0

0

0

1.67

UreaB

0

0

0

0

0

0

0.1609

2.41

Uric acidA

0.0728

0.1259

0.1259

0

0

0

0

0.64

ValineB

0.0349

0

0

0

0

0

0

0.52

SerineB

Table 8.3. Transformed and rescaled intensities and weighted coefficients for a
representative sample. Transformed and rescaled intensity values for a representative
sample and weighted coefficients, calculated for each metabolite associated with the
model parameters using a combination of PLS-DA VIP scores and Spearman correlation
coefficients. APromoting tumor control; BPromoting tumor progression. The coefficients
(either promoting (italic values) or abating (bold values) the associated parameters) were
derived as described in Methods from the metabolomic data from the study in [267]. The
coefficients are rescaled to a positive scale, where a value of zero corresponds to the
minimum, as described in Fig 8.1.

For every model parameter in Table 8.3, 𝑃𝑑𝑒𝑠𝑖𝑟𝑒𝑑 is found by summing the
multiplication of the metabolite intensity values for that patient by the respective
weighted coefficients for pro-parameter metabolites (values in red) and subtracting the
sum of the multiplication of the metabolite intensity values for that patient by the
respective weighted coefficients for anti-parameter metabolites (values in blue). (Fig 8.1,
Step 3). 𝑃𝑚𝑎𝑥 and 𝑃𝑚𝑖𝑛 are respectively calculated using the maximum pro-parameter
and minimum anti-parameter, and the minimum pro-parameter and maximum antiparameter metabolite intensities in the dataset (Fig 8.1, Step 4). Next, the non256

dimensionalized y-coordinate Py values for each model parameter are determined from
𝑃𝑑𝑒𝑠𝑖𝑟𝑒𝑑 , 𝑃𝑚𝑖𝑛 and 𝑃𝑚𝑎𝑥 (Fig 8.1, Step 5). Lastly, the model parameter values are found
as the x-coordinate values corresponding to each Py in Fig 8.2. The resulting values for
the sample case are in Table 8.4.
Parameter

Pmax

Pdesired

Pmin

Py

Parameter Value

Proliferation Rate
Type 1 Macrophage
Polarization Constant
Type 2 Macrophage
Polarization Constant
Angiogenesis Rate (*)
Lactic acid Production
Rate (*)
Monocyte Production
Rate
Drug Effect Constant

1.650

0.584

-0.844

0.573

1.357

1.675

0.439

-0.343

0.388

4.980

0.343
2.437

-0.439
1.406

-1.675
0.000

0.612
0.577

66.7%

0.999

0.071

-0.816

0.489

192.4%

0.470
2.011

-0.542
0.443

-1.804
-0.831

0.555
0.448

0.028
426.3

8.076

Table 8.4. Model parameter values for a representative sample.
𝑃𝑚𝑎𝑥 , 𝑃𝑑𝑒𝑠𝑖𝑟𝑒𝑑 𝑎𝑛𝑑 𝑃𝑚𝑖𝑛 values along with the corresponding model parameter values
calculated for a representative sample from a metabolomic dataset using the proposed
method. Metabolomic data were obtained from the study in [267]. (*) Parameter value is
shown as % of the corresponding value for the baseline tumor.

The tumor behavior simulated by the model with these parameter values is in Fig
8.3 and compared at 400 h in Fig 8.4, showing that for this sample set of metabolite
intensity values, the tumor radius would fall between the BASELINE and HIGH tumor
radii. A consistent pattern from LOW to HIGH was observed for tumor radius, tumor
vessel surface area, and proliferating and necrotic tissue fractions with HIGH, SAMPLE,
MEDIUM, and LOW cases. The LOW case had decreased hypoxic fraction along with
low vascularization, reflecting the values to represent low metabolic dysregulation in
Table 8.2, including a low proliferation rate.
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Fig 8.4. Tumor characteristics compared between different levels of metabolic
dysregulation. Comparison is at 400 h, by which time a steady rate of growth was
achieved. LOW: minimum theoretical dysregulation; BASELINE: dysregulation based on
baseline tumor values; HIGH: maximum theoretical dysregulation; SAMPLE: a
representative patient case for illustration purposes. (A) Tumor radius, (B) tumor vessel
surface area (SA), (C) proliferating tissue fraction, (D) hypoxic tissue fraction, (E)
necrotic tissue fraction, (F) ratio of Type 1 to Type 2 macrophages.

Note that the LOW and HIGH cases are used to define a range of NSCLC
metabolic dysregulation within the limits of the corresponding model parameter (Table
8.2). Individual SAMPLE parameters, however, are calibrated to actual metabolomic
data, which can yield combinations of parameter values that elicit tumor behavior outside
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of the range of the behavior elicited by the LOW and HIGH cases. In other words, an
ordered set of values in the model parameter space does not necessarily yield a
correspondingly ordered set of tumor behavior, since this behavior can be highly
nonlinear.

8.3.5 Simulation of Chemotherapy Response
The metabolomic data from the study in [267] were used to calculate tumor
model parameters for each patient, including the drug effect 𝜆̅𝑒𝑓𝑓𝑒𝑐𝑡 , and perform
simulations of chemotherapy to assess the consistency of the expected response with
each clinical classification. Clinical outcomes included complete response (CR), partial
response (PR), stable disease (SD) and progressive disease (PD). The patient
classifications of CR/PR vs. SD/PD as well as disease control (DC: CR/PR/SD) vs. PD
were evaluated. In Figure 8.5A, there was a significant difference in the average logtransformed anti-parameter metabolite intensity between CR/PR vs. SD/PD as well as
DC vs. PD patient groups, while the average log-transformed pro-parameter metabolite
intensity trended higher in SD/PD and PD patients compared to CR/PR and DC,
respectively. In Figure 8.5B, the results of simulating bolus drug injection in the patient
cohort are shown at 3.4 days post-treatment in terms of tumor radius area-under-curve
(AUC) and fraction of initial tumor radius. In all cases, there was a significant difference
between responders (CR/PR and DC) and non-responders (SD/PD and PD), indicating
that the model-simulated responses were able to classify the patient groups consistent
with the clinical response based on the hypothesized linking of metabolite intensities to
the model parameters (Table 8.1).
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Fig 8.5. Patient classification based on chemotherapy response. (A) Average log
transformed metabolite intensities for patients with clinical therapeutic response data,
classified as CR/PR (complete response/partial response), SD/PD (stable
disease/progressive disease), DC (disease control = CR/PR/SD) or progressive disease
(PD). (B) Simulated post-treatment tumor radius AUC and post-treatment tumor radius
(fraction of initial) after bolus injection of drug for responders (CR/PR and DC) and nonresponders (SD/PD and PD). Simulated tumor metrics were measured at 3.4 days posttreatment (n=3). *p≤0.05; **p≤0.01

8.4 DISCUSSION
This study develops a method to link clinically measurable metabolomic data to
tissue-scale tumor behavior. The tumor model representation is modulated by key
parameters influencing cell proliferation, tumor tissue vascularization, monocyte
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infiltration, tumor-associated macrophage polarization, lactic acid production, and drug
effect. These parameters interact with each other nonlinearly to influence the simulated
tumor progression. A dynamic range for these parameters is established using NSCLC
as a representative cancer in order to enable representation of low to high metabolically
active tumors. This approach enables the simulation of tumor progression based on
particular metabolomic measurements. Metabolomic data obtained from a set of patients
undergoing lung tumor core biopsies is used to show the feasibility of this approach.

Previous work has explored statistical approaches (e.g., machine learning) and
network-oriented techniques (e.g., principal network analysis) to link the metabolome to
tumor tissue-scale behavior; however, results based on these approaches may not
necessarily represent any particular tumor [86, 301]. Although some supervised learning
methods (such as PLS-DA) trained with chemotherapy response data can be used to
predict the outcome of chemotherapy for new patients, they are limited in that they are
only trained by the set of predictor variables (here, the metabolomic data). The
application of a mechanistically-based spatio-temporal model of tumor growth to
simulate chemotherapy extends the predictive capacity of such statistical models and
may provide insight into the mechanisms of treatment resistance. The system proposed
here could recreate the behavior of particular tumors for in silico evaluation prior to
treatment, incorporating patient tumor-specific metabolomic data. An approach
combining data-driven multivariate statistical techniques (i.e., machine learning) with
mechanistic spatiotemporal tissue modeling may be advantageous compared to using
either one alone.

Previous studies have sought to find robust metabolic biomarkers related to
cancer diagnosis, prognosis, and chemotherapeutic efficacy (e.g., [86, 87, 302-304]).
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With a few exceptions [257, 258, 305], the linking of metabolomic data to tissue-scale
behavior has been lacking. Since cancer is a heterogeneous disease, one advantage of
using a spatiotemporal mechanistic model is the ability to simulate in time different
proportions of proliferating, hypoxic and necrotic tissue within the tumor tissue [239].
This can occur with varying vascular densities due to the surrounding host tissue,
causing heterogeneous oxygen distribution. Differences in vasculature between tumors
are expected to affect the delivery and distribution of chemotherapeutics administered
intravenously [239]. In previous work, chemotherapeutic efficacy has been determined in
non-specific tumors [227, 239, 306, 307]. Here, we use metabolic characteristics to
account for potential inter-patient differences in tumor vascularization, which through its
effects influences the delivery and efficacy of chemotherapeutics.

Simulated patient tumor progression as a function of metabolomic data with the
proposed methodology could differ from actual clinical results. The set of metabolites
(Table 8.1) and the weighted coefficients assigned to them (Table 8.3) are critical in
determining the model parameter values. The choice of metabolites depends on the
specific cancer type and is determined from analysis of mass spectroscopy data for a set
of patient data. As such, the set is expected to remain consistent for all patients with the
same cancer type – in this study, NSCLC. However, the set may not be the same across
different studies. For example, evaluating NSCLC patient plasma samples, eight
metabolites were found to be associated with platinum chemotherapy response [86],
while seven metabolites were found in a study evaluating response to first-line
chemotherapy of pemetrexed combined with either cisplatin or carboplatin [87]. Further,
the weighted coefficients calculated via multivariate statistical techniques (i.e., machine
learning) may be different depending on the techniques chosen to calculate them, such
as a neural network or pathway analysis combined with correlation analysis, which
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would potentially arrive at different weights for the same set of metabolites. Such
differences highlight the need to validate any particular technique with actual outcomes
observed in patients. It may also be relevant to explore how correlations between
metabolites may affect the simulated results. Moreover, various combinations of model
parameter values could give similar results. The parameter values reflect the
overlapping of metabolites and tumor biological characteristics, and their combined
effects on tumor progression. Although simulated tumor growth may be similar, it is
expected that under therapy the results would be further affected by therapy-related
parameters. Response to drugs other than cisplatin to reflect actual patient regimens
should be evaluated. Additionally, the association of particular metabolites to model
parameters (Table 8.1) depends on the state-of-the-art of the biological knowledge and
the mass spectrometry (MS) analysis of the tissue samples. As metabolomic knowledge
progresses, it is to be expected that the parameters may need to be calculated based on
additional or different sets of metabolites. Accordingly, the assumptions underlying their
potential effects on the model parameters may need to be revisited. Care must also be
taken to ensure that a consistent set of metabolites are captured during global metabolic
profiling of patient biopsies across samples and analytical batches by using reliable
state-of-the-art metabolite extraction techniques.

As the number of parameters required to discriminate between patients is
unknown, it remains to be verified whether any particular set of parameters and their
range of values can accurately simulate tumors from different patients. It may be
necessary to augment the parameter set with further biologically-relevant information
(e.g., immune cells other than macrophages) in order to achieve this goal. The range of
values for the model parameters may also need to be expanded to accommodate the
biological information, which could lead to redefinition of the scale describing metabolic
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dysregulation. A major constraint is that most of this type of information would be difficult
to measure from individual tumor biopsies. Consequently, the model behavior depends
mainly on the metabolomic information and how this information is weighted and
combined to determine its effect on the model parameters. Using a small set of patient
data, this study used parameter values linked to metabolite intensities modulated by
weights and combinations based on clinical therapeutic responses to show consistency
of the model simulated treatment responses with the clinical data. For future work, the
weighting and combination may need to be adjusted to fine-tune the system response to
match what is observed with a larger test set of patient tumors, and then using this finercalibrated system to predict the response for new patients. As a step towards this goal,
this study establishes a framework to evaluate the complex interactions between
metabolic parameters that drive tissue-scale tumor growth, providing a means to link the
molecular to the tissue-scale behavior.

8.5 SUPPLEMENTARY MATERIAL
8.5.1. Simulation of vascularized tumor growth
8.5.1.1 Tumor Growth
The tumor growth component is based on [210, 211] and represents tumor tissue
in three regions: a proliferating region where cells have sufficient oxygen and nutrients to
proliferate, a hypoxic region where cells have sufficient oxygen and nutrients to survive
but insufficient for proliferation, and a necrotic region where cells lack sufficient oxygen
and nutrients for survival. The non-dimensionalized tumor growth velocity follows
Darcy’s Law [210]:
[Equation 8.5.1]
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where μ is cell-mobility, which models the net effects of cell-cell and cell-matrix
adhesion, P is oncotic pressure, χE is haptotaxis, and E is the density of the extracellular
matrix (ECM). Refer to [210] for a more detailed description of E and χE. The overall
tumor growth can be associated with the rate of volume change by assuming that the
cell density within the proliferating region remains constant:
[Equation 8.5.2]
where  p is the non-dimensionalized net proliferation rate (described below).

8.5.1.2 Tumor Vascularization
The angiogenesis component is based on [212] to represent blood flow, vascular
leakage and vascular network remodeling resulting from wall shear stress and
mechanical stress imposed by the tumor tissue as it changes in time. Briefly, as the
tumor grows within a vascularized environment, the tissue has access to oxygen and
nutrients diffusing from the vasculature. The interstitial flow of oxygen and nutrients is
influenced by tissue pressure and by distance from the nearest vessel. Neo-vessel
sprouts arise from the host vasculature, whose epithelial cell tips migrate semistochastically towards a gradient of tumor angiogenic factors (TAF), which are produced
by tumor tissue:
𝑇
𝑇
𝑇
̅𝑇
(1 − 𝑇)𝟏𝛺𝐻 − 𝜆̅𝑏𝑖𝑛𝑑𝑖𝑛𝑔
0 = ∇ ⋅ (𝐷𝑇 ∇𝑇) + 𝜆̅𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛
𝟏𝑣𝑒𝑠𝑠𝑒𝑙 − 𝜆̅𝐸𝐶𝑀
𝑢𝑝𝑡𝑎𝑘𝑒 𝐸𝑇 − 𝜆𝑑𝑒𝑐𝑎𝑦 𝑇

[Equation 8.5.3]

The TAF T diffuse through the tissue with coefficient 𝐷𝑇 , are produced in the
𝑇
tumor hypoxic region with a rate 𝜆̅𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛
, bind to the surrounding capillary vessels
𝑇
𝑇
with a rate 𝜆̅𝑏𝑖𝑛𝑑𝑖𝑛𝑔
, are uptaken by the ECM (with density E) with a rate 𝜆̅𝐸𝐶𝑀
𝑢𝑝𝑡𝑎𝑘𝑒 , and
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𝑇
decay with a rate 𝜆̅𝑑𝑒𝑐𝑎𝑦
. Refer to [210, 211] for a more detailed description of the

angiogenesis model.

8.5.1.3 Transport of Oxygen and Nutrients

Oxygen and nutrients σ are transported to the tumor from the location of
extravasation from the vasculature. The extravasation rates


ev = neo

and


ev =  pre

represent the rate that σ are supplied from the neo- and pre-existing vasculature,
respectively. These substances, which diffuse with a coefficient 𝐷𝜎 , are respectively
taken up by host tissue cells, and proliferating and hypoxic tumor cells, with rates
𝜆𝜎ℎ𝑜𝑠𝑡 , 𝜆𝜎𝑝𝑟𝑜𝑙𝑖𝑓 , 𝜆𝜎ℎ𝑦𝑝𝑜𝑥𝑖𝑐 and decay with rate 𝜆𝜎𝑁 , in the necrotic region. Under steady-state
conditions, oxygen and nutrient uptake and decay is [19, 210, 308]:

0 =   ( D  ) + ev (x, t , 1vessel , pi ,  , h) −   ( )

[Equation 8.5.4]

where x is position, t is time, 1vessel is the characteristic function for the vasculature
(equals 1 at vessel locations and 0 otherwise), pi is interstitial pressure, and h is the
hematocrit in the vascular network [210]. Extravasation is modulated by the
extravascular interstitial pressure pi, scaled by the effective pressure pe with the weight
of the convective transport component of small molecules, k pi [19]:


ev =  ev 1vessel (x, t )(

p
h
− h min ) + (1 − k pi i )(1 −  )
pe
HD
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[Equation 8.5.5]

H D and ℎ𝑚𝑖𝑛 are constants representing normal and minimum hematocrit necessary for


oxygen extravasation, respectively.

 ev

represents the constant transfer rate from pre-

existing and tumor-induced vessels.

The loss term represents the oxygen and nutrient uptake in the various tissue regions
[210]:

 host
in host tissue
 

in
proliferating
tissue

  =  prolif
in hypoxic tissue
hypoxc


in necrotic tissue
necrotic

[Equation 8.5.6]

8.5.1.4 Tumor Tissue Proliferation
Assuming that tumor tissue proliferation is proportional to the local concentration
of oxygen and nutrients, the non-dimensionalized net proliferation rate is as follows
[211]:
in host tissue
0
 − A in proliferating tissue

p = 
in hypoxic tissue
0

in necrotic tissue
 −GN

[Equation 8.5.7]

where A is the native apoptosis rate of tumor tissue and GN is the rate of volume loss
due to necrosis.

8.5.1.5 Effect of Chemotherapy
Cisplatin is a cell cycle dependent drug; hence, its cytotoxic effect is only exerted
on proliferating cells. Accordingly, the drug effect is included into the proliferation term
for  p , where

 effect is the rate of drug-induced cell death [308]:
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 p =  (1 −  effect c) − A .

[Equation 8.5.8]

This pharmacodynamic model assumes that cell death is instantaneous and that
proliferation and apoptosis rates remain similar before and after the therapy.

8.5.2 Simulation of Baseline Tumor
To simulate a representative lung tumor nodule, the model parameters
determining the proportion of hypoxic and necrotic tissue, as well as the growth rate
were initially calibrated to lung tumor experimental data [309-311]. An average hypoxic
fraction of 20% was found by Zegers et al. in 15 NSCLC patients via Positron Emission
Tomography and Computed Tomography (PET-CT) imaging [311]. In Pan et al., an
average necrotic fraction of 36.5% was found in 14 patients with malignant lung masses
[309]. Growth rate was determined from Xu et al., in which a NSCLC xenograft model
was measured in volume over a period of seven weeks [310]. To reflect the values
obtained from the literature, the model parameters were interpolated until the desired
tumor characteristics were achieved, fitting the model to the experimental data, as
shown in Supplementary Fig 8.1.
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Supplementary Fig 8.1. Fitting of model growth to experimental data. (A) Necrotic
tissue fraction fitted to experimental data [309]. (B) Hypoxic tissue fraction fitted to
experimental data [311]. Gray areas represent the standard deviation of the
experimental data. (C) Baseline tumor growth curve fitted to growth rate observed
experimentally [310]. (D) Simulation of tumor and vasculature, extracellular matrix (ECM)
and oxygen of a representative NSCLC tumor at 400 h, grown using parameter values
as in Table 8.1. In the tumor tissue, colors represent different regions of tumor tissue
(red = proliferating, blue = hypoxia, brown = necrosis). Lines represent vasculature, with
regular grid simulating pre-existing capillary network and irregular lines simulating neoangiogenic vessels stimulated to grow towards tumor up the gradient of tumor
angiogenic factors (TAF). ECM and oxygen color scales represent range from 0 to 1. Bar
= 250 μm.
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The main model parameters and their baseline values are in Supplementary
Table 8.1. The proliferation rate was calibrated as described in Supplementary Fig 8.1.
Oxygen threshold for hypoxia denotes oxygen value at which tumor tissue ceases
proliferation and becomes quiescent (hypoxic). Oxygen threshold for necrosis is oxygen
value at which tumor tissue ceases being hypoxic and becomes necrotic. Oxygen
diffusivity is used to non-dimensionalize the model parameters as noted in the Table.
Oxygen transfer rate from vasculature and the various oxygen uptake rates were
calibrated to achieve sustained tumor proliferation to a distance of 100 μm from
vasculature, matching typical distance of oxygen diffusion. Cisplatin diffusivity was
estimated based on molecule size compared to oxygen, while decay rate was set based
on the drug half-life [214]. Tumor aggressiveness was set to achieve sustained tumor
growth, matching previous calibration [211]. Lactic acid parameters were estimated
based on their effect on tumor aggressiveness and their coupling to the macrophage
polarization to Type 2. Lastly, macrophage polarization constants were set based on
previous measurements [260].

Model Parameter

Parameter Value

Source

1.1**

Calibrated to [310]

Oxygen threshold for hypoxia

0.6540**

Calibrated to [311]

Oxygen threshold for necrosis

0.6500**

Calibrated to [309]

Oxygen diffusivity

1*

[211]

Oxygen transfer rate from
vasculature

5*

[211]

Oxygen uptake rate by
proliferating cells

1.5*

[211]

Oxygen uptake rate by hypoxic
cells

1.3*

[211]

Oxygen uptake rate by tumor
microenvironment

0.12*

[211]

Oxygen decay rate

0.35*

[211]

Tumor proliferation rate
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Cisplatin diffusivity (DG)

0.6*

Estimated

0.5hr half-life

[214]

60**

[211]

1

Estimated

Lactic acid uptake rate

0.12*

Estimated

Lactic acid washout by
vasculature

0.1*

Estimated

Type 1 macrophage
polarization constant

20**

[260]

Type 2 macrophage
polarization constant

12**

[260]

Cisplatin decay rate (𝜆−𝐺
𝑑𝑒𝑐𝑎𝑦 )
Tumor aggressiveness
Lactic acid diffusivity

* Value is rescaled by the square of the simulation system characteristic length
(1cm) and divided by the system characteristic time (1s) multiplied by the
oxygen diffusivity (1 x 10-5cm2s-1) [211]
** Used for baseline tumor parameter values

Supplementary Table 8.1. Tumor model main parameters. All other parameters are
as in [211].

8.5.3. Determination of Range of Model Parameter Values
8.5.3.1 Variation in Tumor Proliferation Rate
The upper and lower bounds for the range of proliferation rate constant values
were calibrated by interpolation of values that spanned biologically-relevant cancer cell
proliferation rates. Tumor radius at 400 h with various values of proliferation rate
constant is shown in Supplementary Fig 8.2. A minimum value of 0.6 for the
proliferation rate constant was chosen as the lower bound, and a maximum value of 2
was chosen as the upper bound. The increase in tumor radius over time remains
relatively linear among all cases, as expected.
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Supplementary Fig 8.2. Determination of range for tumor proliferation rate. Tumor
radius vs. proliferation rate (at 400 h). A value of 0.6 was chosen as the lower bound and
2.0 as the upper bound.

8.5.3.2 Variation in Tumor Vascularization
In order to account for metabolites known to affect tumor angiogenesis, a
parameter was implemented within the angiogenesis model to allow for a decrease in
the tumor vessel density below the baseline value, set in the original model to match a
highly vascularized tumor, such as glioblastoma [211]. The parameter allows control
over the rate of angiogenesis without affecting the TAF production rate or ECM
degradation. There are alternative ways to control angiogenesis, but this approach was
chosen for simplicity to yield the desired control. After the probability of sprout tip
movement in one of the 4 directions based on local TAF concentration is determined
[210], the parameter decreases the frequency in which the vessel growth will activate in
the determined direction. This decrease does not affect the probability of vessel growth,
mitosis, or the semi-stochastic nature of the model. In Supplementary Fig 8.3A, the
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parameter interpolation is shown as tumor vessel surface area vs. angiogenesis rate at
400 h. Supplementary Fig 8.3B shows that decreasing angiogenesis rates (with
respect to angiogenesis rate for baseline tumor) corresponded to decreasing tumor
vessel SA.

Supplementary Fig 8.3. Variation in tumor vascularization. (A) Parameter
interpolation curves for the rate of angiogenesis compared to the baseline case, showing
(A) tumor vessel surface area (SA) vs. angiogenesis rate (at 400 h) and (B) tumor vessel
SA at a tumor radius of 0.4mm.

8.5.3.3 Variation in Macrophage Polarization
Immune system activity is simulated by the Type 1 (M1) and Type 2 (M2)
macrophages in the model. Constants M_M1 and M_M2 affecting polarization to an M1
or M2 phenotype were calibrated using the baseline tumor parameters. As shown in
[260], inclusion of macrophages dynamically affects the hypoxic and necrotic tumor
tissue fractions. The baseline tumor growth (Supplementary Fig 8.1) was matched with
values of M_M1 = 20 and M_M2 = 12 (Supplementary Fig 8.4A), yielding a tumor
radius matching the radius within 1.6% of the baseline case at 400 h. The upper bound
for maximum pro-tumorigenic activity was found by deactivating all Type 1 macrophages
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(M_M1 = 0) and leaving all Type 2 macrophages at the baseline probability constant
(M_M2 = 12) (Supplementary Fig 8.4B). In Supplementary Fig 8.4C, a minimum value
of M_M2 = 2 was chosen as the lower bound for which tumor growth occurred with
minimal immune pro-tumorigenic input.

Supplementary Fig 8.4. Calibration of macrophage polarization to maintain tumor
growth consistent with baseline case and interpolation of upper and lower
bounds. (A) Variation in probability of conversion to Type 2 (M_M2). Value of Type 2
macrophage polarization constant M_M2 = 12 matched the radius to within 1.6% of the
baseline tumor at 400 h while holding Type 1 macrophage polarization constant M_M1
constant at a value of 20. (B) Interpolation of upper and lower bounds of M_M1 at 400 h.
Value of M_M1 = 0 was chosen as the lower bound and M_M1 = 20 was chosen as the
upper bound. (C) Interpolation of upper and lower bounds of M_M2 at 400 h while
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holding M_M1 constant at a value of 20. Value of M_M2 = 2 was chosen as the lower
bound and M_M2 = 12 as the upper bound.

8.5.3.4 Effect of Metabolites on Tumor Vascularization
The effect of metabolites on tumor vascularization is taken into account by
following the proposed method to calibrate the rate of angiogenesis for any particular
sample based on the metabolites known to affect tumor angiogenesis [107, 126, 166,
274, 288], including acetyl-L-carnitine, fumarate, lactic acid, proline, and pyruvate (Table
8.1).

8.5.3.5 Coupling of Lactic Acid to Tumor Aggressiveness
The tumor aggressiveness parameter 𝐺 was coupled to the concentration of
lactic acid within the tumor boundary. This allows the concentration of lactic acid to
modulate the tumor growth:
𝐺

𝐺 = (𝐿 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 )𝐿𝑡𝑢𝑚𝑜𝑟 + 𝑎

[Equation 8.5.9]

𝑚𝑖𝑑𝑝𝑜𝑖𝑛𝑡

where 𝐺 is tumor aggressiveness, 𝐿𝑡𝑢𝑚𝑜𝑟 is the total lactic acid within the tumor
boundary at a given time, and a is a summation constant. The value of the coefficient
multiplying the total lactic acid was found by dividing the baseline tumor aggressiveness
value (𝐺𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 , 60) by the concentration of lactic acid at the mid-point of the growth
phase of the baseline case (𝐿𝑚𝑖𝑑𝑝𝑜𝑖𝑛𝑡 , non-dimensionalized value of 4,400). The value of
the summation constant a was interpolated to find the proliferating tissue fraction that
aligned (within 1.5%) with the baseline case at 400 h (Supplementary Fig 8.5). A
summation constant of α=2 was determined to match most closely to the baseline tumor.
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Supplementary Fig 8.5. Calibration of the summation term in coupled lactic acid
and tumor aggressiveness equation. After including the equation in the model, a
summation term (α) of +2 resulted in a proliferating tissue fraction within 1.5% of the
baseline tumor at 400 h with an aggressiveness value of 60.

8.5.3.6 Coupling of Lactic Acid to Macrophage Polarization
Type 2 macrophage polarization was coupled to lactic acid concentration by
multiplying the coefficient 𝑘𝑙𝑎𝑐 by local lactic acid concentration 𝐿 as follows:
𝑅𝑀2 ∝ 𝑘𝑀2 ∙ 𝑘𝑙𝑎𝑐 ∙ 𝐿 ∙ (𝐶𝑀2𝑓 + 𝑘 𝑇2𝑀2 ∙ 𝐶𝐼𝐿−10 )

[Equation 8.5.10]

The coefficient 𝑘𝑙𝑎𝑐 was calibrated by finding a value for which the Type 2 macrophage
count matched that of the baseline tumor (Supplementary Fig 8.6). At 400 h, the total
number of Type 2 macrophages in the case 𝑘𝑙𝑎𝑐 = 2.2 was within 2.4% of the count for
the baseline case.
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Supplementary Fig 8.6. Interpolation curves for the value of the coefficient
coupling lactic acid with Type 2 macrophage polarization. Comparison to baseline,
showing total Type 2 macrophage count over time. A coefficient value of klac = 2.2 was
within 2.4% of the count for the baseline case at 400 h.

8.5.3.7 Variation in Lactic Acid Production
Once the tumor aggressiveness and Type 2 macrophage polarization were
coupled to the local concentration of lactic acid, the production rate was varied to be
able to represent heterogeneity in tumor metabolism. To prevent over-fitting of the
model, the range of lactic acid production rate was chosen to be 25% to 400% of the
baseline case (1/4x to 4x). The Type 2 macrophage population at 400 h within the host
and tumor tissue increased proportionally as the production rate rose in time, as
expected (Supplementary Fig 8.7).
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Supplementary Fig 8.7. Calibration of lactic acid production rate. Effect of lactic
acid production rate variation on the number of Type 2 macrophages within the tumor
boundary (at 400 h).

8.5.3.8 Variation in Monocyte Production
The production rate (rate of appearance) of monocytes was varied to represent
heterogeneity in immune cell activation. The range of monocyte production was chosen
to be 50% to 200% of the baseline tumor value (1/2x to 2x). The monocyte population at
400 h within the host and tumor tissue decreased exponentially as the production rate
constant increased (Supplementary Fig 8.8).
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Supplementary Fig 8.8. Determination of range for monocyte production rate.
Natural log of monocyte population vs. monocyte production rate constant (at 400 h). A
value of 0.005 was chosen as the lower bound and 0.100 as the upper bound.

8.5.3.9 Variation in Drug Effect
The drug effect was varied to represent heterogeneity in tumor drug resistance.
Cisplatin was simulated with a half-life of 30 minutes. The proliferating tissue fraction
immediately following a bolus drug injection decreased exponentially as the drug effect
constant increased (Supplementary Fig 8.9).
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Supplementary Fig 8.9. Determination of range for drug effect constant. Natural log
of proliferating tissue fraction vs. drug effect constant (at one discrete time point after
systemic drug injection). A value of 10 was chosen as the lower bound and 10,000 as
the upper bound.
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CHAPTER 9

PREDICTION OF RESPONSE TO FIRST-LINE CHEMOTHERAPY BASED ON
PATIENT TUMOR SPECIFIC METABOLOMIC DATA

9.1 INTRODUCTION
The standard of care for intermediate (Stage II) and advanced (Stages III and IV)
NSCLC typically entails resection of the affected lung tissue, followed by chemotherapy
with taxane/platinum derivatives, with or without radiation, to prevent relapse.
Unfortunately, despite these treatments, the cancer recurs in a large percentage of these
patients, presumably due to resistance to chemotherapy. In order to avoid the toxic
exposure associated with needless treatment, it would be beneficial to know a priori which
patients are expected to benefit from drug therapy. This knowledge would allow nonresponding patients to be treated at the outset with second-line therapies, thus gaining
valuable time to pursue a cure. It is non-trivial, however, to make this determination for
particular tumors, as the factors involved include a variety of characteristics (e.g.,
metabolic [312], angiogenic [312]) that span a wide range of physical (nm to cm) and
temporal (second to month) scales. Some attempts to achieve this determination have
included chemosensitivity and chemoresistance assays (e.g., ChemoFx), metabolomic
analysis [149, 313-315] and genomic characterization [316-319], including biomarker
screening and gene expression tests offered commercially (e.g, Veracyte, Orion
Genomics, Rosetta Genomics, Metabolomx), but success to date has been limited.
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Newer approaches to cancer therapy involving molecular profiling represent a
promising avenue, especially as they seek to elucidate the role of the microenvironment
in the evolution of acquired drug resistance in lung cancer. In particular, the development
of gene analysis tools has offered the opportunity to more quickly and cheaply assess
variations in the genetic make-up of tumors. Yet the interpretation of these data for clinical
application is non-trivial. For example, although the detection of genetic variation in
individual patient tumors is considered crucial for the success of personalized medicine,
for the most part it remains unclear how this variation translates to tumor tissue-scale
phenotype. A major reason is that the treatment response of many cancers do not solely
depend on variation on the molecular (e.g., genomic) scale but rather on the combination
of characteristics at multiple scales, including molecular, cellular, and tissue conditions.
Further, the amount of data generated by any one omic analysis is large and can be
difficult to interpret beyond classifications and correlations [252]. Mathematical modeling
and computational techniques have been applied to address these challenges.
Metabolism at the cellular scale (e.g., [256-258]) along with the associated networks [259]
has been modeled, but it has been challenging to link the metabolic to the tissue scale.
Advances in metabolomics and computational modeling, as well as in the estimation of
model parameter values based on metabolome data were reviewed in [253], focusing on
metabolic reaction networks and kinetic models. The utility of computational modeling to
advance the understanding of cancer metabolic reprogramming and to identify potential
therapeutic interventions was recently reviewed in [254].

This study implements a mathematical model-based approach to determine how a
particular patient’s tumor would benefit from first-line chemotherapy. We have recently
established a method to simulate tumor growth by combining tumor metabolomics
282

analysis and computational modeling of the tumor microenvironment [320]. The method
uses data from patient tumor-derived core biopsies and is customizable to specific tumor
characteristics. We hypothesize that this method can accurately predict the impact of a
particular tumor’s metabolites on the response to first-line chemotherapy. Previously,
computational

modeling

has

identified

the

hypoxic

and

hypoglycemic

tumor

microenvironment as a critical component in tumor progression [298-300] and implicated
the dysregulated microenvironment in tumor drug response [227, 239, 260]. In particular,
cancerous lung tissue has been found to have significantly altered metabolite profiles
compared to normal lung [321]. We have shown that comprehensive metabolomic
statistical [322] and machine learning [323] analyses can accurately predict patient
survival as well as distinguish NSCLC drug response and disease stage [267, 324], and
identify key metabolites underlying these differences [267, 322, 323].

9.2 MATERIALS AND METHODS
9.2.1 Modeling of Tumor Growth
The tumor growth model is based on a 2D continuum representation of tissue, as
described in [210, 211]. In summary, a small nodule is simulated to grow in a
vascularized environment within host tissue. Heterogeneous access to oxygen and
nutrients diffusing from the vasculature leads to proliferating, hypoxic and necrotic tumor
tissue regions. Vascularized growth is modeled as in [212] via angiogenesis stimulated
by a gradient of tumor angiogenic factor (TAF) released by hypoxic tissue. Main
equations of the model in [210, 211] are summarized in Supplementary Materials
(Chapter 8, section 8.5). Following [325], the model parameters to be set based on the
patient metabolomics data include: proliferation rate, Type 1 macrophage polarization,
Type 2 macrophage polarization, angiogenesis rate, lactic acid production rate,
monocyte production rate, and drug effect constant. Additionally, based on the
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simulation results obtained with these parameters, the following initial (start of treatment)
values were recorded for each patient: tumor vasculature surface area (SA), drug within
tumor, and tumor proliferating tissue fraction. All other model parameters were set as in
Supplementary Table 9.1.

9.2.2. Modeling of Chemotherapy
Treatment is simulated in response to cisplatin (CDDP), a representative NSCLC
drug routinely administered to non-small cell lung cancer (NSCLC) patients [227].
Assuming bolus administration, the transport of drug c with diffusivity Dc is simulated
based on vascular extravasation within the tumor tissue. Drug uptake by tumor and
normal cells and washout from interstitial space are included in a net rate λc,uptake, which
represents drug half-life (assumed similar to half-life in plasma) [266]:
0 = ∇ ∙ (𝐷𝑐 ∇𝑐) + 𝜆𝑐,𝑒𝑣 (𝐱, 𝑡, 1vessel , 𝑝𝑖 , 𝑐) − 𝜆𝑐,𝑢𝑝𝑡𝑎𝑘𝑒 𝑐

[Equation 9.1]

Drug extravasation λc,TR is assumed constant from the vasculature [19] :
𝑝

𝐶

𝜆𝑐,𝑒𝑣 = 𝜆𝑐,TR 𝟏vessel (𝐱, 𝑡)(1 − 𝑘𝑝,𝑖 𝑝 𝑖 )( 𝐶𝑐,𝑡̅ − 𝑐)
𝑒

𝑐

[Equation 9.2]

where 𝜆𝑐,TR is transfer rate from pre-existing and new vessels, 𝟏vessel (𝐱, 𝑡) equals 1 at
vessel locations and 0 elsewhere, kp,i represents weight of convective transport
component of small molecules, pi is interstitial fluid pressure (IFP), and pe is effective
pressure (IFP at which net volume flux from vasculature is null)[211]. Vascular drug
concentration is initially 𝐶𝑐̅ , with extravasation following first order kinetics for constant
drug infusion Cc,t = 1 - e-αt, with α based on CDDP half-life of 0.5 h [214].

9.2.3 Synthetic Dataset
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A set of Monte-Carlo simulations was obtained by resampling model parameter
values drawn from a normal distribution within their respective ranges (Supplementary
Figure 9.1) and simulating chemotherapy. Synthetic parameter sets were generated by
calling a normal distribution function setting the mean to the midpoint of each predetermined parameter range and standard deviation to one-third the mean. Each vector
of parameter values was set to a length of 150 then truncated to a length of 100 to trim
off any values above or below the pre-determined model parameter ranges. Truncated
vectors of each parameter value were then combined into a single matrix after randomly
mixing the entries to produce a random set of parameter values for 100 simulations. In
total, 284 synthetic dataset simulations were performed for analysis.

9.2.4 Metabolomic Data
Metabolomic datasets based on lung tumor core biopsies from 23 patients in
[267] (Metabolomics Workbench Repository, record ST001527) were retrieved to
simulate patient-specific tumors based on model parameter values as a function of
metabolites as described in [326]. The metabolomic data are described in detail in our
previous publication [267].

9.2.5 Simulation of Patient-Specific Tumors
Model parameter values were first calculated for each patient’s tumor based on
the associated metabolite profiles, generally following the procedure proposed in [326].
The metabolomic data represent log transformed metabolite intensity values measured
from liquid chromatography mass spectroscopy (LC-MS) [267]. Briefly, the transformed
intensity value for each sample is rescaled to a positive scale by summing the absolute
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value of the largest negative value to all intensities (across all metabolites) so that the
largest negative value corresponds to zero. Unlike [326], we skip the step of multiplying
a weight coefficient and instead use the log transformed intensity values directly to
remove any potential information leakage between the original data and the model
parameter calibration. Parameter values are determined by first summing the maximum
metabolite intensity values for pro-parameter (i.e., increasing the parameter) metabolites
and subtracting the sum of the minimum metabolite intensity values for anti-parameter
i.e., decreasing the parameter) metabolites to rescale the desired non-dimensionalized
unit and mapped to the parameter space. Twelve replicates of every patient-specific
simulation were performed and results are reported as averages by sample.

9.2.6 Assessment of Tumor Response
A total of seven evaluation metrics were investigated for determining simulated
tissue response for comparison to clinical response and are summarized in Table 9.1: 1.
Fraction of initial are under the curve (AUC): Area under the curve of fraction of initial
tumor radius vs. time during the post-bolus cisplatin injection growth window. 2.
Proliferating tissue fraction AUC: Area under the curve of proliferating tissue vs. time
during the post-bolus cisplatin injection growth window. 3. Tumor Vasculature SA AUC:
Area under the curve of tumor vasculature surface area vs. time during the post-bolus
cisplatin injection growth window. 4. Fraction of initial radius: Fraction of initial tumor
radius one time step post-bolus injection of cisplatin. 5. Final fraction of initial radius:
Fraction of initial tumor radius at the final time step during the post-bolus cisplatin
injection growth window. 6. Average radius velocity: Average tumor radius velocity
during the post-bolus cisplatin injection growth window. 7. Average proliferating tissue
fraction velocity: Average proliferating tumor tissue fraction velocity during the post-bolus
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cisplatin injection growth window. P-values were determined by 2-sided T-test assuming
equal variances and error bars are reported as the standard deviation for each
evaluation metric. Correlations between and among model parameters, evaluation
metrics, and metabolite values were performed by Pearson correlation and a
significance threshold of p ≤ 0.05. Correlation coefficients ≥ 0.75 are designated as
“strongly correlated” and coefficients ≥ 0.5 < 0.75 are designated as “moderately
correlated”.

Table 9.1. Tumor model simulation evaluation metrics. Orange highlights the area of
interest for each metric.

9.3 RESULTS
9.3.1 Correlation among model parameters and evaluation metrics
We first evaluated the influence of model parameters on the chosen evaluation
metrics. Correlation plots of parameters vs. evaluation metrics for synthetic dataset
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simulations (Supplementary Figure 9.2) reveal that final fraction of initial radius and
average radius velocity correlated positively with proliferation rate, angiogenesis rate,
fraction of initial AUC, proliferating tissue fraction AUC, tumor vasculature SA AUC, and
fraction of initial radius, and correlated negatively with Type 1 macrophage polarization,
average proliferating tissue fraction velocity, initial proliferating fraction, initial tumor
vasculature SA, and initial drug within tumor. Fraction of initial radius was positively
correlated with proliferation rate, lactic acid production constant, drug effect, fraction of
initial AUC, tumor vasculature SA AUC, fraction of initial radius, final fraction of initial
radius, average radius velocity, and initial drug within tumor, and correlated negatively
with angiogenesis rate, proliferating tissue fraction AUC, average proliferating tissue
fraction velocity, initial proliferating fraction, and initial tumor vasculature SA. Tumor
vasculature SA AUC was strongly positively correlated with final fraction of initial radius,
average radius velocity, and fraction of initial AUC; positively correlated with proliferation
rate, angiogenesis rate, lactic acid production constant, fraction of initial radius and
proliferating tissue fraction AUC; negatively correlated with average proliferating tissue
fraction velocity, initial proliferating fraction, drug effect, and initial drug within tumor.

Comparing model parameters vs. evaluation metrics (Supplementary Figure
9.2), proliferation rate was moderately correlated (>0.3) to several of these metrics:
positively with fraction of initial AUC, fraction of initial radius, final fraction of initial radius,
and average radius velocity and negatively with average proliferating tissue fraction,
initial proliferating fraction, and initial tumor vasculature SA in the negative direction. The
other model parameter moderately correlated with the evaluation metrics was
angiogenesis rate: positively with proliferating tissue fraction AUC, tumor vasculature SA
AUC, and initial tumor vasculature SA, and negatively with fraction of initial radius and
initial drug within tumor. Lastly, while were no strong correlations amongst the model
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parameters for synthetic dataset simulations, there were several strong correlations (>
0.75) among the evaluation metrics themselves, including high correlation between final
fraction of initial radius and average radius velocity.

9.3.2 Simulated patient-specific tumor chemotherapy response based on
metabolite profiles
Parameter values were calculated based on each patient tumor metabolomic
profile following the procedure adapted from [325] (Table 9.2). Average parameter
values for each clinical response group normalized as a fraction of average CR value
are shown in Figure 9.1. PD patients trended higher for proliferation rate, Type 2
macrophage polarization, angiogenesis rate, and lactic acid production rate, and trended
lower for Type 1 macrophage polarization, monocyte production rate and drug effect
constant compared to all other clinical classifications. Additionally, PD patients had the
lowest standard deviation for Type 1 macrophage polarization, Type 2 macrophage
polarization, lactic acid production rate, monocyte production rate, and drug effect
constant, implying more consistency in the derived parameters among PD patients than
those within the other clinical response groups.

289

Table 9.2. Table of calibrated model parameters for each patient simulation, from
tumor tissue derived MS-based metabolomics data and quantification of tumor
vascularization, free drug within tumor, and proliferating fraction at start of
treatment. Clinical response groups: CR = complete response; PR = partial response;
SD = stable disease; PD = progressive disease.

Figure 9.1. Average parameter values for patient-specific simulations in each
clinical response group, represented as fraction of average CR patient value. Error
bars represent standard deviation. (*P ≤ 0.1); (**P ≤ 0.05); (***P ≤ 0.01)
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Each patient’s tumor was grown in silico with its particular parameter values to
match the size of the lung tumor nodule simulated in [325] (radius 0.352mm).
Representative images of the simulated tumor tissue, oxygen profile and lactic acid
profile at the start of treatment for each clinical response group are shown in Figure 9.2.
Values for tumor vasculature SA, drug within tumor, and tumor proliferating tissue
fraction at the start of treatment for each patient simulation are also recorded in Table
9.2. Chemotherapy via bolus injection was then simulated and tumor response was
assessed as described in Materials and Methods. Responders included complete
response (CR) or partial response (PR), while non-responders included stable disease
(SD) or progressive disease (PD). Response for each patient simulation is shown as a
heatmap in Figure 9.3. Colors are scaled within row, each of which represents a
different response evaluation metric where red is the lowest value and green is the
highest value. Columns represent the averages of all included replicates for each
patient.
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Figure 9.2. Representative images of simulated tumor tissue prior to bolus
injection of cisplatin. Clinical response groups: CR = complete response; PR = partial
response; SD = stable disease; PD = progressive disease.
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Differences in the evaluation metrics between clinical response groups are
shown in Figure 9.4. Bars represent the average value for all replicates and patients
within each clinical response group and error bars represent the standard deviation. PD
and SD/PD patients had significantly higher final fraction of initial radius than DC and
CR/PR (P≤0.01), respectively. PD and SD/PD patients also had significantly higher
average radius velocity compared to DC and CR/PR (P≤0.05), respectively. PD patients
further had higher final fraction of initial radius compared to all other individual clinical
response groups (P≤0.05 for SD and PR; P≤0.01 for CR). Tumor vasculature SA AUC
was significantly lower in SD/PD patients than CR/PR (P≤0.01), while SD patients
overall had marginally lowest averages and PR patients overall had marginally highest
averages. CR patients had lower fraction of initial AUC compared to PR and SD
(P≤0.01), but not PD patients. Additional metrics of proliferating tissue fraction AUC and
average proliferating tissue fraction velocity had no significant differences between
clinical response groups, although some interesting trends emerge. Proliferating tissue
fraction AUC consistently trended upwards as clinical response worsened, but the
variance was generally high. Fraction of initial AUC also trended upwards from CR to
SD, then dropped slightly for PD, although not significant. Variance is highest in
evaluation metrics involving proliferating tissue. Statistical significance among evaluation
metrics are summarized for DC vs. PD and CR/PR vs. SD/PD in Table 9.3.
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Figure 9.3. Heatmap of chemotherapy evaluation metrics after a single bolus
injection of cisplatin; colors are scaled within row, with red representing lower values
and green representing higher values for each respective evaluation metric. Clinical
response groups: CR = complete response; PR = partial response; SD = stable disease;
PD = progressive disease. N = at least 10.
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Figure 9.4. Evaluation metrics of simulated patient tumors for 80 time steps postbolus drug injection (~144hrs) for DC vs. PD , CR/PR vs. SD/PD, and CR vs. PR vs.
SD vs. PD. Error bars represent standard deviation. Clinical response groups: CR =
complete response; PR = partial response; SD = stable disease; PD = progressive
disease. N = at least 10; (*P ≤ 0.1); (**P ≤ 0.05); (***P ≤ 0.01)

Table 9.3. Summary of statistical significance comparing clinical
chemotherapeutic response outcome groups for all evaluation metrics. CR =
complete response; PR = partial response; SD = stable disease; PD = progressive
disease. N = at least 10; (*P ≤ 0.1); (**P ≤ 0.05); (***P ≤ 0.01)
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9.3.3 Analysis of patient-specific simulations
Patient-specific simulations reveal a few correlations amongst the model
parameters calculated from the metabolomic data (Supplementary Figure 9.3).
Proliferation rate was negatively correlated with monocyte production constant and with
drug effect, while lactic acid production constant was correlated negatively with Type 1
macrophage polarization and positively with Type 2 macrophage polarization. Initial
proliferating fraction was positively correlated with drug effect and Type 1 macrophage
polarization, and negatively correlated with Type 2 macrophage polarization and
proliferation rate. Initial vasculature SA positively correlated with drug effect and
angiogenesis rate. Notably, there were no correlations between model parameters and
evaluation metrics other than initial tumor vasculature SA correlating positively tumor
vasculature SA AUC and negatively with fraction of initial radius.

There were several correlations amongst the evaluation metrics for the patientspecific simulations (Supplementary Figure 9.3). Final fraction of initial radius was
strongly or moderately positively correlated with average radius velocity, fraction of initial
AUC, proliferating tissue fraction AUC, fraction of initial radius, and average proliferating
tissue fraction velocity. Similarly, average radius velocity correlated with fraction of initial
AUC, proliferating tissue fraction AUC, and average proliferating tissue fraction velocity.
Fraction of initial radius was strongly or moderately positively correlated with fraction of
initial AUC, final fraction of initial radius, and average radius velocity.

Interestingly, the patient-specific data showed a few moderate correlations
amongst model parameters, whereas the synthetic data did not. On the other hand,
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while several moderate/strong correlations amongst evaluation metrics were consistent
between the two datasets, the average proliferating tissue fraction velocity was
inconsistent between the datasets. This discrepancy is likely due to the small number of
patient-specific simulations leading to high variance for this evaluation metric across the
patient classifications (Figure 9.4), compared to simulations in the synthetic dataset for
which the number of samples is an order of magnitude higher and the parameter values
span a wider range (Table 9.2 compared to Supplementary Figure 9.1).

Correlations between the metabolomics data and model evaluation metrics
(Figure 9.5) reveal that average radius velocity was moderately positively correlated
with 2-Hydroxybutyric acid. Fraction of initial radius was moderately negatively
correlated with inosine, and tumor vasculature SA AUC was moderately positively
correlated with lactate and methionine sulfoxide.
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Figure 9.5. Correlations of metabolomics data vs. model parameters from patient
cohort simulations. Blank cells indicate no significant correlation.

9.4 DISCUSSION
This study simulates the personalization of NSCLC first-line chemotherapy to
patient tumor-specific metabolomic characteristics, with the ultimate goal of improving
survival by avoiding ineffective treatment. Chemotherapy is the option with best long
term outcomes for unresectable NSCLC [6], especially for patients with stage IIIB-IVB
disease and performance status ≤2. Paclitaxel, gemcitabine, docetaxel, vinorelbine,
298

irinotecan, or pemetrexed are often used in combination with platinum drugs [7].
Randomized clinical trials have concluded that no single regimen may be significantly
more effective than others [8]. Consequently, no reliable method exists to determine
which potential first-line therapy would be most effective for a specific patient, who
essentially is an experimental subject with drug choice and dosing determined post-hoc
first-line therapy based on response and tolerability [6].

Metabolomics has emerged as a method to potentially resolve the link between
genotype and phenotype, giving insight into patient response [23], although no standard
methodology has been developed [86, 87]. One advantage of mass spectrometry (MS)
over other techniques such as nuclear magnetic resonance (NMR) spectroscopy is that
MS has high sensitivity and peak capacity, especially when coupled with liquid
chromatography (LC). Previous lung cancer chemotherapy prediction models have used
metabolomics data derived from sources other than tumor tissue [23], such as serum or
plasma samples [86, 87], with the potential to detect interactions between metabolites
and treatment response. However, the assumption that serum metabolic profiles are
directly linked to tumor tissue behavior may fail, especially for amino acids since lowmass intracellular proteins may have difficulty shedding into circulation [128]. By utilizing
data from fresh tumor tissue samples and using tissue metabolites as a one-time
“signature” to predict future performance, our proposed approach circumvents this
assumption.

This project integrates both patient tumor tissue-derived metabolomics analysis
and tissue-scale modeling to examine why drug therapy may fail, providing an avenue
for radically improving clinical outcomes. By using the tumor tissue as the metabolome
source, the tumor tissue-scale characteristics that may be a prognosticator of drug
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response can be defined. The metabolomic data is used to calibrate the tissue-scale
computational model that simulates treatment response as a function of tissue
characteristics such as proliferation, vascularization, and immune activity modulated by
the metabolic characteristics. Model-based predictions were compared to the actual
response observed in patients. The proposed approach enables the integration and
interpretation of tumor tissue metabolomic data to predict the drug response of individual
patients.

Network-oriented techniques (e.g., principal network analysis) and statistical
approaches (e.g., machine learning) have been applied in previous work to link the
tumor metabolome to tissue-scale behavior, although results obtained may not
necessarily reflect any particular tumor [86, 301]. Supervised learning methods (e.g.,
Supervised Vector Machines or SVM) trained with chemotherapy response data are
limited in that they are trained only by a set of predictor variables (i.e., the metabolomic
data) to predict chemotherapy outcome. Mathematical modeling to simulate
chemotherapy response via mechanistic simulation of spatiotemporal tumor progression
can extend the predictive capacity of network-oriented and statistical approaches by
providing insight into the mechanisms underlying this response. This study shows that
the proposed approach can evaluate the behavior of particular tumors for in silico with a
variety of metrics prior to treatment by incorporating patient tumor-specific metabolomic
data.

Previously, chemotherapeutic response has been determined for non-specific
tumors [227, 239, 306, 307]. However, the linking of metabolomic data to tissue-scale
behavior has been under-studied [257, 258, 305]. A spatiotemporal mechanistic
modeling approach provides for the ability to simulate in time variation in proliferation,
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hypoxia and vascularization within tumor tissue [239], all of which can affect response as
a function of tumor-specific metabolic signatures [326].

Our simulation results have shown that there are differences in several simulated
evaluation metrics between clinical response groups. Generally, PD patients have the
highest final fraction of initial tumor radius, indicating a propensity for the tissue to
regrow faster than other clinical response groups. PD patients also had higher fraction of
initial radius compared to CR patients, indicating acute resistance to chemotherapy
(here, simulated with cisplatin) immediately following bolus injection. Because the drug
affects only proliferating (cell-cycling) tissue in the model, PD and SD/PD patients which
trend lower in proliferating tissue fraction also trend higher with fraction of initial radius
and final fraction of initial radius. Simulation results show a consistent trend for both final
fraction of initial radius and average radius velocity, increasing as clinical response
worsens (Figure 9.4). This is a promising revelation that the proposed model parameter
calibration method using tumor tissue-derived metabolomics data is likely reflecting
clinical response to chemotherapeutics in this generalized case. Proliferating tissue
fraction AUC and average proliferating tissue fraction velocity did not differ between any
clinical response groups, indicating a relatively constant rate of proliferative tissue
development during the post-bolus drug injection growth window. Therefore, we
hypothesize that subsequent drug exposures with dosing regimens that involve multiple
rounds/cycles of chemotherapeutic agent will result in a wider gap between CR/PR
patients and SD/PD patients in terms of final fraction of initial radius and average radius
velocities, and more accurately reflect the true clinical response. It remains to be
evaluated how the complex non-linear interaction between drug effects and tumor
vasculature with overall response results in discrepancies between the clinical response
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groups. Further developments to the modeling platform are needed to account for
multiple dosing regimens and drug types.

The results of this study would need to be validated with metabolic analyses
obtained from different patient datasets and in larger patient populations. Consequently,
model parameters as a function of the tumor tissue metabolome would be expected to
undergo further refinement. A single bolus injection of cisplatin was used as a
representative chemotherapy. However, patients typically may receive chemotherapy or
immunotherapy, or a combination of both, with a variety of drugs currently in use.
Therapeutic regimens often involve multiple doses over days, and cycles over a period
of weeks, which should be accounted for in future work. Simulations of tumor response
may differ from clinically-observed results based on parameters not included in the
model, such as interaction with other therapies (e.g., radiation) or patient lifestyle. It may
therefore be necessary to expand the model parameter set with additional patientspecific information. The model behavior depends primarily on the metabolomic data
and how these data are combined to determine their effect on the model parameters,
which may need further refinement. Lastly, as running multiple and larger sets of model
simulations is computationally expensive, devising a surrogate model to quickly and
accurately calculate model results for particular patients would pave the way towards
practical clinical application.
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9.5 SUPPLEMENTARY MATERIALS

Supplementary Figure 9.1. Histograms of randomly generated parameter values
from synthetic patient dataset.
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Supplementary Figure 9.2. Correlations among model parameters and evaluation
metrics from synthetic dataset. Blank cells indicate no significant correlation.
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Supplementary Figure 9.3. Correlations among model parameters and evaluation
metrics from patient-specific simulations. Blank cells indicate no significant
correlation.
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CHAPTER 10

OVERALL DISCUSSION AND CONCLUSIONS

Our efforts have shown that tumor-tissue derived metabolomics data is capable
of predicting both clinical chemotherapy response classification and survival. Since there
is no standardized methodology for pre-processing metabolomics data in preparation for
analysis, we investigated how variations in pre-treatment and imputation methods may
results in discrepancies in biomarker identification. Overall, we recommend the log
transformation for general purpose pre-processing of MS-derived metabolomics data
along with testing each unique data set by introducing simulated missing values and
evaluating the performance of multiple imputation methods before settling on a specific
method. Patients were then classified according to chemotherapeutic response and
pathological stage by utilizing a combination of PLS-DA for feature selection in addition
to SVM model for training, where a cross-validation resampling procedure revealed
robust predictive modeling performance in the small cohort. Key metabolites identified
include pyruvate, isoleucine, uric acid, creatinine, and serine, among others.
Patients were also risk stratified by the calculation of a metabolite based riskscore after filtering metabolites by Cox-proportional hazards model. Risk score was
calculated as a summation of the model coefficients divided by standard errors multiplied
by log-transformed metabolite intensity. Survival probability was significantly higher in
low risk patients for both OS and PFS. Individual metabolites were also able to separate
patients based on survival in Kaplan-Meier analysis including hypoxanthine, L306

pyroglutamic acid, N6,N6,N6-Trimethyl-L-lysine, proline, adipic acid, benzoic acid, and
inosine for OS; adenine and inosine for PFS. Sex, pathological stage, and age at
diagnosis were included as secondary variables of which sex and pathological stage
were significant for OS in the univariate model (P=0.0127; P=0.0184), while none were
significant for PFS. An ensemble machine learning workflow was also employed to
predict long vs. short survival classifications, stratified by mean OS and PFS in a cohort
of 48 total patients split into training (n=33) and validation (n=15) sets. An ensemble
method of feature selection was used to determine the top key features from the variable
importance ranking and classification performance in each predictive model where
guanosine, lidocaine, guanine, choline, and leucine were among the most important
metabolites for predicting long vs. short OS and glutamine, N6,N6,N6-Trimethyl-L-lysine,
N8-acetylspermidine, pipecolinic acid, and propionylcarnitine were among the most
important metabolites for predicting long vs. short PFS. Limitations of these predictions
include small sample size which was too prohibitive to allow for model validation on an
independent external cohort for patients with clinical chemotherapeutic response.
Additionally, a mix of systemic therapy types were included as not enough data was
available to allow for stratification of patients based on this secondary variable.
Regardless, the strength of the metabolomics data shows value in predicting
chemotherapeutic response even with the inclusion of the potential confounding
variables. For survival analysis, inclusion of secondary variables sex and pathological
stage in the multivariate model for OS revealed the metabolite-based risk score as a
much more significant predictor than either secondary variable.
Mathematical modeling of drug-loaded nanoparticle cytotoxicity in tumor tissue
revealed differences in response including inhomogeneous intratumoral nanoparticle
and drug AUC values, indicating tumor vascular density coupled with variations in drug
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strength non-trivially influence nanoparticle uptake and washout and the associated
tissue response. This serves as a first step towards the development of a principled
approach for predicting nanotherapy efficacy using patient-tumor specific characteristics,
such as proliferative index and vascular density. We also investigated a novel coupling
of a NP kinetic model with a drug pharmacokinetic/pharmacodynamic model to evaluate
the efficacy of cisplatin-loaded PLGA NP’s in heterogeneously vascularized tumor
tissue. Cisplatin-loaded PLGA-NP’s were most effective in decreasing tumor size in the
case of high vascular-induced heterogeneity, a high NP cytosolic transfer coefficient,
and no NP aggregation. These results indicate that model-based customization of PLGA
NP and drug design parameters can be evaluated in silico along with tailored patient
tumor tissue characteristics and may help optimize NP-mediated tumor drug response.

Furthermore, a method to calibrate the mathematical model based on tumortissue derived metabolomics data was developed to allow for evaluation of patientspecific tumors in silico. Metabolites were linked to specific model parameters including
proliferation rate, type 1/type 2 macrophage polarization, monocyte production rate,
angiogenesis rate, drug effect, and lactic acid production as either have anti- or proparameter influences. Model stability analyses revealed parameter ranges in which
patient-specific metabolomic data could be fit to parameter calibration curves to identify
a set of model parameters. A generic cisplatin-bolus injection was simulated across
replicates of patient simulations from the systemic therapy response cohort and shows
consistent observations in the evaluation metrics of final fraction of initial radius and
average radius velocity, with simulation response worsening accordingly with worsening
clinical response. This modeling effort proves that the calibration of a mechanistic model
of tumor growth with patient-specific molecular data is viable. It remains to be evaluated
how the complex non-linear interaction between drug effects and tumor vasculature with
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overall response results in discrepancies between the clinical response groups. Further
developments to the modeling platform are needed to account for multiple dosing
regimens and drug types. Additionally, simulated immunotherapy should be investigated
as an alternative therapy type alone and in combination with chemotherapeutic regimens
to more closely mimic the true clinical therapies in this patient cohort. Integration of
simulated nanotherapy and other pharmacodynamic/pharmacokinetic models of specific
nanotherapy formulations will allow for in silico evaluation of a wide range of therapeutic
options. Ideally, patient-specific therapy responses would be evaluated for specific drug
or immunotherapy regimens as independent analyses, although this would require a
much larger patient cohort. Another limitation of these modeling results include that
these simulated tissue responses have yet to be validated on external experimental
data, which may require collection of paired tissue specimens post-therapy. Although the
metabolomics data has proven useful for predictive modeling with machine-learning
techniques and mathematical model calibration, it may be beneficial to include additional
analysis such as proteomics to complement model calibration which would also allow
linking the proteome to the metabolome via pathway analysis.
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CURRICULUM VITAE

Hunter Allan Miller
580 S Preston St. (Delia Baxter Research Building) Room 107, Louisville, KY 40202
Phone: 731-206-0134 Email: hunter.miller@louisville.edu

Profile:
•

Highly motivated Ph.D. candidate with expertise in metabolomics, lung cancer,
mathematical modeling and simulation of cancer tissue, machine learning, and
the principles of pharmacology and toxicology.

•

Research interests:
o

Metabolic dysregulation in chronic diseases, such as cancer and
Alzheimer’s.

o

Analysis of omics data using machine learning and integration of omics
data into novel mechanistic models of biological systems.

o

Omics data integration and predictive modeling for clinical prognosis in
chronic disease states, such as cancer.

o

Modeling of cellular events and pathways: transcription/translation
regulation, cell signaling pathways, metabolic networks.

Education
University of Louisville – Ph.D., Pharmacology and Toxicology (in progress)
Anticipated graduation date: May 2022
Louisville, KY
August 2018 – Present
University of Louisville – Master of Science, Pharmacology and Toxicology
Louisville, KY
August 2016 – August 2018
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Thesis title: Evaluation of drug-loaded gold nanoparticle cytotoxicity as a function of
tumor tissue heterogeneity.
Relevant Coursework:
•

Advanced Biochemistry I, Pharmacology I, Pharmacology II, Toxicology I, Toxicology
II, Selected Topics in Physiology, Cell Biology, Data Analysis, Molecular Biology,
Scientific Writing.

Murray State University – Bachelor of Science, Chemistry/Biochemistry
Murray, KY
August 2011 – May 2016
Minors: Mathematics, Biology
Relevant Coursework:
•

General College Chemistry, Chemistry and Qualitative Analysis, Organic Chemistry
I, Organic Chemistry II, Fundamentals of Biochemistry I, Biochemistry II, Analytical
Chemistry, Basic Chemical Instrumentation, Basic Physical Chemistry, Calculus and
Analytical Geometry I, Calculus and Analytical Geometry II, Calculus and Analytical
Geometry III, Mechanics Heat and Wave Motion, Electricity Magnetism and Light,
Ordinary Differential Equations, Mathematical Reasoning, Introduction to Numerical
Analysis, Introduction to Cell Biology and Genetics, Human Anatomy and Physiology
I, Human Anatomy and Physiology II, Introduction to Microbiology, Introduction to
Evolutionary Principles.

Skills/Knowledge in Experimental Techniques
Metabolite extraction for mass spectrometry-based metabolomics studies
-

Human lung cancer and glioblastoma tissue biopsies.

-

Human hair samples.

Cell culture and tissue culture
-

Spheroids: cytotoxicity assays, invasion into peptide hydrogel matrices,
nanoparticle diffusion.

3D confocal microscopy (Zeiss LSM 980)
-

Nanoparticle diffusion measurement in spheroids and multi-cell layers.

Cryomicrotome sectioning (Leica CM1950)
-

Multi-layer cell culture sectioning for nanoparticle diffusion measurement.
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Skills/Knowledge in Mathematical Modeling and Programming
R (statistical programming language)
-

Analysis of metabolomics and clinical data
o

Application of machine learning techniques to create prediction
models using large multivariate data sets. (packages: caret,
caretEnsmeble, mdatools, mice)

o

Data visualization. (packages: matrixplot, VIM, ggplot2)

Python (programming language)
-

Conditional generative adversarial networks
o

Surrogate modeling of mechanistic models of cancer. (packages:
keras, tensorflow)

C++ (programming language)
-

Modeling and simulation of cancer tissue growth and response to
chemotherapy
o

Angiogenesis.

o

Nanoparticles as drug delivery vehicles.

o

Macrophage movement, differentiation, and effect on tumor growth.

o

Calibration of spatio-temporal tumor growth model parameters using
metabolomics data.

-

Quantification of score plots (principal component analysis and partial least
squares discriminant analysis).

NVIDIA CUDA (GPU Acceleration of C/C++)
-

Certificate of Competency: Fundamentals of Accelerated Computing with
CUDA C/C++. February 16th, 2021.
Certificate ID Number: 54246c248b5344799021fe775a8e5aa5

MATLAB
-

Simulation of nanoparticle diffusion kinetics across layers of biological
material.
o

PDE toolbox.

ImageJ
-

3D nanoparticle diffusion measurement in spheroids.
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Awards
•

2021 Exemplary Research Scholarship Award, J.B. School of Engineering, from the
Department of Bioengineering, April 27, 2021.

•

Graduate Dean’s Citation, from the University of Louisville Graduate School, March
25, 2022.

Publications
•

Miller, H.A., Rai, S., Yin X., Zhang X., Chesney J., van Berkel V.H., Frieboes, H.B.
Lung cancer metabolomic data from tumor core biopsies enables risk-score
calculation for progression-free and overall survival. Metabolomics 2022 (in press).

•

Miller, H.A., Lowengrub, J., Frieboes, H.B. Modeling of Tumor Growth with Input
from Patient-Specific Metabolomic Data. Ann Biomed Eng 50, 314–329 (2022).
https://doi.org/10.1007/s10439-022-02904-5

•

Winter, S.J., Miller, H.A., Steinbach-Rankins, J.M. Multicellular ovarian cancer
model for evaluation of nano vector delivery in ascites and metastatic environments.
Pharmaceutics 13, 1891 (2021). https://doi.org/10.3390/pharmaceutics13111891

•

Miller, H.A., Yin, X., Smith, S.A., Hu, X., Zhang, X., Yan, J., Miller D.M., van Berkel,
V.H., Frieboes, H.B. Evaluation of disease staging and chemotherapeutic response
in non-small cell lung cancer from patient tumor-derived metabolomic data. Lung
Cancer 156, 20-30 (2021). https://doi.org/10.1016/j.lungcan.2021.04.012

•

Miller, H.A., Emam, R., Lynch, C.M., Bockhorst, S., Frieboes, H.B. Discrepancies in
metabolomic biomarker identification from patient-derived lung cancer revealed by
combined variation in data pre-treatment and imputation methods. Metabolomics 27,
17(4)-37 (2021). https://doi.org/10.1007/s11306-021-01787-2

•

Miller, H.A., Frieboes, H.B. Evaluation of drug-loaded gold nanoparticle cytotoxicity
as a function of tumor vasculature-induced tissue heterogeneity. Ann Biomed
Eng 47, 257–271 (2019). https://doi.org/10.1007/s10439-018-02146-4
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•

Miller, H.A., Frieboes, H.B. Pharmacokinetic/Pharmacodynamics modeling of drugloaded PLGA nanoparticles targeting heterogeneously vascularized tumor
tissue. Pharm Res 36, 185 (2019). https://doi.org/10.1007/s11095-019-2721-5

•

Sims, L. B., Miller, H. A., Halwes, M. E., Steinbach-Rankins, J. M., Frieboes, H. B.
Modeling of nanoparticle transport through the female reproductive tract for the
treatment of infectious diseases. Eur J Pharm Biopharm 138, 37-47 (2019).
https://doi.org/10.1016/j.ejpb.2018.09.003

•

Hudson, S.V., Miller, H.A., Mahlbacher, G.E., Saforo, D., Beverly, L.J., Arteel, G.E.,
Frieboes, H.B.. Computational/experimental evaluation of liver metastasis post
hepatic injury: interactions with macrophages and transitional ECM. Sci
Rep 9, 15077 (2019). https://doi.org/10.1038/s41598-019-51249-y

Works in review or revision:
•

LyBarger, K.S., Miller, H.A., McGuinness, T.B., Frieboes, H.B. CA125 as a predictor
of endometrial cancer lymphovascular space invasion and lymph node metastasis for
risk stratification in the preoperative setting. (in review)

•

Miller, H.A., van Berkel V.H., Frieboes, H.B. Lung cancer survival prediction and
biomarker identification with an ensemble machine-learning analysis of tumor core
biopsy metabolomic data. (in review, submitted to Metabolomics).

Works in progress:
•

Miller, H.A., Frieboes, H.B. Prediction of response to first-line chemotherapy based
on patient-tumor specific metabolomic data. (in preparation)

•

Tran, A., Miller, H.A., LyBarger, K.S., Frieboes, H.B. Endometrial cancer
preoperative risk stratification using machine learning. (in preparation)
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•

Miller, H.A., Taylor, M.J., Bhat, S.S., Suliman, S., Frieboes, H.B. Evaluation of
clinical lung function in idiopathic pulmonary fibrosis patients via hair metabolomics.
(in preparation)

Online Academic and Professional Profiles

Google Scholar:
https://scholar.google.com/citations?hl=en&user=gEJtZZUAAAAJ&view_op=list_works&
gmla=AJsN-F51aJfUUIDjpnC7dWcl5kXJT-P9AMpUCNqvd0DXV_SgZRIDCvbjslwJpYlO8LD4nUgwfkHR-hpYM3dpff4mQ10GKMkjw

Web of Science ResearcherID:
ABD-7664-2021

LinkedIn:
www.linkedin.com/in/hunter-miller-250946238

Abstracts and Presentations (* denotes joint first authorship)

•

Miller H.A. Mechanistic modeling of tumor therapeutic response: Applications in
nanotherapy and immunotherapy. (Annual seminar. Department of Pharmacology
and Toxicology, University of Louisville, September 30th, 2021)

•

*Karmali, D., *Miller H.A., Weaver M., Desai V., Frieboes H.B., Suliman S.A. A
comparison of risk factors that predict mortality in COVID-19 patients across two
surge periods: a single-center study. (American Thoracic Society, 2021)

•

*Desai V., *Miller H.A., Karmali D., Weaver M., Frieboes H.B., Suliman S.A. Risk of
cardiovascular complications in ethnic minorities infected with COVID-19 –
Experience in a mid-sized Midwestern city. (American College of Cardiology, 2021)

•

Winter, S., Miller, H.A., Frieboes, H.B., Steinbach-Rankins, J. Surface-modified
nanoparticle transport evaluated in a multistage model of ovarian cancer. Journal of
Clinical Oncology 38, 15 (2020). 10.1200/JCO.2020.38.15_suppl.e18057

•

Miller H.A. Evaluation of response to lung cancer therapy using machine learning.
(Annual seminar. Department of Pharmacology and Toxicology, University of
Louisville, October 22nd, 2020)
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•

Miller H.A., Lynch C.M., Yin X., Hu X., Zhang X., Yan J., Miller D.M., van Berkel V.,
Frieboes H.B. Modeling of lung cancer tumor response to chemotherapy based on
metabolomic profiling. (Accepted for oral presentation at BMES Annual Meeting
2019, Philadelphia, PA)

•

Miller H.A., Frieboes H.B. Simulating a pharmacokinetic model of cisplatin-loaded
PLGA nanoparticles in heterogeneously vascularized tumor tissue. (Accepted for
poster presentation at Research!Louisville 2018, Louisville, KY).

•

Miller H.A., Frieboes H.B. Simulating a pharmacokinetic model of cisplatin-loaded
PLGA nanoparticles in heterogeneously vascularized tumor tissue. (Accepted for
poster presentation at BMES Annual Meeting 2018, Atlanta, GA).

•

Miller H.A. Evaluation of nanoparticle transport and effect in heterogeneous
vascularized tumor tissue. (M.S. Thesis Defense and Ph.D. proposal. Department of
Pharmacology and Toxicology, University of Louisville, July 11th, 2018)

•

Miller H.A., Frieboes H.B. Simulating the effect of tumor vessel density on drug
loaded gold nanoparticle efficacy. (Accepted for poster presentation at
Research!Louisville 2017).

•

Miller H.A. In silico experimentation of nanotherapy. (1st-year student seminar.
Department of Pharmacology and Toxicology, University of Louisville, April 13th,
2017)

•

Winter S., Miller H.A., Curry K., Frieboes H.B., Steinbach-Rankins J.M. Evaluation of
Surface-Modified Nanoparticle Transport and Metastatic Invasion Using a Novel
Multicellular Ovarian Tumor Spheroid Model. . Research!Louisville (2019)

•

Bockhorst S., Minooei F., Miller H.A., Frieboes H.B., Steinbach-Rankins J.
Personalized Nanomedicine Tailored to Lung Cancer Metabolomic Analysis.
Research!Louisville (2019)

•

Miller H.A., Lynch C.M., Yin X., Zhang X., Hu X., Yan J., Miller D., van Berkel V.,
Frieboes H.B.. Metabolic profiling of NSCLC patient tissue biopsies for personalized
classification. Research!Louisville (2019)

•

Miller H.A., Frieboes H.B.. Evaluation of Cancer Nanotherapy as a Function of
Tumor Vascularization. Research Louisville (2018)

Research and Teaching Experience
University of Louisville

335

Graduate Research Assistant, J.B. Speed School of Engineering, Department of
Bioengineering
•

Performed in silico studies pertinent to nanotherapy and chemotherapy efficacy
for cancer with a mechanistic model of tumor growth.

•

Developed a predictive modeling workflow using statistical and machine learning
techniques for patient cohorts with cancer, idiopathic pulmonary fibrosis, and
COVID-19.

•

Contributed to the development of a calibration method for a mechanistic model
of tumor growth based on human tumor tissue-derived, MS-based metabolomics
data.

•

Managed the handling of patient tissue specimens during metabolite extraction
and cell culture protocols to ensure proper execution and long-term storage.

•

Assisted with development and maintenance of computational tools within the
lab.

•

Assisted with training undergraduate and graduate students in experimental
protocols related to cell culture and metabolite extraction for MS-based
metabolomics, various programming tasks related to a mechanistic model of
tumor growth and machine learning, and scientific writing.

•

Managed all lab protocols, inventory, and hazardous waste compliance to ensure
safety and efficiency during experimental workloads.

Hermann Frieboes Laboratory
Aug 2016 – Present
Murray State University
Undergraduate Research Assistant, Department of Chemistry
•

Contributed to the analysis of solid phase and mobile phase HPLC parameters
for the separation of phenylethylamine, N-methylphenylethylamine and tyramine.

Robert Volp Laboratory
Jan 2016 – May 2016
Murray State University
Mathematics and Chemistry Tutor, Lowry Center
•

Provided free walk-in tutoring at the Lowry Center for Murray State students in
algebra, calculus, general chemistry and organic chemistry.
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Aug 2014 – Dec 2015

Leadership Experience
U.S. Army ROTC, Murray State University

•

Relevant coursework (Aug 2011 – Aug 2013):
o

Physical conditioning lab, Marksmanship/Land Navigation, Army
Fundamentals, Basic Leadership, Team Building and Military
Doctrine, Military Leadership and Management.
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